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ABSTRACT	  
To	   microbes	   and	   humans	   alike,	   iron	   is	   both	   essential,	   and	   potentially	   toxic,	   where	  
homeostatic	  concentrations	  must	  be	  stringently	  maintained.	  Within	  the	   iron-­‐restricted	  
host,	   the	  survival	  and	  proliferation	  of	  microbial	   invaders	   is	   contingent	  upon	  exploiting	  
the	  host	   iron	  pool.	  Staphylococcus	  aureus	   is	   a	   formidable	  pathogen,	  whose	   success	   is	  
partly	  attributable	  to	  its	  multiple,	  and	  often	  redundant	  mechanisms	  for	  acquiring	  iron.	  A	  
decade	   of	   research	   in	   staphylococcal	   iron	   acquisition	   has	   identified	   several	   uptake	  
mechanisms,	   including,	   but	   not	   limited	   to,	   the	   elaboration	   of	   high-­‐affinity	   iron	  
scavenging	   siderophores	   (staphyloferrins	   A	   (SA)	   and	   B	   (SB))	   and	   the	   expression	   of	   an	  
iron-­‐regulated	   surface	   determinant	   (Isd)	   pathway	   for	   heme-­‐iron	   acquisition.	   Factors	  
influencing	  the	  expression	  or	  utility	  of	  these	  systems	  in	  vivo,	  however,	  have	  largely	  gone	  
unaddressed	  and	  were	  the	  subject	  of	  this	  thesis.	  
	   Both	  SA	  and	  SB	  are	  citrate-­‐based	  siderophores	  and,	  in	  Chapter	  2,	  we	  endeavored	  
to	   identify	   the	   enzymatic	   source	   of	   this	   staphyloferrin	   precursor	   molecule.	   We	  
demonstrate	  that	  citrate	  derived	  from	  the	  TCA	  cycle	  citrate	  synthase,	  CitZ,	  is	  essential	  to	  
the	   production	   of	   SA,	   whereas	   SB	   may	   obtain	   citrate	   from	   either	   CitZ,	   or	   the	   iron-­‐
regulated	  citrate	  synthase,	  SbnG.	  Activity	  of	  the	  TCA	  cycle	  is	  thus	  a	  key	  determinant	  in	  
the	   elaboration	   of	   SA.	   Notably,	   the	   TCA	   cycle	   is	   downregulated	   during	   iron-­‐restricted	  
glycolytic	   growth,	   which	   we	   suggest	   has	   fundamental	   implications	   to	   the	   in	   vivo	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and	   SB	   each	   fulfill	   unique,	   yet	   partially	   overlapping,	   roles	   in	   the	   metabolism	   and	  
pathophysiology	  of	  the	  bacterium.	  	  	  
	   Although	   Isd	   has	   been	   extensively	   characterized	   in	   heme-­‐iron	   acquisition,	   isd	  
mutants	   often	   lack	   a	   growth-­‐defective	   heme-­‐dependent	   phenotype.	   In	   Chapter	   3,	  we	  
report	  that	  Isd	  functions	  as	  a	  biologically	  relevant,	  high-­‐affinity	  heme	  acquisition	  system,	  
with	   utility	   on	   physiological	   concentrations	   of	   hemoglobin.	   Isd	   function	   is	   masked	   at	  
high	  heme	  concentrations,	  which	  we	  hypothesized	  to	  occur	  through	   low-­‐affinity	  heme	  
acquisition	  by	  a	  putative	  di-­‐/tripeptide	  (DtpT)	  or	  oligopeptide	  permease	  (Opp).	  No	  Opp	  
was	   found	   to	   function	   in	   heme	   acquisition,	   and	   while	   DtpT	   was	   found	   to	   have	   a	  
reproducible	   yet	   minor	   role	   in	   this	   function,	   under	   the	   conditions	   tested,	   it	   was	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The	  majority	  of	  the	  research	  presented	  in	  this	  thesis	  has	  also	  been	  published	  in	  various	  
peer-­‐reviewed	   journal	   articles,	   or	   in	   book	   chapters	   that	  were	   In	   Press	   at	   the	   time	   of	  
submission.	  For	  co-­‐authored	  manuscripts,	  work	  not	  exclusively	  performed	  by	  Jessica	  R.	  
Sheldon	  is	  indicated	  below.	  
Chapter	  1	  
Comprehensive	   reviews	   of	   bacterial	   iron	   acquisition	   and	  metal	   ion	   homeostasis	   have	  
been	  published	  in	  the	  manuscripts	  listed	  below,	  portions	  of	  which	  comprise	  Chapter	  1.	  
All	  portions	  included	  in	  Chapter	  1	  were	  written	  exclusively	  J.R.S.	  	  
	  
Sheldon,	   J.R.,	   Heinrichs,	   D.E.	   2015.	   Recent	   developments	   in	   understanding	   the	   iron	  
acquisition	  strategies	  of	  Gram-­‐positive	  pathogens,	  FEMS	  Microbiol	  Rev.	  39:592-­‐630	  
The	  manuscript	  was	  written	  by	  J.R.S.	  with	  advice	  from	  and	  editing	  by	  D.E.H.	  	  	  
	  
Sheldon	   J.R.,	   Flannagan,	  R.S.,	  Hannauer,	  M.,	  Heinrichs,	  D.E.	  Metal	   ion	  homeostasis.	   In	  
Staphylococcus:	  genetics	  and	  physiology.	  In	  press.	  Caister	  Academic	  Press.	   	  
J.R.S.	   exclusively	   wrote	   the	   introduction,	   sections	   on	   iron	   chemistry	   and	  
bioavailability,	   and	   acquisition,	   as	  well	   as	  manganese,	   zinc,	   nickel	   and	   cobalt,	   and	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The	   section	   on	   iron	   acquisition	  was	  written	   by	   J.R.S.	   and	  M.H.	   The	   importance	   of	  
metal	  ion	  homeostasis	  within	  the	  host	  was	  written	  by	  R.S.F.	  and	  edited	  by	  J.R.S.	  and	  
D.E.H.	  The	  figures	  were	  generated	  by	  M.H.	  and	  R.S.F.	  	  
	  
Sheldon	   J.R.,	   Laakso,	   H.A.,	   Heinrichs,	   D.E.	   Iron	   acquisition	   strategies	   of	   bacterial	  
pathogens.	  In	  Virulence	  Mechanisms	  of	  Bacterial	  Pathogens,	  5th	  Ed.	  In	  press.	  ASM	  Press,	  
Washington,	  DC.	  	  
Also	  published	  as:	  
Sheldon	   J.R.,	   Laakso,	   H.A.,	   Heinrichs,	   D.E.	   Iron	   acquisition	   strategies	   of	   bacterial	  
pathogens.	  Microbiol.	  Spect.	  In	  press.	  
The	   section	   on	   iron	   metabolism	   in	   health	   and	   disease	   was	   written	   by	   H.A.L.	   and	  
edited	  by	   J.R.S.	  and	  D.E.H.	   	  All	  other	  sections	  were	  written	  by	   J.R.S.	  with	  guidance	  
from	  D.E.H.	  	  
	  
Sheldon	  J.R.,	  Heinrichs,	  D.E.	  2012.	  The	  iron-­‐regulated	  staphylococcal	  lipoproteins.	  Front	  
Cell	  Infect	  Microbiol.	  2:41	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Chapter	  2	  
All	   sections	   of	   Chapter	   2	   have	   been	   published	   previously	   in	   peer-­‐reviewed	   journal	  
articles.	  
Sheldon,	   J.R.,	  Marolda,	  C.L.,	  Heinrichs,	  D.E.	   2014.	   TCA	   cycle	   activity	   in	  Staphylococcus	  
aureus	   is	   essential	   for	   iron-­‐regulated	   synthesis	   of	   staphyloferrin	   A,	   but	   not	  
staphyloferrin	  B:	  the	  benefit	  of	  a	  second	  citrate	  synthase.	  Mol	  Microbiol	  92:824–839.	  
The	  manuscript	   and	   figures	  were	  generated	  by	   J.R.S.	  with	  advisement	   from	  D.E.H.	  
Real-­‐time	   PCR	   was	   performed	   by	   C.L.M.	   The	   sbnG	   mutant	   and	   complementing	  
vector	  were	  generated	  by	  C.L.M.	  All	  other	  experiments,	  mutant	  generation,	  and	  data	  
analysis	  were	  performed	  by	  J.R.S.	  	  
	  
Kobylarz,	  M.J.,	  Grigg,	   J.C.,	  Sheldon,	   J.R.,	  Heinrichs,	  D.E.,	  Murphy,	  M.E.P.	  2014.	  SbnG,	  a	  
citrate	   synthase	   in	  Staphylococcus	   aureus:	   a	   new	   fold	   on	   an	   old	   enzyme.	   J	   Biol	   Chem	  
289:33797–33807.	  
J.R.S.	   performed	   site-­‐directed	   mutagenesis	   of	   SbnG	   active	   site	   residues	   under	  
advisement	  from	  M.M.E.P.	  and	  D.E.H.	  Growth	  characterization	  of	  citZ	  sbnG	  mutants	  
complemented	  with	  vectors	  expressing	  mutated	  and	  wild-­‐type	  SbnG	  was	  performed	  
by	   J.R.S.	   All	   other	   characterization	   of	   the	   crystal	   structure	   and	  phylogeny	   of	   SbnG	  
was	  performed	  by	  members	  of	   the	  Murphy	  Lab	   (M.J.K,	   J.C.G,	  M.M.E.P).	   	  Materials	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SbnG	   were	   written	   by	   J.R.S.	   The	   manuscript	   was	   edited	   by	   J.R.S.,	   D.E.H.,	   and	  
M.M.E.P.	  	  
Chapter	  3	  
Portions	  of	  Chapter	  3	  pertaining	   to	  heme-­‐iron	  acquisition	  by	   Isd	  have	  been	  previously	  
published	  in	  peer-­‐reviewed	  articles.	  All	  of	  the	  data	  on	  the	  functional	  characterization	  of	  
di-­‐/tri-­‐	   and	   oligopeptide	   permeases	   has	   not	   previously	   been	   published.	   USA300	  
dtpT::ΦNΣ	  and	  USA300	  dtpT::ΦNΣ	  ΔisdA::tetM	  mutants,	  along	  with	  the	  complementing	  
plasmid	   (pJC01)	  were	   generated	   by	   a	   former	  Master’s	   student,	   Jhonna	   Collins,	   under	  
supervision	   by	   J.R.S.	   All	   other	   mutants	   were	   generated	   and	   experiments	   were	  
performed	  as	  described	  by	  J.R.S.	  	  
	  
Brozyna,	  J.R.,	  Sheldon,	  J.R.,	  Heinrichs,	  D.E.	  2014.	  Growth	  promotion	  of	  the	  opportunistic	  
human	   pathogen,	   Staphylococcus	   lugdunensis,	   by	   heme,	   hemoglobin,	   and	   coculture	  
with	  Staphylococcus	  aureus.	  MicrobiologyOpen	  3:182–195.	  
The	  methodology	  for	  extracting	  hemoglobin	  and	  assessing	  heme-­‐iron	  utilization	  by	  
the	  staphylococci	  was	  developed	  by	  J.R.S.	  with	  assistance	  from	  D.E.H.	  The	  protocols	  
for	  generating	  markerless	  mutations	   in	   the	   staphylococci	  was	  optimized	   for	  use	   in	  
the	   Heinrichs	   Lab	   by	   J.R.S.	   and	   adapted	   for	   use	   in	   Staphylococcus	   lugdunensis	   by	  
J.R.B.	  Applicable	  materials	  and	  methods	  were	  written	  by	  J.R.S.,	  and	  the	  rest	  of	   the	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Pishchany,	  G.,	  Sheldon,	   J.R.,	  Dickson,	  C.F.,	  Alam,	  M.T.,	  Read,	  T.D.,	  Gell,	  D.A.,	  Heinrichs,	  
D.E.,	  Skaar,	  E.P.	  2014.	  IsdB-­‐dependent	  hemoglobin	  binding	  is	  required	  for	  acquisition	  of	  
heme	  by	  Staphylococcus	  aureus.	  J	  Infect	  Dis	  209:1764–1772.	  
All	   sections	   of	   the	   experiments	   pertaining	   to	   the	   extraction	   of	   hemoglobin,	   and	  
assessment	  of	  mutants	  for	  heme-­‐iron	  utilization	  were	  performed	  by	  J.R.S.	  Applicable	  
sections	   of	   the	   introduction,	   materials	   and	   methods,	   and	   conclusions	   of	   the	  
manuscript	  were	  written	  by	  J.R.S.	  and	  edited	  by	  D.E.H.	  and	  E.P.S.	  All	  other	  sections	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2	  
Chapter	  1	  -­‐ INTRODUCTION	  
1.1. IRON	  	  
1.1.1. Iron	  chemistry	  	  
Iron	  is	  a	  highly	  versatile	  redox-­‐active	  catalyst,	  and	  an	  essential	  micronutrient	  for	  almost	  
all	   living	  organisms,	  with	  the	  notable	  exceptions	  of	  Lactobacillus	  spp.,	  and	  the	  obligate	  
intracellular	   parasites	  Borrelia	   burgdorferi,	   and	   Treponema	   pallidum	   (1–3).	   Due	   to	   its	  
unfilled	  d	  atomic	  orbitals,	   iron	  possesses	   two	   readily	   interchangeable	   stable	  oxidation	  
states,	   Fe2+	   (ferrous)	   and	   Fe3+	   (ferric),	   and	   can	   adopt	   both	   high	   and	   low	   spin	  
conformations	   depending	   on	   the	   ligand	   bound.	   Iron	   exhibits	   octahedral	   coordination	  
geometry,	  with	  six	  potential	  binding	  sites	  along	  three	  axes	  of	  symmetry.	  Flexibility	  exists	  
in	  both	  the	  bond	  length	  and	  angle	  formed	  with	  the	  central	  Fe	  ion,	  as	  determined	  by	  the	  
oxidation	   state	   of	   the	   ion	   and	   the	   ligand	   environment	   (4).	   All	   of	   the	   aforementioned	  
properties	   influence	  the	  ease	  with	  which	  electrons	  are	  gained	  or	   lost	  and,	  accordingly,	  
iron	   possesses	   an	   extensive	   range	   of	   redox	   potentials.	   These	   unique	   electronic	  
characteristics	   make	   iron	   an	   ideal	   cofactor	   for	   metalloproteins	   involved	   in	   electron	  
transfer	  and	  oxidation	  reactions,	  where	  iron	  is	  most	  often	  in	  complex	  with	  the	  sulfhydryl	  
groups	  of	  cysteine	  residues	  in	  the	  form	  of	  iron-­‐sulfur	  clusters,	  or	  in	  the	  tetrapyrrole	  ring	  
of	   heme	   (5).	   Correspondingly,	   iron	   is	   involved	   in	   several	   key	   metabolic	   pathways	   in	  
bacteria,	   including	   photosynthesis,	   nitrogen	   fixation,	   amino	   acid	   synthesis,	   the	  
tricarboxylic	  acid	  (TCA)	  cycle,	  electron	  transport,	  and	  cellular	  respiration.	  	  
	   As	   with	   other	   redox-­‐active	   metals,	   the	   very	   characteristics	   that	   make	   iron	   a	  
favorable	   catalyst	   are	   also	   capable	   of	   promoting	   the	   production	   of	   intoxicating	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intracellular	   reactive	   oxygen	   species	   (ROS).	   ROS,	   such	   as	   superoxide	   anions	   (O2−),	  
hydrogen	   peroxide	   (H2O2),	   and	   hydroxyl	   radicals	   (OH),	   can	   damage	   nucleic	   acids,	  
proteins,	   and	   lipids	   and,	  without	  mitigation,	   compromise	   bacterial	   survival	   (6–9).	   ROS	  
are	  produced	  through	  the	  iron-­‐catalyzed	  Haber-­‐Weiss	  reaction,	  a	  two-­‐step	  reaction	  that	  
makes	  use	  of	  Fenton	  chemistry	  (10,	  11):	  
Fe3+	  +	  O2−	  à	  Fe2+	  +	  O2	  (slow	  reaction)	  
Fe2+	  +	  H2O2	  à	  Fe3+	  +	  OH	  +	  OH−	  (Fenton	  reaction;	  fast)	  
Net	  reaction:	  
O2−	  +	  H2O2	  à	  O2	  +	  OH	  +	  OH−	  
Both	  O2−	  and	  H2O2	  are	  produced	  during	  normal	  aerobic	  metabolism,	  and	  host	  immune	  
cells	  produce	  the	  former	  as	  a	  defense	  against	  invading	  microbes.	  The	  staphylococci,	  as	  
with	   all	   aerobic	   organisms,	   require	   means	   by	   which	   ROS	   are	   detoxified,	   as	   well	   as	  
mechanisms	  to	  sequester	  free	  iron	  within	  the	  cell,	  and	  these	  mechanisms	  are	  discussed	  
in	  later	  sections	  of	  this	  chapter.	  
1.1.2. Bioavailability	  of	  iron	  	  
Although	   iron	   is	  one	  of	   the	  most	  abundant	  elements,	  comprising	  approximately	  5%	  of	  
the	   Earth’s	   crust,	   its	   bioavailability	   is	   limited	   by	   its	   insolubility	   under	   physiological	  
conditions.	   In	   the	   presence	   of	   oxygen	   at	   neutral	   pH,	   iron	   forms	   ferric	   oxyhydroxide	  
precipitates,	   reducing	   the	   concentration	   of	   free	   iron	   to	   10-­‐8-­‐10-­‐9	   M	   (12).	   While	   this	  
concentration	   is	   already	   orders	   of	   magnitude	   less	   than	   what	   is	   required	   to	   support	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microbial	  growth	  (~	  10-­‐6	  M),	  free	  iron	  within	  the	  host	  is	  further	  depleted	  (up	  to	  10-­‐24	  M)	  
through	  binding	   to	  host	  glycoproteins	  such	  as	   transferrin	  and	   lactoferrin,	  coordination	  
with	  heme	   in	  hemoproteins,	   or	   sequestration	  within	   storage	  proteins	   such	   as	   ferritin.	  
Sequestration	   of	   iron	   effectively	   reduces	   the	   potential	   for	   Fenton	   chemistry	   and	   thus	  
the	   generation	   of	   ROS,	   and	   also	   helps	   to	   ensure	   bacteriostasis	   at	   potential	   sites	   of	  
infection.	   The	   withholding	   of	  metals,	   such	   as	   iron,	   to	   effectively	   starve	   pathogens	   of	  
essential	  elements	  is	  referred	  to	  as	  “nutritional	  immunity”	  (13–15),	  and	  is	  an	  important	  
facet	  of	  the	  host	  innate	  immune	  defense.	  Critical	  determinants	  of	  host	  iron	  homeostasis	  
and	  nutritional	  immunity	  are	  summarized	  in	  Table	  1.1.	  	  
1.2. HOST	  IRON	  HOMEOSTASIS	  	  
1.2.1. Iron	  uptake	  and	  metabolism	  
Perturbations	   to	   the	   balance	   of	   iron	  within	   the	   human	   body	   can	   impact	   both	   overall	  
health	  and	  susceptibility	   to	   infectious	  disease.	  Sophisticated	  mechanisms	   thus	  exist	   to	  
control	   the	   daily	   intake	   of	   iron	   required	   for	  metabolic	   processes	   and	   the	   synthesis	   of	  
new	  erythrocytes,	  and	  to	  maintain	  homeostatic	  concentrations	  of	  iron	  both	  systemically	  
and	  cellularly	  (16).	  The	  majority	  of	  the	  3.5	  to	  5	  g	  of	  iron	  within	  the	  body	  is	  located	  within	  
cells,	  in	  association	  with	  heme,	  which	  coordinates	  a	  central	  Fe2+	  ion,	  and	  is	  bound	  within	  
proteins	   such	   as	   hemoglobin	   (Hb)	   or	   myoglobin.	   Hb	   is	   typically	   contained	   within	  
circulating	   erythrocytes,	   however,	   during	   routine	   destruction	   of	   senescent	   cells,	   Hb	   is	  
released	   into	   the	  blood.	  Although	   the	   levels	   of	   extracellular	  Hb	   are	  usually	   low,	   rapid	  
erythrocyte	  lysis	  triggered	  by	  pathological	  conditions	  can	  increase	  the	  concentration	  of	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Table	  1.1.	  Facets	  of	  host	  iron	  homeostasis	  and	  iron-­‐withholding	  as	  a	  function	  of	  the	  
innate	  immune	  defense	  against	  pathogensa	  
Component	   Function	  
Cell	  types	  
Enterocytes	   Absorb	  dietary	  iron	  from	  duodenum	  
Macrophages	   Recycle	  iron	  from	  dead	  or	  senescent	  erythrocytes	  (and	  other	  
cells)	  
Hepatocytes	   Store	  iron	  until	  required;	  synthesize	  hepcidin	  
Cell-­‐associated	  transporters	  and	  enzymes	  
Ferrireductase	   Reduces	   dietary	   Fe3+	   to	   Fe2+	   for	   uptake	   by	   duodenal	  
enterocytes	  
Divalent	  metal	  ion	  
transporter	  (DMT-­‐1;	  aka	  
Nramp2	  or	  DCT1)	  
Mediates	   Fe2+	   uptake	   by	   duodenal	   enterocytes	   and	  
macrophages;	   mediates	   export	   of	   iron	   released	   from	  
transferrin	  within	  endosomes	  	  
Heme	  carrier	  protein	  
(HCP-­‐1)	  
Mediates	  heme	  uptake	  by	  duodenal	  enterocytes	  
Transferrin	  receptor	  	  
(Tfr1	  and	  Tfr2)	  
Mediates	  the	  endocytosis	  of	  holo-­‐transferrin	  	  
Ferrireductase	  STEAP3	   Reduces	  Fe3+	  within	  the	  acidified	  endosome	  to	  facilitate	  iron	  
release	  from	  transferrin	  
Ferroportin	  	   Transports	   iron	   out	   of	   enterocytes	   and	   macrophages	   and	  
into	  the	  plasma	  
Heme	  oxygenase	  (HO-­‐1	  
and	  HO-­‐2)	  
Degrades	   intracellular	   heme	   to	   biliverdin,	   releasing	   carbon	  
monoxide	  and	  iron	  
Biliverdin	  reductase	   Catalyzes	  the	  conversion	  of	  biliverdin	  to	  bilirubin	  
Hephaestin	   Oxidizes	   Fe2+	   to	   Fe3+	   at	   the	   enterocyte	   plasma	   membrane	  
allowing	  for	  sequestration	  by	  transferrin	  (also	  performed	  by	  
circulating	  ceruloplasmin)	  
Nramp1	   Transports	   iron	   (and	   other	   divalent	   metals)	   out	   of	  
phagosomal	   compartment,	   thus	   limiting	   availability	   to	  
intracellular	   pathogens;	   contributes	   to	   the	   acidification	   of	  
the	  phagosome;	  enhances	  NGAL	  expression	  
Regulatory	  hormone	  
Hepcidin	   Binds	   ferroportin	   on	   enterocytes	   and	  macrophages	   leading	  
to	   its	   internalization	   and	   degradation;	   mediates	   the	  
“hypoferremia	   of	   infection”	   by	   limiting	   iron	   release	   from	  
macrophages	  in	  response	  to	  inflammation	  
Intracellular	  iron	  storage	  	  
Ferritin	   Provides	  intracellular	  iron	  storage	  
Extracellular	  iron	  carriers	  





Table	  1.1.	  Continued.	  
Component	   Function	  
Extracellular	  iron	  carriers	  cont’d.	  
Lactoferrin	   Sequesters	  and	  transports	  free	  Fe3+	  at	  mucosal	  surfaces	  
and	   in	   secretions;	   released	   from	  neutrophil	   secondary	  
granules	  at	  sites	  of	  inflammation	  
Haptoglobin	   Scavenges	  free	  extracellular	  hemoglobin	  released	  upon	  
erythrocyte	   lysis;	   haptoglobin-­‐hemoglobin	   complexes	  
are	  endocytosed	  and	  metabolized	  by	  macrophages	  
Hemopexin	   Scavenges	   free	   extracellular	   heme	   released	   upon	  
erythrocyte	   lysis;	   heme-­‐hemopexin	   complexes	   are	  
endocytosed	  and	  metabolized	  by	  macrophages	  
Serum	  albumin	   Abundant	   plasma	   protein;	   binds	   free	   heme	   released	  
into	   the	   bloodstream	   (particularly	   after	   acute	  
hemolysis),	  and	  gradually	  transfers	  it	  to	  hemopexin	  
Neutrophil	   gelatinase	   -­‐
associated	   lipocalin	   (NGAL;	  
aka	   siderocalin,	   lipocalin	   2,	  
and	  24p3)	  
Sequesters	   catecholate	   bacterial	   siderophores;	   serum	  
concentrations	   are	   increased	   in	   response	   to	   bacterial	  
infection	  
2,5	  -­‐	  dihydroxybenzoic	  acid	   Functions	  as	  a	  mammalian	  siderophore-­‐like	  molecule	  to	  
sequester	   extracellular	   iron	   (may	   itself	   be	   used	   as	   a	  
bacterial	  iron	  source)	  	  
aHost	   iron	   homeostasis	   and	   nutritional	   immunity	   have	   been	   extensively	   summarized	  
elsewhere;	  for	  a	  comprehensive	  discussion,	  the	  readers	  are	  referred	  to	  recent	  reviews	  
by	   Cassat	   and	   Skaar	   (17)	   and	   Nairz	   et	   al.	   (18)	   and	   the	   references	   therein.	   Applicable	  
references	  may	  also	  be	  found	  in	  the	  text.	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free	   heme	   and	  Hb	   to	   harmful	   levels.	   Free	   Hb	   is	   thus	   scavenged	   by	   haptoglobin	   (Hp),	  
whereas	   serum	   albumin	   aids	   in	   the	   transfer	   to	   and	   sequestration	   of	   free	   heme	   by	  
hemopexin	   (Hx).	   Through	   receptor-­‐mediated	   endocytosis,	   Hb-­‐Hp	   and	   heme-­‐Hx	   are	  
taken	  up	  by	  macrophages	  or	  hepatocytes	  and	  iron	  released	  from	  these	  complexes	  can	  
either	  be	  stored	  or	  returned	  to	  the	  iron	  cycle.	  	  
Dietary	   iron	  is	  taken	  up	  in	  the	  duodenum	  as	  either	   intact	  heme-­‐iron,	  or	  as	  free	  
Fe2+	   by	   heme	   carrier	   protein-­‐1	   (HCP-­‐1)	   or	   divalent	   metal	   transporter-­‐1	   (DMT-­‐1),	  
respectively,	  both	  of	  which	  are	   localized	  on	   the	  apical	   surface	  of	  enterocytes	   (19–21).	  
Prior	  to	  uptake,	  Fe3+	  is	  reduced	  to	  Fe2+	  by	  ferrireductase,	  whereas	  heme	  is	  degraded	  to	  
release	  Fe2+	  by	  a	  heme	  oxygenase	  (HO-­‐1	  or	  HO-­‐2)	  upon	  uptake	  (22,	  23).	  Fe2+	  within	  the	  
enterocyte	  faces	  three	  potential	  fates;	  1)	  utilization	  in	  cellular	  processes	  such	  as	  heme	  
biosynthesis	   or	   incorporation	   into	   iron-­‐sulphur	   clusters,	   2)	   sequestration	   in	   the	  
multimeric,	  iron-­‐storage	  protein,	  ferritin,	  or	  3)	  release	  from	  the	  cell	  by	  the	  Fe2+	  exporter,	  
ferroportin	   (Fp)	   (For	   review	   see	   17).	   As	   the	   sole	   identified	   cellular	   iron	   exporter	   in	  
mammals,	   Fp	   plays	   a	   crucial	   role	   in	   iron	   homeostasis,	   functioning	   to	   mobilize	   iron	  
primarily	   from	   enterocytes	   and	   macrophages	   (24).	   Upon	   efflux,	   Fe2+	   is	   oxidized	   by	  
hephaestin	  on	  the	  basolateral	  surface	  of	  enterocytes,	  or	  ceruloplasmin	  on	  non-­‐intestinal	  
cells	  and	  within	   the	  plasma,	   thus	  permitting	   the	   iron-­‐loading	  of	   transferrin,	  which	  has	  
poor	  affinity	  for	  Fe2+	  (25).	  
1.2.2. Iron-­‐withholding	  as	  a	  facet	  of	  innate	  immunity	  	  
1.2.2.1. Transferrin	  and	  lactoferrin	  –	  control	  of	  extracellular	  free	  iron	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The	  transferrins	  are	  a	  family	  of	  high-­‐affinity	  Fe3+-­‐binding	  eukaryotic	  glycoproteins,	  which	  
function	   in	   controlling	   the	   availability	   of	   free	   iron	   in	   blood	   and	   bodily	   fluids.	   Serum	  
transferrin	  (Tf)	  mediates	  iron	  uptake	  from	  sites	  of	  absorption	  and	  storage,	  and	  shuttles	  
it	  safely	  to	  sites	  of	  utilization.	  Upon	  delivery	  to	  the	  target	  cell,	  iron-­‐loaded	  Tf	  (holo-­‐Tf)	  is	  
internalized	  by	  endocytosis,	  mediated	  by	  its	  binding	  to	  a	  high-­‐affinity	  Tf	  receptor	  (TfR1	  
or	   TfR2).	   The	   endosome	   is	   acidified	   through	   the	   action	   of	   the	   natural	   resistance-­‐
associated	  macrophage	   protein	   1	   (Nramp1),	   which	   facilitates	   release	   of	   Fe3+	   from	   Tf.	  
Fe3+	   is	   reduced	   to	   Fe2+,	   catalyzed	   by	   the	   ferrireductase	   STEAP3	   (six	   transmembrane	  
epithelial	  antigen	  of	  the	  prostate	  family	  protein	  3),	  and	  exported	  to	  the	  cytosol	  by	  DMT-­‐
1	  (26,	  27).	  Tf	  is	  thus	  invaluable	  to	  host	  iron	  homeostasis	  and	  nutritional	  immunity,	  as	  it	  
serves	  both	   as	   a	   carrier	   and	   as	   a	   scavenger	  of	   free	   iron	  within	   the	  bloodstream,	   thus	  
limiting	   its	   availability	   to	   invading	   pathogens	   (5).	   Whilst	   not	   responsible	   for	   iron	  
transport,	  lactoferrin	  (Lf)	  also	  functions	  in	  innate	  immunity	  by	  maintaining	  bacteriostatic	  
concentrations	  of	  iron	  in	  secretions	  such	  as	  saliva,	  tears,	  mucous,	  and	  milk.	  Further,	  Lf	  is	  
found	   in	   the	   secondary	   granules	   of	   neutrophils,	   and	   degranulation	   in	   response	   to	  
inflammation	   leads	   to	   the	   localized	   release	   of	   Lf	   at	   infectious	   foci,	   and	   a	   further	  
reduction	   in	  available	   iron	   (28).	  While	  both	  Tf	  and	  Lf	  possess	   two	  high-­‐affinity	  binding	  
sites	  for	  Fe3+,	  and	  negligible	  affinity	  for	  Fe2+,	  Lf	  is	  distinct	  from	  Tf	  in	  that	  it	  releases	  iron	  
at	  a	  much	  lower	  pH	  (pH	  3.0	  versus	  5.5,	  respectively),	  thus	  rendering	  it	  a	  useful	  chelator	  
in	  various	  host	  niches.	   (29).	  Both	  glycoproteins	  reversibly	  bind	  Fe3+	  with	  a	  dissociation	  
constant	  as	  high	  as	  1023	  M-­‐1	  at	  physiological	  pH	  (30),	   thus,	  as	  discussed	   in	  subsequent	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sections,	  bacteria	  require	  high-­‐affinity	  acquisition	  systems	  to	  exploit	  Tf	  and/or	  Lf	  as	  iron	  
sources	  within	  the	  host.	  
1.2.2.2. Hepcidin	  –	  modulator	  of	  the	  hypoferremia	  of	  infection	  
In	   addition	   to	  Tf	   and	   Lf,	   sophisticated	  and	  dynamic	  processes	  exist	  within	   the	  host	   to	  
directly	   counter	   infection	   through	   iron-­‐withholding.	   Much	   of	   this	   response	   is	  
orchestrated	   by	   the	   iron-­‐regulatory	   peptide	   hormone,	   hepcidin,	   which	   is	   secreted	   by	  
hepatocytes	  and	  regulates	  the	  internalization	  and	  degradation	  of	  Fp	  by	  enterocytes	  and	  
macrophages	   (31).	   The	   release	   of	   hepcidin	   occurs	   primarily	   in	   response	   to	   excess	  
extracellular	   iron,	  or	   as	  part	  of	   the	   inflammatory	   response,	  which	   in	   the	   latter	   case	   is	  
stimulated	  by	  the	  production	  of	  pro-­‐inflammatory	  cytokines	  such	  as	  interleukin-­‐6	  (IL-­‐6)	  
(32).	   With	   the	   degradation	   of	   Fp,	   dietary	   iron	   uptake	   is	   halted,	   iron	   release	   from	  
macrophages	   is	   significantly	   reduced,	   and	   iron	   is	   stored	   intracellularly.	   Overall,	   this	  
process	  may	  result	  in	  a	  decrease	  in	  serum	  Tf	  levels	  by	  as	  much	  as	  30	  percent,	  and	  when	  
triggered	  by	  invading	  microbes,	  is	  referred	  to	  as	  the	  “hypoferremia	  of	  infection”	  (33).	  	  
1.2.2.3. Nrf2	  and	  Nramp1	  –	  control	  of	  iron	  availability	  to	  intracellular	  pathogens	  
While	  beneficial	   in	  controlling	  growth	  of	  extracellular	  pathogens,	  sequestration	  of	   iron	  
within	   the	   macrophage	   could	   inadvertently	   enhance	   the	   availability	   of	   this	   essential	  
nutrient	  to	  intracellular	  pathogens.	  Fortunately,	  the	  hepcidin-­‐dependent	  degradation	  of	  
Fp	   in	   response	   to	   inflammation	   may	   be	   offset	   by	   enhanced	   transcription	   of	   the	   Fp-­‐
encoding	   gene,	   SLC40A1,	   in	   the	   presence	   of	   intracellular	   pathogens.	   In	   a	   recently	  
developed	  model,	  bacteria	  such	  as	  Salmonella	  typhimurium	   induce	  production	  of	  nitric	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oxide	  (NO)	  within	  the	  macrophage	  through	  an	  inducible	  nitric	  oxide	  synthase	  (iNOS).	  NO	  
interacts	   with	   a	   redox-­‐sensitive	   host	   transcription	   factor,	   nuclear	   factor	   erythroid	   2	  
(Nfr2),	  which	  in	  turn	  enhances	  transcription	  of	  SLC40A1 (34,	  35).	  The	  localized	  induction	  
of	   Fp	   expression	   could	   enhance	   the	   ability	   of	   infected	   macrophages	   to	   combat	  
intracellular	  infections	  by	  depleting	  cellular	  iron	  stores	  that	  otherwise	  may	  promote	  the	  
growth	   of	   internalized	   microorganisms.	   Additionally,	   for	   bacteria	   residing	   within	  
membrane-­‐bound	   vacuoles	   or	   phagosomes,	   expression	   of	  Nramp1	  promotes	   efflux	   of	  
cations,	   such	  as	   Fe2+,	   from	   the	  phagosomal	   lumen,	   further	   reducing	   the	  availability	  of	  
intracellular	   iron	   to	   these	   invading	   pathogens	   (36–38).	   Indeed,	   humans	   with	  
polymorphisms	   in	   the	   gene	   encoding	   Nramp1	   (SCL11A1)	   have	   an	   increased	   risk	   of	  
infection	  by	  intracellular	  pathogens,	  such	  as	  Mycobacterium	  tuberculosis	  (39,	  40).	   
1.2.2.4. NGAL	  and	  2,5-­‐DHBA	  –	  a	  siderophore-­‐binding	  protein	  and	  a	  mammalian	  
siderophore	  
In	   addition	   to	   its	   pleiotropic	   effects	   on	  macrophage	   function,	   Nramp1	   also	   promotes	  
expression	   of	   neutrophil	   gelatinase-­‐associated	   lipocalin	   (NGAL;	   also	   known	   as	  
siderocalin,	   lipocalin	   2,	   and	   24p3),	   an	   acute	   phase	   protein	   secreted	   primarily	   by	  
neutrophils	  that	  scavenges	  catechol-­‐type	  siderophores	  produced	  by	  bacteria	  (41,	  42,	  43,	  
and	   see	   section	   1.3.5.2).	   Indeed,	   NGAL	   binds	   enterobactin,	   a	   siderophore	   widely	  
synthesized	   by	   the	   Enterobacteriaceae,	   and	   NGAL-­‐deficient	   (NGAL-­‐/-­‐)	   mice	   are	  
hypersusceptible	  to	  Gram-­‐negative	  bacterial	  infections	  (41).	  Despite	  lacking	  an	  intrinsic	  
ability	  to	  bind	   iron,	  NGAL	  actually	  appears	  to	  function	  primarily	   in	  the	  maintenance	  of	  
extracellular	  and	  intracellular	  iron	  concentrations	  within	  the	  host.	  The	  transport	  of	  iron	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by	  NGAL	  is	  purportedly	  aided	  by	  the	  mammalian	  siderophore,	  2,5-­‐dihydroxybenzoic	  acid	  
(2,5-­‐DHBA),	   which	   is	   structurally	   similar	   to	   the	   2,3-­‐DHBA	   iron-­‐binding	   moiety	   of	  
enterobactin	  (44,	  45).	  2,5-­‐DHBA	  likely	  serves	  to	  scavenge	  free	  iron	  and,	  when	  bound	  to	  
NGAL,	  may	  effectively	  be	  shuttled	  across	  cellular	  membranes	  (44).	  Notably,	  2,5-­‐DHBA	  is	  
capable	  of	  promoting	  growth	  of	  Escherichia	  coli	   in	  a	  mammalian	  model,	  therefore	   it	   is	  
not	   surprising	   that	   synthesis	   of	   2,5-­‐DHBA	   is	   downregulated	   during	   infection,	   freeing	  
NGAL	  to	  bind	  to	  bacterial	  siderophores	  (44).	  
1.2.3. Perturbations	   of	   iron	   homeostasis	   influencing	   susceptibility	   to	   infectious	  
disease	  	  
Although	  iron	  homeostasis	   is	  stringently	  controlled,	  many	  hereditary	  disease	  states,	  as	  
well	   as	   excess	   exposure	   to	   the	   element,	   can	   result	   in	   an	   imbalance	   in	   iron	   levels,	  
impacting	  both	  overall	  health	  of	  the	  host	  and	  susceptibility	  to	  infectious	  disease	  (Table	  
1.2).	  The	  most	  common	  genetic	  disease	   influencing	  host	   iron	  metabolism	  is	  hereditary	  
hemochromatosis	   (HH),	   largely	   caused	   by	   defects	   to	   the	   gene	   encoding	   human	  
hemochromatosis	  protein,	  HFE	  (for	  high	  Fe).	  Although	  the	  exact	  molecular	  mechanisms	  
governing	   HH	   are	   still	   unclear,	   recent	   insights	   suggest	   that	   HFE	   is	   involved	   in	   iron-­‐
sensing	  and	  the	  regulation	  of	  hepcidin	  production	  (46).	  HFE	  is	  thought	  to	  participate	  in	  
the	  formation	  of	  an	  iron-­‐sensing	  complex,	  which	  in	  the	  presence	  of	  high	  levels	  of	  holo-­‐Tf	  
activates	   a	   signal	   cascade	   promoting	   transcription	   of	   the	   gene	   encoding	   hepcidin	  
(HAMP)	   (47).	   Deactivation	   of	   this	   regulatory	   complex	   and/or	   cascade	   results	   in	  
inadequate	  production	  of	  hepcidin,	  leading	  to	  excessive	  intestinal	  iron	  absorption	  and	  	  
	  	  
12	  
Table	  1.2.	  Examples	  of	  diseases	  and	  conditions	  compromising	  iron	  homeostasis	  within	  
the	  host	  and	  associated	  infectious	  diseases.	  	  
Disease	  or	  
condition	  
Effects	  on	  iron	  metabolism	   Examples	   of	  





Partial	   or	   complete	   hepcidin	  
deficiency	   leading	   to	   excess	  
dietary	   iron	   absorption	   and	  
recycling	  
Vibrio	   vulnificus,	  
Yersinia	   enterocolitica,	  






Reduced	   or	   absent	   Tf	  
production	  due	  to	  defects	   in	  Tf-­‐
encoding	   gene	   (or	   nutritional	  
deficiency,	   e.g.	   kwashiorkor)	  
leading	   to	   iron	   overload,	   Tf-­‐
saturation,	   and	   decreased	  
erythropoiesis	  
Pneumonia	   and	   other	  
acute	   bacterial	  
infections	   of	   undefined	  
etiology,	   infections	  
associated	   with	  
transfusional	   iron	  
overload	   or	   iron	  
chelation	  therapy	  	  
(50–55)	  
See	  below	  
Aceruloplasminemia	   Mutation	   to	   the	   gene	   encoding	  
ceruloplasmin	   yielding	   an	  
unstable	   or	   non-­‐functional	  
protein	   and	   resulting	   in	  
impaired	  iron	  transport	  out	  cells	  
of	  the	  central	  nervous	  system	  
Potentially	   those	  
associated	   with	   iron	  




Consumption	   of	   excess	   iron	  
leads	  to	  increased	  serum	  ferritin	  
and	  Tf-­‐saturation	  	  
Active	   Mycobacterium	  





Excess	   iron	   in	   the	   bloodstream	  
due	   to	   repeated	   blood	  
transfusions	   often	   as	   treatment	  
for	   β-­‐thalassemia	   or	   sickle	   cell	  
anemia	  	  
Klebsiella	   spp.,	   Yersinia	  





Inhalation	   of	   iron	   through	  
occupational	   exposure	   or	  
cigarette	   smoking	   results	   in	  
increased	   iron	   in	   lungs/alveolar	  
macrophages	  
Acinetobacter	  






Used	   in	   the	   treatment	   of	   iron	  
overload	  diseases,	   however	   this	  
derivative	   of	   a	   microbial	  
siderophore	   can	   be	   used	   as	   an	  
iron	  source	  by	  some	  pathogens	  
Yersinia	   spp.,	   Klebsiella	  
spp.,	   Rhizopus	   oryzae,	  





recycling	   (67).	   The	   net	   result	   of	   the	   aforementioned	   dysregulation	   is	   abnormally	   high	  
levels	   of	   free	   iron	   within	   the	   body,	   broadly	   referred	   to	   as	   iron	   overload.	   Other	   less	  
common	   hereditary	   iron	   overload	   diseases	   are	   principally	   associated	   with	   genetic	  
defects	   in	   the	   genes	   encoding	   ceruloplasmin	   (CP)	   and	   transferrin	   (TF),	   resulting	   in	  
aceruloplasminemia	   and	   atransferrinemia/hypotransferrinemia,	   respectively	   (68).	   The	  
absence	   of	   ceruloplasmin	   impairs	   the	   ability	   of	   Fp	   to	   export	   iron	   in	   cells	   lacking	   an	  
alternate	   ferroxidase	   (e.g.	   hephaestin),	   as	   is	   the	   case	   with	   astrocytes	   of	   the	   central	  
nervous	   system,	   leading	   to	   iron	   accumulation	   in	   the	   brain	   and	   progressive	  
neurodegeneration	  (69).	  Reduced	  or	  absent	  serum	  Tf	  similarly	  impairs	  the	  trafficking	  of	  
iron	   throughout	   the	  body,	  as	  well	   as	   the	  production	  of	  hepcidin	   (as	  discussed	  above),	  
leading	   to	   accretion	   primarily	   within	   the	   liver	   and	   heart.	   Further,	   inadequate	   iron	  
delivery	   to	   hematopoietic	   cells	   in	   the	   bone	   marrow	   by	   Tf	   results	   in	   decreased	   Hb	  
availability	  and	  causes	  microcytic,	  hypochromic	  anemia	  (70).	  The	  symptoms	  of	  HH	  and	  
aceruloplasminemia	   are	   most	   effectively	   delayed	   or	   reduced	   through	   phlebotomy	  
and/or	   chelation	   therapy	   (47,	   71),	   while	   atransferrinemia/hypotransferrinemia	   is	  
managed	  primarily	  through	  transfusion	  of	  whole	  blood	  or	  purified	  apo-­‐Tf	  (55).	  	  
	   Not	  only	  do	  diseases	  impacting	  host	  iron	  homeostasis	  enhance	  the	  risk	  of	  severe	  
and	   invasive	   infections,	   but	   oftentimes	   so	   do	   their	   clinical	   interventions	   (Table	   1.2).	  
Indeed,	  whilst	  thalassemia	  and	  sickle	  cell	  disease	  (SCD)	  can	  result	  in	  iron	  overload,	  it	  is	  
often	  the	  treatment	  for	  these	  conditions	  that	  leads	  to	  hyperferremia.	  Both	  thalassemia	  
and	   SCD	   are	   characterized	   by	   the	   abnormal	   formation	   of	   adult	   Hb	   (HbA),	   a	  
heterotetramer	   comprised	   of	   two	   α-­‐globin	   subunits	   and	   two	   β-­‐globin	   subunits.	   In	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thalassemia,	  genetic	  defects	  can	  impact	  the	  synthesis	  of	  either	  of	  the	  globin	  subunits	  (α-­‐
thalassemia	   versus	   β-­‐thalassemia),	   resulting	   in	   ineffective	   erythropoiesis	   and	  
accelerated	   hemolysis	   of	   existing	   erythrocytes	   (72).	   SCD	   is	   due	   specifically	   to	   a	   single	  
amino	   acid	   change	   in	   the	   β-­‐globin	   subunit,	  which	   results	   in	   the	   polymerization	   of	   Hb	  
tetramers	   into	   rigid	   fibers	  and	  gives	   rise	   to	   the	  sickle-­‐shaped	  erythrocytes	   from	  which	  
the	   disorder	   derives	   its	   name	   (73,	   74).	   Sickle	   cells	   are	   inherently	   fragile	   and	   their	  
instability	   contributes	   to	   the	   development	   of	   hemolytic	   anemia.	   As	  with	   thalassemia,	  
the	  symptoms	  of	  SCD	  may	  be	  treated	  with	  frequent	  blood	  transfusions,	  which	  enhances	  
the	  risk	  not	  only	  of	   iron	  overload,	  but	  also	  the	  frequency	  and	  severity	  of	  bacterial	  and	  
fungal	  infections.	  	  
In	  an	  effort	  to	  combat	  iron	  overload	  from	  any	  of	  the	  aforementioned	  disorders,	  
treatment	   may	   include	   phlebotomy	   or	   iron	   chelation	   therapy.	   Among	   the	   chelators	  
commonly	   employed	   in	   iron	   overload	   is	   deferoxamine	   (DFO),	   the	   mesylate	   salt	  
derivative	  of	  the	  microbial	  siderophore	  desferrioxamine	  B	  (71,	  75).	  As	  described	  in	  detail	  
in	   subsequent	   sections,	   siderophores	   are	   low	   molecular	   weight,	   high-­‐affinity	   iron-­‐
binding	   compounds,	   and	   despite	   the	   clinical	   advantages	   of	   DFO	   being	   a	   strong	   and	  
effective	  chelator	  in	  many	  cases	  of	  iron	  overload,	  the	  risk	  of	  infection	  in	  these	  patients	  is	  
further	  confounded	  by	  the	  fact	  that	  this	  siderophore	  may	  be	  used	  as	  an	  iron	  source	  by	  
various	   pathogenic	   or	   opportunistically	   pathogenic	   microorganisms	   (64–66).	   The	  
treatment	   of	   iron	   overload	   diseases	   is	   thus	   a	   delicate	   balancing	   act	   in	   attempting	   to	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Even	  within	  the	  healthy	  host,	  microbes	  that	  scavenge	  enough	  iron	  have	  the	  potential	  to	  
cause	  infection.	  The	  paucity	  of	  available	  iron	  within	  the	  host	  has	  ultimately	  instigated	  an	  
evolutionary	  war	   between	   hosts	   and	   pathogens,	   where	   successful	   invaders	   express	   a	  
diverse	  complement	  of	  mechanisms	  for	  exploiting	  the	  host	  iron	  pool	  and	  circumventing	  
nutritional	  immunity.	  In	  effect,	  for	  every	  mechanism	  employed	  by	  the	  host	  to	  sequester	  
iron,	   bacterial	   pathogens	   have	   evolved	   means	   to	   evade	   this	   withholding	   strategy.	  
Accordingly,	  a	  diverse	  array	  of	   iron	  acquisition	  strategies	  exist	  amongst	  Gram-­‐negative	  
and	   Gram-­‐positive	   pathogens,	   some	   of	   which	   are	   highly	   conserved	   and	   widely	  
employed,	  and	  others	  are	  highly	  specific	  and	  intricately	  linked	  to	  the	  pathophysiology	  of	  
a	  given	  bacterium.	  Broadly,	  and	  as	  summarized	   in	  Figure	  1.1,	   the	  mechanisms	  for	   iron	  
uptake	  by	  pathogenic	  bacteria	  include:	  i)	  the	  extraction	  and	  capture	  of	  heme-­‐iron	  from	  
host	  hemoproteins	  through	  the	  use	  of	  secreted	  proteins	  (hemophores)	  or	  cell	  surface-­‐
associated	  receptors,	  ii)	  the	  acquisition	  of	  Tf	  and	  Lf-­‐bound	  iron	  through	  specific	  surface-­‐
associated	  binding	  proteins	  or	  the	  secretion	  of	  siderophores,	  and	  iii)	  the	  uptake	  of	  free	  
inorganic	   iron	   facilitated	   by	   Fe3+	   reductases	   and	   associated	   Fe2+	   permeases.	   In	   the	  
subsequent	  sections,	   the	  general	   strategies	   for	   iron	  acquisition	  by	  bacterial	  pathogens	  
are	  outlined,	  followed	  by	  a	  detailed	  discussion	  on	  the	  mechanisms	  that	  are	  employed	  by	  
the	   infamous	  Gram-­‐positive	   pathogen,	  Staphylococcus	   aureus,	   to	   obtain	   this	   essential	  
nutrient	   and	   maintain	   iron	   homeostasis	   within	   the	   host.	   For	   further	   details	   on	   iron	  
acquisition	   in	   other	   bacterial	   pathogens,	   the	   reader	   is	   referred	   to	   several	   recent	  







Figure	  1.1.	  The	  host	  versus	  pathogen	  battle	  for	  iron.	  	  
Cartoon	  representation	  of	  the	  various	  strategies	  used	  by	  the	  host	  to	  sequester	  iron	  from	  
invading	  pathogens	  and	  the	  counterstrategies	  used	  by	  pathogens	  to	  obtain	  host	  iron.	  On	  
mucosal	  surfaces,	  Lf	  sequesters	  iron	  yet	  bacteria	  can	  obtain	  iron	  from	  this	  glycoprptoein	  
by	   secreting	   siderophores	   (i-­‐iii),	   or	   by	   secreting	   reductases	   (pink	  pill)	   that	   reduce	   iron	  
from	  Fe(III)	  to	  Fe(II),	  releasing	  it	  from	  Lf	  (v-­‐viii).	  Bacteria	  can	  obtain	  iron	  bound	  to	  heme	  
by	   secreting	  hemolysins,	  which	   release	   intracellular	  Hb	  and	  Hm	   into	   the	  blood.	  While	  
the	  host	  uses	  Hb	  and	  Hm	  scavenging	  proteins	  to	  sequester	  these	  iron	  sources,	  bacteria	  
have	  mechanisms	   to	   counter	   these	   systems	   (1-­‐12).	  Macrophages	  move	   iron	   from	   the	  
phagosome	  and	  the	  cell	  using	  Nramp1	  and	  ferroportin,	  respectively,	  to	  keep	  iron	  from	  
intracellular	   pathogens.	   In	   response	   to	   binding	   by	   the	   iron	   homeostasis	   hormone	  
hepcidin,	   membrane-­‐bound	   ferroportin	   is	   degraded,	   thus	   withholding	   iron	   in	  
intracellular	   compartments.	   Fe(II)	   that	   is	   secreted	   is	   rapidly	   oxidized	  by	   ceruloplasmin	  
(Cp),	   and	   the	   Fe(III)	   is	   quickly	   picked	   up	   by	   Tf	   (a-­‐b).	   Tf-­‐bound	   iron	   is	   scavenged	   by	  
bacteria	  using	  Tf-­‐binding	  proteins	  (c)	  or	  through	  secretion	  of	  siderophores	  (d-­‐f).	  Bacteria	  
can	   also	   obtain	   iron	   using	   the	   mammalian	   siderophore	   2,5-­‐DHBA	   (g).	   Neutrophils	  
secrete	  NGAL	   (aka	   siderocalin,	   lipocalin	   2,	   or	   24p3)	   (I),	  which	   serves	   to	   capture	   some	  
bacterial	  siderophores	  (II,	  III).	  Some	  bacteria	  synthesize	  and	  secrete	  stealth	  siderophores	  
that	   are	   not	   bound	   by	   NGAL	   and	   can	   remove	   Tf-­‐bound	   iron	   even	   in	   the	   presence	   of	  
NGAL	   (IV-­‐VI).	   Lf,	   lactoferrin;	   Tf,	   transferrin;	   sid,	   siderophore;	   Hp,	   haptoglobin;	   Hx,	  






1.3.1. Coordinated	  regulation	  of	  iron	  acquisition	  and	  virulence	  gene	  expression	  
Iron,	  or	   lack	  thereof,	   is	  a	  fundamental	  sensory	  cue	  in	  bacterial	  pathogens,	  and	  triggers	  
the	  coordinated	  regulation	  of	  genes	  involved	  in	  both	  iron	  acquisition	  and	  virulence.	  The	  
response	  to	  iron	  deprivation	  in	  prokaryotes	  is	  largely	  controlled	  by	  two	  separate	  families	  
of	   highly	   conserved,	   iron-­‐responsive	   regulators	   that	   repress	   transcription	   of	   iron	  
acquisition	  genes	  when	  the	  concentration	  of	  intracellular	  iron	  is	  high,	  and	  alleviate	  this	  
repression	  when	   iron	   is	   limiting.	   In	  Gram-­‐negative	   bacteria,	   and	   the	   low	   guanine	   and	  
cytosine	   (G+C)	  content	  Gram-­‐positive	  Firmicutes,	   such	  as	  Staphylococcus	  spp.,	  Bacillus	  
spp,	   and	   Listeria	   monocytogenes,	   iron	   homeostasis	   is	   controlled	   by	   members	   of	   the	  
ferric	   uptake	   regulator	   (Fur)	   superfamily	   (79).	   The	   high	   G+C	   content	   Gram-­‐positive	  
Actinobacteria,	   Corynebacterium	   diphtheriae	   and	   Mycobacterium	   spp.,	   utilize	   an	  
alternate	   iron-­‐responsive	   regulator,	   the	   diphtheria	   toxin	   repressor	   (DtxR;	   IdeR	   in	   the	  
Mycobacteriaceae),	   to	   regulate	   both	   iron	   uptake	   and	   virulence	   gene	   expression	   (80).	  
Notably,	  whilst	  little	  primary	  sequence	  similarity	  exists	  between	  members	  of	  these	  two	  
families,	  Fur	  and	  DtxR-­‐like	  proteins	  possess	  similar	  domain	  architecture,	  and	  function	  in	  
a	  comparable	  manner.	  In	  brief,	  both	  Fur	  and	  DtxR	  are	  homodimeric	  metalloregulators,	  
bearing	  an	  N-­‐terminal	  helix-­‐turn-­‐helix	  DNA-­‐binding	  domain,	  and	  a	  C-­‐terminal	  metal	  co-­‐
repressor	   binding	   site	   that	   also	   functions	   in	   dimerization	   of	   the	   protein	   (79,	   81).	  
Coordination	   of	   Fe2+	   within	   each	   protein	   subunit	   induces	   a	   conformational	   change	  
rendering	   the	   iron-­‐loaded	   repressor	   proficient	   for	   DNA	   binding,	   which	   occurs	   at	   a	  
consensus	  sequence	  located	  within	  the	  promoter/operator	  region	  of	  the	  targeted	  gene	  
(79,	   82–84).	   Association	   of	   Fur-­‐Fe2+	   or	  DtxR-­‐Fe2+	  with	   the	   operator	   of	   iron-­‐responsive	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genes	   effectively	   bars	   RNA	  polymerase	   from	  binding	   the	   promoter,	   thereby	   inhibiting	  
transcription	  under	   iron-­‐replete	  conditions.	  When	   intracellular	   iron	  concentrations	  are	  
low,	  the	  metal	  is	  no	  longer	  readily	  available	  to	  interact	  with	  the	  repressor,	  the	  complex	  
dissociates	  from	  DNA,	  and	  transcription	  proceeds	  (82,	  85).	  	  
	   The	  overwhelming	  majority	  of	   iron	  acquisition	  strategies	  employed	  by	  bacterial	  
pathogens,	  as	  discussed	  below,	  are	  at	  least	  partially	  regulated	  by	  members	  of	  the	  Fur	  or	  
DtxR	  superfamilies.	  In	  addition	  to	  their	  role	  in	  iron	  acquisition,	  Fur	  and	  DtxR	  both	  play	  a	  
key	  role	  in	  virulence,	  and	  have	  been	  shown	  to	  directly	  or	   indirectly	  (e.g.	  through	  small	  
Fur/DtxR-­‐regulated	   RNAs)	   control	   the	   expression	   of	   factors	   contributing	   to	  
pathogenicity,	   including	   the	   secretion	   of	   toxins,	   production	   of	   adhesins,	   formation	   of	  
biofilms,	  and	  regulation	  of	  quorum	  sensing	  (86,	  87).	  Indeed,	  DtxR	  was	  initially	  identified,	  
as	   its	   name	   implies,	   as	   an	   iron-­‐dependent	   negative	   regulator	   of	   diphtheria	   toxin	  
production	   in	   C.	   diphtheriae	   (83,	   88).	   Further,	   both	   Fur	   and	   DtxR	   have	   been	  
demonstrated,	   through	   relevant	   in	   vivo	  models,	   to	   influence	   the	   colonization,	   survival	  
and/or	  proliferation	  of	  numerous	  bacterial	  pathogens	  within	  the	  host	  including,	  but	  not	  
limited	   to,	   S.	   aureus,	  Helicobacter	   pylori,	  Haemophilus	   influenzae,	   L.	   monocytogenes,	  
Campylobacter	   jejuni,	   Vibrio	   cholerae,	   and	  M.	   tuberculosis	   (For	   reviews	   see	   87,	   89).	  
Although	  the	  role	  of	  these	  metalloregulatory	  proteins	   in	  vivo	   is	  no	  doubt	  complex	  and	  
multifactorial,	  it	  appears	  to	  reflect	  a	  common	  strategy	  employed	  by	  bacterial	  pathogens	  




1.3.2. General	  strategies	  for	  heme-­‐iron	  acquisition	  
While	   bacterial	   pathogens	   express	   a	   plethora	   of	   iron	   acquisition	   systems	   capable	   of	  
exploiting	   a	  multitude	  of	   host	   iron	   sources,	   heme	   represents	   a	   particularly	   auspicious	  
target,	   as	   it	   comprises	   approximately	   75	   per	   cent	   of	   the	   total	   mammalian	   iron	   pool.	  
Indeed,	  heme	   is	   a	  preferred	   iron	   source	   for	  pathogens	   such	  as	  S.	   aureus	   (90),	   and	  an	  
obligate	   requirement	   for	   heme	   auxotrophs	   including	   staphylococcal	   small	   colony	  
variants	  (SCVs)	  (91),	  Bartonella	  spp.,	  Bacteroides	  spp.,	  Porphyromonas	  gingivalis	  and	  H.	  
influenzae	   (92).	   As	   heme	   exists	   primarily	   in	   association	   with	   Hb	   within	   circulating	  
erythrocytes,	  pathogens	  have	  evolved	  sophisticated	  mechanisms	  to	  access	  heme	  from	  
intracellular	  hemoproteins.	  The	  secretion	  of	  hemolysins	  is	  a	  tactic	  commonly	  employed	  
by	   extracellular	   and	   facultative	   intracellular	   pathogens	   to	   enhance	   local	   heme	  
availability	   (Figure	   1.1).	   Indeed,	   as	   described	   above,	   the	   expression	   of	   such	   cytolytic	  
factors	  is	  often	  induced	  under	  conditions	  of	  iron	  starvation	  and	  during	  bacteremia,	  and	  
has	  long	  been	  recognized	  as	  an	  important	  multifaceted	  determinant	  of	  pathogenicity	  in	  
many	  bacteria	  (93).	  Upon	  its	  release	  from	  damaged	  erythrocytes,	  Hb,	  or	  spontaneously	  
dissociated	  heme,	  may	  then	  be	  captured	  by	  bacteria	  expressing	  specific	  secreted	  and/or	  
cell	  surface-­‐associated	  heme/Hb-­‐binding	  proteins.	  	  
1.3.3. Extracellular	  mechanisms	  of	  heme	  capture	  
In	  a	  number	  of	  bacterial	  pathogens,	  the	  acquisition	  of	  extracellular	  heme	  as	  a	  cofactor	  
or	  iron	  source	  is	  initiated	  by	  the	  synthesis	  and	  secretion	  of	  small,	  soluble,	  heme-­‐binding	  
proteins	   referred	   to	   as	   hemophores	   (94).	   Hemophores	   are	   capable	   of	   both	   capturing	  
free	  heme	  and	  appropriating	  it	  from	  various	  hemoproteins.	  Hemophore-­‐bound	  heme	  is	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subsequently	   transferred	   to	   specific	   heme-­‐binding	   receptor	   proteins	   localized	   on	   the	  
outer	  membrane	   in	  Gram-­‐negative	  bacteria,	  or	   the	  cell	  wall	   in	  Gram-­‐positive	  bacteria,	  
both	   of	  which	   help	  mediate	   uptake	   through	   the	   cell	   envelope.	   Bacterial	   hemophores	  
have	   best	   been	   characterized	   in	   Gram-­‐negative	   bacteria,	   with	   the	   paradigmatic	  
hemophore	  system	  being	  HasA	   (for	  heme	  acquisition	  system)	  and	  its	  outer	  membrane	  
receptor	   HasR	   from	   Serratia	   marcescens	   (Figure	   1.2)	   (94,	   95).	   The	   NEAT-­‐domain	   (for	  
near-­‐iron	  transporter;	  see	  section	  1.5.2.1.1	  –	  “Structure	  and	  function	  of	  NEAT	  domains”)	  
containing	   hemophores,	   IsdX1	   and	   IsdX2,	   of	   the	   Bacillus	   cereus	   group	   (including	   B.	  
anthracis,	   B.	   cereus	   and	   B.	   thuringiensis)	   represent	   the	   first	   identification	   of	  
hemophores	  in	  Gram-­‐positive	  bacteria,	  but	  are	  notably	  absent	  from	  other	  Gram-­‐positive	  
pathogens	   such	   as	   Staphylococcus	   spp.,	   Clostridium	   spp,	   and	   Streptococcus	   spp.	   (96).	  
The	  expression	  of	  hemophores	  by	  B.	  anthracis,	  in	  particular,	  may	  be	  a	  reflection	  of	  the	  
complexity	  of	   its	   cell	   surface,	  which	  possesses	  both	  an	  antiphagocytic	  protein	   capsule	  
and,	  like	  other	  bacilli,	  a	  crystalline	  protein	  array	  referred	  to	  as	  the	  S	  (surface)-­‐layer	  (97–
99).	   The	   utilization	   of	   both	   extracellular	   and	   cell	   surface-­‐associated	   heme-­‐binding	  
proteins	  may	   help	   facilitate	   the	   passage	   of	   heme	   across	   the	   fortified	  B.	   anthracis	   cell	  
envelope.	   For	   each	   hemophore	   system	   exists	   unique	   specificities	   for	  
heme/hemoproteins,	   mechanisms	   of	   heme	   extraction	   and	   binding,	   and	   methods	   of	  
heme	  transfer	  to	  associated	  cell	  surface	  receptors;	  while	  such	  particulars	  fall	  outside	  the	  
scope	  of	  this	  chapter,	  several	  detailed	  reviews	  are	  available	  on	  the	  subject	  (For	  further	  







Figure	  1.2.	  Model	  of	  iron	  uptake	  mechanisms	  in	  Gram-­‐negative	  and	  Gram-­‐positive	  
bacteria.	  	  
Shown	  are	  cartoon	  diagrams	  depicting	  the	  envelope	  proteins	  required	  for	  the	  uptake	  up	  
iron,	  or	  iron	  scavenged	  from	  siderophores,	  heme	  or	  Tf.	  This	  is	  a	  composite	  diagram	  and	  
represents	   mechanisms	   used	   by	   many	   different	   pathogenic	   bacteria.	   OM,	   outer	  
membrane;	  PG,	  peptidoglycan;	  CM,	  cytoplasmic	  membrane;	  sid,	  FeIII-­‐siderophore;	  Hm,	  
heme;	   Tf,	   transferrin;	   OMP,	   outer	   membrane	   porin;	   HO,	   heme	   oxygenase;	   Hb,	  
hemoglobin;	  Hp,	  haptoglobin.	  The	  figure	  was	  adapted	  from	  Hood	  and	  Skaar,	  2012	  (101).	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1.3.4. Heme	  capture	  at	  the	  cell	  surface	  
1.3.4.1. A	  universal	  mechanism	  for	  iron	  transport	  through	  the	  Gram-­‐negative	  cell	  
envelope	  
The	   outer	   membrane	   in	   Gram-­‐negative	   bacteria	   serves	   as	   a	   coarse	   selective	   barrier,	  
restricting	  potentially	   toxic	   compounds,	   such	  as	   antibiotics,	   from	  unfettered	  access	   to	  
the	   periplasmic	   space.	   Porins	   allow	   for	   the	   non-­‐specific	   diffusion	   of	   small	   (<	   600	  Da),	  
hydrophilic	   molecules	   and	   ions,	   including	   Fe2+	   (Figure	   1.2),	   through	   the	   outer	  
membrane,	   while	   the	   uptake	   of	   some	   nutrients,	   including	   disaccharides,	   nucleosides,	  
and	  phosphates	  occurs	   through	  facilitated	  diffusion	   (102–104).	   In	  contrast,	   the	  uptake	  
of	   larger	   molecules,	   and/or	   those	   present	   at	   exceedingly	   low	   concentrations	   in	   the	  
extracellular	  milieu	   requires	  dedicated	  high-­‐affinity,	   energy-­‐dependent	   transporters	   to	  
traverse	   the	  outer	  membrane	   (103,	  104).	   Iron	  complexes,	   such	  as	  heme,	  Tf,	  and	  most	  
siderophores	  exceed	  the	  size	  exclusion	  criteria	  for	  unimpeded	  diffusion	  across	  the	  outer	  
membrane,	  and	  thus	  the	  uptake	  of	  iron	  from	  these	  substrates	  is	  invariably	  facilitated	  by	  
iron-­‐regulated,	  TonB-­‐dependent	  outer	  membrane	  receptors	  (Figures	  1.2	  and	  1.3).	  
1.3.4.1.1. Structure,	  function,	  and	  regulation	  of	  TonB-­‐dependent	  transporters	  	  
As	   introduced	   above	   for	   hemophores,	   specific	   outer	   membrane	   receptors	   in	   Gram-­‐
negative	   bacteria	   serve	   as	   the	   recipients	   of	   heme,	   either	   through	   transfer	   from	  
hemophores,	  or	  directly	  from	  the	  external	  environment,	  whereupon	  they	  facilitate	  the	  
transport	   of	   heme,	   intact,	   into	   the	   periplasm.	   Acquisition	   of	   iron	   from	   Tf	   and	   Lf	   is	  
similarly	   mediated	   by	   specific	   TonB-­‐dependent	   transporters	   (TBDTs),	   which	   interact	  







Figure	  1.3.	  Model	  of	  TonB-­‐dependent	  transport	  in	  Gram-­‐negative	  bacteria.	  	  
Depicted	   is	   an	   iron-­‐siderophore	   complex	   (blue	   hexagon)	   entering	   through	   a	   TonB-­‐
dependent	   transporter	   (TBDT)	   in	   the	   outer	  membrane	   (OM).	   Although	   shown	   here	   is	  
the	   transport	   of	   an	   iron	   siderophore	   complex,	   iron	   and	   other	   iron	   complexes	   utilize	  
similar	   uptake	  mechanisms	   (e.g.	   FeIII,	   heme;	   see	   Figure	   1.2).	  Movement	   through	   the	  
TBDT	  requires	  an	  interaction	  of	  the	  TonB	  box	  (located	  near	  the	  N-­‐terminus	  of	  the	  TBDT	  
sequence)	  with	  the	  TonB	  protein,	  with	  the	  energy	  for	  conformational	  changes	  provided	  
by	   the	   proton	   motive	   force	   captured	   by	   the	   ExbB	   and	   ExbD	   proteins.	   Once	   in	   the	  
periplasm,	   the	   iron-­‐loaded	   siderophore	   complex	   is	   recognized	   by	   a	   substrate	   binding	  
protein,	  which	  delivers	  the	  complex	  to	  an	  ABC	  transporter	  in	  the	  cytoplasmic	  membrane	  
(CM).	  Depending	  on	  the	  particular	  system,	  iron	  is	  released	  from	  the	  siderophore	  in	  the	  
cytoplasm	  by	   either	   destruction	   of	   the	   siderophore,	   or	   by	   reduction	   on	   the	  metal	   (as	  
shown).	   Intracellular	   iron,	  via	  Fur,	  negatively	  regulates	  transcription	  of	  genes	  encoding	  
high-­‐affinity	  iron	  acquisition	  systems.	  In	  some	  TBDTs,	  an	  N-­‐terminal	  extension	  is	  present	  
to	  provide	  an	  extra	  layer	  of	  control	  of	  gene	  expression,	  in	  addition	  to	  Fur.	  This	  involves	  
an	  anti-­‐sigma	  factor	  and	  ECF	  sigma	  factor,	  allowing	  for	  gene	  expression	  in	  response	  to	  


















of	  siderophores	  or	  reductases	  as	  an	  intermediary	  (discussed	  further	  in	  the	  section	  1.3.5	  -­‐	  
“General	   strategies	   for	   transferrin-­‐iron	   acquisition”	   and	   summarized	   in	   Figure	   1.2).	  
While	  the	  vast	  majority	  of	  TBDTs	  are	  involved	  in	  the	  acquisition	  of	  iron,	  other	  substrates	  
such	  as	  vitamin	  B12,	  nickel	  complexes,	  colicins,	  phages,	  and	  carbohydrates	  may	  also	  gain	  
entry	  to	  the	  periplasmic	  space	  through	  these	  transporters	  (106).	  To	  date,	  approximately	  
50	  TBDT	   structures	  have	  been	   solved,	   alone	  and	   in	   complex	  with	   various	   ligands,	   and	  
each	  consists	  of	  a	  transmembrane-­‐spanning	  β-­‐barrel	  encircling	  an	  independently	  folded	  
N-­‐terminal	  plug	  domain	  (see	  Figure	  1.4).	  Substrate	  binding	  residues	  are	  located	  on	  the	  
exofacial	   side	  of	   the	  plug,	   lining	   the	   interior	  of	   the	  pore,	  and	  on	  extracellular	   loops	  of	  
the	   β-­‐barrel,	   and	   are	   customized	   to	   accommodate	   binding	   of	   the	   preferred	   substrate	  
(105).	   The	  N-­‐terminus	   of	   the	   pore	   domain	   also	   contains	   a	  weakly	   conserved	  motif	   of	  
approximately	  seven	  amino	  acid	  residues,	  referred	  to	  as	  the	  TonB-­‐box,	  responsible	  for	  
interacting	   with	   the	   TonB	   protein	   which	   is	   part	   of	   the	   TonB-­‐ExbB-­‐ExbD	   complex,	   as	  
described	  below.	  
	   In	  addition	  to	  the	  plug	  and	  barrel	  domains	  of	  canonical	  TBDTs,	  a	  subset	  of	  these	  
proteins,	   including	  HasR	  of	  S.	  marcescens	   (107),	   the	   ferric	  citrate	   receptor,	  FecA,	  of	  E.	  
coli	  (108),	  and	  the	  ferric	  pyoverdine	  receptor,	  FpvA,	  of	  Pseudomonas	  aeruginosa	  (Figure	  
1.4)	  (109),	  possess	  a	  third	  domain,	  localized	  within	  the	  periplasm	  and	  designated	  the	  “N-­‐
terminal	  extension,”	  or	  “signaling	  domain”	  (Figure	  1.3)	  (110–112).	  TBDTs	  bearing	  such	  a	  
domain	   are	   subject	   not	   only	   to	   regulation	   by	   Fur,	   but	   are	   also	   capable	   of	   fine-­‐tuning	  
their	  own	  expression	  through	  a	  σ/anti-­‐σ	  factor	  signaling	  cascade	  induced	  upon	  binding	  




Figure	  1.4.	  Structure	  of	  a	  representative	  TBDT.	  	  
A	  ribbon	  diagram	  of	  the	  Pseudomonas	  aeruginosa	  FpvA	  receptor,	  bound	  to	  pyoverdine.	  
The	  structure	   (PDB	  2W16)	   illustrates	  the	  22-­‐stranded	  β-­‐barrel	   (green)	  surrounding	  the	  
N-­‐terminal	   'plug'	   domain	   (yellow),	   which	   is	   attached	   to	   the	   N-­‐terminal	   extension	  
signaling	  domain	  (red).	  Pyoverdine	  bound	  to	  the	  receptor	  is	  shown	  using	  orange	  space	  
filling.	   The	   side	   and	   top	   views	   of	   the	   structure	   are	   illustrated.	   In	   the	   latter	   view,	   the	  
pyoverdine	   has	   been	   removed.	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   Briefly,	  and	   in	  general,	  an	  anti-­‐σ	  factor	   localized	  to	  the	   inner	  membrane	  serves	  
to	  sequester	  an	  associated	  and	  often	  co-­‐transcribed	  extracytoplasmic	  function	  (ECF)	  σ-­‐
factor	  under	  non-­‐activating	  conditions	  (i.e	  in	  the	  absence	  of	  substrate).	  In	  the	  presence	  
of	  a	  substrate,	  the	  N-­‐terminal	  extension	  of	  the	  TBDT	  interacts	  with	  the	  associated	  anti-­‐σ	  
factor,	  promoting	  release	  of	  the	  once-­‐bound	  σ-­‐factor	  into	  the	  cytosol.	  The	  ECF	  σ-­‐factor	  
in	  turn	  directs	  RNA	  polymerase	  to	  transcribe	  the	  operon	  encoding	  the	  transporter	  and	  
any	   accompanying	   genes	   involved	   in	   substrate	   acquisition	   (e.g.	   hemophore	   or	  
siderophore	  biosynthesis	  genes)	  (105).	  In	  this	  manner,	  a	  signal	  can	  be	  relayed	  from	  the	  
cell	  surface	  to	  the	  cytoplasm	  indicating	  the	  availability	  of	  substrates	  for	  acquisition,	  and	  
the	   bacterium	   can	   respond	   with	   commensurate	   expression	   of	   the	   cognate	   TBDT	   for	  
uptake.	  
The	  outer	  membrane	  of	  Gram-­‐negative	  bacteria	  lacks	  an	  energy	  source,	  and	  thus	  
the	   proton	  motive	   force	   of	   the	   cytoplasmic	  membrane	   is	   required	   to	   fuel	   the	   active	  
transport	   of	   iron	   complexes	   into	   the	   periplasm.	   Transduction	   of	   energy	   to	   the	   outer	  
membrane	  is	  mediated	  by	  the	  inner	  membrane	  complex	  TonB-­‐ExbB-­‐ExbD	  (113),	  through	  
a	  mechanism	  which	  is	  not	  yet	  fully	  understood	  and	  the	  details	  of	  which	  are	  outside	  the	  
scope	   of	   this	   chapter,	   although	   several	   comprehensive	   reviews	   on	   the	   subject	   are	  
available	   (104,	   105,	   114,	   115).	   In	   brief,	   TonB	   bears	   three	   functional	   domains;	   an	   N-­‐
terminal	   signal	   sequence	   that	   targets	   the	  protein	   for	   translocation	   to	   the	   cytoplasmic	  
membrane,	  a	  proline-­‐rich	  periplasmic	  spacer	  region	  thought	  to	  confer	  flexibility	  to	  TonB	  
and	  allowing	  it	  to	  span	  the	  periplasmic	  space,	  and	  a	  C-­‐terminal	  domain	  which	  interacts	  
with	  TonB-­‐boxes	  of	  TBDTs.	  Binding	  of	  an	  iron	  complex	  to	  its	  respective	  TBDT	  promotes	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unfolding	  of	  the	  TonB	  box,	  which	  signals	  to	  TonB-­‐ExbB-­‐ExbD	  that	  a	  substrate	   is	  bound	  
and	  ready	  for	  transport.	  Although	  the	  exact	  nature	  of	  the	  signaling	  between	  the	  TonB-­‐
box	  and	  TonB-­‐ExbB-­‐ExbD	  is	  unknown,	  it	  induces	  the	  TonB-­‐box	  to	  physically	  engage	  TonB	  
(Figure	  1.3)	  (116,	  117),	  energizing	  the	  transporter	  for	  uptake	  of	  the	  bound	  iron	  complex.	  
While	  it	  is	  commonly	  acknowledged	  that	  the	  plug	  domain,	  which	  otherwise	  occludes	  the	  
β-­‐barrel	  pore,	  must	  then	  undergo	  a	  conformational	  change	  to	  allow	  for	  passage	  of	  the	  
substrate	   into	   the	   periplasm,	   and	   likely	   involves	   at	   least	   partial	   expulsion	   of	   the	   plug	  
from	   the	   pore	   (118),	   the	   nature	   of	   this	   domain	   rearrangement	   has	   yet	   to	   be	   fully	  
characterized	  and	  indeed	  remains	  a	  point	  of	  contention	  (105,	  119).	  	  
1.3.4.2. ABC	  transporters	  for	  heme	  transport	  across	  the	  inner	  membrane	  
Once	  within	  the	  periplasm,	  heme	  must	  subsequently	  be	  transported	  across	   the	  Gram-­‐
negative	   inner	   membrane	   and	   into	   the	   cytosol,	   a	   process	   mediated	   by	   ABC-­‐type	  
transporters.	   Notably,	   while	   this	   discussion	   specifically	   pertains	   to	   heme	   transport	   in	  
Gram-­‐negative	  bacteria,	   transport	  occurs	  analogously	   in	  Gram-­‐positive	  bacteria	  across	  
the	   cytoplasmic	   membrane,	   and	   is	   similarly	   applicable	   to	   the	   uptake	   of	   other	   iron	  
substrates,	  including	  siderophores	  and	  Fe3+	  (Figure	  1.2).	  Canonical	  prokaryotic	  ABC-­‐type	  
transporters	  consist	  of	  three	  central	  components	  (Figure	  1.5);	  i)	  a	  dedicated	  high-­‐affinity	  
substrate-­‐binding	  protein	  (SBP),	  which	  captures	  and	  shuttles	  the	  substrate	  through	  the	  
periplasmic	   space	   in	   Gram-­‐negative	   bacteria,	   or	   is	   lipid-­‐anchored	   to	   the	   cytoplasmic	  
membrane	  and	  captures	  heme	  from	  the	  external	  milieu	  in	  Gram-­‐positive	  bacteria,	  ii)	  an	  
associated	   permease,	   usually	   comprised	   of	   two	   integral	   transmembrane	   protein	  




Figure	  1.5.	  Structure	  of	  E.	  coli	  BtuCDF.	  	  
A	  ribbon	  diagram	  of	  the	  E.	  coli	  BtuCDF	  complex	  (PDB	  2QI9),	  representative	  of	  the	  iron-­‐
siderophore/cobalamin	  family	  of	  cytoplasmic	  membrane	  transporters.	  The	  two	  lobes	  of	  
the	  substrate	  binding	  protein	  BtuF	   (magenta)	  are	  docked	  on	  top	  of	   the	  two	  permease	  
domains	   (BtuC,	  monomers	   colored	  yellow	  and	  green),	  which	  are	  associated	  with	  ATP-­‐
binding	  proteins	  (BtuD,	  monomers	  colored	  red	  and	  blue).	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hydrolysis	   (120).	   In	  Gram-­‐negative	  bacteria,	   the	  periplasm	  is	  a	  dynamic	  and	  congested	  
space	   and	   thus	   SBPs	   play	   an	   essential	   role	   in	   the	   trafficking	   of	   scantily	   available	  
substrates,	   such	   as	   heme,	   to	   the	   inner	  membrane.	   Further,	   the	   specificity	   of	   an	  ABC-­‐
type	  transporter	   is	  most	  often	  governed	  by	  the	   ligand(s)	  bound	  by	   its	  cognate	  SBP.	  To	  
date,	   over	   50	   heme-­‐specific	   SBPs	   have	   been	   putatively	   identified	   (121),	   although	   few	  
have	  been	  structurally	  and	  functionally	  characterized.	  	  
	   The	   vast	   majority	   of	   SBPs	   involved	   in	   the	   coordination	   of	   inorganic	   iron	   and	  
organic	  iron	  complexes,	  such	  as	  heme,	  siderophores,	  and	  cobalamin,	  are	  categorized	  as	  
Class	  III	  (Cluster	  A)	  SBPs	  (122,	  123).	  These	  proteins	  are	  found	  exclusively	  in	  association	  
with	  ABC	  transporters,	  and	  possess	  two	  independently	  folded	  domains,	  each	  comprised	  
of	   a	   central	   β-­‐sheet	   surrounded	  by	  α-­‐helices,	   that	   are	   joined	  by	   an	  α-­‐helical	   linker	   of	  
approximately	  20	  amino	  acid	  residues	  (122).	  The	  substrate	  (e.g.	  heme)	  is	  coordinated	  in	  
an	   interdomain	   cleft,	   and	   in	   Class	   III	   SBPs,	   binding	   involves	   minimal	   conformational	  
changes	  to	  the	  protein,	  owing	  to	  inflexibility	  of	  the	  α-­‐helical	  spine.	  Docking	  of	  a	  SBP	  with	  
its	   cognate	   ABC	   transporter	   is	   facilitated	   by	   salt	   bridges	   formed	   between	   highly	  
conserved	  glutamic	  acid	  residues	   located	  at	  the	  apex	  of	  each	  SBP	   lobe,	  and	  positively-­‐
charged	   patches	   of	   arginine	   and/or	   lysine	   residues	   on	   the	   periplasmic	   face	   of	   the	  
permease	   subunits.	   The	   formation	   of	   this	   stable	   SBP:ABC	   transporter	   complex,	   as	  
illustrated	  in	  the	  paradigmatic	  example	  of	  the	  E.	  coli	  vitamin	  B12-­‐specific	  SBP,	  BtuF,	  and	  
its	  associated	  transporter,	  BtuCD	  (Figure	  1.5)	  (124),	  is	  necessary	  to	  induce	  translocation	  
of	  the	  substrate.	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1.3.4.3. Heme	  transport	  through	  the	  Gram-­‐positive	  cell	  envelope	  
Whilst	   not	   possessing	   an	   outer	   membrane	   through	   which	   heme	   must	   be	   actively	  
transported,	   the	   thick	   peptidoglycan	   layer	   (~20-­‐40	   nm)	   of	   Gram-­‐positive	   bacteria	  
impedes	  the	  accessibility	  of	  heme	  to	  cell	  membrane-­‐associated	  receptor	  proteins.	  This	  
impediment	   necessitates	   a	   means	   by	   which	   heme	   can	   be	   conveyed	   through	   the	   cell	  
wall,	  particularly	  when	  the	  concentration	  of	  available	  extracellular	  heme	  is	  low	  (<	  50	  nM	  
range)	   (125–127).	   Indeed,	  mechanisms	   that	   shuttle	  heme	   from	   the	   cell	   surface	   to	   the	  
cytoplasmic	  membrane	  have	  been	  described	   in	  a	  number	  of	  Gram-­‐positive	  pathogens	  
including	   S.	   aureus,	   S.	   lugdunensis,	   B.	   anthracis,	   L.	   monocytogenes,	   Streptococcus	  
pyogenes,	  and	  C.	  diphtheriae	   (For	  a	  recent	  comprehensive	  review	  see	  76)	   (Figure	  1.2).	  
The	  best	  characterized	  of	  these	  mechanisms	  is	  the	  paradigmatic	  iron-­‐regulated	  surface	  
determinant	  (Isd)	  pathway	  of	  S.	  aureus,	  as	  discussed	  in	  depth	  in	  section	  1.5.2.	  	  
1.3.5. General	  strategies	  for	  transferrin-­‐iron	  acquisition	  
As	  introduced	  previously,	  an	  important	  facet	  of	  innate	  immunity,	  and	  indeed	  one	  of	  the	  
first	  lines	  of	  defense	  against	  invading	  bacterial	  pathogens,	  is	  the	  low	  availability	  of	  iron	  
at	  host	  mucosal	  surfaces,	  and	  within	  the	  serum	  and	  lymph,	  owing	  to	  sequestration	  by	  Lf	  
and	   Tf,	   respectively.	   As	  with	   the	   utilization	   of	   heme-­‐iron	   complexes,	  many	   successful	  
pathogens	  are	  capable	  of	  circumventing	  iron	  withholding	  by	  Tf	  and	  Lf,	  by	  usurping	  iron	  
sequestered	   by	   these	   host	   glycoproteins.	   Three	   main	   mechanisms	   exist	   for	   the	  
utilization	  of	  Tf	  and/or	  Lf	  by	  bacteria	   (see	  Figures	  1.1	  and	  1.2);	   the	  elaboration	  of	  cell	  
surface-­‐associated	  Tf-­‐	  or	   Lf-­‐specific	  binding	  proteins	   (Tbps	  and	  Lbps,	   respectively),	   the	  
secretion	   of	   siderophores,	   and	   the	   extracellular	   release	   of	   broad	   substrate	   range	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reductases,	   which	   reduce	   Fe3+	   to	   Fe2+	   for	   subsequent	   uptake	   by	   inorganic	   iron	  
permeases.	  All	  three	  mechanisms	  ultimately	  function	  to	  liberate	  iron	  from	  Tf	  and/or	  Lf	  
prior	  to	  its	  transport	  into	  the	  cell.	  
1.3.5.1. Transferrin	  and	  lactoferrin-­‐binding	  proteins:	  the	  TbpA/TbpB	  paradigm	  
The	   establishment	   of	   infection	   by	   pathogenic	   Neisseriaceae,	   Pasteurellaceae,	   and	  
Moraxellaceae	   species	   unequivocally	   begins	   with	   colonization	   of	   a	   specific	   mucosal	  
surface,	   such	   as	   the	   urogenital	   tract	   (Neisseria	   gonorrhoeae)	   or	   the	   upper	   respiratory	  
tract	   (Neisseria	  meningitidis,	  Moraxella	   catarrhalis,	   and	  Haemophilus	   influenzae).	   Iron	  
available	   to	  mucosal	  pathogens	  exists	  predominantly	   in	   the	  extracellular	   state	  and,	  as	  
such,	  survival	  and	  proliferation	  of	   the	  aforementioned	  bacteria	  are	  undoubtedly	  aided	  
by	  their	  capacity	  to	  exploit	  host	  Tf	  and/or	  Lf	  directly	  as	  iron	  sources.	  Unlike	  most	  Gram-­‐
negative	   pathogens,	   the	   ability	   of	   these	   microbes	   to	   utilize	   iron-­‐containing	   host	  
glycoproteins	  is	  not	  facilitated	  by	  the	  production	  of	  siderophores	  (as	  discussed	  below),	  
but	   instead	   is	   mediated	   by	   highly	   specific,	   cell	   surface-­‐associated	   Tf	   or	   Lf-­‐binding	  
proteins	   (128–130).	   The	   paradigmatic	   Tf-­‐receptor	   in	   Gram-­‐negative	   bacteria	   is	   a	   Fur-­‐
regulated	   bipartite	   system	   consisting	   of	   an	   outer	   membrane	   receptor	   protein,	   TbpA	  
(131),	  and	  a	  surface-­‐associated	  lipoprotein,	  TbpB	  (132)	  (Figure	  1.2).	  Both	  TbpA	  and	  TbpB	  
bind	  Tf,	  however	  TbpA	  non-­‐discriminantly	  binds	  both	  apo-­‐	  and	  holo-­‐Tf,	  whereas	  TbpB	  
selectively	   binds	   holo-­‐Tf	   (133).	   TbpB	   purportedly	   functions	   as	   bait	   to	   capture	   iron-­‐
loaded	   Tf	   from	   the	   extracellular	   milieu	   and	   deliver	   it	   to	   TbpA	   for	   TonB-­‐dependent	  
uptake.	   Similarly,	   many	   pathogenic	   Neisseriaceae	   and	  Moraxellaceae	   are	   capable	   of	  
exploiting	  Lf	  as	  an	  iron	  source	  (134),	  and	  employ	  a	  TonB-­‐dependent	  outer	  membrane	  Lf	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receptor	   (LbpA)	   (135),	   and	   an	   accessory	   Lf-­‐binding	   lipoprotein	   (LbpB)	   (136),	   which	  
together	   function	   analogously	   to	   the	   TbpA/TbpB	   system.	   In	   contrast	   to	   heme	   and	  
siderophores,	  which	  are	  transported	  intact	  through	  the	  outer	  membrane,	  iron	  must	  first	  
be	  liberated	  from	  Tf	  and	  Lf	  prior	  to	  uptake.	  Although	  the	  details	  of	  iron	  extraction	  from	  
Tf/Lf-­‐binding	   proteins	   are	   outside	   the	   scope	  of	   this	   chapter	   (For	   details	   see	   77),	   both	  
TbpA	   and	   LbpA	   interact	   with	   a	   ferric-­‐iron	   binding	   protein	   A	   (FbpA)	   (137)	   which	   is	  
structurally	  similar	  to	  a	  single	  lobe	  of	  eukaryotic	  Tf	  and	  effectively	  serves	  as	  a	  bacterial	  
Tf,	   shuttling	   insoluble	   and	   potentially	   toxic	   Fe3+	   and	   small	   Fe3+-­‐complexes	   between	  
biological	   membranes	   (138).	   FbpA	   delivers	   Fe3+	   to	   its	   associated	   permease,	   FbpBC,	  
which	   together	   comprise	   an	   ABC	   transporter	   that	   represents	   a	   “nodal	   point”	   for	   Fe3+	  
utilization	   in	   a	   number	   of	   Gram-­‐negative	   pathogens	   (138–141)	   (Figure	   1.2).	   Indeed,	  
FbpABC	   is	  required	  for	   iron	  uptake	  from	  Tf,	  Lf,	  and	  Fe3+	  chelates,	  such	  as	  ferric	  citrate	  
and	   iron	  pyrophosphate	   in	  pathogenic	  Neisseria	  spp.	   (140–142).	  Together,	  TbpA/TbpB	  
and	   LbpA/LbpB,	   coupled	   with	   FbpABC,	   form	   a	   distinct	   mechanism	   by	   which	   mucosal	  
pathogens	   lacking	   endogenous	   siderophore	   production	   can	   exploit	   predominant	   iron	  
sources	  within	  their	  host	  environment.	  
1.3.5.2. Siderophores	  
In	   contrast	   to	   the	   relatively	   limited	  prevalence	  of	   Tf-­‐	   and	   Lf-­‐binding	  proteins	  amongst	  
bacterial	  pathogens,	  siderophores	  are	  ubiquitously	  employed	  as	  a	  strategy	  to	  pirate	  iron	  
from	   host	   glycoproteins,	   and	   to	   scavenge	   residual	   free	   iron	   from	   the	   external	  milieu.	  
Synthesized	   and	   secreted	   in	   response	   to	   iron	   deprivation,	   siderophores	   are	   low	  
molecular	  weight	  (generally	  less	  than	  1	  kDa),	  soluble	  molecules	  with	  high	  specificity	  and	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affinity	  for	  Fe3+	  (143).	  Indeed,	  enterobactin	  is	  one	  of	  the	  strongest	  iron	  chelators	  known,	  
with	  an	  estimated	  affinity	  of	  10-­‐52	  M	  (144).	  Not	  only	  are	  siderophores	  widely	  expressed	  
by	  both	  pathogenic	  and	  nonpathogenic	  bacteria,	  they	  are	  often	  produced	  by	  fungi	  and	  
graminaceous	   plants	   to	   promote	   growth	  under	   iron-­‐limited	   conditions	   (145),	   and	   2,5-­‐
DHBA	  was	  most	  recently	  identified	  as	  a	  novel	  mammalian	  siderophore	  (44,	  45).	  To	  date,	  
several	   hundred	   siderophores	   have	   been	   identified,	   over	   270	   of	   which	   have	   been	  
structurally	   characterized.	   This	   has	   revealed	   a	   diverse	   array	   of	   structures,	   which	   yet	  
share	  a	  limited	  number	  of	  iron-­‐coordinating	  functional	  groups	  (For	  a	  comprehensive	  list	  
see	   the	  Appendix	  1	  of	   reference	  145).	  Consequently,	   siderophores	   can	  be	  categorized	  
based	  on	  the	  functional	  groups	  involved	  in	  iron	  coordination,	  which	  include	  catecholate,	  
hydroxamate,	   and	   α-­‐hydroxycarboxylate	   types.	   A	   fourth,	   non-­‐descript	   category	   is	  
comprised	  of	  siderophores	  employing	  more	  than	  one	  of	  the	  aforementioned	  classes	  of	  
coordinating	  moieties,	  and	  is	  thus	  referred	  to	  as	  “mixed	  type”	  (143).	  Regardless	  of	  type,	  
siderophores	  tend	  to	  stably	  coordinate	  a	  single	  Fe3+	   ion	  in	  a	  hexadentate	  fashion,	  with	  
oxygen	  atoms	  serving	  as	  the	  most	  common	  ligand	  (145).	  	  
1.3.5.2.1. Siderophore	  biosynthesis	  
The	   biosynthesis	   of	   siderophores	   typically	   follows	   one	   of	   two	   modes	   of	   assembly,	  
delineated	   by	   the	   requirement,	   or	   lack	   thereof,	   for	   large	   multimodular	   enzymatic	  
scaffolds	   referred	   to	   as	   nonribosomal	   peptide	   synthetases	   (NRPS).	   NRPS-­‐based	  
siderophore	   synthesis	   involves	   the	   activation	   and	   incorporation	   of	   non-­‐proteinogenic	  
amino	  acids	  into	  an	  elongating	  chain,	  the	  sequence	  of	  which	  is	  dictated	  by	  the	  order	  of	  
the	   NRPS	   domains,	   in	   lieu	   of	   an	   RNA	   template	   (For	   a	   detailed	   discussion	   of	   NRPS	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siderophore	  synthesis,	  see	  146).	  In	  addition	  to	  the	  synthesis	  of	  numerous	  macrocyclic	  or	  
“aryl	   capped”	   peptidic	   siderophores	   (143),	   including	   enterobactin,	   bacillibactin	   of	  
Bacillus	  spp.	  (Figure	  1.6),	  mycobactin	  of	  M.	  tuberculosis,	  yersiniabactin	  of	  Yersinia	  spp.,	  
and	  vibriobactin	  of	  V.	   cholerae,	  NRPS	  enzymes	  also	  give	   rise	   to	  antimicrobial	  peptides	  
and	  peptide-­‐based	  antibiotics	  such	  as	  penicillin,	  daptomycin,	  and	  vancomycin	  (146).	   In	  
contrast,	  NRPS-­‐independent	  siderophore	  (NIS)	  synthesis	  employs	  an	  alternate	  family	  of	  
synthetases,	  which	   catalyze	   the	   condensation	   of	   alternating	   amino	   alcohols,	   alcohols,	  
dicarboxylic	   acids,	   and	   diamines	   via	   amine	   or	   ester	   bond	   formation,	   giving	   rise	   to	  
nonpeptidic	   siderophores	   (For	   a	   detailed	   discussion	   of	   NIS	   siderophore	   synthesis,	   see	  
147).	   The	   majority	   of	   carboxylate	   and	   α-­‐hydroxycarboxylate	   type	   siderophores	   are	  
synthesized	  using	  NIS-­‐type	  pathways,	  including	  staphyloferrins	  A	  and	  B	  of	  S.	  aureus	  (as	  
discussed	  in	  section	  1.5.1.1),	  alcaligin	  of	  Bordetella	  pertussis	  and	  B.	  bronchiseptica,	  and	  
aerobactin	   of	   the	   Enterobacteriaceae	   (145).	   Interestingly,	   petrobactin,	   which	   is	  
produced	   by	   pathogenic	  Bacillus	   spp.,	   is	   synthesized	   using	   a	   unique	   NIS/NRPS	   hybrid	  
system	  (148).	  	  
1.3.5.2.2. Stealth	  siderophores	  
As	   described	   in	   section	   1.2.2.4,	   neutrophils	   of	   the	  mammalian	   host	   secrete	  NGAL,	   an	  
acute-­‐phase	  protein	  capable	  of	   sequestering	  bacterial	   siderophores	   in	  defense	  against	  
iron	  piracy	  and,	  unsurprisingly,	  bacterial	  invaders	  have	  responded	  by	  evolving	  tactics	  to	  
counter	   this	   affront	   to	   their	   acquisition	   of	   iron.	   NGAL	   coordinates	   Fe3+-­‐siderophores	  
within	  a	  cup-­‐shaped	  ligand	  binding	  pocket	  (calyx)	  that	  is	  large,	  broad,	  and	  shallow,	  and	  
is	  uniquely	  lined	  with	  polar	  and	  positively-­‐charged	  residues	  (43,	  149).	  As	  such,	  the	  NGAL	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calyx	  is	  ideally	  suited	  to	  the	  sequestration	  of	  negatively-­‐charged	  Fe3+	  siderophores,	  such	  
as	   the	   catecholates.	   To	   circumvent	   the	   effects	   of	   NGAL,	   some	   pathogenic	   bacteria	  
elaborate	   more	   than	   one	   siderophore,	   often	   including	   an	   NGAL-­‐sensitive	   (e.g.	  
catecholate)	   and	  an	  NGAL-­‐immune	   siderophore	   (e.g.	   a	   structurally	  modified	  aromatic,	  
or	  one	  that	  simply	  lacks	  aromatic-­‐binding	  motifs).	  Siderophores	  that	  evade	  the	  effects	  of	  
NGAL	   are	   aptly	   referred	   to	   as	   “stealth	   siderophores,”	   and	   are	   often	   associated	   with	  
virulence	   potential.	   The	   production	   of	   a	   stealth	   siderophore	   is	   exemplified	   by	  
uropathogenic	  E.	  coli	  and	  Salmonella	  enterica	  serovars,	  where	  iron	  acquisition	  by	  NGAL-­‐
sensitive	   enterobactin	   is	   complemented	   by	   production	   of	   glucosylated	   enterobactin	  
derivatives,	   such	   as	   salmochelin	   S4	   (Figure	   1.6)	   (150);	   the	   addition	   of	   bulky	   glucose	  
residues	  to	  the	  catechol	  moieties	  of	  the	  siderophore	  renders	  it	  sterically	  discordant	  for	  
NGAL-­‐binding.	   Indeed,	   despite	   the	   extremely	   high	   affinity	   of	   enterobactin	   for	   Fe3+,	  
salmochelin	   appears	   to	   be	   required	   for	   the	   virulence	   of	   S.	   enterica	   (151).	   Similarly,	  
pathogenic	  Bacillus	  spp.	  secrete	  both	  bacillibactin	  and	  petrobactin,	   the	   latter	  of	  which	  
bears	  3,4-­‐DHBA	  moieties	  in	  lieu	  of	  the	  common	  2,3-­‐DHBA	  moieties,	  where	  the	  position	  
of	   the	   carboxylates	   also	   renders	   the	   siderophore	   incompatible	   for	   binding	   by	   NGAL	  
(Figure	  1.6).	  Notably,	  petrobactin	   is	  uniquely	  required	  for	  the	  virulence	  of	  B.	  anthracis	  
(148).	  While	  staphyloferrins	  A	  and	  B	  of	  S.	  aureus	  are	  not	  structurally	  modified	  to	  evade	  







Figure	  1.6.	  Structures	  of	  representative	  catechol-­‐containing	  stealth	  and	  non-­‐stealth	  
siderophores.	  
Stealth	  siderophores	  are	  not	  bound	  by	  mammalian	  NGAL	  (siderocalin).	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1.3.5.2.3. Siderophore	  efflux	  
To	  mediate	  iron	  uptake	  from	  the	  external	  milieu,	  newly	  synthesized	  siderophores	  must	  
first	   be	   exported	   from	   the	   cytoplasm.	   Siderophore	   export	   is,	   to	   date,	   poorly	  
characterized,	  but	   in	  both	  Gram-­‐negative	  and	  Gram-­‐positive	  bacteria,	   transport	  across	  
the	  cytoplasmic	  membrane	  appears	  to	  be	  mediated	  by	  exporters	  of	  the	  major	  facilitator	  
superfamily	   (MFS)	   (152).	   Subsequent	   transport	   across	   the	   outer	  membrane	   in	   Gram-­‐
negative	   bacteria	   is	   performed	   by	   multi-­‐domain	   efflux	   pumps	   of	   the	   resistance-­‐
nodulation	   cell	   division	   (RND)	   or	  ABC	   transporter-­‐type	   families,	   and	  most	   often	   these	  
export	  proteins	  are	  encoded	  from	  the	  biosynthetic	  locus	  of	  the	  associated	  siderophore.	  
1.3.5.2.4. Uptake	  of	  endogenous	  and	  exogenous	  siderophores	  
As	   discussed	   prior,	   the	   transport	   of	   iron-­‐loaded	   siderophores	   back	   across	   the	   Gram-­‐
negative	  outer	  membrane	  is	  mediated	  by	  specific	  TBDTs,	  and	  in	  both	  Gram-­‐negative	  and	  
Gram-­‐positive	  pathogens,	  ABC	  transporters	  facilitate	  passage	  of	  the	  siderophore,	  intact,	  
across	  the	  cytoplasmic	  membrane	  (Figure	  1.2).	  Whilst	  some	  SBPs	  and	  ABC	  transporters	  
are	  highly	  specific	  for	  a	  given	  siderophore,	  others	  possess	  broad	  substrate	  specificity	  for	  
catecholate,	  carboxylate	  or	  α-­‐hydroxycarboxylate-­‐type	  siderophores	  and,	  as	  such,	  may	  
allow	  for	  the	  appropriation	  of	  siderophores	  from	  heterologous	  microorganisms.	  Bacteria	  
capable	   of	   exploiting	   these	   “xenosiderophores”	   may	   be	   afforded	   a	   competitive	  
advantage	   in	   polymicrobial	   communities,	   where	   they	   are	   potentially	   able	   to	   pilfer	  
multiple	   iron-­‐chelating	   molecules,	   without	   the	   energetic	   demands	   of	   synthesizing	  
siderophores	   de	   novo.	   Indeed,	   some	   bacteria	   including	   S.	   lugdunensis	   (153),	   L.	  
monocytogenes	   (127),	   and	   S.	   pyogenes,	   are	   wholly	   dependent	   upon	   the	   uptake	   of	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xenosiderophores	  to	  access	  the	  Tf-­‐iron	  pool	  within	  the	  host,	  and	  the	  general	  trend	  is	  for	  
the	   expression	   of	   several	   more	   siderophore	   importers	   than	   exporters	   overall.	   The	  
conserved	   ferric	   hydroxamate	   uptake	   (Fhu)	   system	   is	   but	   one	   example	   of	   a	   broad	  
substrate	  range	  Fe3+-­‐siderophore	  importer,	  homologs	  of	  which	  are	  found	  in	  each	  of	  the	  
aforementioned	   organisms,	   along	   with	  many	   other	   Gram-­‐negative	   and	   Gram-­‐positive	  
pathogens,	   including	   S.	   aureus	   (see	   section	   1.5.1.2.1	   –	   “Utilization	   of	   hydroxamate	  
siderophores	  as	  an	  iron	  source	  by	  S.	  aureus”).	  
1.3.5.2.5. Iron	  release	  from	  siderophores	  
Upon	   delivery	   of	   the	   iron-­‐loaded	   siderophore	   to	   the	   cytoplasm,	   two	   possible	  
mechanisms	  exist	  for	  the	  release	  of	  iron	  for	  cellular	  processes:	  i)	  reductive	  iron	  release	  
from	  the	  siderophore	  using	  a	  ferrisiderophore	  reductase,	  leaving	  the	  molecule	  intact	  for	  
possible	  recycling,	  or	  ii)	  reduction	  of	  iron	  concurrent	  with	  hydrolysis	  of	  the	  siderophore	  
backbone,	   as	   has	   been	   shown	   for	   tris-­‐catecholate	   siderophores	   such	   as	   enterobactin	  
and	  bacillibactin	  (143).	  The	  dissociation	  of	  iron	  from	  the	  intact	  siderophore	  is	  considered	  
to	   be	   the	   more	   prevalent	   method,	   as	   specialized	   enzymes	   are	   not	   required	   and	  
reutilization	  of	  the	  siderophore	  would,	  ostensibly,	  be	  more	  energetically	  favourable.	  	  
1.3.5.3. Extracellular	  ferric	  iron	  reductases	  
In	   premise,	   bacterial	   pathogens	   could	   utilize	   cell	   surface-­‐associated	   or	   secreted	   Fe3+	  
reductases,	  which	  reduce	  Fe3+	  to	  Fe2+,	  not	  only	  to	  access	  insoluble	  Fe3+-­‐precipitates,	  but	  
also	  to	  non-­‐specifically	  liberate	  iron	  from	  host	  iron	  complexes	  such	  as	  Tf,	  Lf,	  and	  ferritin	  
(Figure	  1.1).	  The	  uptake	  of	  solubilized	  Fe2+	  through	  the	  cell	  envelope	  occurs	  by	  way	  of	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inorganic	   iron	   permeases	   (Figure	   1.2),	   obviating	   the	   need	   for	   dedicated	   uptake	  
mechanisms	   for	  each	   individual	   iron	   chelate.	   Indeed,	  extracellular	   and/or	   cell	   surface-­‐
associated	   reductase	   activity	   has	   been	   reported	   for	   H.	   pylori	   (154,	   155)	   and	   the	  
facultatively	   intracellular,	   ruminant	   pathogen	   Mycobacterium	   avium	   subsp.	  
paratuberculosis	  (156),	  although	  the	  molecular	  determinants	  and	  substrate	  specificities	  
of	   these	   enzymes	   are	   not	   well-­‐defined.	   Similarly,	   L.	   monocytogenes	   is	   capable	   of	  
mobilizing	   iron	   from	   a	   wide	   range	   of	   complexes,	   including	   Tf,	   Lf,	   Hb,	   catecholamine	  
stress	  hormones,	  and	  exogenous	  siderophores,	  through	  what	  is	  thought	  to	  be	  a	  potent	  
broad	   substrate	   specificity	   Fe3+-­‐reductase	   (157–160).	   A	   Fe3+-­‐reductase	   (FepB)	   was	  
recently	  described	   in	  L.	  monocytogenes,	  which	   functions	  as	  part	  of	   the	  Fe3+	  permease	  
system,	   FepABC	   (for	   Fe-­‐dependent	   peroxidase),	   however	   it	   is	   unclear	   if	   the	  
aforementioned	   activity	   can	   fully	   be	   ascribed	   to	   this	   enzyme	   (161);	   indeed,	   alternate	  
functions	   have	   been	   described	   for	   this	   enzyme	   in	   E.	   coli	   and	   S.	   aureus	   (see	   section	  
1.5.3.1).	   Interestingly,	   homogentisic	   acid	   (HGA)	   of	   Legionella	   pneumophila,	   and	   the	  
associated	   pyomelanin	   pigment,	   HGA-­‐melanin,	   were	   both	   shown	   to	   reduce	   Fe3+	  
complexes	  such	  as	  Tf	  and	  ferritin,	  where	  mobilized	  Fe2+	  was	  subsequently	  transported	  
by	   the	   universal	   ferrous	   iron	   permease,	   FeoB	   (see	   section	   1.5.5)	   (162,	   163).	   Notably,	  
siderophore	  production	  by	  L.	  pneumophila	  was	  found	  to	  be	  inversely	  correlated	  to	  HGA-­‐
melanin	   secretion,	   suggesting	   that	   the	   two	   mechanisms	   are	   likely	   differentially	  
regulated	  and	  may	   fulfill	   distinct	   roles	   in	   iron	  acquisition	  by	   this	  bacterium	   (162).	   The	  
interplay	  between	  well-­‐defined	   iron	  acquisition	  strategies	  and	  Fe3+-­‐reductases	  has	  not	  
yet	  been	  investigated,	  nor	  is	  it	  known	  if	  these	  enzymes	  contribute	  to	  the	  in	  vivo	  survival	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or	  pathogenicity	  of	   these	  organisms.	   It	   is	   interesting	   to	   speculate	   that	  Fe3+-­‐reductases	  
may	   provide	   a	  means	   of	   accessing	   host	   intracellular	   iron	   stores,	   such	   as	   ferritin.	   This	  
notion,	   however	   has	   only	   been	   preliminarily	   investigated	   in	   M.	   avium	   subsp.	  
paratuberculosis,	  where	   Fe3+	   reductase	   expression	   was	   observed	   in	   association	   with	  
intracellular	   mycobacteria	   of	   naturally	   infected	   bovine	   intestinal	   tissue	   (156).	   Clearly,	  
while	   reductive	   iron	   release	   seems	   to	   be	   a	   viable	   means	   for	   pathogens	   to	   access	   a	  
multitude	   of	   host	   iron	   complexes,	   to	   which	   they	   may	   not	   have	   specific	   receptors	   or	  
acquisition	   pathways,	   it	   is	   a	   currently	   underappreciated	   and	   underexplored	   facet	   of	  
bacterial	  iron	  acquisition.	  	  
1.3.6. General	  strategies	  for	  inorganic	  iron	  acquisition	  
While	  Fe2+	  uptake	  is	   important,	  particularly	   in	  anoxic	  and/or	  acidic	  environments,	  such	  
systems	   are	   sparsely	   characterized	   in	   most	   microorganisms,	   owing	   to	   the	   obscuring	  
influence	  of	  siderophore	  and	  heme-­‐iron	  uptake	  systems.	  In	  Gram-­‐negative	  bacteria,	  it	  is	  
believed	  that	  Fe2+	   ions	  are	  capable	  of	  diffusing	  across	  the	  outer	  membrane	   in	  a	  TonB-­‐
independent	   fashion,	   and	   that	   elemental	   iron	   is	   then	   actively	   transported	   across	   the	  
cytoplasmic	  membrane.	  Two	  inorganic	  iron	  acquisition	  systems	  are	  widely	  conserved	  in	  
both	  Gram-­‐positive	   and	  Gram-­‐negative	   pathogens;	   the	   ferrous	   iron	   transport	   system,	  
Feo,	  and	  functional	  analogues	  of	  Fet3p-­‐Ftrp1,	  a	  high-­‐affinity,	  reductive	  iron	  permease	  in	  
Saccharomyces	   cerevisiae	   (164).	  Whilst	   not	   an	   exhaustive	   list	   of	   prokaryotic	   inorganic	  
iron	   uptake	  mechanisms,	   these	   two	   transporters	   represent	   the	   best	   characterized	   of	  
these	  systems	  to	  date.	  Homologues	  of	  both	  systems	  appear	  to	  be	  present	   in	  S.	  aureus	  
and,	  as	  such,	  will	  be	  discussed	  in	  detail	  in	  subsequent	  sections.	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1.4. STAPHYLOCOCCUS	  AUREUS	  
1.4.1. The	  staphylococci	  
The	   genus	   Staphylococcus	   is	   comprised	   of	   over	   70	   species	   and	   subspecies	   of	   Gram-­‐
positive,	   low	   G+C	   content	   (30-­‐40%)	   bacteria	   within	   the	   phylum	   Firmicutes.	   As	   their	  
name	   implies,	   the	   staphylococci	   bear	   spherical	  morphology	   (approx.	   diameter	   0.5-­‐1.8	  
μM)	  and	  through	  division	  along	  random	  planes,	  cluster	  irregularly	  (staphyle-­‐,	  grape-­‐like).	  
Members	   of	   this	   genus	   are	   generally	   catalase-­‐positive,	   facultative	   anaerobes	   that	   are	  
subdivided	  based	  on	  their	  expression	  of	  secreted	  coagulase,	  a	  polypeptide	  that	  binds	  to	  
and	   activates	   prothrombin,	   leading	   to	   the	   conversion	   of	   serum	   fibrinogen	   to	   fibrin.	  
Staphylococcal	  species	  capable	  of	  secreting	  coagulase	  (coagulase-­‐positive	  staphylococci;	  
CoPS)	   are	   able	   to	   co-­‐opt	   the	   host	   coagulation	   cascade,	   allowing	   for	   the	   deposition	   of	  
fibrin,	  which	  leads	  to	  clotting	  and	  promotes	  abscess	  formation,	  persistent	  infection	  and	  
furthers	   the	  potential	   for	  dissemination	   (165).	  The	  CoPS	  are	  comprised	  of	  seven	  often	  
opportunistic	   pathogens	   of	   humans	   and	   animals	   which	   bear	   clinical,	   agricultural,	   and	  
veterinary	   relevance:	   the	   notorious	   human	   pathogen,	   S.	   aureus;	   S.	   intermedius,	   S.	  
pseudintermedius,	   and	   S.	   schleiferi	   subsp.	   coagulans,	  which	   colonize	   and	   may	   cause	  
cutaneous	   infections	   in	   domestic	   animals;	  S.	   hyicus,	   the	   causative	   agent	   of	   greasy	   pig	  
disease	   (exudative	   epidermidis);	  S.	   delphini,	  which	   causes	   skin	   lesions	   in	   dolphins	   and	  
other	   mammals;	   and	   S.	   lutrae,	  which	   was	   isolated	   from	   postmortem	   bacteriological	  
examination	   of	   otters	   (166–171).	   In	   contrast,	   the	   coagulase-­‐negative	   staphylococci	  
(CoNS)	  are	  largely	  regarded	  as	  non-­‐pathogenic	  constituents	  of	  the	  normal	  microflora	  of	  
the	  skin	  and	  mucous	  membranes.	  Specific	  CoNS,	  however,	  possess	  pathogenic	  potential,	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such	   as	   S.	   epidermidis	   and	   S.	   lugdunensis,	   which	   have	   been	   increasingly	   linked	   to	  
infections	  of	   implanted	  or	   indwelling	  medical	  devices	  and	   to	  native	  valve	  endocarditis	  
(172,	   173),	   and	   S.	   saprophyticus,	   which	   is	   the	   second	   most	   common	   cause	   of	  
uncomplicated	   urinary	   tract	   infections	   in	   women	   (174,	   175).	   Despite	   the	   growing	  
appreciation	   of	   CoNS	   as	   opportunistic	   pathogens,	   particularly	   in	   nosocomial	   settings,	  
relatively	   little	   is	   known	   about	   the	   mechanisms	   governing	   their	   pathogenicity	   and	  
virulence	  relative	  to	  S.	  aureus.	  	  
1.4.2. Pathogenesis	  and	  virulence	  factors	  of	  S.	  aureus	  
S.	   aureus	   is	   undoubtedly	   the	  most	   formidable	  member	  of	   the	   staphylococci	   and	   is	  	  
often	  deemed	  to	  be	  the	  leading	  cause	  of	  infections	  of	  the	  bloodstream,	  skin,	  soft	  tissue,	  
and	   lower	   respiratory	   tract	   (176).	   S.	   aureus	   is	   notorious	   for	   the	   rapid	   acquisition	   of	  
antibiotic	   resistance,	   from	   initial	   reports	   of	   penicillin-­‐resistance	   in	   1944	   (177),	   to	   the	  
rapid	  and	  global	  spread	  of	  methicillin-­‐resistant	  S.	  aureus	  (MRSA)	  within	  hospitals	  over	  a	  
60-­‐year	  period	  (178,	  179).	  The	  more	  recent	  emergence	  of	  community-­‐associated	  MRSA	  
(CA-­‐MRSA),	   capable	   of	   causing	   serious	   morbidity	   and	   mortality	   in	   otherwise	   healthy	  
individuals	   (179–184),	   emphasizes	   the	   need	   for	   novel	   treatments	   based	   on	   a	   sound	  
understanding	  of	  the	  mechanisms	  governing	  S.	  aureus	  survival	  and	  virulence	  within	  the	  
host.	  	  
	   Although	  S.	  aureus	  is	  capable	  of	  infecting	  virtually	  every	  organ	  and	  tissue	  within	  
the	  body,	  the	  vast	  majority	  of	  infections	  caused	  by	  this	  bacterium	  are	  those	  of	  the	  skin	  
and	  soft	  tissue	  (SSTIs),	  with	  CA-­‐MRSA	  being	  the	  most	  frequent	  cause	  of	  purulent	  SSTIs	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requiring	  medical	  intervention	  (185).	  Nasal	  carriage	  of	  S.	  aureus	  is	  a	  major	  risk	  factor	  for	  
subsequent	   infection,	   and	   notably	   approximately	   20%	   and	   30%	   of	   individuals	   are	  
persistently	  and	   transiently	   colonized,	   respectively,	  by	   the	  prospective	  pathogen	   (186,	  
187).	  While	  the	  host	  factors	  contributing	  to	  carrier	  versus	  non-­‐carrier	  state	  are	  not	  yet	  
fully	  elucidated,	  most	  often	  staphylococcal	  infections	  begin	  with	  a	  physical,	  medical,	  or	  
immunological	   insult,	  allowing	  the	  pathogen	  to	  gain	  entry	   into	  the	  host.	   In	  the	  case	  of	  
SSTIs,	  a	  breach	   in	  the	  skin	  allows	  the	  pathogen	  to	  bypass	  this	   first	   line	  of	  defense	  and	  
access	  deeper	  layers	  of	  tissue;	  upon	  penetrance,	  a	  complex	  cellular	  response	  is	  initiated	  
whereupon	   immune	   cells	   are	   recruited	   to	   the	   site	   of	   invasion.	   To	   promote	   both	   skin	  
colonization,	   as	   well	   as	   its	   survival	   and	   dissemination	   beyond	   the	   initial	   locus	   of	  
infection,	   S.	   aureus	   deploys	   a	   vast	   arsenal	   of	   both	   surface-­‐associated	   and	   secreted	  
virulence	  factors,	  as	  summarized	  briefly	  below	  and	  in	  Figure	  1.7.	  	  
	   Adherence	  to	  the	  host	  epithelium	  is	  required	  for	  colonization	  by	  S.	  aureus,	  and	  
unsurprisingly	   many	   of	   the	   factors	   contributing	   to	   this	   pre-­‐infectious	   state	   are	  
associated	  with	  tissue	  attachment	  and	  immune	  evasion.	  While	  colonization	  is	  a	  complex	  
and	   multifactorial	   process,	   which	   is	   incompletely	   understood,	   numerous	   MSCRAMM	  
family	  proteins	   (microbial	   surface	  components	   recognizing	  adhesive	  matrix	  molecules)	  
have	  been	   implicated	   in	   this	  process.	  Notably,	  both	  clumping	   factor	  B	   (ClfB)	  and	   iron-­‐
regulated	   surface	   determinant	   protein	   A	   (IsdA)	   are	   though	   to	   function,	   in	   part,	   as	  
adhesins	  facilitating	  colonization.	  While	  it	  is	  believed	  that	  ClfB	  interacts	  with	  loricrin	  and	  
cytokeratin-­‐10	  of	  epithelial	  cells,	  as	  well	  as	  fibrinogen	  within	  the	  blood,	  the	  host	  ligands	  







Figure	  1.7.	  Repertoire	  of	  virulence	  factors	  elaborated	  by	  S.	  aureus.	  	  
The	   factors	   depicted	   in	   this	   figure	   interfere	   with	   the	   host	   defense	   system,	   enabling	  
bacterial	  colonization,	  dissemination,	  and	  proliferation,	  along	  with	  damage	  to	  host	  cells	  
and	  tissues.	  Modified	  with	  permission	  from	  D.E.	  Heinrichs	  and	  R.S.	  Flannagan	  (2015).	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glycosylation	  of	  wall	  teichoic	  acid	  was	  shown	  to	  be	  required	  for	  efficient	  adherence	  to	  
nasal	  epithelial	  cells	  in	  vitro	  and	  in	  vivo,	  although	  again,	  the	  host	  cell	  receptor	  governing	  
this	   interaction	   has	   not	   been	   identified	   (192).	   Additionally,	   S.	   aureus	   is	   able	   to	   resist	  
antimicrobial	  peptides	  (AMPs)	  produced	  by	  epithelial	  cells	  and	  leukocytes,	  allowing	  it	  to	  
survive	   on	   the	   skin	   upon	   attachment	   and	   resist	   insult	   from	   host	   immune	   cells;	  
staphylococcal	  proteases	  aureolysin	  and	  V8	  degrade	  cathelicidins	  (193,	  194),	  whereas	  α-­‐
defensins	  may	  be	  bound	  and	  inactivated	  by	  staphylokinase	  (195).	  Further,	  S.	  aureus	  can	  
reduce	  the	  net	  anionic	  charge	  of	  its	  cell	  envelope	  through	  D-­‐alanylation	  of	  teichoic	  and	  
lipoteichoic	   acid	   and/or	   L-­‐lysinylation	   of	   phosphatidylglycerol	   (via	   DltABCD	   and	  MprF,	  
respectively)	  (196–199),	  thereby	  reducing	  the	  affinity	  of	  cationic	  AMPs	  for	  the	  bacterial	  
cell	  surface	  (200).	  	  
	   Following	  colonization,	  staphylococci	  that	  are	  able	  to	  invade	  host	  tissues	  induce	  
a	   localized	   release	   of	   proinflammatory	   cytokines,	   which	   recruits	   polymorphonuclear	  
leukocytes	  (PMNs)	  and	  macrophages	  to	  the	  site	  of	  infection.	  While	  some	  staphylococci	  
may	  be	  successfully	  phagocytosed	  and	  destroyed,	  others	  are	  able	  to	  persist	  in	  abscesses	  
and/or	  escape	  and	  disseminate	  to	  other	  tissues	  and	  organs	  via	  the	  lymph	  and	  blood.	  S.	  
aureus	  expresses	  an	  array	  of	  multifunctional	  virulence	  factors	  to	  counter	  the	  effects	  of	  
PMNs,	   including	  molecules	   that	   i)	   inhibit	  PMN	  recruitment	  and	  activation	  during	  early	  
stages	   of	   infection	   (e.g.	   chemotaxis	   inhibitory	   protein	   of	   staphylococci	   (CHIPS)	   and	  
staphylococcal	  staphylococcal	  complement	  inhibitors	  (SCINs))	  (201,	  202),	  ii)	  mitigate	  the	  
microbicidal	   activities	   of	   PMNs,	   including	   damage	   by	   ROS	   (e.g.	   catalase,	   superoxide	  
dismutase,	   and	   staphyloxanthin)	   and	   AMPs	   (203,	   204,	   205,	   and	   as	   above)	   iii)	   inhibit	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phagocytosis	   (e.g.	   extracellular	   fibrinogen-­‐binding	   protein	   (Efb),	   clumping	   factor	   A	  
(ClfA),	   capsular	   polysaccharides,	   staphylococcal	   protein	   A	   (SpA),	   and	   second	   binding	  
protein	  of	  immunoglobulin	  (Sbi))	  (206–208)	  and	  iv)	  actively	  destroy	  PMNs	  (e.g.	  secreted	  
cytolytic	   toxins	   such	   as	   Panton-­‐Valentine	   leukocidin	   (PVL),	   leukocidins	   AB	   and	   ED,	  
phenol	  soluble	  modulins	  (PSMs),	  α-­‐toxin,	  and	  γ-­‐toxin)	  (209,	  210).	  Notably,	  both	  SpA	  and	  
Sbi	  inhibit	  opsonophagocytosis,	  not	  by	  obscuring	  the	  surface	  of	  the	  cell	  with	  fibrinogen,	  
as	  with	  Efb	  and	  ClfA,	  but	   rather	  by	  binding	   the	  Fcγ	   region	  of	   IgG	   (211,	  212).	  Not	  only	  
does	   this	   prevent	   the	   immediate	   clearance	  of	  S.	   aureus,	  but	   it	   also	  prevents	   the	  host	  
from	  developing	   protective	   immunity	   against	   future	   infections.	   Further,	  S.	   aureus	   can	  
circumvent	   both	   humoral	   and	   cell-­‐mediated	   immunity	   through	   the	   action	   of	  
superantigens	   such	   as	   toxic	   shock	   syndrome	   toxin-­‐1	   (TSST-­‐1),	   staphylococcal	  
enterotoxins	  B	  and	  C	  (SEB	  and	  SEC,	  respectively),	  and	  the	  multifunctional	  SpA.	  TSST-­‐1,	  
SEB,	  and	  SEC	  bind	  the	  Vβ	  region	  of	  T	  cell	  receptors,	  whereas	  SpA	  interacts	  with	  the	  VH3	  
region	   of	   IgM	   on	   B	   lymphocytes,	   leading	   to	   the	   non-­‐specific	   activation	   and	   clonal	  
expansion	   of	   T	   cell	   and	   B	   cell	   populations,	   respectively.	   While	   SpA-­‐induced	   B	   cell	  
expansion	  leads	  to	  subsequent	  anergy	  and	  collapse	  (213),	  the	  extensive	  activation	  (up	  to	  
20%	   of	   the	   population)	   and	   proliferation	   of	   T	   cells,	   as	   induced	   by	   staphylococcal	  
superantigens,	   may	   lead	   to	   massive	   immune	   dyregulation	   and	   cytokine	   storm;	   this	  
potentially	  fatal	  illness	  is	  referred	  to	  as	  toxic	  shock	  syndrome	  (TSS)	  and	  presents	  as	  rash,	  
fever,	  hypotension,	   and	   in	   severe	   cases,	  multi-­‐organ	   failure	   (214–216).	  Notably,	  many	  
survivors	   of	   TSS	   fail	   to	   develop	   protective	   antibodies	   against	   the	   superantigen,	   and	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although	  T	  cell	  exhaustion	  has	  been	  proposed	  as	  a	  possible	  explanation,	  the	  reasons	  for	  
this	  remain	  obscure	  (214).	  	  
	   In	   addition	   to	   their	   potential	   role	   as	   superantigens,	   many	   staphylococcal	  
enterotoxins,	  as	  their	  name	  implies,	  may	   induce	  vomiting	  and	  diarrhea	  upon	   ingestion	  
(i.e.	   staphylococcal	   food	   poisoning).	   Further,	   staphylococcal	   enterotoxin	   A	   (SEA)	   was	  
recently	  implicated	  in	  the	  formation	  of	  hepatic	  abscesses	  in	  a	  murine	  bacteremia	  model,	  
where	   SEA	   enhanced	   both	   the	   number	   of	   abscesses	   and	   the	   number	   of	   bacteria	  
recovered	  from	  within	  these	  abscesses,	  as	  well	  as	  the	  recruitment	  of	  neutrophils	  to	  the	  
site	   of	   infection	   (217).	   While	   promoting	   an	   influx	   of	   neutrophils	   may	   seem	  
counterintuitive	   to	  establishing	  an	   infection,	   abscesses	   are	   a	   common	  presentation	  of	  
staphylococcal	   infection.	  Mature	   staphylococcal	   abscesses	   are	   comprised	   of	   a	   central	  
nidus	   of	   viable	   bacteria	   and	   PMNs,	   surrounded	   by	   necrotic	   PMNs	   and	   cellular	   debris	  
(pus),	  confined	  within	  a	  fibrous	  pseudocapsule.	  Whilst	  abscess	  formation	  historically	  has	  
been	   considered	   a	   defense	  mechanism	  by	   the	   host	   to	   contain	   invading	  microbes	   and	  
protect	   surrounding	   healthy	   tissue	   from	   damage,	   it	   appears	   S.	   aureus	   subverts	   these	  
efforts,	   instead	   utilizing	   the	   abscess	   environment	   to	   enhance	   replication	   and	  
subsequent	  dissemination	  (218).	   Indeed,	  the	  maturation	  and	  rupture	  of	  staphylococcal	  
abscesses	   can	   lead	   to	   serious	   severe	   and	   invasive	   illnesses	   such	   as	   bacteremia	   and	  
sepsis,	   to	   hematogenous	   spread	   of	   the	   bacteria	   and	   to	   secondary	   waves	   of	   abscess	  
formation	  (219,	  220).	  Many	  of	  the	  virulence	  factors	  described	  above	  contribute	  to	  this	  
process,	   including	   coagulase,	   as	   well	   as	   von	  Willebrand	   factor	   binding	   protein,	   which	  
both	   facilitate	  deposition	  of	   the	   fibrous	  barrier	  delineating	   the	  abscess	  and	  protecting	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the	  staphylococcal	  community	  from	  further	  attack	  by	  immune	  cells	  (221).	  Both	  α-­‐toxin	  
and	   α-­‐type	   PSMs	   promote	   dermonecrosis	   and	   have	   been	   shown	   essential	   to	   the	  
maximal	  formation	  of	  skin	  abscesses	  in	  rabbits	  infected	  with	  CA-­‐MRSA	  (222),	  whereas	  γ-­‐
toxin	  is	  not	  required	  for	  this	  process	  but	  rather	  is	  strongly	  upregulated	  in	  human	  blood	  
and	  has	  been	  implicated	  in	  iron	  acquisition	  (223).	  	  
	   In	   addition	   to	   requiring	   means	   to	   evade	   the	   host	   immune	   system,	   the	  
staphylococci	  must	  also	  adapt	  to	  the	  nutrient	  limited	  conditions	  within	  the	  host	  in	  order	  
to	   survive	   and	   replicate.	   To	   meet	   its	   nutritional	   requirements,	   S.	   aureus	   encodes	  
multiple	  confirmed	  transporters	  of	  branched	  chain	  amino	  acids	  (e.g.	  brnQ1	  and	  brnQ2),	  
several	   putative	   oligopeptide	   permeases	   (e.g.	   opp1-­‐5A;	   see	   Section	   1.5.3.2),	   and	   a	  
plethora	   of	   iron	   and/or	   heme	   acquisition	   systems.	   As	   described	   previously,	   iron	  
deprivation	   is	   a	   fundamental	   cue	   indicating	   entry	   into	   the	   host,	   and	   results	   in	   the	  
upregulation	  of	   several	   iron	  uptake	   systems,	  many	  of	  which	  are	   required	   for	  maximal	  
virulence	   within	   the	   host	   (223–226).	   The	   iron	   acquisition	   strategies	   of	   S.	   aureus	   are	  
depicted	  in	  Figure	  1.8	  and	  are	  summarized	  in	  Section	  1.5.	  
1.4.3. Iron	  as	  a	  key	  sensory	  signal	  in	  the	  staphylococci	  	  
As	  with	  other	  Firmicutes,	  Fur	   is	  known	  or	  anticipated	  to	   regulate	   the	  expression	  of	  all	  
dedicated	   iron	   acquisition	   systems	   of	   S.	   aureus	   (227,	   228).	   Additionally,	   Fur	   acts	  
indirectly	  on	  the	  expression	  of	  select	  virulence	  factors	  and	  immunomodulatory	  factors,	  
through	  control	  of	  other	  regulatory	  proteins	  such	  as	  CodY,	  RsbU,	  and	  Sae,	  or	  small	  RNAs	  




Figure	  1.8.	  Iron	  acquisition	  systems	  in	  the	  staphylococci.	  
A,	   Siderophore-­‐dependent	   iron	   uptake	   systems.	   B,	   Siderophore-­‐independent	   iron	  
uptake	   systems.	   Each	   system	   is	   discussed	   in	   the	   text,	   with	   the	   exception	   of	   SitABC,	  
which	   is	   a	   dedicated	   manganese	   transporter	   in	   S.	   aureus.	   The	   open	   reading	   frame	  
accession	   number,	   based	   on	   S.	   aureus	   COL	   genome,	   for	   each	   of	   the	   iron-­‐regulated	  
substrate-­‐binding	   proteins	   (blue)	   is	   indicated.	   The	   directionality	   indicated	   for	   each	   of	  
the	   genes	   is	   as	   in	   the	   genome.	   The	   red	   star	   represents	   heme	   and	   the	   open	   star	  
represents	  protoporphyrin	  IX.	  Hb,	  hemoglobin;	  Hp,	  haptoglobin.	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networks	   is	  outside	   the	  scope	  of	   this	   chapter,it	   is	  evident	   that	  Fur	  plays	  an	   important	  
role	   in	   the	  pathophysiology	  of	   the	   staphylococci.	  Reciprocal	  expression	  of	   iron	  uptake	  
genes	  and	   immune	  evasion	  factors	  suggest	  the	  staphylococci	  prioritize	   iron	  acquisition	  
over	  escape	  from	  immune	  cells	  under	  iron	  restriction	  and,	  indeed,	  fur	  mutants	  are	  more	  
susceptible	  to	  neutrophil-­‐mediated	  killing.	  Fur	  does,	  however,	  coordinate	  up-­‐regulation	  
of	  secreted	  toxins	  under	  iron	  restriction,	  specifically	  cytolysins	  and	  hemolysins,	  allowing	  
for	   access	   to	   host-­‐sequestered	   iron,	   and	   therefore	   is	   an	   important	   facet	   of	   iron	  
homeostasis	  in	  vivo	  (227).	  
	   Iron	  homeostasis	  is	  also	  closely	  linked	  to	  the	  oxidative	  stress	  response,	  whereby	  
fur	  itself	  is	  controlled,	  in	  part,	  by	  the	  peroxide	  stress	  regulator,	  PerR	  (230–232).	  Briefly,	  
under	  conditions	  of	  oxidative	  stress,	  PerR	  helps	  to	  mitigate	  production	  of	   iron-­‐induced	  
ROS	   by	   de-­‐repressing	   fur,	   thus	   allowing	   Fur	   to	   repress	   iron	   acquisition.	   Fur	   is	   also	   a	  
positive	   regulator	   of	   catalase	   expression	   (katA),	   which	   further	   helps	   to	   allay	   the	  
generation	  of	  ROS	  by	  catalyzing	  the	  decomposition	  of	  H2O2	  to	  H2O	  and	  O2	  when	  iron	  is	  
in	  excess	  (230).	  The	  means	  by	  which	  Fur	  positively	  regulates	  genes	  in	  the	  staphylococci	  
is	  unknown	  but,	  as	  with	  E.	  coli	  and	  B.	  subtilis,	   is	   likely	  due	  to	  the	  action	  of	  small	  RNAs	  
(sRNAs),	   that	   are	   under	   negative	   regulation	   by	   Fur	   (233,	   234).	   While	   not	   yet	  
demonstrated	   for	   the	   staphylococci,	   it	   is	   likely	   that	   sRNAs	   are	   involved	   both	   in	   the	  
regulation	   of	   katA,	   as	   well	   as	   the	   iron-­‐sparing	   response	   (see	   below).	   The	  
multidimensional	   nature	   of	   the	   regulation	   of	   iron	   uptake	   is	   necessary	   both	   to	   ensure	  
adequate	   acquisition	   for	  metabolic	   purposes,	   while	   at	   the	   same	   time,	   eschewing	   the	  
production	  of	  toxic	  free	  radicals.	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1.4.3.1. The	  “iron-­‐sparing	  response”	  -­‐	  metabolic	  rearrangement	  during	  iron-­‐starvation	  	  
Fur	   fulfills	   two	   essential	   roles	   in	   iron	   homeostasis;	   in	   addition	   to	   derepressing	   iron	  
acquisition	   systems	   to	   facilitate	   uptake	   during	   starvation,	   Fur	   also	   coordinates	   a	  
metabolic	  rearrangement	  that	  helps	  to	  reduce	  cellular	  demands	  for	  iron,	  referred	  to	  as	  
the	   “iron-­‐sparing	   response”.	   Characterized	   in	   both	   S.	   aureus	   and	  B.	   subtilis,	   the	   iron-­‐
sparing	  response	  suppresses	  expression	  of	  “low	  priority”	  iron-­‐containing	  enzymes,	  thus	  
reserving	   iron	   for	   indispensible	  metabolic	   pathways	   (233,	   235,	   236).	   At	   a	  mechanistic	  
level,	  sRNA	  coordinates	  the	  iron-­‐sparing	  response.	  In	  B.	  subtilis,	  the	  sRNA	  FsrA,	  aided	  by	  
three	   small	   Fur	   basic	   proteins	   (FbpA-­‐C,	   proposed	   to	   act	   as	   RNA	   chaperones),	   post-­‐
transcriptionally	   represses	   expression	   of	   some	   non-­‐essential	   iron-­‐containing	   enzymes	  
(233,	   236,	   237).	   Most	   notably,	   TCA	   cycle	   activity	   is	   significantly	   reduced	   under	   iron	  
restriction	   (e.g.,	   aconitase	   and	   succinate	   dehydrogenase	   are	   iron-­‐sulphur	   cluster-­‐
containing	  enzymes	  and	  major	  targets	  of	  FsrA	  in	  B.	  subtilis),	  whereas	  the	  expression	  of	  
glycolytic	   enzymes	   is	   increased.	   The	   accumulation	   and	   subsequent	   fermentation	   of	  
glycolysis-­‐derived	  pyruvate	   is	  proposed	   to	   facilitate	   two	  additional	   activities	  beneficial	  
to	  growth	  under	  iron	  starvation.	  Firstly,	  it	  allows	  for	  the	  production	  of	  staphyloferrin	  B	  
precursors	   (oxaloacetate	   and	   acetyl-­‐CoA,	   see	   Section	   1.5.1.1)	   in	   the	   absence	   of	   TCA	  
cycle	  activity	  and,	  secondly,	  the	  accumulation	  of	  acidic	  end-­‐products	  within	  the	  vicinity	  
of	   invading	   staphylococci	  may	   help	   liberate	   iron	   from	   Tf	   (235,	   238).	   In	   summary,	   the	  
actions	   of	   the	   iron-­‐sparing	   response	   allow	   bacteria	   to	   prioritize	   iron	   utilization	  within	  




1.5. STAPHYLOCOCCAL	  STRATEGIES	  FOR	  IRON	  ACQUISITION	  
1.5.1. Transferrin-­‐iron	  acquisition	  by	  the	  staphylococci	  	  
Unlike	   the	   Neisseriaceae,	   Pasteurellaceae,	   and	   Moraxellaceae,	   described	   above,	   no	  
specific	   receptors	   for	   the	   binding	   of	   Tf	   and/or	   Lf	   have	   been	   identified	   in	   the	  
staphylococci.	   As	   such,	   the	   acquisition	   of	   iron	   from	   host	   glycoproteins	   by	   S.	   aureus	  
appears	  to	  be	  wholly	  dependent	  upon	  the	  elaboration	  of	  endogenous	  siderophores,	  the	  
usurping	  of	  xenosiderophores,	  and	  the	  utilization	  of	  catecholamine	  stress	  hormones	  to	  
liberate	  iron	  from	  Tf,	  as	  described	  below.	  
1.5.1.1. Staphyloferrin	  A	  and	  staphyloferrin	  B	  –	  siderophores	  of	  S.	  aureus	  
In	   response	   to	   iron	   starvation,	   two	   α-­‐hydroxycarboxylate	   type	   siderophores	   may	   be	  
produced	  by	   the	  staphylococci:	   staphyloferrin	  A	   (SA)	  and/or	  staphyloferrin	  B	   (SB).	  The	  
biosynthesis	  of	  SA	  and	  SB	  has	  been	  well-­‐characterized	  within	  the	   last	  decade,	  and	  the	  
enzymes	  for	  the	  generation	  and	  export	  of	  the	  two	  staphyloferrins	  are	  encoded	  from	  the	  
Fur-­‐regulated	   loci	   sfaABCD	   (239,	   240)	   and	   sbnABCDEFGHI,	   respectively	   (241–243)	  
(Figure	  1.8).	  The	  vast	  majority	  of	  both	  CoPS	  and	  CoNS	  encode	  for	  the	  production	  of	  SA,	  
with	   the	   notable	   exception	   of	   S.	   lugdunensis,	   which	   bears	   a	   large	   deletion	   in	   the	   sfa	  
locus	  (153,	  240,	  244).	  In	  contrast,	  despite	  early	  reports	  describing	  SB	  production	  by	  the	  
CoNS	  (245–247),	  relatively	  few	  CoNS	  genomes	  (e.g.	  S.	  arlettae,	  S.	  equorum)	  possess	  the	  
SB	  biosynthetic	  locus,	  and	  instead	  its	  production	  seems	  to	  be	  largely	  limited	  to	  S.	  aureus	  
and	  other	  CoPS.	  A	  third,	  structurally	  uncharacterized	  siderophore,	  named	  aureochelin,	  
was	   reported	   in	   S.	   aureus,	   but	   no	   further	   studies	   have	   been	   done	   to	   elucidate	   its	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structure	  (248).	  Deletion	  of	  the	  loci	  for	  both	  SA	  and	  SB	  production	  is	  sufficient	  to	  abolish	  
S.	  aureus	  growth	  in	  iron-­‐restricted	  media	  containing	  serum	  or	  Tf	  (240,	  249)	  suggesting,	  
at	  the	  very	  least,	  that	  these	  are	  the	  predominant	  siderophores	  produced	  by	  S.	  aureus.	  
1.5.1.1.1. Biosynthesis	  of	  SA	  and	  SB	  
Both	  SA	  and	  SB	  coordinate	  iron	  through	  citrate-­‐based	  moieties,	  where	  SA	  is	  assembled	  
from	  two	  units	  of	  citrate	  that	  are	  linked	  by	  a	  central	  D-­‐ornithine	  backbone	  (239).	  SfaC	  is	  
a	   putative	   pyridoxal	   5'-­‐phosphate(PLP)-­‐dependent	   amino	   acid	   racemase,	   which	  
functions	   ostensibly	   to	   catalyze	   the	   formation	   of	   D-­‐ornithine	   from	   its	   antipode	   (L-­‐
ornithine)	  prior	   to	   incorporation	   into	   the	  siderophore	   (239,	  240).	  Condensation	  of	   the	  
citrate	  molecules	  with	  D-­‐ornithine	  is	  catalyzed	  by	  NIS	  synthetases	  SfaB	  and	  SfaD,	  which	  
are	   sufficient	   to	   reconstitute	   functional	   SA	   in	   vitro	   in	   the	   presence	   of	   the	  
aforementioned	  substrates	  and	  ATP	  (239).	  Although	  citrate	  is	  an	  essential	  precursor	  to	  
the	   synthesis	  of	  both	   SA	  and	  SB,	   expression	  of	   the	  TCA	   cycle	   citrate	   synthase,	  CitZ,	   is	  
downregulated	   under	   iron-­‐restriction	   by	   way	   of	   the	   iron-­‐sparing	   response,	   as	   above	  
(233,	   235,	   236).	   Further,	   the	   biosynthetic	   locus	   for	   SA	   does	   not	   encode	   a	   dedicated	  
citrate	   synthase	   (239),	   further	   obfuscating	   an	   obvious	   source	   of	   citrate	   for	   SA	  
production;	   elucidation	   of	   the	   source	   of	   citrate	   for	   staphyloferrin	   production	   is	   the	  
subject	  of	  Chapter	  2	  of	  this	  thesis.	  Upon	  synthesis,	  efflux	  of	  apo-­‐SA	  is	  mediated	  by	  SfaA,	  
a	   membrane	   transport	   protein	   of	   the	   major	   facilitator	   superfamily	   (MFS),	   where	  




	   While	   functionally	   similar	   to	   SA,	   SB	   is	   a	   chemically	   distinct	   siderophore	  
assembled	   by	   three	   NIS	   synthetases,	   SbnCEF,	   from	   one	   unit	   each	   of	   citrate	   and	   α-­‐
ketoglutarate	  (α-­‐KG)	  and	  two	  units	  of	  L-­‐2,3-­‐diaminopropionate	  (L-­‐Dap)	  (241).	  SbnH	  is	  a	  
PLP-­‐dependent	   carboxylase,	   which	   also	   aids	   in	   the	   assembly	   of	   functional	   SB	   by	  
decarboxylating	   the	   biosynthetic	   intermediate	   β-­‐citryl-­‐2,3-­‐diaminopropionic	   acid	   to	  
citryl-­‐diaminoethane,	   allowing	   for	   subsequent	   incorporation	   of	   the	   second	   L-­‐Dap	   unit	  
(241).	  While	  SbnA	  and	  SbnB	  were	  previously	  shown	  essential	  to	  the	  production	  of	  L-­‐Dap,	  
and	   indeed	  to	  the	  production	  of	   functional	  SB	   in	  vitro	   (250),	   the	  biosynthetic	  pathway	  
for	  this	  important	  precursor	  of	  both	  siderophores	  and	  antibiotics	  was	  recently	  detailed.	  
In	  brief,	   SbnA	  and	  SbnB	   function	   in	   tandem	   to	  generate	   L-­‐Dap	  and	  α-­‐KG,	  where	  SbnA	  
first	  catalyzes	  the	  formation	  of	  a	  novel	  amino	  acid	  intermediate,	  N-­‐(1-­‐amino-­‐1-­‐carboxyl-­‐
2-­‐ethyl)-­‐glutamic	  acid	  (ACEGA)	  from	  substrate	  molecules	  O-­‐phospho-­‐L-­‐serine	  (OPS)	  and	  
L-­‐glutamate.	   In	   the	  presence	  of	  NAD+,	   SbnB	  oxidatively	  hydrolyzes	  ACEGA	   releasing	   L-­‐
Dap	   and	   α-­‐KG	   (251),	   thus	   providing	   two	   of	   the	   three	   SB	   precursor	   molecules.	  
Additionally,	  SbnG	  is	  a	  novel	  citrate	  synthase,	  catalyzing	  the	  in	  vitro	  formation	  of	  citrate	  
from	   oxaloacetate	   (OAA)	   and	   acetyl	   coenzyme	   A	   (acetyl-­‐CoA)	   (252);	   thus,	   it	   would	  
appear	   that	   sbn	   encodes	   all	   the	   of	   enzymes	   necessary	   to	   generate	   the	   three	   SB	  
precursor	  molecules	  and	  assemble	  them	  into	  functional	  SB.	  Notably,	  deletion	  of	  the	  SB	  
biosynthetic	  locus	  does	  not	  impair	  synthesis	  of	  SA,	  suggesting	  that	  citrate	  is	  not	  derived	  
from	  SbnG	   for	  SA	   synthesis,	   as	   is	   addressed	   further	   in	  Chapter	  2.	   Following	  assembly,	  
apo-­‐SB	   is	   secreted	   into	   the	   extracellular	   milieu	   in	   part	   by	   SbnD,	   another	   MFS	   efflux	  
protein,	  and	  by	  an	  alternate,	  as	  yet	  unidentified,	  exporter	  (152).	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1.5.1.1.2. Transport	  of	  holo-­‐SA	  and	  SB	  
Subsequent	   to	   export,	   SA	   and	   SB	   solubilize	   and	   bind	   iron	   from	   precipitated	   ferric	  
hydroxides	  in	  the	  extracellular	  environment,	  or	  strip	  iron	  from	  host	  Tf	  and/or	  Lf.	  Uptake	  
of	   ferrated	   SA	   or	   SB	   occurs	   by	   way	   of	   the	   dedicated	   ABC-­‐type	   transporters	   HtsABC	  
(initially	   described	   as	   a	   heme-­‐transport	   system)	   and	   SirABC	   (for	   staphylococcal	   iron-­‐
regulated),	  respectively,	  whose	  encoding	  genes	  are	  located	  adjacent	  to,	  but	  transcribed	  
divergently	   from,	   the	   biosynthetic	   loci	   of	   their	   cognate	   siderophores	   (240,	   243,	   253)	  
(Figure	  1.8).	  Both	  HtsBC	  and	  SirBC	  represent	  the	  heterodimeric	  permease	  components	  
of	   these	   transporters,	  which	   are	   energized	   to	   transport	   Fe3+-­‐staphyloferrin	   complexes	  
through	   the	   activity	   of	   a	   non-­‐dedicated	   and	   genetically-­‐unlinked	   ATPase,	   FhuC	   (240,	  
254).	   As	   previously	   reviewed,	   HtsA	   and	   SirA	   are	   Class	   III	   (Cluster	   A-­‐II)	   iron-­‐regulated,	  
substrate	  binding	   lipoproteins	  (IRLPs;	  hereafter	  simply	  referred	  to	  as	  substrate	  binding	  
proteins	   (SBPs)),	  with	  a	  bilobate	  structure	  comprised	  of	  two	   independently	   folded	  α/β	  
domains	   linked	  by	   a	   long	  α-­‐helical	   spine	   (122,	   for	   a	   detailed	   review	  of	   staphylococcal	  
substrate	  binding	  proteins	  see	  123).	  Fe3+-­‐SA	  and	  SB	  are	  coordinated	  in	  a	  shallow,	  basic,	  
cleft	  formed	  between	  the	  two	  lobes	  of	  HtsA	  and	  SirA,	  respectively,	  and	  while	  HtsABC	  (as	  
the	  name	  implies)	  was	  previously	  implicated	  in	  heme-­‐iron	  acquisition	  (90),	  it	  is	  unlikely	  
that	  the	  binding	  pocket	  of	  HtsA	  also	  coordinates	  heme	  (240,	  255,	  256).	  A	  dual	  role	  for	  
the	  HtsBC	  permease	  in	  heme	  and	  Fe-­‐SA	  acquisition	  has	  not,	  however,	  been	  conclusively	  
disproven.	  
Although	  SA	  and	  SB	  are	  both	  anionic,	  α-­‐hydroxycarboxylate-­‐type	   siderophores,	  
their	  transporters	  are	  not	  substitutable,	  as	  HtsABC	  is	  dedicated	  to	  the	  transport	  of	  Fe-­‐
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SA,	  and	  SirABC	  is	  dedicated	  to	  the	  transport	  of	  Fe-­‐SB	  (240,	  241).	  The	  exquisite	  selectivity	  
of	   SirA	   and	  HtsA	   for	   their	   cognate	   Fe3+-­‐siderophores,	  with	   affinities	   in	   the	   nanomolar	  
range	  (255,	  256),	  suggests	  that	  these	  SBPs	  must	  possess	  exacting	  means	  of	  coordinating	  
Fe-­‐SB	  and	  Fe-­‐SA	  complexes,	  respectively.	  Recent	  resolution	  of	  the	  crystal	  structures	  for	  
both	   apo-­‐	   and	  holo-­‐HtsA	  paved	   the	  way	   for	   the	   interrogation	   of	   the	   specific	   residues	  
involved	  in	  SA	  coordination	  (240,	  256).	  Four	  key	  residues,	  R104,	  R126,	  H209,	  and	  R306	  
have	  been	  identified	  as	  essential	  to	  Fe3+-­‐staphyloferrin	  A	  binding	  (257).	  Three	  of	  these	  
residues,	  R104,	  R126	  and	  R306,	  are	  clustered	  together	  within	  the	  HtsA	  binding	  pocket	  
and	   form	   a	   positively	   charged	   platform	  upon	  which	   Fe-­‐SA	   is	   coordinated	   through	   the	  
terminal	   carboxyl	  moieties	   of	   citrate	   (Figure	  1.9).	  An	   additional	   key	   contact	   is	   formed	  
between	  H209	  and	  the	  carbonyl	  group	  on	  the	  ornithine	  backbone	  of	   the	  more	  deeply	  
buried	   citrate,	   which,	   like	   the	   arginine	   residues,	   is	   highly	   conserved	   amongst	   HtsA	  
orthologues.	  Despite	   the	  high	   sequence	   similarity	  between	  SirA	  and	  HtsA	   (~32%),	   and	  
overall	  structural	  conservation	  between	  these	  proteins,	  only	  one	  coordinating	  residue	  is	  
conserved	  between	  SirA	  and	  HtsA	  (R125	  and	  R126,	  respectively)	  (255,	  257).	  The	  lack	  of	  
conserved	   binding	   residues	   between	   SirA	   and	   HtsA,	   differential	   orientation	   of	   their	  
associated	   siderophores	  within	   the	   binding	   pocket	   (the	   long	   axis	   of	   Fe-­‐SB	   is	   oriented	  
perpendicularly	   to	   the	   protein	   domain	   interface	   in	   SirA,	  whereas	   Fe-­‐SA	   is	   rotated	   90°	  
relative	  to	  this	  in	  HtsA),	  and	  distinct	  conformational	  changes	  induced	  in	  the	  C-­‐terminal	  
domains	   of	   these	   proteins	   upon	   ligand	  binding	   are	   all	   likely	   to	   contribute	   to	   the	   high	  
degree	  of	  specificity	  these	  receptors	  possess	  for	  their	  cognate	  Fe3+	  siderophores.	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Figure	  1.9.	  HtsA-­‐staphyloferrin	  structures.	  	  
Ribbon	  diagram	  of	  S.	  aureus	  HtsA	  (PDB	  3LI2)	  coloured	  from	  the	  N-­‐terminus	  (blue)	  to	  the	  
C-­‐terminus	   (red),	   also	   illustrating	   the	   surface	   of	   the	   protein	   and	   the	   bound	   Fe3+-­‐SA	  
molecule,	  shown	  in	  stick	  format	  (panel	  A).	  Shown	  in	  panel	  B	  is	  the	  stick	  structure	  of	  Fe3+-­‐
SA,	  bound	  to	  iron	  (red	  sphere),	  and	  coordinated	  by	  a	  rigid,	  positively-­‐charged	  platform	  
in	  HtsA	  (PDB	  3LI2).	  In	  SA,	  carbon,	  nitrogen	  and	  oxygen	  are	  coloured	  cyan,	  blue	  and	  red,	  
respectively.	   The	   Arg	   residues	   from	   HtsA	   are	   shown	   in	   stick	   format,	   with	   carbons,	  
nitrogens	  and	  oxygens	  coloured	  yellow,	  blue	  and	  red,	  respectively.	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  While	  this	  specificity	  precludes	  SirA	  and	  HtsA	  from	  functioning	  broadly	  in	  the	  uptake	  of	  
exogenous	  siderophores,	  it	  may	  serve	  the	  organism	  well	  for	  the	  high	  affinity	  acquisition	  
of	   low	   amounts	   of	   SA	   and	   SB	   in	   the	   extracellular	  milieu	   and	   further	  may	   render	   the	  
staphylococci	  competitive	  against	  other	  organisms	  attempting	  to	  appropriate	  SA	  and	  SB	  
to	   meet	   their	   own	   iron	   demands	   (255,	   256).	   As	   with	   other	   SBPs,	   the	   docking	   and	  
subsequent	   uptake	   of	   holo-­‐HtsA	   and	   holo-­‐SirA	   is	   mediated	   by	   salt	   bridges	   formed	  
between	   conserved	   glutamic	   acid	   residues	   on	   each	   domain	   of	   the	   substrate	   binding	  
proteins	  (E110	  and	  E250	  in	  HtsA,	  E109	  and	  E245	  in	  SirA),	  and	  positive	  patches	  comprised	  
of	   three	   conserved	   arginine/lysine	   residues	   on	   the	   exofacial	   side	   of	   their	   respective	  
permeases	  (124,	  255,	  257).	  Specific	  reductions	  in	  the	  interglutamic	  acid	  distances	  upon	  
ligand	   binding	   by	   HtsA	   and	   SirA	   are	   proposed	   to	   help	   the	   associated	   permease	  
distinguish	  between	  apo-­‐	  and	  holo-­‐	  forms	  of	  these	  receptor	  proteins	  (255).	  	  
1.5.1.2. Transport	  of	  exogenous	  siderophores	  
As	   previously	   described,	   in	   addition	   to	   utilizing	   endogenously	   produced	   siderophores,	  
many	   bacteria	   are	   also	   capable	   of	   appropriating	   siderophores	   produced	   by	   other	  
microorganisms,	   termed	   xenosiderophores.	   Although	   unable	   to	   synthesize	  
hydroxamate-­‐type	   siderophores	   (248),	   S.	   aureus	   has	   long	   been	   reported	   to	   scavenge	  
iron	   using	   desferrioxamine	   B,	   a	   hydroxamate	   siderophore	   produced	   by	   Streptomyces	  
pilosus,	   and	   its	  mesylate	   salt,	   Desferal,	   a	   widely	   used	   drug	   for	   the	   treatment	   of	   iron	  
overload	   diseases,	   as	   introduced	   in	   Section	   1.2.3	   (253,	   258,	   259).	   Early	   investigations	  
revealed	  that	  this	  attribute	  was	  not	  limited	  to	  the	  uptake	  of	  desferrioxamine	  B,	  but	  also	  
included	   other	   hydroxamate	   siderophores	   including	   ferrichrome	   (from	   the	   fungus	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Ustilago	  sphaerogena),	   coprogen	   (from	  Neurospora	  crassa),	   and	  aerobactin	   (produced	  
by	  some	  members	  of	  the	  Enterobacteriaceae),	  as	  well	  as	  catechol	  siderophores	  such	  as	  
enterobactin	   (259,	   260).	   To	   exploit	   these	   xenosiderophores	   as	   an	   iron	   source,	   the	  
staphylococci	   require	   additional	   uptake	   systems	   specific	   to	   hydroxamate	   and/or	  
catechol-­‐type	  siderophores.	  
1.5.1.2.1. Utilization	  of	  hydroxamate	  siderophores	  	  
The	  use	  of	   hydroxamate	   siderophores	  by	   the	   staphylococci	   has	   been	   attributed	   to	   an	  
ABC	   transport	   system,	   termed	   Fhu	   (for	   ferric	   hydroxamate	   uptake).	   Conserved	  
components	   of	   this	   iron-­‐regulated	   transporter	   include	   two	   integral	   transmembrane	  
proteins,	  FhuB	  and	  FhuG,	  and	  the	  FhuC	  ATPase	  (254,	  259).	  Fe3+-­‐hydroxamate	  binding	  in	  
S.	   aureus	   is	   facilitated	   by	   two	   paralogous	   and	   partially	   redundant	   SBPs,	   FhuD1	   and	  
FhuD2	  (261–263),	  where	  FhuD2	  recognizes	  common	  hydroxamate	  features	  allowing	  for	  
the	  accommodation	  of	  a	  wide	  variety	  of	  these	  siderophores	  (264).	  FhuD2	  has	  also	  been	  
identified	   as	   a	   staphylococcal	   virulence	   factor,	   with	   a	   potential	   role	   in	   dissemination,	  
since	  its	  disruption	  yielded	  a	  strain	  with	  reduced	  staphylococcal	  burden	  in	  the	  blood	  and	  
kidneys	  of	  infected	  mice	  (220,	  265).	  Recent	  structural	  characterization	  of	  apo-­‐	  and	  holo-­‐
FhuD2	   (in	  complex	  with	   ferrichrome	  or	   ferrioxamine	  B)	   revealed	   that,	   similar	   to	  other	  
Class	  III	  (Cluster	  A-­‐II)	  SBPs	  (122),	  the	  protein	  undergoes	  minimal	  conformational	  changes	  
upon	   siderophore	   binding,	   an	   important	   facet	   of	   vaccine	   targets	   where	   well-­‐ordered	  
epitopes	  are	  desired	  (263,	  264,	  266).	  Notably,	  FhuD2	  has	  indeed	  attracted	  attention	  as	  a	  
potential	  anti-­‐staphylococcal	  vaccine	  target	  (265,	  266),	  and	  immunization	  of	  mice	  with	  
FhuD2	   conferred	   resistance	   to	   lethal	   challenge	   by	   S.	   aureus	   in	   a	   sepsis	   model.	   The	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protective	  effects	  of	  immunization	  were	  attributed	  not	  only	  to	  opsonophagocytic	  killing	  
mediated	  by	   functional	  antibodies	  derived	  against	  FhuD2,	  but	  also	   to	   the	   inhibition	  of	  
bacterial	  proliferation	  through	  blocking	  FhuD2	  iron	  acquisition	  (265).	  
1.5.1.2.2. Utilization	  of	  catechols/catecholamine	  stress	  hormones	  as	  an	  iron	  source	  	  
The	  catechol	  family	  of	  siderophores	  are	  also	  recognized	  by	  receptors	  expressed	  by	  the	  
staphylococci	   (143,	   249).	   Moreover,	   in	   the	   presence	   of	   serum,	   catecholamine	   stress	  
hormones	   have	   also	   been	   shown	   to	   stimulate	   the	   growth	   of	   bacteria,	   including	  
members	  of	  the	  CoNS	  (267–270).	  This	  phenomenon	  has	  been	  attributed	  to	  the	  ability	  of	  
these	  hormones,	  including	  epinephrine,	  norepinephrine,	  and	  dopamine,	  to	  promote	  the	  
reduction	   of	   Tf-­‐bound	   Fe3+	   to	   Fe2+,	   eliciting	   an	   exchange	   of	   iron	   from	   Tf	   to	  
catecholamine	  (271).	  The	  ability	  of	  S.	  aureus	  to	  utilize	  Fe-­‐bound	  catecholamines,	  as	  well	  
as	   catechol	   siderophores,	   such	   as	   enterobactin,	   is	   afforded	   by	   the	   expression	   of	   the	  
widely	   conserved	   staphylococcal	   siderphore	   transport	   system,	   SstABCD	   (249),	   where	  
SstA	   and	   SstB	   are	   the	   transmembrane	   domains,	   SstC	   is	   an	   ATPase,	   and	   SstD	   is	   the	  
catechol/catecholamine-­‐binding	   lipoprotein	   (249,	   272).	   SstD	   binds	   catechol	  
siderophores	  and	  catecholamine	  hormones	  with	  micromolar	  affinity,	   in	  contrast	  to	  the	  
much	  higher	  affinity	  observed	  for	  HtsA	  and	  SirA	  for	  SA	  and	  SB.	  The	  reduced	  affinity	  of	  
SstD	   for	   its	   ligands	  may	  reflect	  a	  sacrifice	  of	   ligand	  affinity	   for	  greater	   ligand	  diversity.	  
Indeed,	   the	  Sst	   transport	  system	  enhances	  S.	  aureus	  growth	   in	   the	  presence	  of	  serum	  
and	   catechols	   or	   catecholamines,	   but	   only	   in	   the	   absence	   of	   SA	   and	   SB	   production	  
which,	  when	  present,	  mask	  the	  function	  of	  SstABCD	  (249).	  However,	  inactivation	  of	  sst	  
does	   reduce	   bacterial	   burden	   in	  murine	   organs	   during	   a	   systemic	  model	   of	   infection,	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indicating	   it	   does	   play	   a	   role	   in	   iron	   acquisition	   in	   vivo	   (249).	   This	   suggests	   that,	   in	  
conjunction	   with	   siderophores,	   catechols/catecholamines	   may	   be	   at	   sufficient	  
concentrations	   to	   subvert	   the	   bacteriostatic	   effects	   of	   Tf	   and/or	   Lf	   and	   allow	   for	  
proliferation	  and	  dissemination	  to	  occur	  within	  the	  host;	  this	  may	  be	  particularly	  true	  in	  
the	  gastrointestinal	  tract,	  where	  catecholamine	  stress	  hormones,	  Lf,	  and	  bacteria	  all	  co-­‐
localize	   (273,	   274).	   Conditions	   that	   enhance	   catecholamine	   hormone	   levels,	   such	   as	  
stress,	  neuron	  damage,	  or	  therapeutic	  treatment	  (268,	  273,	  275),	  could	  further	  enhance	  
the	  risk	  of	  staphylococcal	  infection.	  	  
1.5.2. Heme-­‐iron	  acquisition	  by	  the	  staphylococci	  	  
Despite	  possessing	  numerous	  siderophore-­‐mediated	  systems	  for	  the	  acquisition	  of	  iron	  
from	   serum	   Tf,	   the	   preferred	   iron	   source	   for	   S.	   aureus	   is	   heme	   (90).	   To	   access	   the	  
lucrative	   host	   heme-­‐iron	   pool,	   the	   staphylococci	   express	   not	   only	   hemolysins	   to	  
facilitate	  erythrocyte	  lysis	  (276),	  but	  also	  at	  least	  one	  high-­‐affinity	  acquisition	  system	  to	  
capture	   free	   heme-­‐iron.	   The	   Isd	   pathway	   of	   S.	   aureus	   is	   the	   most	   extensively	  
characterized	   heme-­‐iron	   acquisition	   system	   of	   Gram-­‐positive	   pathogens,	   and	   indeed	  
serves	   as	   the	   archetype	   for	   orthologous	   mechanisms	   that	   transfer	   extracted	   heme,	  
intact,	  from	  the	  cell	  surface	  to	  the	  cytoplasm.	  Although	  alternate	  mechanisms	  of	  heme-­‐
iron	   acquisition	   have	   been	   proposed	   for	   S.	   aureus,	   as	   discussed	   below,	   no	   alternate	  





1.5.2.1. Iron-­‐regulated	  surface	  determinant	  pathway	  –	  The	  S.	  aureus	  paradigm	  
In	  S.	  aureus,	  Isd	  is	  comprised	  of	  nine	  iron-­‐regulated	  proteins	  directly	  involved	  in	  heme-­‐
iron	   acquisition,	   and	   sortase	  B	   (SrtB)	  which	   is	   also	   encoded	   from	  within	   the	   Isd	   locus	  
(277,	   278).	   In	   brief,	   three	   heme-­‐binding	   proteins,	   IsdB,	   IsdH/HarA,	   and	   IsdA,	   are	  
covalently	  anchored	   to	  peptidoglycan	  by	  sortase	  A	   (SrtA)	   (279)	  while	  a	   fourth,	   IsdC,	   is	  
tethered	  by	   its	  C-­‐terminus	   to	   the	  cell	  wall	  by	  SrtB	   (277,	  278,	  280,	  281).	  The	  proposed	  
architectural	   arrangement	   of	   these	   cell	   wall-­‐anchored	   proteins	   (see	   Figures	   1.2	   and	  
1.8B)	  bears	  resemblance	  to	  a	  funnel,	  and	  extensive	  experimental	  evidence	  suggests	  that	  
heme	  extracted	  from	  hemoproteins	  bound	  by	  IsdB	  and	  IsdH	  at	  the	  cell	  surface	  is	  relayed	  
through	   the	   cell	   wall	   by	   IsdA	   and	   IsdC.	   IsdC	   effectively	   serves	   as	   the	   central	   conduit	  
through	  which	   heme	   is	   directed	   to	   the	   substrate-­‐binding	   lipoprotein,	   IsdE	   (282,	   283),	  
and	  its	  associated	  membrane	  permease,	  IsdF.	  IsdE	  and	  IsdF	  are	  both	  components	  of	  an	  
ABC	  transporter	  (284,	  285),	  whose	  activity	  is	  powered	  by	  an	  undefined	  ATPase.	  IsdD	  is	  a	  
predicted	  membrane	  protein	  purportedly	   functioning	   in	  conjunction	  with	   IsdEF.	  A	  role	  
for	  this	  protein	  in	  heme	  translocation,	  however,	  has	  not	  been	  conclusively	  determined,	  
and	   homologues	   of	   isdD	   are	   absent	   from	   the	   genomes	   of	   other	   Gram-­‐positive	  
pathogens.	  Once	  internalized,	  heme	  is	  degraded	  by	  one	  of	  two	  heme	  monooxygenases,	  
IsdG	  or	  IsdI,	  releasing	  free	  iron	  from	  the	  tetrapyrrole	  ring	  for	  use	  by	  the	  bacterium	  (286,	  
287).	  
1.5.2.1.1. Structure	  and	  function	  of	  NEAT	  domains	  
The	   binding	   of	   hemoproteins,	   extraction	   of	   heme,	   and	   subsequent	   shuttling	   of	   heme	  
through	   the	   cell	   wall	   by	   Isd	   proteins	   is	   facilitated	   by	   NEAr	   iron	   Transporter	   (NEAT)	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domains,	  so	  termed	  for	  their	  initial	  identification	  in	  proteins	  whose	  genes	  are	  located	  in	  
proximity	  to	  others	  encoding	  putative	  Fe3+	  transporters	  (288).	  NEAT	  domains	  are	  heme	  
and/or	  hemoprotein	  binding	  modules	  consisting	  of	  ~120	  residues	  which,	  while	  variable	  
in	  primary	  amino	  acid	  sequence,	  are	  highly	  conserved	  in	  secondary	  structure	  (289).	  The	  
canonical	   NEAT	   domain	   adopts	   an	   immunoglobulin-­‐like	   sandwich	   fold,	   comprised	   of	  
eight	  antiparallel	  β-­‐strands	  and	  a	   conserved	  SXXXXY	   sequence	  which	   forms	  a	  310-­‐helix	  
(α-­‐helix)	  referred	  to	  as	  the	  “lip”	  region	  (289–296).	  Heme	  coordination	  occurs	  between	  
one	  of	   the	  β-­‐strands	   (β8),	  which	  contains	  an	  essential	  YXXXY	  heme-­‐binding	  motif,	  and	  
the	   lip	   region,	  where	   the	   first	   tyrosine	   of	   the	   heme-­‐binding	  motif	   (e.g.	   Y166	   of	   IsdA)	  
non-­‐covalently	   binds	   the	   central	   iron	   atom	  of	   heme,	   and	   the	   second	   tyrosine	   residue	  
(e.g.	  Y170	  of	  IsdA)	  provides	  a	  stabilizing	  hydrogen	  bond	  to	  the	  first	  tyrosine	  (Figure	  1.10)	  
(291,	   293–295).	   Together	   these	   interactions	   facilitate	   strong	   coordination	   of	   heme	  
within	  the	  NEAT	  domain,	  where	  conservation	  of	  the	  first	  tyrosine	  serves	  as	  a	  predictor	  
of	  NEAT	  domain	  function	  in	  heme-­‐binding	  (291).	  
While	  NEAT	  domains	  have	  been	  most	  extensively	  characterized	  in	  Gram-­‐positive	  
pathogens	   including	   S.	   aureus,	   S.	   pyogenes,	   B.	   anthracis,	   B.	   cereus	   and	   L.	  
monocytogenes,	   a	   recent	   bioinformatics	   study	   has	   revealed	   that	   they	   are	   widely	  
distributed	  within	  the	  phylum	  Firmicutes,	  and	  are	  present	  in	  both	  pathogenic	  and	  non-­‐
pathogenic	   organisms	   (289).	   In	   addition	   to	   their	   phylogenetic	   distribution,	   NEAT	  
domains	  are	  also	   found	  distributed	   in	  variable	  number	  within	   individual	  heme-­‐binding	  
proteins.	  In	  S.	  aureus,	  IsdB	  and	  IsdH	  possess	  two	  and	  three	  NEAT	  domains	  (Figure	  1.11),	  
respectively,	  whereas	  IsdA	  and	  IsdC	  each	  possess	  one	  (290–295).	  Individual	  NEAT	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Figure	  1.10.	  Overall	  structure	  of	  the	  NEAT	  domain	  of	  S.	  aureus	  IsdA.	  
The	  ribbon	  diagram	  of	  PDB	  2ITF	  illustrates	  the	  structure,	  coloured	  from	  the	  N-­‐terminus	  
(blue)	   to	   the	   C-­‐terminus	   (red).	   Heme	   bound	   by	   the	   domain,	   as	   well	   as	   the	   two	   key	  
tyrosine	   residues	   are	   shown	   as	   sticks,	   with	   carbon,	   nitrogen	   and	   oxygen	   coloured	  
yellow,	  blue	  and	  red,	  respectively.	  The	  iron	  in	  heme	  is	  shown	  as	  a	  red	  sphere.	  
	  
Figure	  1.11.	  Domain	  architecture	  of	  representative	  NEAT	  domain	  containing	  proteins	  
of	  S.	  aureus.	  
S.	  aureus	  IsdH	  and	  IsdB	  are	  compared.	  Numbers	  represent	  percent	  identity,	  followed	  by	  
percent	  total	  similarity	  between	  the	  NEAT	  domains.	  Domains	  shaded	  in	  grey	  designate	  
heme-­‐binding	  NEAT	  domains.	   For	  each	  NEAT	  domain,	   the	   sequence	   involved	   in	  either	  
heme	   or	   hemoglobin	   binding	   is	   indicated.	   LPXTG	   and	   LPQTG	   represent	   the	   sorting	  




domains	  have	  also	  evolved	  different	   functionality	  within	  the	  same	  protein,	  as	  dictated	  
by	  variability	  in	  their	  amino	  acid	  sequence	  or	  protein	  structure,	  and	  may	  include	  roles	  in	  
hemoprotein	   binding,	   heme	   extraction,	   heme	   transfer	   with	   the	   same	   protein	   and/or	  
heme	  transfer	   to	  other	  NEAT	  domain-­‐containing	  proteins	  mediated	  by	  protein-­‐protein	  
interactions.	  
	   The	   initial	   recognition	   and	   binding	   of	   Hb	   in	   S.	   aureus	   is	  mediated	   by	   IsdB	   and	  
IsdH	  (126,	  297,	  298).	  The	  N-­‐terminal	  NEAT	  domains	  of	  these	  proteins	  are	  specific	  for	  Hb	  
(or	  Hb-­‐haptoglobin)	  (297,	  299–302)	  where	  IsdB-­‐N1	  and	  IsdH-­‐N2	  can	  bind	  both	  subunits	  
of	  the	  Hb	  heterodimer	  or	  tetramer	  (αHb	  and	  βHb),	  while	  IsdH-­‐N1	  binds	  only	  αHb	  (Figure	  
1.12B	  and	  1.13)	   (292,	  303,	  304).	  Hb	  binding	  by	   these	  NEAT	  domains	   is	  mediated	  by	  a	  
conserved	  five-­‐amino	  acid	  aromatic	  motif	  (YYHFF	  in	  IsdH-­‐N1,	  and	  FYHYA	  in	  IsdH-­‐N2	  and	  
IsdB-­‐N1)	   located	  within	   an	  α-­‐helical	   loop	   structure	   at	   the	  end	  of	   the	  NEAT	  domain	  β-­‐
sandwich	   (see	   Figures	   1.11	   and	   1.13);	   mutation	   of	   any	   one	   of	   these	   key	   residues	  
severely	  hinders	  Hb	  and/or	  haptoglobin	  binding	  (126,	  292,	  300,	  303).	  In	  contrast,	  the	  C-­‐
terminal	   NEAT	   domains	   (IsdB-­‐N2	   and	   IsdH-­‐N3)	   are	   specific	   for	   the	   binding	   of	   heme	  
through	  the	  conserved	  YXXXY	  motif	  (see	  Figure	  1.11)	  (290,	  300).	  	  
Efficient	   Hb	   binding	   and	   heme	   extraction	   by	   IsdB	   and	   IsdH	   is	   facilitated	   by	   a	  




Figure	  1.12.	  Heme	  release	  from	  hemoglobin	  requires	  multiple	  domains.	  	  
In	  panel	  A	  is	  a	  ribbon	  diagram	  illustrating	  the	  structure	  of	  the	  linker	  region	  that	  resides	  
between	  IsdH	  NEAT	  domains	  2	  and	  3,	  as	  determined	  by	  NMR	  (PDB	  2LHR).	  Panel	  B	   is	  a	  
model	  of	   IsdH-­‐	  or	   IsdB-­‐dependent	  heme	  extraction	   from	  Hb	  tetramers.	  Subsequent	   to	  
binding	   to	   the	   α	   subunit	   of	   Hb,	   the	   IsdH	   or	   IsdB	   NEAT	   domains,	   linked	   by	   the	   linker	  
region,	   put	   strain	   on	   the	   tetramers,	   causing	   their	   dissociation	   and	   the	   loss	   of	   heme,	  
which	   is	  picked	  up	  by	  the	  C-­‐terminally	   located,	  heme-­‐binding	  NEAT	  domain	  present	   in	  
each	   of	   the	   proteins.	   Please	   note	   that	   this	   process,	   as	   shown,	   has	   not	   been	  





Figure	  1.13.	  Interaction	  of	  S.	  aureus	  IsdH	  NEAT	  domain	  1	  with	  the	  alpha	  chain	  of	  
human	  Hb.	  	  
The	  ribbon	  diagram	  of	  PDB	  3SZK	  illustrating	  the	  binding	  of	  IsdH-­‐N1	  (orange)	  to	  the	  αHb	  
subunit	  (red)	  of	  the	  α:β	  Hb	  dimer.	  More	  detail	  on	  the	  structure	  can	  be	  found	  in	  Kumar	  et	  
al	   (303).	   IsdH-­‐N1	  residues	  shown	  to	  be	  critical	   for	  Hb	  binding	  are	  shown	   in	  sticks	  with	  
carbon,	   nitrogen	   and	   oxygen	   coloured	   yellow,	   blue	   and	   red,	   respectively.	   The	   K11	  
residue	   in	   αHb,	   shown	   critical	   for	   Hb:IsdH	   binding,	   is	   shown	   in	   stick	  with	   carbon	   and	  
nitrogen	  coloured	  green	  and	  blue,	  respectively.	  Also	  shown	  in	  stick	  format	  are	  the	  heme	  
molecules	   bound	   in	   each	   of	   the	   subunits	   of	   Hb,	   with	   carbon,	   nitrogen	   and	   oxygen	  









IsdH-­‐N2)	  contiguous	  with	  a	  α-­‐helical	  linker	  region	  of	  ~70	  amino	  acid	  residues	  and	  the	  C-­‐
terminal	  NEAT	  domain	   (IsdB-­‐N2	   and	   IsdH-­‐N3)	   (Figures	   1.11	   and	   1.12)	   (302,	   304–307).	  
The	  linker	  region	  is	  comprised	  of	  an	  inflexible	  three-­‐helix	  bundle,	  which	  holds	  the	  N-­‐	  and	  
C-­‐terminal	  receptor	  domains	  apart	  by	  ~40	  Å	  in	  an	  elongated	  dumbbell-­‐like	  conformation	  
(Figure	  1.12B)	  (302,	  307).	  In	  IsdH,	  the	  linker	  region	  positions	  IsdH-­‐N3	  directly	  inline	  with	  
a	   globin	   heme	   pocket	   of	   the	   Hb	   tetramer/heterodimer	   bound	   to	   IsdH-­‐N2,	   and	   it	   has	  
been	  proposed	  that	  this	  orientation	  facilitates	  rapid	  transfer	  of	  heme	  from	  Hb	  to	  IsdH-­‐
N3	  (302).	  Additionally,	  steric	  strain	  induced	  on	  the	  Hb	  molecule	  by	  the	  linker	  region	  may	  
facilitate	   Hb	   dissociation	   and/or	   heme	   release,	   allowing	   for	   capture	   of	   heme	   by	   the	  
associated	  heme-­‐binding	  NEAT	  domain	  (302,	  304,	  307).	  While	  IsdH-­‐N1	  has	  been	  shown	  
to	  bind	  both	  Hb	  and	  haptoglobin	   (297,	  299–302),	   the	  exact	   function	  of	   this	  domain	   in	  
heme-­‐iron	  acquisition	  has	  yet	  to	  be	  determined. 
	   Once	  heme	  is	  extracted,	  bidirectional	  exchange	  may	  occur	  between	  IsdB-­‐N2	  and	  
IsdH-­‐N3,	   however	   all	   other	   heme	   transfer	   reactions	   occur	   in	   a	   unidirectional	   fashion	  
from	  IsdB-­‐N2	  or	  IsdH-­‐N3	  to	  the	  single	  NEAT	  domain	  of	  either	  IsdA	  or	  IsdC	  (see	  Figure	  1.2	  
and	   1.8B)	   (282,	   308,	   309).	   Self-­‐transfer	   between	   Isd	   proteins	   may	   also	   facilitate	   the	  
movement	  of	  heme	  through	  the	  thick	  cell	  wall	  (~30	  nm)	  (125),	  and	  physical	  interaction	  
between	   IsdC	  molecules	  has	   recently	  been	  demonstrated	   (For	  a	  model	   see	  310,	  311).	  
IsdC	   serves	   as	   a	   universal	   channel	   within	   the	   Isd	   pathway	   as	   heme	   is	   funneled	   from	  
holo-­‐IsdA	   through	   IsdC	   to	   apo-­‐IsdE	   (283,	   293).	  Heme	   transfer	   between	   Isd	   proteins	   is	  
driven	  in	  part	  by	  affinity,	  where	  each	  protein	  in	  the	  sequential	  shuttle	  mechanism	  has	  a	  
higher	  affinity	  for	  heme	  than	  the	  last	  (312),	  as	  well	  as	  through	  ultra-­‐weak	  (≥	  micromolar	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affinity),	   transient	   “handclasp”-­‐type	   protein-­‐protein	   interactions	   (282,	   310,	   313).	  
Handclasp	   transfer	   involves	   a	   short-­‐lived	   stereospecific	   protein-­‐protein	   complex	  
wherein	   heme	   is	   passed	   between	   the	   conserved	   tyrosine	   residues	   of	   donor	   and	  
recipient	   proteins	   (282,	   310,	   311,	   313).	   Such	   interactions	   are	   governed	   by	   specific	  
structural	  motifs,	  as	  has	  been	  demonstrated	  by	  the	  unambiguous	  lack	  of	  heme	  transfer	  
from	  holo-­‐IsdA	  to	  apo-­‐IsdE	  (282,	  310);	  an	  extended	  β7/β8	  loop	  region	  comprised	  of	  six	  
amino	  acids,	  present	  in	  IsdC	  but	  not	  IsdA,	  is	  required	  for	  heme	  transfer	  between	  holo-­‐
IsdC	  and	  apo-­‐IsdE	  (310,	  313).	  Indeed,	  chimeric	  expression	  of	  the	  IsdC	  β7/β8	  loop	  region	  
in	   IsdA	  enables	  heme	  transfer	  to	  IsdE	  (310).	  Unlike	  the	  other	  cell	  surface-­‐anchored	  Isd	  
proteins,	  IsdE	  does	  not	  possess	  a	  NEAT	  domain	  or	  conserved	  tyrosine	  residue	  for	  heme	  
coordination.	   IsdE	   is	   a	   Class	   III	   SBP	   bearing	   a	   bilobate	   structure	   formed	   by	  N-­‐	   and	   C-­‐	  
terminal	   domains	   bridged	   by	   a	   long	   α-­‐helical	   backbone	   (122,	   284,	   314).	   Heme	  
coordination	   by	   IsdE	   occurs	   within	   a	   deep	   hydrophobic	   groove	   between	   the	   two	  
domains	  by	  axial	  histidine	  and	  methionine	  residues	  (H229	  and	  M78)	  (Figure	  1.14)	  (284,	  
285).	   Notably,	   disruption	   of	   isdE	   (which	   presumably	   should	   abolish	   heme	   transport	  
through	  the	  cell	  membrane)	  reduces	  but	  does	  not	  eliminate	  growth	  on	  heme	  as	  a	  sole	  
iron	   source	   (284),	   suggesting	   that	   an	   alternate	   mechanism	   for	   heme-­‐iron	   acquisition	  





Figure	  1.14.	  Overall	  structure	  of	  the	  S.	  aureus	  IsdE	  substrate	  binding	  protein.	  
	  The	   ribbon	   diagram	   of	   PDB	   2Q8Q	   illustrates	   the	   structure,	   coloured	   from	   the	   N-­‐
terminus	  (blue)	  to	  the	  C-­‐terminus	  (red).	  Heme	  is	  bound	  between	  the	  two	   lobes	  of	  the	  
protein	   and	   the	   iron	   center	   is	   coordinated	   by	   the	   sulphur	   group	   of	   M78	   and	   the	  
imidazole	  nitrogen	  of	  H229.	  The	  heme	  and	  M78	  and	  H229	  side	  chains	  are	  shown	  in	  stick	  
format,	  with	  carbon,	  nitrogen,	  oxygen	  and	  sulphur	  coloured	  yellow,	  blue,	  red,	  and	  dark	  
yellow,	  respectively.	  The	  iron	  in	  heme	  is	  shown	  as	  a	  red	  sphere.	  
	  	  
73	  
1.5.2.2. The	  biological	  relevance	  of	  the	  S.	  aureus	  Isd	  system	  
Despite	  extensive	  characterization	  of	  the	  Isd	  system	  in	  S.	  aureus,	  and	  the	  upregulation	  
of	   isd	  genes	   in	  human	  blood	  and	   serum	   (223),	   single	   isd	  deletion	  mutants	  have	  often	  
failed	  to	  yield	  robust	  phenotypes	  on	  heme	  or	  Hb	  as	  a	  sole	  iron	  source	  (315,	  316).	  Whilst	  
it	   is	  probable	  that	  S.	  aureus	  possesses	  multiple	  mechanisms	  for	  heme-­‐iron	  acquisition,	  
methodological	   inadequacies	   in	   the	   aforementioned	   studies,	   including	   the	   use	   of	  
supraphysiological	   concentrations	   of	   heme/hemoproteins,	   likely	   hindered	   the	  
evaluation	  of	  Isd	  as	  a	  high-­‐affinity	  heme-­‐iron	  acquisition	  system.	  Indeed,	  the	  biological	  
relevance	   of	   the	   Isd	   system	   is	   highlighted	   by	   the	   fact	   that	   single	   deletion	  mutants	   of	  
isdA,	   isdB,	   isdC,	   isdG,	   isdH	   or	   isdI	   alone	   are	   sufficient	   to	   attenuate	   staphylococcal	  
virulence	  and/or	  burden	  in	  murine	  models	  of	  infection	  (126,	  298,	  301,	  317).	  Moreover,	  
several	   of	   these	   proteins	   are	   required	   for	   the	   formation	   of	   staphylococcal	   abscesses,	  
which	   facilitate	   persistence	   and	   further	   dissemination	   within	   the	   host	   (220).	   Further,	  
individuals	  suffering	  from	  staphylococcal	  infections	  often	  express	  anti-­‐IsdA,	  IsdB,	  and/or	  
IsdH	   antibodies	   (318,	   319),	   which	   has	   prompted	   efforts	   in	   utilizing	   these	   proteins	   as	  
potential	   vaccine	   antigens	   (320–322).	   Efforts	   to	   reconcile	   the	   discrepancies	   in	   the	  
relevance	  of	  Isd	  as	  a	  heme-­‐iron	  acquisition	  system	  in	  S.	  aureus	  are	  detailed	  in	  Chapter	  3.	  	  
1.5.3. Alternate	  mechanisms	  for	  heme-­‐iron	  acquisition	  	  
Given	   that	   disruption	   of	   the	   Isd	   system	   does	   not	   abolish	   heme-­‐iron	   acquisition	   by	   S.	  
aureus	   (315,	  316),	   it	   is	  presumed	   that	   there	  exists	   another	  mechanism	   to	   incorporate	  
heme-­‐iron	   into	   the	   cell.	   Although	   no	   alternate	  mechanisms	   for	   heme-­‐iron	   acquisition	  
have	   been	   conclusively	   identified	   in	   the	   staphylococci,	   current	   efforts	   are	   focused	   on	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characterizing	  homologues	  of	   transporters	   involved	   in	  heme	  uptake	   in	  other	  bacteria,	  
such	   as	   E.	   coli,	   which	   has	   largely	   served	   as	   the	   model	   organism	   for	   bacterial	   iron	  
homeostasis.	   Two	   such	   avenues	   of	   investigation	   are	   actively	   being	   pursued;	  
interrogation	   of	   the	   function	   of	   transporter	   bearing	   homology	   both	   to	   the	   Fe2+	  
acquisition	  system	  Fet3p-­‐Ftrp1	  of	  Baker’s	  yeast	  and	  an	   iron	  transporter	   (EfeUOB)	   in	  E.	  
coli,	   and	   characterization	   of	   the	   role	   of	   putative	   peptide	   permeases	   in	   heme-­‐iron	  
acquisition.	  
1.5.3.1. FepABC	  (EfeUOB)	  -­‐	  a	  conserved	  but	  enigmatic	  pathway	  for	  iron	  acquisition	  
Preliminary	   investigations	   identified	   a	   Fur-­‐regulated	   locus	   bearing	   homology	   to	   the	  
elemental	  ferrous	  iron	  uptake	  system,	  efeUOB,	  of	  E.	  coli	  (323,	  324),	  as	  potentially	  being	  
involved	  in	  the	  acquisition	  of	   inorganic	  and/or	  heme	  iron	  in	  the	  staphylococci.	  Termed	  
fepABC	   (for	   Fe-­‐dependent	   peroxidase),	   this	   operon,	   which	   is	   distributed	   sparsely	  
amongst	   both	   CoPS	   and	   CoNS,	   was	   initially	   characterized	   in	   an	   effort	   to	   identify	  
substrates	   of	   the	   twin-­‐arginine	   translocation	   (Tat)	   pathway	   and	   is	   transcribed	  
contiguous	   to	   tatAC	   (325).	   FepB,	   a	   homologue	   of	   EfeB	   and	   member	   of	   the	   Dye-­‐
decolorizing	  heme	  peroxidase	   (DyP)	   superfamily,	  was	   isolated	  as	   the	   sole	   substrate	  of	  
Tat	   in	  S.	  aureus	  and	  S.	  carnosus	   (325,	  326).	  DyP	  family	  peroxidases	  have	  widely	  varied	  
functions.	  However,	  insofar	  as	  iron	  is	  concerned,	  both	  E.	  coli	  and	  S.	  aureus	  members	  of	  
this	   family	   (EfeB	   and	   YfeX,	   and	   FepB,	   respectively)	   have	   been	   ascribed	   a	   novel	   heme	  
deferrochelatase	  activity,	  whereby	   iron	   is	  extracted	   from	  heme,	   leaving	   the	  porphyrin	  
ring	  intact	  (324,	  327).	  Structural	  characterization	  of	  EfeB	  in	  complex	  with	  heme	  and	  PPIX	  
revealed	   that	  both	  molecules	  are	  coordinated	  at	   the	   same	  site	   in	  a	  manner	   similar	   to	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heme	  coordination	  by	  other	  DyP	  peroxidases,	  and	  that	  overexpression	  of	  EfeB	  from	  E.	  
coli	   resulted	   in	   the	   accumulation	   of	   PPIX	   (328).	   However,	   this	   proposed	   activity	   is	  
contentious,	  and	  the	  rationale	  of	  PPIX	  production	  by	  cells	  has	  been	  questioned,	  as	  this	  
byproduct	  is	  both	  toxic	  and	  lacks	  a	  natural	  degradative	  pathway,	  and	  it	  has	  instead	  been	  
suggested	   that	   EfeB/FepB	   oxidizes	   porphyrinogens	   to	   porphyrins	   (329).	   Should	   FepB	  
possess	  deferrochelatase	  activity,	   it	   suggests	  a	  means	  by	  which	   the	  staphylococci	  may	  
acquire	  iron	  from	  heme	  in	  the	  absence	  of	  a	  dedicated	  heme	  transporter.	  
	   In	   addition	   to	   FepB,	   fepABC	   also	   encodes	   a	   putative	   iron-­‐binding	   lipoprotein,	  
FepA,	  which	   bears	   homology	   to	   EfeO	   and	  other	  members	   of	   the	   imelysin-­‐like	   protein	  
superfamily.	  Members	  of	  this	  family	  possess	  a	  conserved	  motif	  (GxHxxE)	  which	  has	  been	  
implicated	   in	  the	  binding	  of	  divalent	  metal	  cations,	  specifically	  Fe2+	  (330–332),	  and	  are	  
almost	  always	  located	  in	  close	  proximity	  to	  a	  DyP-­‐type	  peroxidase.	  Additionally,	  the	  fep	  
operon	   encodes	   for	   FepC,	   an	   integral	   transmembrane	   protein	   and	   EfeU	   homologue,	  
both	   of	   which	   share	   ~25%	   sequence	   similarity	   to	   the	   Fe3+	   permease,	   Ftrp1,	   of	  
Saccharomyces	  cerevisiae	  (164,	  327,	  333).	  In	  E.	  coli,	  EfeU	  is	  required	  for	  Fe2+	  uptake	  at	  
low	  pH	   (333,	  334).	  Cumulatively,	   the	   similarities	  between	  Fep	  proteins	  and	  other	   iron	  
transporters,	   coupled	   with	   the	   finding	   that	   fep-­‐tat	   mutants	   are	   debilitated	   for	  
radioactive	   iron	   uptake	   (325),	   support	   a	   role	   for	   fepABC	   in	   staphylococcal	   iron	  
acquisition.	  Further,	  FepB	  was	  recently	  demonstrated	  to	  bind	  both	  heme	  and	  the	  heme	  
precursor	   protoporphyrin	   IX	   (PPIX),	   and	   both	   FepA	   and	   FepB	   together	   were	   able	   to	  
restore	   heme	   iron	   utilization	   when	   heterologously	   expressed	   in	   an	   E.	   coli	   mutant	  
deficient	  for	  this	  ability	  (327).	  A	  model	  has	  been	  proposed,	  analogous	  to	  the	  activity	  of	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E.	   coli	   EfeUOB,	   whereby	   iron	   is	   extracted	   from	   heme	   through	   FepB	   deferrochelatase	  
activity,	  is	  captured	  by	  FepA,	  and	  transported	  into	  the	  cell	  via	  FepC	  (327).	  Alternatively,	  
it	   has	   been	   shown	   in	   B.	   subtilis	   that	   EfeUOB	   is	   responsible	   for	   both	   Fe3+	   and	   Fe2+	  
acquisition,	   where	   EfeB	   utilizes	   its	   peroxidase	   activity	   to	   oxidize	   Fe2+	   to	   Fe3+	   prior	   to	  
binding	  to	  EfeO	  (335).	  Although	  not	  yet	  proven	  experimentally,	  it	  is	  likely	  fepABC	  plays	  a	  
role	   in	   the	  acquisition	  of	   iron	   in	   the	  staphylococci,	  and	  may	  potentially	  be	   involved	   in	  
both	   heme-­‐iron	   extraction	   and	   inorganic	   iron.	   The	   preferred	   iron	   substrate	   for	   this	  
system,	  however,	  has	  yet	  to	  be	  determined.	  
1.5.3.2. Peptide	  permeases	  as	  putative	  heme-­‐iron	  acquisition	  systems	  in	  S.	  aureus	  
Recent	  literature	  and	  preliminary	  data	  from	  our	  lab	  suggest	  that	  the	  unidentified	  heme-­‐
uptake	  pathway	  in	  S.	  aureus	  may	  involve	  a	  peptide	  permease	  under	  the	  control	  of	  the	  
global	  transcriptional	  regulator,	  CodY.	  Indeed,	  codY	  disruption	  in	  B.	  anthracis	  has	  been	  
shown	  to	   inhibit	  growth	  on	  heme	  as	  a	   sole	   iron	  source	   (336),	   likely	   through	  an	  as	  yet	  
unidentified	   heme	   uptake	   system	   that	   is	   indirectly	   regulated	   by	   CodY	   (337).	   In	   S.	  
pneumoniae,	  codY	  can	  only	  be	  inactivated	  when	  suppressor	  mutations	  also	  exist	  in	  fatC	  
and	  amiC,	   genes	  which	   encode	   the	  membrane	  permease	   components	   of	   a	   Fe3+/heme	  
and	  an	  oligopeptide	  ABC	  transporter,	  respectively.	  It	  has	  been	  proposed	  that	  AmiC	  may	  
also	  function	  in	  heme	  uptake	  and	  that	  combined	  derepression	  of	  both	  fatC	  and	  amiC	  in	  
a	   codY	   mutant	   may	   lead	   to	   a	   lethal	   accumulation	   of	   iron	   (338).	   A	   role	   for	   peptide	  
permeases	  in	  heme-­‐iron	  acquisition	  is	  not	  unprecedented,	  as	  a	  dipeptide	  permease	  in	  E.	  
coli	   (DppA/NikA)	   is	   also	   involved	   in	  both	  nickel	   and	  heme	  acquisition	   (323,	   339,	   340),	  
and	   a	   homologous	   transporter	   in	  H.	   influenzae	   has	   been	   implicated	   in	   the	   uptake	   of	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both	  free	  and	  hemoprotein-­‐associated	  heme	  (341).	  Indeed,	  an	  oligopeptide	  permease	  in	  
S.	   aureus	   (opp1)	   is	   demonstrably	   upregulated	   during	   iron-­‐restricted	   growth	   (342	   and	  
data	  not	  shown),	  and	  to-­‐date	  has	  no	  known	  function	  in	  nitrogen	  metabolism.	  	  
	   As	  with	  the	  ABC	  transporters	  previously	  described,	  OPPs	  are	  generally	  comprised	  
of	   a	   SBP,	   two	   transmembrane	   proteins,	   and	   two	   ATPases.	   Most	   strains	   of	   S.	   aureus	  
encode	  for	  at	   least	   four	  complete,	  but	  putative,	  oligopeptide	  permease	  (OPP)	  systems	  
including	   opp1;	   opp2,	   and	   its	   orphan	   SBP,	   opp5A	   (renamed	   nikBCDE	   and	   nikA,	  
respectively,	  due	   to	   their	  purported	  role	   in	  nickel	  uptake);	  opp3;	  and	  opp4	   (343–345).	  
Notably,	   CA-­‐MRSA	   strain	   USA300	   possesses	   an	   additional	   OPP,	   encoded	   from	   the	  
arginine	   catabolic	  mobile	   genetic	  element	   (ACME),	   a	  31	  kb	  genomic	   island	   thought	   to	  
have	  been	  acquired	  horizontally	   from	  S.	   epidermidis	   (346,	   347).	   The	  ACME	  cassette	   is	  
postulated	  to	  enhance	  skin	  colonization	  and/or	  transmission	  amongst	  hosts	  by	  USA300,	  
due	   in	   part	   to	   the	   speculated	   role	   of	   the	   arginine	   deiminase	   cluster	   in	  mitigating	   the	  
acidity	   of	   the	   skin	   through	   the	   production	   of	   ammonia,	   a	   novel	   spermidine	  
acetyltransferase	   (SpeG)	   which	   provides	   resistance	   to	   toxic	   polyamines,	   and	   metal	  
and/or	  nutrient	  acquisition	  through	  the	  ACME-­‐encoded	  OPP	  (ACME-­‐OPP)	  (348).	  Neither	  
of	  the	  aforementioned	  hypotheses	  has	  been	  borne	  out	  experimentally,	  and	  indeed,	  only	  
opp3	   and	   a	   proton-­‐driven	   di-­‐/tri-­‐	   peptide	   permease	   (dtpT)	   have	   been	   implicated	   in	  
peptide	  acquisition	  in	  S.	  aureus	  (345).	  Interestingly,	  opp1,	  dtpT	  and	  nikA/nikBCDE	  have	  
each	   been	   implicated	   in	   staphylococcal	   virulence	   (225,	   226,	   344,	   349),	   although	   the	  
exact	  mechanism	  by	  which	  these	  permeases	  contribute	  to	  pathogenesis	  is	  unknown.	  To	  
date,	   no	   substrates	   have	   been	   identified	   for	   Opp1,	   Opp4,	   or	   ACME-­‐OPP,	   nor	   have	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NikA/NikBCDE,	  Opp3,	  or	  DtpT	  been	  robustly	  tested	  for	  the	  uptake	  of	  other	  substrates.	  In	  
Chapter	  3	  of	  this	  thesis,	  we	  address	  the	  potential	  role	  for	  these	  permeases	  in	  heme-­‐iron	  
acquisition.	  	  
1.5.4. The	  fate	  of	  intracellular	  heme	  
Upon	  uptake,	  internalized	  heme	  faces	  three	  potential	  fates:	  i)	  direct	  incorporation	  into	  
bacterial	   hemoproteins,	   ii)	   cytosolic	   destruction	   of	   the	   heme-­‐iron	   complex,	   releasing	  
iron	  for	  use	  as	  a	  nutrient,	  or	  iii)	  efflux	  during	  periods	  of	  excess	  to	  guard	  against	  toxicity.	  
In	  many	  Proteobacteria,	  the	  import	  of	  heme	  is	  coupled	  with	  its	  rapid	  seizure	  by	  heme-­‐
carrier	  molecules,	  where	  heme	  is	  received	  directly	  from	  an	  associated	  ABC	  transporter	  
at	   the	   cytoplasmic	   membrane	   (350–352),	   and	   ostensibly	   is	   shuttled	   safely	   to	   either	  
heme	   storage	   or	   degradation	   pathways	  within	   the	   cell.	  While	   such	   heme	   chaperones	  
have	  not	  been	  identified	  in	  the	  staphylococci,	  pathways	  for	  both	  heme	  degradation	  and	  
efflux	  have	  been	  characterized.	  	  
	   The	  liberation	  of	  iron	  from	  the	  heme	  necessitates	  heme-­‐degrading	  enzymes	  and,	  
to	  this	  effect,	  eukaryotic	  organisms	  employ	  heme	  oxygenases	  (HOs)	  that	  convert	  heme	  
to	   biliverdin	   and	   iron	   with	   the	   release	   of	   carbon	  monoxide	   (CO)	   (353).	   Similarly,	   the	  
Gram-­‐positive	   pathogen	   C.	   diphtheriae	   and	   Gram-­‐negative	   pathogens	  N.	   meningitidis	  
and	   P.	   aeruginosa	   employ	   canonical	   HOs	   that	   are	   structurally	   and	   mechanistically	  
comparable	  to	  their	  eukaryotic	  counterparts	  to	  facilitate	  iron	  release	  from	  heme	  (354–
356).	  Research	  within	  the	  last	  decade	  has	  revealed	  a	  separate	  class	  of	  heme-­‐degrading	  
enzymes	   that	   are	   distinct	   from	   traditional	   HOs,	   the	   IsdG-­‐family	   of	   heme	   oxygenase	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proteins,	   first	   recognized	   in	   S.	   aureus	   (286,	   357).	   These	   non-­‐canonical	   HOs	   degrade	  
heme	   to	   novel	   chromophores	   termed	   staphylobilins,	   with	   the	   release	   of	   iron	   and	  
formaldehyde	   (Figure	  1.15)	   (358,	  359).	   The	  distinct	  degradation	  products	  of	   IsdG-­‐type	  
HOs	   reflect	   different	   metabolic	   requirements	   of	   the	   bacteria	   in	   which	   they	   are	  
employed,	   as	   well	   as	   unique	   structural	   and	   mechanistic	   properties	   of	   these	   heme-­‐
degrading	  proteins	  (reviewed	  in	  360).	  	  
1.5.4.1. Non-­‐canonical	  heme	  monooxygenases	  –	  IsdG	  and	  IsdI	  
A	  paucity	  of	  potential	  HO	  homologues	   in	  bacteria	  outside	  of	  Corynebacterium	  spp.,	  N.	  
meningitidis,	   and	   P.	   aeruginosa	   led	   to	   a	   search	   for	   proteins	   capable	   of	   fulfilling	   this	  
function	  in	  Gram-­‐positive	  pathogens.	  Two	  putative	  heme-­‐degrading	  enzymes,	  IsdG	  and	  
its	  paralogue,	  IsdI,	  were	  identified	  in	  S.	  aureus	  based	  on	  sequence	  similarity	  to	  a	  family	  
of	   monooxygenases	   capable	   of	   oxidizing	   aromatic	   polyketides	   (an	   activity	   consistent	  
with	  heme	  degradation),	  and	  on	  their	  association	  with	  the	  Isd	  heme	  acquisition	  pathway	  
(286,	  361).	  Despite	  lacking	  significant	  sequence	  similarity	  to	  canonical	  HOs,	  IsdG	  and	  IsdI	  
were	   indeed	   shown	   capable	   of	   cleaving	   the	   heme	   tetrapyrrole	   to	   release	   iron	   (286).	  
Although	  initially	  reported	  to	  degrade	  heme	  to	  biliverdin	  (286,	  357),	  IsdG-­‐like	  enzymes	  
are	  now	  known	  to	  convert	  heme	  to	  a	  mixture	  of	  chromophoric	  5-­‐oxo-­‐δ-­‐bilirubin	  and	  15-­‐
oxo-­‐β-­‐bilirubin,	   collectively	   referred	   to	   as	   the	   “staphylobilins”	   (Figure	   1.15)	   (359).	  
Additionally,	  unlike	  canonical	  HOs,	  which	  release	  a	  meso	  carbon	  atom	  in	  the	  form	  of	  CO,	  
degradation	  of	  heme	  by	  IsdG	  and	  IsdI	  instead	  yields	  formaldehyde	  (358).	  The	  unique	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Figure	  1.15.	  Degradation	  of	  heme.	  	  
The	  top	  half	  of	  the	  figure	  portrays	  the	  degradation	  of	  heme	  by	  the	  non-­‐canonical	  IsdG/I-­‐
family	   of	   enzymes	   (shown	   is	   IsdI;	   PDB	   3LGN)	   to	   the	   'staphylobilins',	   Fe	   and	  
formaldehyde	  (HCHO).	  The	  lower	  half	  of	  the	  figure	  portrays	  the	  degradation	  of	  heme	  by	  
the	  canonical	  heme	  oxygenase	  HmuO	  (PDB	  1IW0)	  of	  C.	  diphtheriae	  to	  biliverdin	  with	  the	  
release	  of	   Fe	   and	  CO.	   The	  proteins	   are	   shown	   in	   ribbon	   format	   coloured	   from	   the	  N-­‐
terminus	   (blue)	   to	   the	   C-­‐terminus	   (red).	   Heme	   molecule	   bound	   in	   the	   proteins	   are	  
shown	  in	  stick	  format	  with	  carbon,	  nitrogen	  and	  oxygen	  coloured	  yellow,	  blue	  and	  red,	  
respectively.	   The	   iron	   center	   is	   shown	   as	   a	   red	   sphere.	   The	   His	   axial	   ligand,	   with	   its	  




degradation	   products	   of	   IsdG-­‐like	   HOs	   suggest	   a	   novel	   mechanism	   by	   which	   iron	   is	  
released	  from	  heme	  by	  these	  proteins.	  
	   Distinct	   from	   canonical	   HOs	   which	   are	   monomeric	   and	   α-­‐helical	   in	   structure,	  
IsdG-­‐like	  HOs	  are	  homodimeric	  proteins,	  which	  adopt	  a	  ferredoxin-­‐like	  fold	  and	  form	  a	  
β-­‐barrel	   at	   the	   dimer	   interface	   (Figure	   1.15)	   (287).	   Both	   IsdG	   and	   IsdI	   possess	   two	  
separate	  active	  sites	  each	  bearing	  an	  NWH	  catalytic	  triad	  on	  either	  side	  of	  the	  β-­‐barrel;	  
heme	   is	   coordinated	   in	   a	  deep	  hydrophobic	   cleft	   by	  propionate	   groups	   that	   form	   salt	  
bridges	  with	  two	  arginine	  residues	  and	  a	  conserved	  histidine	  (H)	  residue	  that	  binds	  the	  
central	  iron	  atom	  (362).	  Opposite	  the	  aforementioned	  histidine,	  a	  conserved	  asparagine	  
(N)	   residue	   essential	   for	   enzymatic	   activity	   purportedly	   serves	   to	   stabilize	   reaction	  
intermediates	  and	  enhance	  the	  reactivity	  of	   IsdG/IsdI	  for	  heme	  (287,	  362).	  Unlike	  with	  
canonical	   HOs,	   binding	   of	   heme	   to	   IsdG	   and	   IsdI	   results	   in	   severe	   distortion	   to	   the	  
planarity	  of	  the	  porphyrin	  ring,	  an	  effect	  referred	  to	  as	  “heme	  ruffling”	  (362).	  Ruffling	  is	  
mediated	   by	   a	   conserved	   tryptophan	   (W)	   residue	   and	   is	   proposed	   to	   enhance	   the	  
reactivity	  of	  IsdG	  and	  IsdI	  for	  heme,	  alter	  the	  regioselectivity	  of	  these	  enzymes	  relative	  
to	   canonical	  HOs,	   and	  eliminate	   the	  need	   for	   the	   catalytic	  hydrogen-­‐bonding	  network	  
found	  in	  classic	  HOs	  (362–364).	  Steric	  distortion	  induced	  by	  ruffling	  promotes	  oxidative	  
cleavage	   at	   either	   the	   β	   or	   δ-­‐meso	   carbon,	   allowing	   for	   the	   production	   of	   the	   two	  
different	  staphylobilins,	  and	  precluding	  the	  release	  of	  CO	  (358,	  362),	  a	  potentially	  toxic	  
metabolite	  for	  the	  staphylococci	  (365,	  366).	  It	  should	  be	  noted	  that	  the	  sustained	  heme-­‐
degradative	   activity	   of	   IsdG-­‐like	   enzymes	   requires	   molecular	   oxygen	   and	   a	   dedicated	  
source	  of	  electrons	  (i.e.	  a	  reductase).	  Recently,	  the	  iron	  utilization	  oxidoreductase,	  IruO,	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was	   identified	   as	   the	   terminal	   electron	   donor	   for	   IsdG	   and	   IsdI	   (367).	   IruO	   promotes	  
more	   rapid	   in	   vitro	   heme	   degradation	   with	   IsdI	   than	   IsdG,	   suggesting	   that	   an	   as	   yet	  
unidentified	   reductase	   may	   be	   involved	   in	   heme	   degradation	   by	   the	   latter.	   Further	  
efforts	  are	  required	  to	  elucidate	  the	  in	  vivo	  role	  of	  IruO	  in	  heme-­‐iron	  utilization,	  as	  well	  
as	   to	   determine	   the	   biological	   role	   of	   the	   unique	   heme-­‐degradation	   products,	  
formaldehyde	   and	   the	   staphylobilins.	   Further,	   it	   is	   not	   yet	   known	   if	   the	   fate	   of	   intact	  
exogenously	   acquired	  heme	  differs	   from	   that	  of	   endogenously	   synthesized	  heme	   (see	  
heme	  biosynthesis	  section	  below).	  
	   It	   should	   be	   noted	   that	   heme-­‐degrading	   enzymes	   have	   broader	   functionality	  
than	  simply	  the	  liberation	  of	  iron	  from	  heme.	  Expression	  of	  the	  paralogous	  IsdG	  and	  IsdI	  
enzymes	  of	  S.	  aureus	  has	  been	  shown	  to	  be	  differentially	  regulated	  by	  iron	  and	  heme,	  
where	  both	  IsdG	  and	  IsdI	  are	  transcriptionally	  regulated	  by	  iron	  and	  Fur,	  but	  the	  former	  
is	   further	  regulated	  post-­‐translationally	  by	  heme	  (317).	  An	  amino	  acid	  motif	   forming	  a	  
flexible	   loop	  within	   IsdG,	   absent	   in	   IsdI,	   is	   a	   critical	   determinant	   in	   targeting	   IsdG	   for	  
degradation	  in	  the	  absence	  of	  heme,	  through	  an	  unknown	  mechanism	  (368).	  It	  has	  been	  
proposed	   that	  differential	   regulation	  of	   these	  heme-­‐degrading	  enzymes	  allows	   for	   the	  
fine-­‐tuning	  of	  heme	  homeostasis	  within	  the	  cell,	  where	  IsdI	  promotes	  liberation	  of	  iron	  
from	   heme	   during	   early	   stages	   of	   infection,	   prior	   to	   significant	   erythrocyte	   lysis,	   and	  
IsdG	  helps	  alleviate	  the	  risk	  of	  toxicity	  once	  heme	  has	  accumulated	  intracellularly	  (317).	  
Several	   mechanisms	   exist	   to	   alleviate	   the	   toxic	   effects	   of	   heme,	   and	   include	   limiting	  
uptake	   through	   heme-­‐specific	   transporters,	   enhancing	   degradation	   through	   the	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expression	   of	   HOs,	   and	   reducing	   endogenous	   synthesis,	   all	   of	   which	   necessitate	   the	  
coordinated	  effort	  of	  elaborate	  heme-­‐sensing	  systems.	  
1.5.4.2. Sensing	  and	  avoiding	  heme	  toxicity	  
High	  concentrations	  of	  heme	  are	  toxic	  to	  the	  bacterial	  cell	  and,	  as	  such,	  mechanisms	  of	  
heme	   acquisition,	   synthesis,	   and	   catabolism	   must	   be	   tightly	   balanced.	   The	   exact	  
mechanism	   of	   heme	   toxicity	   is	   unknown,	   and	   likely	   to	   be	   multifaceted.	   The	   most	  
plausible	   explanation,	   to	   date,	   is	   that	   heme	   itself	   is	   toxic	   due	   to	   oxidative	   damage	  
inflicted	  on	  DNA	  through	  the	  generation	  of	  ROS	  (369–371),	  however	  this	  hypothesis	  has	  
yet	  to	  be	  fully	  borne	  out	  experimentally.	  Three	  main	  mechanisms	  exist	  to	  subvert	  heme	  
toxicity	   in	   the	   staphylococci.	   First,	   Fur	   mediates	   repression	   of	   heme	   uptake	   systems	  
when	  iron	  is	  present	  in	  excess,	  as	  previously	  discussed,	  although	  rapid	  uptake	  of	  heme	  
by	   Isd	   and	   other	   heme	   transporters	   may	   still	   induce	   toxicity.	   Second,	   IsdG	   and	   IsdI	  
promote	   concurrent	   heme	   degradation	   and	   iron	   release,	  where	   iron	   storage	   proteins	  
such	  as	   ferritin	  or	  bacterioferritin	  may	   then	  sequester	   free	   iron.	  Notably,	  as	  discussed	  
above,	   IsdG	  and	  IsdI	  are	  differentially	  regulated	  by	  iron	  and	  heme,	  where	  IsdG	  protein	  
stability	  is	  enhanced	  in	  the	  presence	  of	  heme,	  suggesting	  an	  ability	  of	  these	  enzymes	  to	  
fine-­‐tune	   heme	  homeostasis	   in	   different	   environments	   (317).	   Third,	   the	   staphylococci	  
express	   a	   two-­‐component	   heme	   sensing	   system	   (HssRS),	   capable	   of	   detecting	   and	  
exporting	  excess	  heme	  through	  a	  heme-­‐regulated	  transporter	  (HrtAB)	  (372–374).	  	  
Although	   the	   exact	   mechanism	   of	   heme	   recognition	   by	   HssS	   is	   unknown,	  
exposure	   of	   this	   membrane-­‐localized	   sensor	   histidine	   kinase	   to	   heme	   stimulates	   its	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autophosphorylation.	  Through	  a	  phosphorylation	  cascade,	  HssS	  activates	   the	  response	  
regulator,	  HssR,	  which	  in	  its	  phosphorylated	  form	  is	  capable	  of	  binding	  to	  a	  direct	  repeat	  
within	   the	  promoter	   of	  hrtAB,	   inducing	   expression	  of	   the	   encoded	  heme	  efflux	   pump	  
(HrtAB).	  Through	  the	  coordinated	  efforts	  of	  HssRS-­‐HrtAB,	  excess	  heme	  is	  then	  exported	  
into	  the	  extracellular	  environment,	  thereby	  reducing	  potential	  toxicity.	  As	  with	  free	  iron,	  
the	   maintenance	   of	   heme	   homeostasis	   is	   essential	   to	   maintaining	   staphylococcal	  
viability	  and,	  accordingly,	  it	  is	  not	  surprising	  that	  the	  hssRS-­‐hrtAB	  system	  is	  found	  widely	  
distributed	  amongst	  both	  pathogenic	  and	   commensal	  Staphylococcus	   spp.,	   in	  addition	  
to	   other	   Gram-­‐positive	   genera,	   including	   Listeria,	   Corynebacterium,	   Bacillus	   and	  
Enterococcus.	  
1.5.4.3. Endogenous	  heme	  synthesis	  in	  S.	  aureus	  	  
In	  addition	  to	  possessing	  a	  plethora	  of	   iron	  uptake	  systems,	  the	  staphylococci	  are	  also	  
capable	   of	   synthesizing	   heme	   endogenously	   through	   the	   coordinated	   expression	   of	  
hemAXCDBL,	   hemEHY,	   and	   hemN	   (375,	   376).	   While	   these	   genes	   are	   largely	  
uncharacterized	  in	  the	  staphylococci,	  early	  steps	  of	  heme	  synthesis	  from	  generation	  of	  
the	   porphyrin	   precursor	   δ-­‐aminolevulinic	   acid	   (ALA)	   to	   the	   cyclic	   heme	   precursor,	  
uroporphyrinogen	  III,	  have	  been	  attributed	  to	  expression	  of	  hemCDBL	  in	  S.	  aureus	  (376,	  
377).	  Notably,	  S.	   aureus	  mutants	   unable	   to	   synthesize	   heme	   (e.g.	  hemB	  mutants)	   are	  
known	   to	   display	   atypical	   morphology,	   referred	   to	   as	   small	   colony	   variants	   (SCV),	  
enhanced	  resistance	  to	  antibiotics,	  and	  unusual	  pervasiveness	  within	  the	  host	  (91).	  The	  
phenotype	  of	  SCV	  mutants	  has	  been	  attributed	  to	  their	  inability	  to	  respire,	  as	  heme	  is	  an	  
essential	  cofactor	  in	  cytochromes	  of	  the	  electron	  transport	  chain.	  The	  last	  step	  of	  heme	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synthesis	   is	   insertion	  of	   iron	   into	   the	   tetrapyrrole	   ring,	   and	   thus	   it	   is	   likely	   that	  heme	  
synthesis	  is	  activated	  when	  iron	  is	  not	  limiting.	  As	  previously	  described,	  the	  transport	  of	  
exogenous	   heme	   is	   favoured	   when	   iron	   concentrations	   are	   low,	   and	   is	   likely	  
incorporated	  directly	  into	  heme-­‐containing	  proteins,	  as	  well	  as	  degraded	  and	  utilized	  as	  
a	  source	  of	  iron.	  	  
1.5.5. Acquisition	  of	  inorganic	  iron	  
Due	  to	  the	  overshadowing	  effects	  of	  heme-­‐	  and	  siderophore-­‐based	  iron	  acquisition,	  and	  
the	  relative	  lack	  abundance	  of	  bioavailable	  inorganic	  iron,	  no	  acquisition	  system	  for	  the	  
uptake	  of	  free	  iron	  has	  been	  conclusively	  identified	  in	  the	  staphylococci.	  In	  anoxic,	  low	  
pH	  (reducing)	  environments,	  Fe2+	  may	  be	  directly	  imported	  by	  way	  of	  high-­‐affinity	  Fe2+	  
transporters,	  whereas	  at	  neutral	  pH	  under	  aerobiosis,	  iron,	  prior	  to	  its	  uptake	  must	  first	  
be	   reduced	   to	   its	   Fe2+	   form	   by	   secreted	   and/or	   cell-­‐associated	   reductases.	   Although	  
FepABC	  (EfeUOB),	  as	  described	  above,	  may	  be	  involved	  in	  the	  uptake	  of	  free	  iron	  and/or	  
heme,	  the	  perceived	  substrate	  of	  this	  transporter	  remains	  contentious.	  To	  date,	  the	  sole	  
other	  transporter	  implicated	  in	  inorganic	  iron	  acquisition	  in	  S.	  aureus	  is	  the	  ferrous	  iron	  
importer,	  FeoAB.	  
	   Although	  FeoAB	  appears	  to	  be	  a	  highly	  conserved,	  ubiquitous,	  Fe2+	  importer,	  this	  
system	  has	  not	  been	  functionally	  interrogated	  in	  any	  Gram-­‐positive	  pathogen.	  Feo	  was	  
first	   identified	   in	  E.	  coli	  and,	   in	  this	  organism	  and	  other	  γ-­‐proteobacteria,	  consists	  of	  a	  
small	   hydrophilic,	   cytoplasmic	   protein	   of	   unknown	   function	   (FeoA),	   a	   bonafide	   Fe2+	  
permease	   (FeoB),	   and	   another	   small	   hydrophilic	   protein	   (FeoC)	   that	   bears	   a	   winged	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helix-­‐turn-­‐helix	  motif	  implicated	  in	  DNA-­‐binding,	  as	  well	  as	  a	  putative	  iron-­‐sulfur	  cluster	  
binding	   site	   (378–382).	   FeoA	   purportedly	   interacts	   with	   the	   N-­‐terminal	   cytoplasmic	  
domain	  of	  FeoB,	  and	  indeed	  is	  required	  for	  FeoB-­‐mediated	  uptake	  of	  Fe2+	  in	  E.	  coli	  and	  
S.	   enterica,	   although	   the	   exact	   function	   of	   this	   protein	   remains	   unknown	   (379,	   382).	  
While	  initially	  proposed	  to	  serve	  as	  a	  transcription	  factor	  (380),	  FeoC	  instead	  appears	  to	  
function	   as	   a	   posttranslational	   regulator	   of	   FeoB.	   The	   activity	   of	   FeoC	   protects	   FeoB	  
from	  proteolytic	  degradation,	  and	  it	  has	  been	  suggested	  that	  iron-­‐sulfur	  cluster	  binding	  
to	   the	   former	  may	   serve	   as	   a	   redox	   and/or	   iron	   sensor,	  mediating	   the	   availability	   of	  
FeoB	  for	  iron	  import	  (383).	  Fe2+	  predominates	  in	  low	  oxygen,	  low	  pH	  environments	  and,	  
indeed,	  expression	  of	   feoABC	   is	   induced	  under	  these	  conditions	   in	  a	  number	  of	  Gram-­‐
negative	  pathogens	  including	  E.	  coli	  O157:H7,	  Shigella	  flexneri,	  and	  S.	  enterica	  (333,	  383,	  
384).	  Homologues	  of	   the	   feoAB	  operon	  have	  been	   identified	   in	   the	  staphylococci,	  and	  
similarities	   in	   domain	   architecture	   between	   E.	   coli	   FeoB	   and	   the	   staphylococcal	  
homologue	   suggest	   it	   likely	   functions	   in	   Fe2+	   acquisition.	   Further,	   while	   feoC	  
homologues	  have	  not	  been	  conclusively	  identified	  in	  the	  staphylococci,	  small	  proteins	  of	  
similar	   structure	   do	   exist	   within	   the	   staphylococcal	   feo	   gene	   cluster	   (380).	   These	  
commonalities,	  coupled	  with	  the	  known	  upregulation	  of	  feoB	  during	  iron	  starvation	  in	  S.	  
aureus	  (385,	  386),	  support	  the	  notion	  feoAB	  (and	  feoC)	  may	  function	  in	  Fe2+	  acquisition	  
in	  the	  staphylococci.	  Indeed,	  further	  investigation	  is	  also	  required	  to	  determine	  if	  feoAB	  
plays	  a	  role	  in	  staphylococcal	  virulence,	  particularly	  in	  anoxic	  and/or	  acidic	  niches	  within	  





As	  detailed	  above,	  the	  ability	  of	  S.	  aureus	  to	   invade	  and	  cause	   infections	  of	  significant	  
morbidity	  and	  mortality	  is	  inexorably	  linked	  to	  the	  sophisticated	  strategies	  it	  employs	  to	  
overcome	  iron	  sequestration	  within	  the	  host.	  Considerable	  effort	  in	  the	  last	  decade	  by	  
many	  laboratories,	  including	  our	  own,	  has	  helped	  to	  elucidate	  key	  mechanisms	  involved	  
in	  the	  acquisition	  of	  iron	  by	  S.	  aureus,	  including	  the	  elaboration	  of	  staphyloferrins	  A	  and	  
B,	   the	   utilization	   of	   xenosiderophores,	   and	   the	   expression	   of	   the	   Isd	   system.	   Indeed,	  
previous	  research	  has	  paved	  the	  way	  for	  elucidation	  of	  the	  finer	  mechanistic	  details	  of	  
these	  pathways,	  which	   is	   critical	   to	   fully	  understanding	   the	   role	   these	   iron	  acquisition	  
systems	   play	   in	   the	   pathophysiology	   of	   this	   notorious	   pathogen.	   In	   this	   thesis,	   we	  
address	  such	  outstanding	  questions	   for	  both	  siderophore-­‐dependent	  and	   independent	  
iron	   acquisition	   mechanisms	   in	   S.	   aureus.	   Specifically,	   we	   investigate	   the	   means	   by	  
which	   the	   key	   precursor	   molecule	   citrate	   is	   obtained	   for	   staphyloferrin	   biosynthesis	  
under	   iron-­‐restriction	   (Chapter	   2),	   and	  elucidate	  how	   the	  procurement	  of	   citrate	  may	  
fundamentally	  and	  differentially	  impact	  the	  expression	  of	  the	  staphyloferrins	  in	  specific	  
host	  niches.	  Further,	  we	  strive	  to	  reconcile	  the	  differences	  in	  the	  literature	  with	  respect	  
to	   the	   role	   of	   Isd	   in	   heme-­‐iron	   acquisition	   by	   clarifying	   its	   functionality	   at	   low	   versus	  
high	  heme	  availability,	  and	  lastly,	  we	  address	  the	  potential	  role	  of	  peptide	  permeases	  as	  
alternate	  heme	  transporters	  in	  S.	  aureus	  (Chapter	  3).	  The	  hypotheses	  and	  objectives	  to	  
tackle	  these	  research	  aims	  are	  detailed	  below.	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1.7. HYPOTHESES	  AND	  OBJECTIVES	  	  
1.7.1. Chapter	  2	  hypotheses	  
2.1) SbnG	  is	  a	  novel	  citrate	  synthase,	  capable	  of	  generating	  citrate	  as	  a	  precursor	  to	  
staphyloferrin	  B	  production,	  independent	  of	  TCA	  cycle	  activity.	  
2.2) CitZ	  is	  indispensible	  for	  staphyloferrin	  A	  production,	  and	  thus	  staphyloferrin	  A	  
biosynthesis	  is	  inextricably	  linked	  to	  central	  metabolism.	  	  
1.7.2. Chapter	  2	  objectives	  
2.1) To	   assess	   the	   contribution	   of	   sbnG	   and	   citZ	   to	   staphyloferrin	   biosynthesis	   by	  
disrupting	  both	  citrate	  synthases	   in	  S.	  aureus	  and	  assessing	   the	  ability	  of	   these	  
mutants	  to	  grow	  in	  iron-­‐restricted	  media.	  	  
2.2) To	   characterize	   siderophore	   production	   by	   S.	   aureus	   in	   the	   absence	   of	   citZ	  
and/or	  sbnG.	  	  
2.3) To	   further	   characterize	   the	   role	   of	   SbnG	   as	   a	   citrate	   synthase	   in	   S.	   aureus	   by	  
assessing	   siderophore	   production	   of	   citZ	   sbnG	  mutants	   complemented	  with	   in	  
trans	  by	  vectors	  expressing	  SbnG	  bearing	  active	  site	  mutations.	  
2.4) To	   assess	   the	   contribution	   of	   citZ	   and	   sbnG	   to	   staphylococcal	   survival	   and	  
virulence	  in	  murine	  models	  of	  infection.	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1.7.3. Chapter	  3	  hypotheses	  
3.1) S.	   aureus	   possesses	   both	   high	   and	   low-­‐affinity	   heme-­‐iron	   acquisition	   systems,	  
where	   Isd	   represents	   the	   dedicated	   high-­‐affinity	   system	   for	   heme-­‐iron	  
acquisition.	  
3.2) The	   alternate	   low-­‐affinity	   heme	   uptake	   pathway	   in	   S.	   aureus	   is	   a	   putative	  
peptide	  permease.	  
1.7.4. Chapter	  3	  objectives	  
3.1) To	  elucidate	  the	  role	  of	   isd	  on	  the	  utilization	  of	  high	  and	  low	  concentrations	  of	  
heme-­‐iron.	  
3.2) To	  determine	  if	  the	  differences	  observed	  in	  isd	  phenotypes	  between	  authors	  can	  
be	  attributed	  to	  methodology.	  
3.3) To	   develop	   a	   robust	   and	   reproducible	   methodology	   for	   assessing	  
heme/hemoprotein	  utilization.	  
3.4) To	  generate	  di-­‐/tri-­‐peptide	  (dtpT)	  and	  oligopeptide	  permease	  (opp)	  mutants	  in	  S.	  
aureus	  USA300,	  including	  a	  full	  dtpT	  and	  opp-­‐deficient	  strain.	  
3.5) To	   assess	   the	   ability	   of	   dtpT	   and/or	   opp-­‐deficient	   S.	   aureus	   strains	   to	   utilize	  
heme/hemoproteins	   as	   a	   sole	   iron	   source	   using	   the	   methods	   optimized	   in	  
Objective	  3.3.	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Chapter	  2	  -­‐ WHY	  STAPHYLOCOCCUS	  AUREUS	  REQUIRES	  TWO	  
CITRATE	  SYNTHASES	  
2.1. INTRODUCTION	  
Iron	  is	  a	  growth-­‐limiting	  nutrient	  and,	  correspondingly,	  an	  important	  sensory	  trigger	  for	  
gene	   expression	   and	  metabolic	   changes	   in	   bacteria.	  While	   ferric	   iron	   forms	   insoluble	  
hydroxide	  or	  oxyhydroxide	  precipitates	  under	  aerobic	  conditions	  at	  neutral	  pH,	  ferrous	  
iron	  catalyzes	  the	  formation	  of	  damaging	  free	  radicals	  inside	  cells	  (1).	  Accordingly,	  iron	  
within	  the	  mammalian	  host	  is	  found	  in	  complex	  with	  heme	  in	  hemoproteins,	  bound	  to	  
the	   intracellular	   storage	   protein,	   ferritin,	   or	   sequestered	   in	   glycoproteins	   including	  
transferrin	  (2,	  3).	  Sequestration	  of	  iron	  renders	  it	  both	  bioavailable	  and	  nontoxic	  to	  the	  
host	  (4),	  while	  at	  the	  same	  time	  reducing	  the	  circulating	  concentration	  of	  free	  iron	  (10-­‐9	  
to	   10-­‐10	   M)	   to	   well	   below	   that	   required	   to	   support	   microbial	   growth	   (5,	   6).	   Invading	  
bacteria,	   including	  the	  formidable	  human	  and	  animal	  pathogen	  Staphylococcus	  aureus,	  
require	  means	  to	  circumvent	  this	   'iron-­‐withholding'	  strategy	  of	  the	  host.	  The	  response	  
of	   S.	   aureus	   to	   iron	   deprivation	   is	   mediated	   by	   the	   transcriptional	   ferric	   uptake	  
repressor,	   Fur,	   which	   facilitates	   the	   derepression	   of	   several	   key	   iron	   acquisition	  
pathways	   and	   additional	   virulence	   factors	   (7–9).	   	   Exploitation	   of	   multiple	   host	   iron	  
sources	  by	  S.	  aureus	  undoubtedly	  contributes	  to	  its	  ability	  to	  cause	  severe	  and	  invasive	  




	   A	  common	  strategy	  employed	  by	  bacteria	  to	  overcome	  iron	  limitation	  is	  to	  divest	  
transferrin	  of	  its	  iron	  through	  the	  synthesis	  and	  secretion	  of	  low	  molecular	  weight,	  high-­‐
affinity	   iron	   chelators	   known	   as	   siderophores.	   S.	   aureus	   elaborates	   two	   α-­‐
hydroxycarboxylate	   siderophores,	   staphyloferrin	   A	   (SA)	   and	   staphyloferrin	   B	   (SB)	   (13–
16),	   synthesized	   by	   enzymes	   encoded	   from	   the	   sfaABCD	   (17,	   18)	   and	   sbnABCDEFGHI	  
(19,	   20)	   loci,	   respectively.	   Both	   siderophores	   coordinate	   iron	   through	   citrate-­‐derived	  
moieties,	   where	   SA	   contains	   two	   citrate	   molecules	   linked	   by	   a	   central	   D-­‐ornithine	  
backbone,	  and	  SB	  is	  comprised	  of	  one	  molecule	  each	  of	  citrate	  and	  α-­‐ketoglutarate	  (α-­‐
KG),	   and	   two	   molecules	   of	   L-­‐2,3-­‐diaminopropionate	   (L-­‐Dap),	   one	   of	   which	   is	  
decarboxylated	   to	   form	  1,2-­‐diaminoethane	   (15,	  17,	  21).	  Recently,	   it	  was	   revealed	   that	  
both	   α-­‐KG	   and	   L-­‐Dap	   can	   be	   derived	   enzymatically	   from	   gene	   products	   of	   the	   SB	  
biosynthetic	   locus,	  where	  SbnA	  and	  SbnB	   together	   catalyze	   the	   formation	  of	   these	  SB	  
precursors	   from	   O-­‐phospho-­‐L-­‐serine	   and	   L-­‐glutamate	   (22).	   We	   have	   also	   shown	   that	  
SbnG	   catalyzes	   the	   iron-­‐regulated	   synthesis	   of	   citrate	   from	   oxaloacetate	   (OAA)	   and	  
acetyl	  coenzyme	  A	  (acetyl	  CoA)	  (23).	  Based	  upon	   in	  vitro	  studies,	   it	  would	  appear	  that	  
sbn	   encodes	   the	   necessary	   enzymes	   for	   the	   formation	   of	   all	   three	   SB	   precursor	  
molecules	   and	   the	   biosynthetic	   machinery	   necessary	   to	   generate	   SB	   under	   iron-­‐
restricted	  growth	  conditions.	  Conversely,	  the	  biosynthetic	  locus	  for	  SA	  does	  not	  encode	  
a	  citrate	  synthase	  (17,	  18)	  and,	  further,	  an	  S.	  aureus	  mutant	  deleted	  for	  the	  entire	  sbn	  
locus,	   including	  sbnG,	   is	   still	   capable	  of	  producing	  SA	   (18).	  Citrate	  must,	   therefore,	  be	  
synthesized	  by	  another	  enzyme	   in	   the	  cell,	  prior	   to	   its	   incorporation	   into	  SA.	  The	  only	  
other	  known	  citrate	  synthase	  in	  S.	  aureus	  is	  that	  of	  central	  metabolism,	  CitZ.	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   The	   generation	   of	   biosynthetic	   intermediates	   in	   S.	   aureus	   occurs	   via	   the	  
glycolytic,	   pentose	   phosphate,	   and	   tricarboxylic	   acid	   pathways.	   Under	   nutrient	   rich	  
conditions,	  glucose,	  through	  carbon	  catabolite	  repression,	  strongly	  represses	  TCA	  cycle	  
activity,	   and	   metabolism	   favours	   glycolysis	   (24–26).	   During	   the	   exponential	   phase	  
growth	   in	  glucose-­‐	  and	  glutamate/glutamine-­‐containing	  media,	  pyruvate	   is	  catabolized	  
to	  acetic	  acid	  or	   lactic	  acid	  under	  aerobic	  or	  anaerobic	  conditions,	  respectively.	  During	  
the	   transition	   to	   post-­‐exponential	   phase	   growth,	   these	   incompletely	   oxidized	  
metabolites	  are	  assimilated	  from	  the	  culture	  medium	  and	  used	  to	  generate	  acetyl-­‐CoA	  
which	  can	  be	  further	  catabolized	  by	  the	  TCA	  cycle	  (27–30).	  Paradoxically,	  while	  citrate	  is	  
a	  central	  component	  of	  both	  SA	  and	  SB,	  TCA	  cycle	  activity	  is	  also	  down-­‐regulated	  during	  
iron	   starvation	   as	   part	   of	   a	   Fur-­‐coordinated	   metabolic	   rearrangement	   known	   as	   the	  
iron-­‐sparing	   response,	   which	   has	   been	   studied	   in	   both	   S.	   aureus	   and	   Bacillus	   subtilis	  
(31–33).	   The	   iron-­‐sparing	   response	   reduces	   iron	   demands	   of	   the	   cell	   by	   suppressing	  
pathways	  bearing	  iron-­‐containing	  enzymes,	  such	  as	  the	  TCA	  cycle,	  while	  simultaneously	  
up-­‐regulating	  glycolytic	  and	  fermentative	  pathways.	  With	  repression	  of	  CitZ	  under	  iron-­‐
starvation	  conditions,	  an	  important,	  and	  as	  yet	  unanswered	  question,	   is	  from	  where	  is	  
citrate	  derived	  for	  incorporation	  into	  the	  S.	  aureus	  staphyloferrins?	  
	   In	  this	  chapter,	  we	  investigate	  the	  enzymatic	  source	  of	  citrate	  as	  a	  precursor	  for	  
staphyloferrin	   production	   in	   S.	   aureus.	   We	   demonstrate	   that	   TCA	   cycle	   activity	   is	  
essential	   for	   the	   synthesis	   of	   SA	   but	   not	   SB.	   Only	   SB	   is	   produced	   in	   iron-­‐restricted,	  
glucose-­‐containing	  culture	  media;	   that	   is,	  during	  exponential	  phase	  growth	  when	  cells	  
are	   deriving	   energy	   from	   glycolysis.	   For	   SB	   production,	   citrate	   is	   contributed	   by	   the	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activity	   of	   both	   citZ	   and	   sbnG,	   the	   latter	   of	   which	   is	   highly	   expressed	   under	   iron-­‐
restriction.	   Notably,	   homologues	   of	   sbnG	   have	   been	   identified	   in	   the	   genetic	   loci	  
encoding	   the	   citrate-­‐containing	   siderophores	   vibrioferrin	   and	   achromobactin,	  
suggesting	   that	   this	   novel	   citrate	   synthase	   may	   have	   evolved	   to	   specifically	   supply	  
citrate	   for	   siderophore	   biosynthesis	   (23),	   and	   indeed	   we	   demonstrate	   that	   SbnG	   is	  
incapable	   of	   fulfilling	   the	   function	   of	   CitZ	   in	   the	   TCA	   cycle.	   To	   gain	   insight	   into	   the	  
mechanism	   and	   activity	   of	   SbnG	   relative	   to	   other	   citrate	   synthases,	   catalytic	   residues	  
required	  for	  maximal	  SbnG	  activity	  and	  SB	  synthesis	  were	  identified.	  Together,	  citZ	  and	  
sbnG	  appear	  to	  fulfill	  unique,	  but	  overlapping	  roles	  in	  the	  provision	  of	  citrate	  to	  the	  cell,	  
and	   indeed	  appear	   to	  have	  distinct	   impacts	  on	   the	   survival	   and	  virulence	  of	  S.	  aureus	  
within	  the	  host.	  	  
2.2. MATERIALS	  AND	  METHODS	  
2.2.1. Bacterial	  strains	  and	  growth	  conditions	  
All	  bacterial	   strains	  and	  plasmids	  employed	   in	   this	   study	  are	  summarized	   in	  Table	  2.1.	  
Unless	   otherwise	   indicated,	   experiments	   were	   performed	   using	   S.	   aureus	   strain	  
Newman	  or	   its	   isogenic	  mutants.	  For	  genetic	  manipulations,	  S.	  aureus	  and	  Escherichia	  
coli	  were	  routinely	  cultured	  in	  Difco	  tryptic	  soy	  broth	  (TSB;	  BD	  Canada,	  Mississauga,	  ON,	  
Canada)	   or	   Difco	   Luria-­‐Bertani	   Broth	   (LB;	   BD	   Canada),	   respectively.	   Where	   required,	  
agar	  was	  added	  to	  media	  at	  a	  concentration	  of	  1.5%	  (w/v)	  yielding	  tryptic	  soy	  agar	  (TSA)	  
and	  Luria-­‐Bertani	  agar	  (LBA).	  	  Antibiotics,	  when	  required	  to	  maintain	  plasmids	  or	  select	  
for	  recombinants,	  were	  added	  at	  the	  following	  concentrations:	  ampicillin,	  100	  μg/mL;	  	  
	  	  
127	  
Table	  2.1.	  Bacterial	  strains	  and	  plasmids	  used	  in	  this	  study.	  	  
Strain	  or	  plasmid	  designation	   Descriptiona	   Reference	  
Escherichia	  coli	  	  
DH5α	   80dlacZΔM15	   recA1	   endA1	   gyrA96	   thi-­‐1	  
hsdR17(rK−	   mK+)	   supE44	   relA1	   deoR	  
Δ(lacZYA-­‐argF)U169,	  phoA	  
Promega	  
DC10B	   E.	   coli	   cloning	   host	   without	   cytosine	  
methylation,	   allows	   for	   uptake	   of	   plasmid	  
DNA	  directly	  by	  S.	  aureus;	  dam+	  dcm-­‐	  
(34)	  
Staphylococcus	  aureus	  
RN4220	   Prophage-­‐cured	   laboratory	   strain;	   rK−	   mK+;	  
accepts	  foreign	  DNA	  
(35)	  
	  
H627	  (Newman)	   Wild-­‐type	  clinical	  osteomyelitis	  isolate	   (36)	  
H187	  (RN6390)	   Wild-­‐type	  prophage-­‐cured	  laboratory	  strain	   (37)	  
H306	   RN6390	   sirABC::Km;	   SB	   transport-­‐deficient	  
mutant;	  KmR	  
(20)	  
H1448	   RN6390	   htsABC::Tc;	   SA	   transport-­‐deficient	  
mutant;	  TetR	  
(18)	  
H1331	   Newman	  ΔsbnABCDEFGHI::Tc;	  staphyloferrin	  
B-­‐deficient	  strain;	  TetR	  
(18)	  
H1665	   Newman	   ΔsfaABCD::Km;	   staphyloferrin	   A-­‐
deficient	  strain;	  KmR	  
(18)	  
H1666	   Newman	   ΔsbnABCDEFGHI::Tc	  	  
ΔsfaABCD::Km;	   	   staphyloferrin	   A	   and	   B-­‐
deficient	  strain;	  TetR,	  KmR	  
(18)	  
H2576	   Newman	   ΔcitZ;	   TCA	   cycle	   citrate	   synthase	  
mutant	  
(38)	  
H2705	   Newman	   ΔsbnG;	   sbn-­‐encoded	   citrate	  
synthase	  mutant	  
(38)	  
H2708	   Newman	   ΔcitZ	   ΔsbnG;	   citrate	   synthase-­‐
deficient	  strain	  
(38)	  
H852	  (WT	  S.	  aureus/pALC)	   H627	  containing	  empty	  pALC2073	  vector	   (38)	  
H2852	  (ΔcitZ/pALC)	   H2576	  containing	  empty	  pALC2073	  vector	   (38)	  
H2871	  (ΔcitZ	  sbnG/pALC)	   H2708	  containing	  empty	  pALC2073	  vector	   (38)	  
H2797	  (ΔcitZ/pcitZ)	   H2576/pcitZ;	   citZ	   mutant	   complemented	  
with	  citZ	  
(38)	  
H2664	  (ΔcitZ/psbnG)	   H2576/psbnG;	  citZ	  mutant	  bearing	  the	  sbnG	  
complementation	  vector	  
This	  study	  
H2855	  (ΔcitZ	  sbnG/pcitZ)	   H2708/pcitZ;	   citZ	   sbnG	   mutant	  
complemented	  with	  citZ	  
(38)	  
H2856	  (ΔcitZ	  sbnG/psbnG)	   H2708/pCM317;	   citZ	   sbnG	   mutant	  
complemented	  with	  sbnG	  
(38)	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Table	  2.1.	  Continued	  
Strain	  or	  plasmid	  designation	   Descriptiona	   Reference	  
Staphylococcus	  aureus	  
H2973	  (ΔcitZ	  sbnG/pE46Q)	   H2708/pE46Q	   citZ	   sbnG	   mutant	  
complemented	  with	  sbnG	  variant	  E46Q	  
(39)	  
H2974	  (ΔcitZ	  sbnG/pH47A)	   H2708/pH47A	   citZ	   sbnG	   mutant	  
complemented	  with	  sbnG	  variant	  H47A	  
(39)	  
H2975	  (ΔcitZ	  sbnG/pR72A)	   H2708/pR72A	   citZ	   sbnG	   mutant	  
complemented	  with	  sbnG	  variant	  R72A	  
(39)	  
H2976	  (ΔcitZ	  sbnG/pH96A)	   H2708/pH96A	   citZ	   sbnG	   mutant	  
complemented	  with	  sbnG	  variant	  H96A	  
(39)	  
H2977	  (ΔcitZ	  sbnG/pE151Q)	   H2708/pE151Q	   citZ	   sbnG	   mutant	  
complemented	  with	  sbnG	  variant	  E151Q	  
(39)	  
H2982	  (ΔcitZ	  sbnG/pD177A)	   H2708/pD177A	   citZ	   sbnG	   mutant	  
complemented	  with	  sbnG	  variant	  D177A	  
(39)	  
Plasmids	  
pALC2073	   E.	   coli/S.	   aureus	   shuttle	   vector	   for	   gene	  
expression	   in	   S.	   aureus;	   AmpR,	   CmR	  
(respectively)	  
(40)	  
pKOR1	   E.	   coli/S.	   aureus	   shuttle	   vector	   for	   allelic	  
replacement	   in	   S.	   aureus;	   AmpR,	   CmR	  
(respectively)	  
(41)	  
pKOR1ΔcitZ	  (pJS013)	  	   pKOR1	   derivative	   for	   in-­‐frame,	   markerless	  
deletion	  of	  citZ	  
(38)	  
pKOR1ΔsbnG	  (pCM318)	   pKOR1	   derivative	   for	   in-­‐frame,	   markerless	  
deletion	  of	  sbnG	  
(38)	  
psbnG	  (pCM317)	   pALC2073-­‐sbnG;	   pALC2073	   derivative	   for	  
expression	  of	  sbnG	  
(38)	  
pcitZ	  (pCM320)	   pALC2073-­‐citZ;	   pALC2073	   derivative	   for	  
expression	  of	  citZ	  
(38)	  
pE46Q	  (pJS037)	   pALC2073	   derivative	   expressing	   sbnG	   variant	  
E46Q	  
(39)	  
pH47A	  (pJS038)	   pALC2073	   derivative	   expressing	   sbnG	   variant	  
H47A	  
(39)	  
pR72A	  (pJS039)	   pALC2073	   derivative	   expressing	   sbnG	   variant	  
R72A	  
(39)	  
pH96A	  (pJS040)	   pALC2073	   derivative	   expressing	   sbnG	   variant	  
H96A	  
(39)	  
pE151Q	  (pJS041)	   pALC2073	   derivative	   expressing	   sbnG	   variant	  
E151Q	  
(39)	  
pD177A	  (pJS042)	   pALC2073	   derivative	   expressing	   sbnG	   variant	  
D177A	  
(39)	  
a.	   Tc;	   tetracycline	   resistance	   determinant,	   Km;	   kanamycin	   resistance	   determinant,	   TetR;	  




chloramphenicol,	   10	   μg/mL;	   kanamycin,	   30	   μg/mL,	   tetracycline,	   4	   μg/mL,	   and	  
anhydrotetracycline,	  250	  ng/mL	  (Sigma	  Aldrich,	  Oakville,	  ON	  Canada).	  	   	  
	   For	   bacterial	   growth	   in	   iron-­‐restricted	  media,	   glassware	  was	  washed	  overnight	  
with	   0.1	   M	   HCl	   to	   remove	   contaminating	   iron,	   or	   was	   prepared	   in	   sterile	   vessels	  
composed	   of	   polypropylene.	   All	   iron-­‐restricted	   media	   were	   prepared	   using	   water	  
purified	   with	   a	   Milli-­‐Q	   water	   filtration	   system	   (EMB	   Millipore,	   Billerica,	   MA).	   Where	  
required,	  media	  components	  were	  chelex-­‐treated	  using	  5	  g	  Chelex-­‐100	  resin	   (Bio-­‐Rad,	  
Mississauga,	   ON,	   Canada)	   per	   100	   mL,	   incubated	   overnight	   at	   4°C.	  Where	   indicated,	  
media	   were	   sometimes	   supplemented	   with	   the	   non-­‐metabolizable	   iron	   chelator	  
ethylenediamine-­‐di(o-­‐hydroxyphenylacetic	   acid)	   (EDDHA;	   LGC	   Standards	   GmbH,	  
Teddington,	  Middlessex,	  UK).	  Media	  employed	  in	  the	  assessment	  of	  growth	  under	  iron-­‐
deplete	   conditions	   were	   as	   follows:	   i)	   Roswell	   Park	   Memorial	   Institute	   1640	   media	  
(RPMI),	   prepared	   as	   directed	   by	   the	  manufacturer	   (Life	   Technologies,	   Burlington,	  ON,	  
Canada)	   and	  without	   chelex	   treatment	   ii)	   Tris	  Minimal	   Succinate	   (TMS),	   as	   previously	  
described	   (42),	   and	   treated	  with	   Chelex-­‐100	  where	   required	   iii)	   Tris	  Minimal	   Glucose	  
(TMG),	   prepared	   as	   directed	   for	   TMS	   except	   succinate	   was	   replaced	   with	   0.4%	   w/v	  
glucose,	   and	   iv)	   chemically-­‐defined	   medium	   with	   glucose	   (CDM-­‐G).	   For	   CDM-­‐G,	   10X	  
stocks	   of	   defined	   amino	   acids,	   vitamins,	   glucose,	   and	   salts	   were	   prepared,	   chelexed	  
where	   required,	   and	   added	   at	   the	   concentrations	   indicated;	   L-­‐alanine	   (60	   μg	  ml-­‐1),	   L-­‐
arginine	  (50	  μg	  ml-­‐1),	  L-­‐aspartic	  acid	  (90	  μg	  ml-­‐1),	  L-­‐cysteine	  (20	  μg	  ml-­‐1),	  L-­‐glutamic	  acid	  
(100	  μg	  ml-­‐1),	   glycine	   (50	  μg	  ml-­‐1),	   L-­‐histidine	   (20	  μg	  ml-­‐1),	   L-­‐isoleucine	   (30	  μg	  ml-­‐1),	   L-­‐
leucine	  (90	  μg	  ml-­‐1),	   L-­‐lysine	  (50	  μg	  ml-­‐1),	   L-­‐methionine	  (3	  μg	  ml-­‐1),	   L-­‐phenylalanine	  (40	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μg	   ml-­‐1),	   L-­‐proline	   (80	   μg	   ml-­‐1),	   L-­‐serine	   (30	   μg	   ml-­‐1),	   L-­‐threonine	   (30	   μg	   ml-­‐1),	   L-­‐
tryptophan	  (10	  μg	  ml-­‐1),	  L-­‐tyrosine	  (50	  μg	  ml-­‐1),	  and	  L-­‐valine	  (80	  μg	  ml-­‐1),	  L-­‐thiamine	  (169	  
μg	  ml-­‐1),	  nicotinic	  acid	  (12.3	  μg	  ml-­‐1),	  panthotenic	  acid	  (5	  μg	  ml-­‐1)	  biotin	  (1	  μg	  ml-­‐1),	  D-­‐
glucose	   (0.5%	   w/v),	   K2HPO4	   (7	   mg	   ml-­‐1)	   and	   KH2PO4	   (2	   mg	   ml-­‐1).	   Divalent	   ions	   were	  
added	  without	   chelex	   treatment,	   at	   the	   following	   concentrations;	  MgSO4	  (50	  μg	  ml-­‐1),	  
(NH4)2SO4	  (1000	  μg	  ml-­‐1),	  MgCl2	  (95.3	  μg	  ml-­‐1)	  and	  CaCl2	  (11.1	  μg	  ml-­‐1),	  and	  the	  medium	  
was	  sterilized	  via	  filtration.	  For	   iron-­‐replete	  conditions,	  30	  μM	  FeSO4	  was	  added	  to	  the	  
above	   media.	   Bacteria	   were	   routinely	   cultivated	   at	   37°C,	   unless	   otherwise	   indicated,	  
with	   shaking	   at	   200-­‐220	   rpm	   and	   a	   flask	   to	   volume	   ratio	   of	   at	   least	   10:1,	   unless	  
otherwise	   indicated	  (e.g.	   in	  growth	  curves	  using	  the	  Bioscreen	  C	  machine,	  see	  below).	  
To	  achieve	  S.	  aureus	  growth	  under	  anaerobic	  conditions,	  bacteria	  were	  cultured	  in	  flasks	  
where	  the	  flask-­‐to-­‐medium	  ratio	  was	  5:4,	  as	  described	  previously	  (43).	  	  
2.2.2. Bacterial	  growth	  curves	  	  
Growth	  assessment	  of	   the	  citZ	  mutant	   relative	   to	   the	  wildtype	   (both	  containing	  blank	  
pALC2073),	   the	   citZ-­‐complemented	   strain,	   and	   the	   citZ	   mutant	   bearing	   the	   sbnG	  
complementation	  vector	  was	  performed	  in	  TSB	  (for	  Figures	  2.4	  and	  2.8).	  Single,	  isolated	  
colonies	  grown	  for	  24	  h	  on	  TSA	  plates	  were	  resuspended	  and	  cultivated	  for	  4	  h	  in	  5	  mL	  
TSB	  until	  OD600	  was	  approximately	  1.	  Cells	  were	  washed	  twice	  in	  sterile	  PBS,	  normalized	  
to	  an	  OD600	  of	  0.1,	  and	  5	  μL	  of	  the	  resuspension	  was	  used	  to	  inoculate	  200	  μL	  aliquots	  of	  
TSB.	   Chloramphenicol	   was	   added	   to	   all	   media	   for	   maintenance	   of	   the	   plasmids,	   and	  
anhydrotetracyline	   was	   provided	   to	   induce	   expression.	   Cultures	   were	   grown	   in	   a	  
Bioscreen	   C	   machine	   (Growth	   Curves	   USA,	   Piscataway,	   NJ)	   at	   37°C	   with	   continuous	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medium	  amplitude	  shaking,	  and	  OD600	  was	  assessed	  every	  15	  min.	  For	  graphical	  clarity,	  
growth	  at	  4-­‐hour	  intervals	  is	  illustrated.	  
2.2.3. Assessment	  of	  bacterial	  growth	  yield	  in	  iron-­‐restricted	  media	  
For	   assessing	   growth	   yield	   under	   iron-­‐restriction	   (for	   Figures	   2.1	   and	   2.7),	   single,	  
isolated	  colonies	  of	  S.	  aureus,	  grown	   for	  24	  h	  on	  TSA,	  were	   resuspended	   in	  120	  μL	  of	  
chelex-­‐treated	   medium.	   One	   hundred	   microliters	   of	   the	   resuspension	   were	   used	   to	  
inoculate	  2	  mL	  of	  the	  same	  media	  containing	  0.5	  μM	  EDDHA	  and	  cultures	  were	  grown	  
for	  8	  –	  10	  h,	  until	  OD600	  was	  approximately	  1.	  These	  precultures	  were	  normalized	  to	  an	  
OD600	  of	  1,	  and	  subcultured	  (1:400)	   into	  2	  mL	  of	  the	  same	  media	  containing	  0.25	  –	  0.5	  
μM	  EDDHA,	  a	   concentration	  of	   chelator	   that	   inhibits	   growth	  of	   a	   known	   siderophore-­‐
deficient	   strain	   (Δsfa	   Δsbn;	   H1666),	   while	   still	   allowing	   for	   robust	   growth	   of	   the	  
wildtype.	   Chloramphenicol	   was	   added	   for	   strains	   harbouring	   pALC2073	   or	   its	  
derivatives.	  Cultures	  were	   incubated	   in	  14	  mL	   round-­‐bottom	  polypropylene	   tubes	  and	  
growth	   was	   assessed	   by	   determining	   OD600	   at	   12,	   24,	   and	   36	   h.	   For	   growth	   curves	  
performed	  in	  iron-­‐restricted	  media	  (Figure	  2.7),	  precultures	  were	  prepared	  as	  described	  
above	   in	   CDM-­‐G	   containing	   EDDHA	   and	   chloramphenicol.	   	   Cells	   were	   prepared	   and	  
growth	  curves	  were	  performed	  as	  described	  for	  TSB,	  using	  CDM-­‐G.	  
2.2.4. Assessment	  of	  siderophore	  production	  	  
Concentrated	   spent	   culture	   supernatants	   containing	   secreted	   siderophores	   were	  
prepared	   from	  10-­‐500	  mL	  cultures	  of	  S.	  aureus	  grown	   for	  30	  –	  36	  h	   in	   chelex-­‐treated	  
media	   without	   EDDHA,	   a	   medium	   which	   allows	   growth	   of	   even	   the	   staphyloferrin-­‐
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deficient	  strain,	  thus	  allowing	  for	  sufficient	  growth	  to	  be	  able	  to	  assess	  the	  supernatant	  
for	  staphyloferrins.	  Growth	  was	  assessed	  via	  OD600	  and	  culture	  densities	  normalized	  to	  
approximately	   2.	   Bacterial	   cells	  were	   pelleted	   via	   centrifugation,	   and	   the	   supernatant	  
was	   lyophilized	  overnight.	  Dried	  material	  was	   resuspended	   in	  1	  mL	  sterile	  ddH2O,	  and	  
the	  pH	  was	  normalized	  to	  7.5	  before	  being	  applied	  to	  plates	  to	  assess	  growth	  promotion	  
of	  wildtype	  S.	  aureus	  strain	  RN6390	  or	   its	  Δsir	  (growth	  of	  this	  mutant	   is	  dependent	  on	  
SA	   in	  supernatant)	  or	  Δhts	   (growth	  of	   this	  mutant	   is	  dependent	  on	  SB	   in	  supernatant)	  
derivatives,	  as	  previously	  described	   (18).	  Ten	  microliters	  of	   siderophores	  were	  applied	  
to	  sterile	  paper	  disks	  placed	  on	  TMS	  agar	  seeded	  with	  	  ~1	  x	  104	  CFU/mL	  of	  the	  reporter	  
strain	  and	  10	  μM	  EDDHA.	  Growth	  about	  the	  disk	  was	  measured	  after	  24	  and	  48	  h.	  	  
2.2.5. Assessment	  of	  glucose,	  acetate	  and	  lactate	  in	  culture	  supernatants	  
S.	  aureus	  Newman	  was	  grown	  in	  25-­‐mL	  volumes	  of	  TMS	  (in	  250-­‐mL	  Erlenmeyer	  flasks)	  
and	   culture	   supernatants	   were	   assessed	   for	   concentrations	   of	   glucose,	   acetate	   and	  
lactate	  using	  kits	  purchased	  from	  R-­‐biopharm	  (Washington,	  Missouri).	  	  
2.2.6. Real-­‐time	  PCR	  
Quantitative	   real-­‐time	   PCR	  was	   performed	   as	   described	   previously	   (18).	   In	   brief,	   RNA	  
was	  prepared	  from	  10-­‐mL	  cultures	  of	  S.	  aureus	  Newman	  grown	  in	  chelex-­‐treated	  TMS,	  
TMG,	  or	  RPMI,	  with	  and	  without	  iron,	  prepared	  in	  triplicate.	  Cells	  were	  collected	  at	  an	  
OD600	  of	  approximately	  1.0,	  and	  RNA	  was	  extracted	  using	  an	  Aurum	  Total	  RNA	  Mini	  Kit	  
as	   described	   by	   the	  manufacturer	   (Bio-­‐Rad;	   Hercules,	   CA).	   RNA	   (500	   ng)	   was	   reverse	  
transcribed	  and	  PCR-­‐amplified	  using	  iScriptTM	  One-­‐Step	  RT-­‐PCR	  Kit	  with	  SYBR	  Green	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Table	  2.2.	  Oligonucleotides	  used	  in	  this	  study.	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Table	  2.2	  Continued	  
Primer	  paira,b,c	   Sequence	  (5’-­‐3’)	   Application	  






For	   RT-­‐PCR	   of	   the	  





































































For	   generating	   SbnG	  
variant	  D177A	  
a. Sequences	   in	   bold	   denote	   the	   attB1	   or	   attB2	   sequences	   for	   site-­‐specific	  
recombination	  with	  pKOR1.	  
b. Phos/	  denotes	  a	  5’	  phosphate	  on	  the	  primer.	  
c. Restriction	  sites	  for	  cloning	  are	  underlined.	  
d. Italicized	  sequences	  represent	  the	  codon	  altered	  in	  the	  indicated	  SbnG	  variant,	  
with	  the	  underlined	  sequences	  denoting	  the	  exact	  nucleotides	  changed	  relative	  




(Bio-­‐Rad)	  and	  the	  primers	  described	  in	  Table	  2.2.	  Data	  were	  normalized	  relative	  to	  
expression	  of	  the	  housekeeping	  gene	  rpoB.	  
2.2.7. Construction	  of	  S.	  aureus	  citrate	  synthase	  mutants	  
Oligonucleotides	  used	  in	  generating	  or	  complementing	  citrate	  synthase	  mutants	  can	  be	  
found	   in	   Table	   2.2.	   An	   in-­‐frame,	  markerless	   deletion	   of	   citZ	   was	   generated	   using	   the	  
methods	  described	  by	  Bae	  and	  Schneewind	  (2006)	  and	  the	  plasmid	  pKOR1	  (41).	  In	  brief,	  
~1000-­‐bp	  regions	  upstream	  and	  downstream	  of	  citZ	  were	  amplified	  using	  primer	  pairs	  
attB2-­‐UP-­‐citZ-­‐F	   and	  UP-­‐citZ-­‐R,	   and	  DOWN-­‐citZ-­‐F	   and	  attB1-­‐DOWN-­‐citZ-­‐R,	   respectively.	  
The	   fragments	  were	   blunt	   end	   ligated	   using	   a	   phosphate	   added	   to	   the	   3’	   end	   of	   the	  
upstream	   amplicon.	   The	   fusion	   of	   these	   fragments	   represents	   a	   311	   codon	   (933	   bp)	  
deletion	  in	  citZ,	  from	  codon	  17	  to	  codon	  327.	  The	  linear	  construct	  was	  introduced	  into	  
pKOR1	   through	   site-­‐specific	   recombination,	   generating	   pKOR1ΔcitZ.	   Similarly,	   the	  
plasmid	  pKOR1ΔsbnG	  for	  the	  markerless,	  in-­‐frame	  deletion	  of	  sbnG	  was	  generated	  using	  
primer	   pairs	   attB1-­‐UP-­‐sbnG-­‐F	   and	   UP-­‐sbnG-­‐R,	   and	   DOWN-­‐sbnG-­‐F	   and	   attB2-­‐DOWN-­‐
sbnG-­‐R,	  representing	  a	  699-­‐bp	  deletion	  from	  the	  end	  of	  the	  sbnF	  to	  17	  codons	  upstream	  
of	  sbnH.	  The	  vectors	  were	  constructed	  in	  E.	  coli	  DH5α	  and	  passaged	  through	  RN4220	  at	  
30°C	  before	  introduction	  into	  S.	  aureus	  Newman	  by	  electroporation.	  Recombination	  was	  
performed	  as	  described	  (41).	  Selection	  of	  citZ	  recombinants	  was	  performed	  in	  TSB	  or	  on	  
TSB	   agar	   supplemented	   with	   0.4%	   (w/v)	   glucose	   and	   1.5%	   (w/v)	   Casamino	   acids	   (BD	  
Canada)	   to	   repress	   TCA	   cycle	   activity.	   Successful	   Newman	   ΔcitZ	   (H2576)	   and	   ΔsbnG	  
(H2705)	  mutants	  were	  screened	  through	  sensitivity	  to	  chloramphenicol,	   indicating	   loss	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of	   the	  pKOR1	  backbone,	   and	   confirmed	   through	  PCR	  and	   sequencing.	   	  Newman	  ΔcitZ	  
sbnG	   (H2708)	   was	   similarly	   generated	   through	   recombination	   of	   H2576	   with	  
pKOR1ΔsbnG,	  as	  above.	  
2.2.8. Complementation	  of	  citZ	  and	  sbnG	  
Complementation	   of	   the	   citZ	  mutation	   was	   performed	   by	   amplifying	   the	   gene	   using	  
primers	   citZ-­‐F-­‐SacI	   and	   citZ-­‐R-­‐SacI.	   The	   amplicon	   was	   cloned	   into	   pALC2073	   (40),	  
generating	  pcitZ.	   Similarly,	   an	   sbnG	  complementation	   vector	   (psbnG)	  was	   constructed	  
using	   primers	   sbnG-­‐F-­‐KpnI	   and	   sbnG-­‐R-­‐SacI	   and	   pALC2073.	   Both	   citZ	   and	   sbnG	  were	  
constitutively	  expressed	  without	   induction	  by	   the	   leaky	  Pxyl/tetO	  promoter	  of	  pALC2073	  
(40).	  
2.2.9. Construction	  of	  SbnG	  variant	  complementation	  vectors	  
To	  assess	  the	  role	  of	  residues	  implicated	  in	  SbnG	  enzymatic	  function	  in	  the	  production	  
of	   SB	   within	   the	   cell,	   whole	   plasmid	   mutagenesis	   was	   employed	   to	   generate	  
complementation	   vectors	   expressing	   sbnG	   mutated	   for	   these	   residues.	   Using	   the	  
previously	   constructed	   psbnG	   vector	   as	   a	   template,	   complementary	   mutagenesis	  
primers,	   as	   indicated	   in	   the	   Table	   2.2,	   were	   used	   to	   amplify	   plasmids	   bearing	   SbnG	  
variants	   E46Q,	   H47A,	   R72A,	   H96A,	   E151Q,	   and	   D177A.	   Structural	   characterization	   of	  
SbnG	   and	   superposition	   of	   the	   putative	   SbnG	   active	   site	   on	   that	   of	   known	   citrate	  
synthases	   and	   class	   II	   metal-­‐dependent	   aldolases	   was	   used	   in	   the	   selection	   of	   the	  
aforementioned	   residues	   (39).	   Following	   amplification,	  methylated	   template	  DNA	  was	  
removed	   through	  digestion	  with	  DpnI,	   the	  enzyme	  was	  heat	   inactivated	  at	   80°C	   for	   5	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min,	  and	  the	  resulting	  reaction	  mixes	  were	  used	  in	  the	  transformation	  of	  E.	  coli	  DC10B.	  
Plasmids	   bearing	   the	   correct	   mutation	   were	   confirmed	   through	   sequencing,	   and	  
introduced	  to	  S.	  aureus	  Newman	  ΔcitZ	  sbnG	   (H2708)	   through	  electroporation.	  As	  with	  
other	   pALC2073	   derivatives,	   the	   sbnG	   variants	   were	   constitutively	   expressed	   without	  
induction	  (40).	  
2.2.10. Assessment	  of	  SB	  production	  by	  S.	  aureus	  expressing	  SbnG	  variants	  
Concentrated	  spent	  supernatants	  of	  the	  citrate-­‐synthase	  deficient	  mutant	  (ΔcitZ	  sbnG)	  
complemented	   in	  trans	  by	  plasmids	  bearing	  the	  sbnG	  variants,	  as	  described	  above	  and	  
in	   Table	   2.1,	   were	   prepared	   from	   triplicate	   10	  mL	   cultures	   of	   these	   strains	   grown	   in	  
RPMI,	  a	  media	  conducive	  only	  to	  the	  production	  of	  SB	  (38).	  	  The	  presence	  of	  SB	  in	  these	  
concentrated	  supernatants	  was	  assessed	  as	  described	  above.	  	  
2.2.11. Murine	  model	  of	  systemic	  infection	  
Murine	  experiments	  were	  performed	  essentially	   as	  previously	  described	   (44).	   In	  brief,	  
six-­‐week-­‐old,	   female,	   BALB/c	  mice	   (Charles	   River	   Laboratories)	  were	   tail-­‐vein	   injected	  
with	   100	   μL	   of	   bacterial	   cell	   suspensions	   containing	   5-­‐7	   x	   106	   CFU	   of	   S.	   aureus.	   In	  
preparing	  for	   injection,	  cells	  were	  grown	  until	  mid-­‐to-­‐late	   log	  phase	   in	  TSB	  (OD600	  =	  2-­‐
2.5),	  washed	  twice,	  and	  resuspended	  in	  phosphate	  buffered	  saline	  (PBS)	  to	  an	  OD600	  of	  
approximately	  0.35	  in	  the	  same	  buffer	  (corresponding	  to	  a	  cell	  density	  of	  5	  x	  107	  to	  7	  x	  
107	  CFU/mL).	  Following	  injection,	  the	  infection	  was	  allowed	  to	  proceed	  for	  96	  h	  before	  
mice	  were	  weighed,	  euthanized	  with	  sodium	  pentobarbital,	  and	  the	  kidneys,	  hearts,	  and	  
livers	  were	  harvested.	   Extracted	  organs	  were	  homogenized	   for	  10	   seconds	   in	  4	  mL	  of	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PBS	   containing	   0.1%	   (v/v)	   Triton-­‐X100,	   serially	   diluted	   in	   the	   same	   buffer,	   and	   10	   μL	  
drops	  of	  each	  dilution	  were	  plated	  on	  TSA.	   	  Following	  10-­‐12	  h	  growth,	   the	  number	  of	  
viable	  bacterial	  cells	  per	  organ	  was	  determined.	  
2.2.12. 	  Murine	  skin	  abscess	  model	  
Bacterial	  cells	  for	  injection	  were	  prepared	  essentially	  as	  above,	  but	  were	  resuspended	  to	  
an	  OD600	  of	  approximately	  2.0	  in	  PBS	  (corresponding	  to	  a	  cell	  density	  of	  3.0	  x	  108	  to	  5	  x	  
108	   CFU/mL)	   subsequent	   to	  washing.	   The	   day	   prior	   to	   injection,	   BALB/c	  mice	   (n	  of	   6	  
mice	  per	  strain)	  were	  depilated	  by	  first	  shaving	  the	  right	  hindquarter	  and	  back	  with	  an	  
electric	   razor,	   and	   then	   applying	   NairTM	  3	   in	   1	   Hair	   Removal	   Lotion	   for	   Sensitive	   Skin	  
(Church	  &	  Dwight	  Canada	  Corp.;	  Mississauga,	  ON)	  at	  1	  minute	   intervals	   to	   the	  shaved	  
area	  to	  remove	  any	  residual	  fur.	  Mice	  were	   injected	  subcutaneously	  on	  the	  right	  flank	  
with	  50	  μL	  of	  the	  bacterial	  suspension	  containing	  1.5	  x	  107	  to	  2.5	  x	  107	  CFU	  of	  S.	  aureus	  
Newman	  or	   its	   isogenic	  mutants.	   Photographs	   of	   each	   abscess,	   along	  with	   a	   ruler	   for	  
scale,	  were	  taken	  every	  24	  h	  for	  7	  days,	  and	  the	  abscess	  area	  was	  quantified	  using	  Fiji	  
(Image	  J)	  version	  2.0.0-­‐rc-­‐11/1.49e	  (45).	  
2.3. RESULTS	  
2.3.1. Staphyloferrin	   B-­‐deficient	   S.	   aureus	   grows	   poorly	   in	   iron-­‐restricted	   media	  
containing	  glucose	  	  
As	  mentioned	  above,	  S.	  aureus	  synthesizes	  and	  secretes	  both	  staphyloferrin	  A	  (SA)	  and	  
staphyloferrin	   B	   (SB),	   and	   both	   are	   citrate-­‐based	   siderophores.	   The	   TCA	   cycle	   citrate	  
synthase,	   citZ,	   is	   essential	   for	   generating	   citrate	   within	   the	   cell	   yet	   the	   TCA	   cycle	   is	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repressed	  under	   iron-­‐restricted	  growth	  conditions	  where	  production	  of	  staphyloferrins	  
would	  presumably	  be	  required	  to	  enhance	  growth.	  We	  recently	  reported	  that	  within	  the	  
biosynthetic	  locus	  for	  SB,	  one	  gene,	  sbnG,	  encodes	  a	  novel	  citrate	  synthase.	  The	  goal	  of	  
this	   study	   was	   to	   define	   the	   importance	   of	   both	   citZ	   and	   sbnG	   to	   staphyloferrin	  
production	   in	   S.	   aureus.	   Our	   previous	   studies	   examining	   staphyloferrin	   production	  
utilized	  a	  succinate-­‐based	  medium	  (Tris	  Minimal	  Succinate;	  TMS)	  that	  contained	  a	  TCA	  
cycle	   intermediate	   (succinate)	   and	   the	   chemically	   ill-­‐defined	   Casamino	   acids.	   In	   that	  
medium,	  we	  could	   readily	  detect	   that	  S.	  aureus	   secreted	  both	  SA	  and	  SB	   (18,	  21).	  For	  
the	   current	   study,	   we	   sought	   to	   use	   a	   completely	   chemically-­‐defined,	   iron-­‐restricted	  
growth	   medium.	   Accordingly,	   we	   selected	   RPMI	   and	   chemically-­‐defined	   media	   with	  
glucose	  (CDM-­‐G),	  which	  both	  employ	  glucose	  as	  a	  carbon	  source.	  Surprisingly,	  we	  found	  
that,	   relative	   to	  wildtype	   S.	   aureus	   and	   a	   staphyloferrin	   A-­‐deficient	  mutant	   (sfa),	   the	  
staphyloferrin	  B-­‐deficient	  mutant	  (sbn)	  was	  unable	  to	  grow	  by	  24	  hours	  in	  either	  RPMI	  
(Fig.	  2.1A)	  or	  CDM-­‐G	  (Fig.	  2.1B)	  chelated	  with	  a	  low	  concentration	  (0.25	  μM)	  of	  the	  non-­‐
metabolizable	   iron	   chelator	   ethylenediamine-­‐di(o-­‐hydroxyphenylacetic	   acid)	   (EDDHA).	  
Notably,	  the	  lack	  of	  growth	  was	  comparable	  to	  that	  of	  a	  sfa	  sbn	  mutant	  that	  is	  incapable	  
of	  producing	  either	  SA	  or	  SB,	  suggesting	  that	  the	  SB-­‐deficient	  strain	  was	  also	  unable	  to	  
produce	  SA	  in	  these	  media.	  	  The	  observed	  growth	  deficiency	  was	  due	  to	  an	  inability	  of	  
the	   sbn	   mutant	   to	   acquire	   trace	   amounts	   of	   iron	   from	   the	   medium,	   because	  
supplementation	   of	   the	   medium	   with	   30	   μM	   FeSO4	   readily	   promoted	   growth	   of	   all	  




Figure	  2.1.	  Staphyloferrin	  B-­‐deficient	  mutants	  are	  impaired	  for	  growth	  in	  iron-­‐
restricted	  media	  containing	  glucose.	  
Growth	   yield	   of	   S.	   aureus	   siderophore	   biosynthesis	  mutants	   compared	   to	   that	   of	   the	  
wildtype	  (WT)	  after	  24	  hours	  in	  RPMI	  (A)	  or	  CDM-­‐G	  (B),	  chelated	  with	  0.25	  μM	  EDDHA	  (-­‐
Fe)	  or	  supplemented	  with	  30	  μM	  FeSO4	  (+Fe).	  	  -­‐SA,	  S.	  aureus	  sfa	  mutant	  lacking	  the	  SA	  
biosynthetic	  cluster;	  -­‐SB,	  S.	  aureus	  sbn	  mutant	  lacking	  the	  SB	  biosynthetic	  cluster.	  	  Error	  
bars	   represent	   standard	   error	   of	   the	   mean.	   N.S.,	   not	   significant;	   ***	   P	   <	   0.001,	   as	  





2.3.2. Glucose	  suppresses	  staphyloferrin	  A	  (SA)	  production	  
To	  determine	  if	  the	  iron-­‐restricted	  growth	  defect	  of	  the	  sbn	  mutant	  in	  RPMI	  and	  CDM-­‐G	  
was	  due	   to	  a	   lack	  of	   SA	  production,	  we	  grew	   strains	   in	  unchelated	  CDM-­‐G	  and	  RPMI.	  	  
Note	   that	   without	   chelation	   of	   trace	   amounts	   of	   contaminating	   iron,	   these	   media	  
contain	  enough	  iron	  so	  as	  to	  allow	  growth	  of	  even	  the	  staphyloferrin-­‐deficient	  (i.e.	  sfa	  
sbn)	  mutant	   (Figure	   2.2A,	   inset).	   	   An	   iron-­‐limited	  medium	   that	   allowed	   growth	   of	   all	  
mutants,	  even	  the	  SA-­‐	  SB-­‐	  mutant,	  is	  important	  because	  it	  allows	  for	  the	  examination	  of	  
metabolites	  from	  the	  spent	  culture	  supernatants.	  	  The	  spent	  culture	  supernatants	  were	  
concentrated	   and	   assessed	   for	   the	   presence	   of	   staphyloferrins	   using	   agar	   plate	  
bioassays.	  In	  these	  assays,	  S.	  aureus	  strains	  proficient	  in	  the	  utilization	  of	  only	  SA	  (i.e.	  sir	  
mutant)	  or	  SB	  (i.e.	  hts	  mutant)	  as	  an	   iron	  source	  were	  supplied	  with	  the	  concentrated	  
culture	   supernatants	   of	   wildtype	   S.	   aureus,	   and	   its	   staphyloferrin-­‐deficient	   mutants	  
grown	  in	  CDM-­‐G	  (Fig.	  2.2A)	  or	  RPMI	  (data	  not	  shown),	  as	  a	  sole	  iron	  source.	  As	  shown	  in	  
Figure	   2.2A,	   none	   of	   the	   spent	   culture	   supernatants	   promoted	   the	   growth	   of	   the	   sir	  
mutant,	   whose	   growth	   in	   this	   bioassay	   is	   wholly	   dependent	   upon	   the	   uptake	   of	   SA	  
which	  might	  be	  present	  in	  the	  supplied	  supernatant.	  These	  results	  confirm	  that	  the	  iron-­‐
restricted	  growth	  defect	  of	   the	  sbn	  mutant	   in	  CDM-­‐G	  and	  RPMI	   is	  due	   to	  a	   lack	  of	  SA	  
synthesis	  by	  S.	  aureus.	  	  	  
In	  agreement	  with	  our	  previous	  studies	  (18,	  21),	  we	  confirmed	  here	  that	  both	  SA	  
and	  SB	  are	  produced	  when	  S.	  aureus	  is	  grown	  in	  iron-­‐restricted	  TMS	  (Fig.	  2.2B).	  	  We	  also	  
confirmed	  that	  both	  siderophores	  were	  produced	  to	  similar	  levels	  when	  S.	  aureus	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Figure	  2.2.	  Staphyloferrin	  A	  synthesis	  is	  inhibited	  in	  S.	  aureus	  during	  glycolytic	  growth.	  	  
In	  A-­‐C,	  agar	  plate	  bioassays	  were	  performed	  using	  supernatant	  extracts	  prepared	  from	  
S.	  aureus	  Newman	  strains	  (wildtype	  (WT)	  and	  its	  isogenic	  mutants),	  as	  indicated	  in	  the	  x-­‐
axes,	  that	  were	  grown	  for	  36	  hours	  in	  CDM-­‐G	  (panel	  A),	  or	  TMS	  (panel	  B).	  In	  panel	  C,	  WT	  
S.	  aureus	  was	  grown	   in	  TMS	  media	  where	  glucose	  replaced	  succinate	   (TMG)	  or	  where	  
0.4%	  (w/v)	  glucose	  was	  added	  in	  addition	  to	  the	  succinate	  (TMS	  +	  Glc).	  	  In	  each	  of	  panels	  
A,	  B	  and	  C,	  the	  left	  side	  (labeled	  SA	  (Δsir))	  is	  a	  measure	  for	  the	  presence	  of	  SA	  in	  culture	  
supernatants,	   since	   spent	   culture	   supernatants	   were	   supplied	   to	   a	   sir	   mutant	  
impregnated	   in	   agar	   plate	   bioassays	   (see	   Materials	   and	   Methods).	   The	   sir	   mutant	   is	  
defective	   for	   SB	   uptake	   and	   therefore	   growth	   promotion	   in	   this	   iron-­‐restricted	   solid	  
media	  relies	  on	  supplying	  SA	  to	  the	  bacteria.	  In	  each	  of	  panels	  A,	  B	  and	  C,	  the	  right	  side	  
(labeled	   SB	   (Δhts))	   is	   a	  measure	   for	   the	  presence	  of	   SB	   in	   culture	   supernatants,	   since	  
spent	  culture	   supernatants	  were	   supplied	   to	  an	  hts	  mutant	   impregnated	   in	  agar	  plate	  
bioassays	   (see	  Materials	  and	  Methods).	  The	  hts	  mutant	   is	  defective	  for	  SA	  uptake	  and	  
therefore	  growth	  promotion	  in	  this	  iron-­‐restricted	  solid	  media	  relies	  on	  supplying	  SB	  to	  
the	   bacteria.	   	   Panel	   A	   (inset)	   demonstrates	   that,	   in	   order	   to	   prepare	   spent	   culture	  
supernatants	   from	   all	   strains,	   media	   not	   treated	   with	   Chelex-­‐100	   (i.e.	   iron-­‐restricted	  
media	   that	   were	   not	   specifically	   deferrated)	   were	   used	   in	   order	   to	   allow	   sufficient	  
growth	  so	  as	  to	  facilitate	  detection	  of	  staphyloferrins	  in	  culture	  supernatants.	  	  In	  panel	  
D,	  S.	  aureus	  Newman	  was	  grown	  in	  triplicate	  cultures	  of	  25-­‐mL	  TMS	  (in	  250	  mL	  flasks)	  
containing	  the	  indicated	  (x-­‐axis)	  concentrations	  of	  glucose,	  and	  cultures	  were	  incubated	  
at	  37°C	  for	  36	  hours.	  At	  the	  36-­‐hour	  time	  point,	  determinations	  were	  made	  for	  optical	  
density	   (OD600),	   supernatant	   pH,	   and	   the	   presence	   of	   SA	   and	   SB	   in	   the	   supernatants	  
using	  the	  assay	  as	  described	  for	  panels	  A-­‐C.	  For	  panels	  E	  and	  F,	  S.	  aureus	  Newman	  was	  
cultured	   (as	   per	   panel	   D)	   in	   TMS	   +	   22.2	  mM	   glucose	   and	   determinations	  were	  made	  
throughout	  the	  growth	  curve	  for	  glucose	  (panel	  E)	  and	  acetate	  and	  lactate	  (panel	  F).	  For	  
panels	  A-­‐F,	  error	  bars	   represent	  standard	  error	  of	   the	  mean,	  and	  the	  data	  plotted	  are	  





was	  cultured	  in	  TMS	  under	  either	  aerobic	  or	  anaerobic	  conditions	  (data	  not	  shown).	  	  To	  
confirm	   if	  glucose	  was	   the	   factor	   inhibiting	  SA	  production	   in	  CDM-­‐G	  and	  RPMI	  media,	  
we	  altered	  TMS	  media	  in	  two	  different	  ways.	  In	  one,	  we	  replaced	  the	  succinate	  in	  TMS	  
with	  glucose	   (TMG),	  and	   in	   the	  other	  we	  simply	  added	  glucose	  to	  TMS	  (i.e.	   the	  media	  
contained	   both	   succinate	   and	   glucose;	   TMS	   +	   Glc).	   	   We	   then	   assessed	   siderophore	  
production	   from	   cultures	   grown	   in	   both	   media.	   As	   shown	   in	   Fig.	   2.2C,	   SA	   was	   not	  
produced	   in	   either	   media,	   demonstrating	   that	   glucose	   in	   the	   growth	   media	   strongly	  
suppressed	  the	  synthesis	  of	  SA.	  	  
To	  examine	   in	   greater	  detail	   the	  effect	  of	   glucose	   in	   the	   growth	  media	  on	   the	  
suppression	   of	   SA	   synthesis,	   we	   assessed	   SA	   and	   SB	   production	   in	   TMS	   medium	  
containing	  glucose	  in	  decreasing	  concentrations,	  starting	  with	  22	  mM	  (0.4	  %	  Glc,	  w/v).	  
Figure	  2.2D	  illustrates	  that	  while	  SB	  was	  readily	  detected	  when	  cells	  were	  grown	  at	  all	  
concentrations	  of	  glucose,	  SA	  was	  only	  detectable	  once	  the	  initial	  glucose	  concentration	  
dropped	  below	  the	  5	  mM	  range.	  	  This	  correlated	  with	  our	  observation	  that,	  for	  cultures	  
where	  the	  starting	  glucose	  concentration	  was	  22	  mM,	  the	  cells,	  which	  grew	  to	  optical	  
densities	   of	   between	   5	   and	   6	   after	   36	   hours	   incubation	   at	   37°C,	   did	   not	   completely	  
consume	   the	  glucose	   from	   the	  media	   (Fig.	   2.2E).	   The	  36-­‐hour	   supernatant	  of	   cultures	  
grown	   in	  this	  media	  had	  an	  average	  pH	  of	  5.6	  (Fig.	  2.2D),	  and	  this	  correlated	  with	  the	  
accumulation	  of	  acetic	  acid	  (Fig.	  2.2F).	  The	  presence	  of	  acetic	  acid	  and	  lack	  of	  lactic	  acid	  
in	   the	   culture	  media	   is	   indicative	  of	   aerobic	   culture	   conditions,	   as	  would	  be	  expected	  
since	  the	  flask-­‐to-­‐volume	  ratio	  of	  these	  cultures	  was	  maintained	  at	  or	  above	  10:1	  (43).	  
These	   data	   are	   in	   close	   agreement	   with	   previous	   work	   demonstrating	   that	   acetate	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accumulates	   in	   the	  S.	  aureus	   culture	  medium	  during	  exponential	  growth	  phase,	  and	   is	  
depleted	  from	  the	  medium	  only	  after	  the	  glucose	  is	  exhausted	  (27).	  	  	  
2.3.3. Staphyloferrin	  A	  biosynthetic	  and	  transport	  genes	  are	  expressed	  under	  iron-­‐
restriction,	  even	  in	  the	  presence	  of	  glucose	  
The	   lack	  of	   SA	   in	   spent	   culture	   supernatants	  of	  glucose-­‐containing	  media	  might	   result	  
from	  reduced	  expression	  of	  SA	  biosynthetic	  genes	   in	   these	  culture	  conditions.	  To	   rule	  
this	  out,	  we	  assessed	  the	  expression	  of	  both	  SA	  transcripts	  (sfaA	  and	  sfaD)	  in	  cells	  grown	  
under	   iron-­‐restriction	   in	  media	  with	  or	  without	  glucose.	   	  We	  observed	   that	  both	  sfaA	  
and	  sfaD	  were	  significantly	  upregulated	  in	  iron-­‐depleted	  TMG	  versus	  iron-­‐replete	  TMG	  
(Fig.	  2.3A),	  consistent	  with	  their	  established	  regulation	  by	  iron	  concentration,	  via	  the	  Fur	  
protein,	  in	  the	  growth	  medium	  (18).	  	  Further,	  the	  transcript	  levels	  were	  not	  significantly	  
different	   between	   cells	   cultured	   in	   iron-­‐limited	   TMS	   versus	   TMG	   growth	   media	   (Fig.	  
2.3B).	  
To	  ensure	  that	  the	  growth	  defect	  of	  the	  sbn	  mutant	  in	  glucose-­‐containing	  media	  
could	  not	  be	  attributed,	  at	  least	  in	  part,	  to	  a	  reduction	  in	  SA	  reentry,	  we	  also	  evaluated	  
the	  expression	  of	  HtsA,	   the	  receptor	   for	   ferric-­‐SA	  uptake,	   in	  cells	  grown	   in	  TMS,	  TMG,	  
and	   RPMI.	   Western	   blotting	   for	   HtsA	   demonstrated	   that	   HtsA	   was	   expressed	   to	  
equivalent	  levels	  when	  cells	  were	  grown	  in	  each	  of	  the	  three	  types	  of	  media	  (data	  not	  
shown).	   In	   summary,	   the	   hindered	   growth	   of	   the	   sbn	   (i.e.	   SB-­‐deficient)	   mutant	   in	  
glucose-­‐containing	   media,	   therefore,	   cannot	   be	   attributed	   to	   reduced	   expression	   of	  





Figure	  2.3.	  Staphyloferrin	  A	  biosynthesis	  genes	  are	  expressed	  under	  iron-­‐restriction.	  
A,	  Expression	  levels	  of	  sfaA	  and	  sfaD	  were	  assessed	  using	  real-­‐time	  PCR	  in	  cultures	  of	  S.	  
aureus	  Newman	  grown	  in	  TMG	  with	  (+Fe)	  or	  without	  (-­‐Fe)	  FeSO4.	  Data	  was	  normalized	  
relative	  to	  the	  expression	  of	  rpoB,	  and	  expression	  of	  each	  gene	  in	  TMG	  containing	  iron	  
was	   set	   to	   1	   as	   the	   comparator.	   B,	   The	   expression	   of	   the	   same	   genes	   was	   similarly	  
compared	   in	   cells	   grown	   in	   TMS	   (i.e.	   succinate-­‐containing	   medium)	   versus	   TMG	   (i.e.	  
glucose-­‐containing	  medium),	   and	   expression	   in	   TMS	  was	   set	   to	   1	   as	   the	   comparator.	  
Error	   bars	   represent	   standard	   error	   of	   the	   mean	   and	   statistical	   significance	   was	  
determined	  using	  the	  Student’s	  unpaired	  t-­‐test,	  with	  P-­‐values	  as	  indicated.	  	  Data	  are	  the	  
average	  of	  four	  biological	  replicates.	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2.3.4. citZ	   mutants	   exhibit	   altered	   colony	   morphology,	   enter	   stationary	   phase	  
early	  
From	  the	  above	  results,	  we	  reasoned	  that	   the	   lack	  of	  SA	  production,	   in	  growth	  media	  
that	   contained	   concentrations	   of	   glucose	   high	   enough	   so	   as	   to	   not	   be	   completely	  
depleted	   during	   bacterial	   growth,	   was	   due	   to	   suppression	   of	   TCA	   cycle	   activity	   and,	  
more	   specifically,	   the	   lack	   of	   CitZ	   activity	   (i.e.	   citrate	   synthase	   to	   provide	   citrate	   as	   a	  
precursor	   for	   SA).	   To	   address	   the	   role	   of	   citZ	   in	   providing	   citrate	   as	   a	   siderophore	  
precursor,	  we	  first	  generated	  a	  markerless,	  in-­‐frame	  deletion	  of	  citZ.	  	  Consistent	  with	  a	  
previous	  report	   (46),	   the	  citZ	  mutant	  displayed	  enhanced	  pigmentation	  (Fig.	  2.4A)	  and	  
reduced	   colony	   size	   (data	   not	   shown)	   relative	   to	   the	   wildtype,	   both	   of	   which	   were	  
restored	  upon	  complementation	   in	   trans	   (Fig.	  2.4A).	   	   	  Additionally,	  when	  assessed	   for	  
growth	  in	  rich	  media	  (i.e.	  TSB),	  the	  citZ	  mutant	  entered	  stationary	  phase	  earlier	  than	  the	  
wild-­‐type	  (Fig.	  2.4B),	  a	  phenotype	  that	  has	  been	  described	  for	  other	  TCA	  cycle	  mutants	  
(47).	  Again,	  this	  phenotypic	  defect	  was	  ameliorated	  by	  expression	  of	  citZ	  in	  trans	  in	  the	  
mutant	  (Fig.	  2.4B).	  
2.3.5. Requirement	  of	  citZ	  for	  synthesis	  of	  SA,	  but	  not	  SB	  
Given	  that	  SA	  is	  only	  produced	  in	  media	  lacking	  glucose,	  or	  once	  it	  has	  been	  exhausted	  
from	  culture	  media	   (see	  Fig.	  2.2),	  we	   first	   sought	   to	  determine	   if	   the	  citZ	  mutant	  was	  
capable	  of	  producing	  SA	  in	  TMS,	  a	  media	  conducive	  to	  SA	  production.	   	  Using	  assays	  as	  
above,	  the	  data	  demonstrate	  that	  spent	  culture	  supernatants	  of	  the	  S.	  aureus	  citZ	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Figure	  2.4.	  citZ	  mutants	  have	  an	  enhanced	  yellow	  color	  and	  enter	  stationary	  phase	  
early	  during	  growth	  in	  rich	  media.	  
A,	   TSB	   agar	   plate,	   containing	   chloramphenicol	   for	   maintenance	   of	   plasmids,	  
demonstrating	  the	  colour	  of	  wildtype	  S.	  aureus	  (WT)	  and	  its	  isogenic	  citZ	  mutant	  (ΔcitZ).	  
Strains	  contained	  either	  a	  vehicle	  control	  (pALC	  =	  pALC2073)	  or	  pALC2073	  carrying	  the	  
citZ	   gene	   (pcitZ).	   B,	   Growth	   kinetics	   of	   S.	   aureus	   strains	   in	   TSB,	   as	   indicated,	   in	   a	  
Bioscreen	  C	  machine.	  Data	  are	   representative	  of	   three	   independent	  experiments,	   and	  
error	  bars	  signify	  standard	  error	  of	  the	  mean.	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mutant	   grown	   in	   TMS	   do	   not	   contain	   SA,	   and	   that	   complementation	   in	   trans	   of	   citZ	  
restores	   SA	   production	   (Fig.	   2.5).	   These	   results	   confirm	   our	   hypothesis	   that	   citZ	  
expression	   is	   indispensible	   for	  SA	  biosynthesis.	  Of	  particular	  note,	  and	  consistent	  with	  
our	  data	  described	  above,	   SB	   synthesis	   continues	   in	   the	  citZ	  mutant,	   albeit	   to	   slightly	  
lower	  levels	  than	  in	  WT	  cells	  (Fig.	  2.5).	  These	  data	  confirm	  that	  S.	  aureus	  must	  have	  an	  
alternate	  method	  of	  synthesizing	  citrate	  for	  generating	  SB	  under	  iron-­‐restricted	  growth	  
conditions.	  	  	  
2.3.6. Deletion	   of	   citZ	   and	   sbnG	   impairs	   growth	   under	   iron-­‐restriction	   by	  
abolishing	  staphyloferrin	  production	  	  
As	  discussed	  in	  the	  preceding	  section,	  S.	  aureus	  must	  have	  another	  citrate	  synthase	  that	  
is	  used	  for	  SB	  synthesis,	  but	  that	  is	  unable	  to	  provide	  citrate	  for	  SA	  synthesis.	  	  Our	  group	  
had	   previously	   demonstrated	   that,	   in	   vitro,	   the	   product	   of	   sbnG	   has	   citrate	   synthase	  
activity	   (23),	   but	   had	   not	   yet	   shown	   the	   requirement	   of	   sbnG	   for	   SB	   synthesis	   in	   S.	  
aureus.	  Whether	  grown	  in	  RPMI	  (Fig.	  2.6)	  or	  TMS	  medium	  (data	  not	  shown),	  the	  sbnG	  
gene	  is	  highly	  induced	  upon	  iron	  starvation.	  To	  clarify	  the	  respective	  roles	  of	  sbnG	  and	  
citZ	  in	  SB	  synthesis,	  we	  generated	  an	  in-­‐frame,	  markerless	  deletion	  of	  sbnG	  in	  both	  wild-­‐
type	  S.	  aureus	  and	   the	  citZ	  mutant.	   	  With	   these	  citrate	   synthase	  mutants	   in	  hand,	  we	  
proceeded	   to	   assess	   their	   growth	   and	   SB	   production	   in	   chemically-­‐defined,	   iron-­‐
restricted	   media	   where	   SA	   production	   is	   effectively	   suppressed.	   As	   shown	   in	   Figure	  
2.7A,	  while	  neither	  single-­‐locus	  deletion	  abolished	  the	  growth	  of	  S.	  aureus	  in	  RPMI,	  the	  
citZ	  sbnG	  double	  mutant	  was	  profoundly	  encumbered	  for	  growth	  after	  24	  h.	  The	  growth	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Figure	  2.5.	  citZ	  is	  required	  for	  SA,	  but	  dispensable	  for	  SB	  production.	  
Siderophore	   production	   from	   wildtype	   S.	   aureus	   Newman	   (WT)	   and	   derivatives	  
(indicated	  on	  the	  x-­‐axis)	  grown	  in	  TMS	  medium	  (i.e.	  permissive	  to	  SA	  and	  SB	  synthesis)	  
was	   assessed	   using	   agar	   plate	   bioassays.	   See	   legend	   to	   Figure	   2.2	   for	   a	   detailed	  
explanation	  of	   the	  assay.	   	  Data	  are	   representative	  of	   three	   independent	  experiments,	  
and	  error	  bars	  signify	  standard	  error	  of	  the	  mean.	  
Figure	  2.6.	  Expression	  pattern	  of	  sbnG	  during	  growth	  in	  RPMI	  medium.	  
Expression	   levels	   of	   sbnG	  were	   measured	   during	   growth	   in	   iron-­‐replete	   (black	   bars)	  
versus	  iron-­‐deplete	  (white	  bars)	  RPMI.	  Data	  were	  normalized	  relative	  to	  the	  expression	  
of	  rpoB,	  and	  expression	  of	  sbnG	  in	  S.	  aureus	  Newman	  growing	  in	  iron-­‐replete	  RPMI	  was	  
set	   to	   1	   as	   the	   comparator.	   Error	   bars	   represent	   standard	   error	   of	   the	   mean	   and	  









Figure	  2.7.	  A	  citZ	  sbnG	  mutant	  fails	  to	  synthesize	  SA	  and	  SB,	  a	  phenotype	  that	  is	  
complemented	  by	  addition	  of	  exogenous	  citrate.	  	  	  
A,	  Growth	  yield	  of	  S.	  aureus	   citZ	   and	  sbnG	  mutants	   compared	   to	   that	  of	   the	  wildtype	  
(WT)	  after	  24	  hours	  in	  RPMI	  (-­‐Fe)	  or	  RPMI	  supplemented	  with	  30	  μM	  FeSO4	  (+Fe).	  	  Data	  
are	   representative	   of	   three	   independent	   experiments,	   where	   error	   bars	   represent	  
standard	   error	   of	   the	   mean.	   N.S.,	   not	   significant;	   ***	   P	   <	   0.001,	   as	   determined	   by	  
Student's	  unpaired	  t-­‐test.	  	  B,	  Growth	  curves	  (in	  Bioscreen	  C	  machine)	  of	  S.	  aureus	  WT	  or	  
mutants	  complemented	  with	  vehicle	  control	  (pALC;	  =	  pALC2073)	  or	  pALC2073	  carrying	  
sbnG	  or	  citZ	  as	  indicated.	  Data	  are	  representative	  of	  three	  independent	  experiments.	  In	  
panels	  C	  and	  D,	  agar	  plate	  bioassays	  were	  performed	  using	  the	  assay	  that	  is	  described	  in	  
detail	  in	  the	  legend	  to	  Figure	  2.2.	  	  In	  panel	  C,	  supernatant	  extracts	  were	  prepared	  from	  
S.	  aureus	  strains,	  as	   indicated	   in	   the	  x-­‐axis,	  which	  were	  grown	   for	  36	  hours	   in	  CDM-­‐G	  
and	   analyzed	   for	   the	   presence	  of	   SB.	   In	   panel	  D,	   supernatant	   extracts	  were	   prepared	  
from	  S.	  aureus	  strains,	  as	   indicated	  in	  the	  x-­‐axis,	  that	  were	  grown	  for	  36	  hours	   in	  TMS	  
with	   (+)	   or	  without	   (-­‐)	   addition	   of	   5	  mM	   sodium	   citrate.	   	  Media	   indicates	   that	  media	  
alone,	  without	  addition	  of	  bacteria,	  was	   concentrated	  and	  used	   in	   the	  plate	  bioassay.	  
Data	   are	   the	   average	   of	   three	   biological	   replicates,	   and	   error	   bars	   represent	   the	  






defect	   was	   found	   to	   be	   iron-­‐dependent,	   as	   supplementation	   with	   free	   iron	   (30	   μM	  
FeSO4)	  restored	  growth	  to	  wildtype	  levels	  for	  all	  strains	  (Fig.	  2.7A).	  Similar	  results	  were	  
observed	   in	   CDM-­‐G,	   where	   complementation	   of	   citZ	   sbnG	   with	   either	   sbnG	   or	   citZ	  
resulted	  in	  growth	  kinetics	  comparable	  to	  wildtype	  (Fig.	  2.7B),	  indicating	  that	  both	  citZ	  
and	  sbnG	  can	  play	  a	  role	  in	  SB	  production,	  and	  that	  expression	  of	  at	  least	  one	  of	  the	  two	  
citrate	  synthases	  is	  essential	  for	  the	  iron-­‐restricted	  growth	  of	  S.	  aureus.	  
To	  confirm	  that	  both	  citZ	  and	  sbnG	  contribute	  to	  SB	  synthesis,	  we	  assessed	  for	  
the	   presence	   of	   SB	   in	   spent	   culture	   supernatants	   of	   the	   citZ	   sbnG	  mutant	   alone,	   or	  
complemented	  with	  either	  citZ	  or	  sbnG	  in	  CDM-­‐G.	  As	  demonstrated	  in	  Figure	  2.7C,	  the	  
citZ	  sbnG	  mutant	  does	  not	  produce	  SB,	  confirming	  that	  the	  iron-­‐restricted	  growth	  defect	  
of	   this	  mutant	   is	   due	   to	   a	   lack	  of	   synthesis	   of	   both	   staphyloferrins.	   Complementation	  
with	  either	  citZ	  or	  sbnG	  in	  trans	  resulted	  in	  restoration	  of	  SB	  synthesis,	  confirming	  that	  
both	  citZ	  and	  sbnG	  can	  feed	  citrate	  into	  the	  SB	  synthetic	  process	  (Fig	  2.7C).	   	  Together,	  
the	   data	   garnered	   from	   assessing	   growth	   and	   siderophore	   production	   of	   the	   citrate	  
synthase	   mutants	   clearly	   establishes	   the	   essentiality	   of	   citZ	   to	   SA	   synthesis,	   and	   the	  
functional	   redundancy	  of	  citZ	  and	  sbnG	   in	   the	  provision	  of	   citrate	   to	  SB	  production	   in	  
vitro.	  
We	   next	   examined	   whether	   citrate,	   when	   added	   to	   culture	   media,	   could	  
complement	  the	  defects	  in	  the	  ability	  of	  citZ	  and	  citZ	  sbnG	  mutants	  to	  synthesize	  SA	  and	  
SB.	  Simple	  growth	  promotion	  assays	  were	  insufficient	  to	  demonstrate	  this	  since	  citrate	  
can	  act	  as	  a	  siderophore	  itself,	  chelating	  iron	  in	  the	  medium	  and	  delivering	  it	  to	  the	  cells.	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Indeed,	  citrate	  will	  promote	  the	  growth	  of	  all	  S.	  aureus	   strains	   tested,	   including	  the	  S.	  
aureus	  sfa	  sbn	  mutant,	  a	  strain	  incapable	  of	  synthesizing	  SA	  and	  SB	  (data	  not	  shown).	  In	  
S.	  aureus,	  the	  transport	  system	  for	  ferric	  citrate	  has	  yet	  to	  be	  identified.	  We	  therefore	  
needed	  to	  test	  for	  whether	  or	  not	  citrate,	  when	  added	  to	  culture	  media,	  could	  allow	  for	  
synthesis	  of	   SA	  and/or	  SB	  by	  using	  our	  SA/SB	  plate	  bioassays	  as	  described	  above.	  We	  
grew	  cultures	   in	  TMS	  media	  with	  or	  without	  5	  mM	  citrate,	  concentrated	  spent	  culture	  
supernatants,	   and	   assessed	   for	   the	   presence	  of	   SA	   and	   SB.	   As	   illustrated	   in	   Fig.	   2.7D,	  
addition	  of	  citrate	  could	  overcome	  the	  block	  in	  SA	  synthesis	  in	  a	  citZ	  mutant,	  and	  could	  
also	  overcome	   the	  block	   in	  both	  SA	  and	  SB	   synthesis	   in	   the	  citZ	  sbnG	   double	  mutant.	  
Importantly,	   growth	   promotion	   by	   citrate	   in	   the	   media	   was	   not	   detected	   in	   these	  
bioassays,	  which	  incorporate	  the	  strong	  chelator	  EDDHA	  into	  the	  plates,	  as	  media	  alone	  
with	   citrate,	   when	   concentrated	   equivalent	   to	   spent	   culture	   supernatants,	   did	   not	  
promote	  the	  growth	  of	  S.	  aureus	  in	  the	  plate	  bioassay	  (Fig.	  2.7D).	  	  
The	  functional	  redundancy	  of	  sbnG	  and	  citZ	  in	  providing	  citrate	  as	  a	  precursor	  to	  
SB	  production	  led	  us	  to	  test	  whether	  or	  not	  sbnG	  could	  complement	  the	  citZ	  mutation	  
insofar	  as	  its	  role	  in	  central	  metabolism.	  	  Our	  results	  show	  that	  when	  introduced	  to	  the	  
citZ	   mutant,	   the	   multi-­‐copy	   plasmid	   expressing	   sbnG	   is	   incapable	   of	   alleviating	   the	  
intense	   yellow	   pigmentation	   or	   in	   rescuing	   the	   citZ	  mutant	   from	   the	   growth	   defect	  
associated	  with	  early	  entry	  into	  stationary	  phase	  (Figure	  2.8).	  Further,	  the	  sbnG	  mutant	  
alone	  does	  not	  exhibit	   these	  hallmark	   traits	  of	  TCA	  cycle	  disruption	   (data	  not	   shown).	  
Thus,	  it	  appears	  that	  the	  primary	  and	  perhaps	  exclusive	  role	  of	  sbnG	  is	  to	  provide	  citrate	  




Figure	  2.8.	  Overexpression	  of	  SbnG	  in	  a	  citZ	  mutant	  fails	  to	  restore	  wild-­‐type	  
pigmentation	  or	  growth.	  	  
A,	   TSB	   agar	   plate,	   containing	   chloramphenicol	   for	   maintenance	   of	   plasmids,	  
demonstrating	  the	  colour	  of	  wildtype	  S.	  aureus	  (WT)	  and	  its	  isogenic	  citZ	  mutant	  (ΔcitZ).	  
Strains	   contained	   either	   a	   vehicle	   control	   (pALC	   =	   pALC2073)	   or	   pALC2073	   carrying	  
either	  the	  citZ	  gene	  (pcitZ)	  or	  sbnG	   (psbnG).	  B,	  Growth	  kinetics	  of	  S.	  aureus	  strains,	  as	  
indicated,	   in	   TSB	   in	   a	   Bioscreen	   C	   machine.	   Data	   are	   representative	   of	   three	  
independent	  experiments,	  and	  error	  bars	  signify	  standard	  error	  of	  the	  mean.	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2.3.7. 	  SbnG	   active	   site	   variants	   demonstrate	   reduced	   SB	   production	   in	   a	   citrate	  
synthase-­‐deficient	  strain	  of	  S.	  aureus	  	  
Since	  previous	  work	  by	  our	  lab	  demonstrated	  the	  activity	  of	  SbnG	  as	  a	  citrate	  synthase	  
in	   vitro	   (23),	   we	   sought	   to	   gain	   further	   insight	   into	   the	   catalytic	   mechanism	   of	   the	  
enzyme	   through	   characterization	   of	   the	   active	   site.	   Based	   upon	   crystal	   structure	  
elucidation,	  superposition	  of	  this	  structure	  with	  those	  of	  class	  I	  and	  II	  citrate	  synthases,	  
and	   homology	   with	   class	   II	   metal-­‐dependent	   aldolases,	   a	   putative	   active	   site	   was	  
identified	  in	  SbnG	  consisting	  of	  two	  histidine	  residues	  (H47	  and	  H96),	  two	  glutamic	  acid	  
residues	  (E46	  and	  E151),	  an	  aspartic	  acid	  residue	  (D177),	  and	  an	  arginine	  residue	  (R72)	  
(Figure	   2.9)	   (39).	   However,	   although	   SbnG	   and	   its	   active	   site	   variants	   (E46Q,	   H47A,	  
R72A,	   H96A,	   E151Q,	   and	  D177A)	  were	   effectively	   expressed	   and	   purified	   from	  E.	   coli	  
BL21,	   these	  proteins	   (including	  wild-­‐type	  SbnG),	  exhibited	  poor	  enzymatic	  activity	   in	  a	  
commercial	  assay	  assessing	  citrate	  synthase	  activity,	  purportedly	  due	  to	  the	  absence	  in	  
vitro	   of	   an	   as-­‐yet-­‐unidentified	   staphylococcal	   cofactor	   (23,	   39).	   To	   circumvent	   this	  
problem,	   we	   assessed	   the	   ability	   of	   SbnG	   and	   its	   variants	   expressed	   in	   trans	   from	   a	  
multi-­‐copy	   plasmid	   (pALC2073)	   to	   restore	   SB	   production	   in	   the	   S.	   aureus	   citZ	   sbnG	  
mutant.	  As	  detailed	  above,	  and	  as	  shown	  in	  Figure	  2.10,	  expression	  of	  wild-­‐type	  SbnG	  in	  
trans	   restores	  SB	  production	   in	  this	  citrate	  synthase-­‐deficient	  strain.	   In	  contrast,	  all	  six	  
SbnG	  variants	  exhibited	  severely	  reduced	  SB	  production	  relative	  to	  wildtype,	  where	  the	  
D177A	   variant	  was	  most	   strongly	   impaired,	   such	   that	   the	   level	   of	   SB	   production	  was	  








Figure	  2.9.	  The	  proposed	  active	  site	  of	  SbnG.	  	  	  	  	  
SbnG	  active	  site	  residues	  are	  shown	  as	  sticks	  with	  carbon,	  oxygen,	  and	  nitrogen	  in	  light	  
blue,	   red,	   and	  blue,	   respectively.	  A	   single	  Ca2+	   (yellow	   sphere)	   is	   bound	  by	  Glu151	   and	  
Asp177.	  Water	  molecules	  are	  shown	  as	  small	  blue	  spheres,	  and	  metal-­‐ligand	  bonds	  are	  





Figure	  2.10.	  SbnG	  variants	  are	  impaired	  for	  citrate-­‐dependent	  production	  of	  SB.	  
	  Agar	   plate	   bioassays	   were	   performed	   using	   supernatant	   extracts	   prepared	   from	   a	  
citrate	  synthase-­‐deficient	  strain	  of	  S.	  aureus	  Newman	  (ΔcitZ	  ΔsbnG)	  complemented	  with	  
vectors,	   as	   indicated,	   expressing	   wild	   type	   SbnG,	   SbnG	   variants	   E46Q,	   H47A,	   R72A,	  
H96A,	   E151Q,	   and	   D177A	   or	   a	   blank	   pALC2073	   vector	   control	   (vehicle).	   Strains	   were	  
grown	  for	  36	  h	  in	  RPMI	  1640,	  a	  medium	  conducive	  to	  the	  production	  of	  SB	  (but	  not	  SA),	  
and	   supernatants	  were	   assessed	   for	   SB	   through	   their	   ability	   to	   promote	   growth	   of	   S.	  
aureus	   RN6390	   seeded	   in	   iron-­‐restricted	   Tris	   minimal	   succinate	   agar	   plates.	   Growth	  
radius	  about	  paper	  disks,	  to	  which	  the	  supernatants	  were	  applied,	  was	  measured	  after	  
48	  h	  and	  reflects	  the	  average	  of	  three	  biological	  replicates	  for	  each	  strain.	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2.3.8. citZ,	   especially	   when	   combined	   with	   an	   sbnG	   mutation,	   is	   required	   	   for	  
maximal	  virulence	  
	  A	   well-­‐established	   murine	   bacteremia	   model	   was	   used	   to	   assess	   the	   relative	   and	  
cumulative	  contributions	  of	  the	  staphylococcal	  citrate	  synthases	  to	   in	  vivo	  survival	  and	  
virulence.	  Groups	  of	  ten	  BALB/c	  mice	  per	  strain	  were	  injected	  via	  tail	  vein	  with	  5-­‐7	  x	  106	  
CFU	   of	  wildtype	   S.	   aureus,	  or	   its	   isogenic	   citZ,	   sbnG,	  or	   citZ	   sbnG	  mutants.	   Four	   days	  
post-­‐challenge,	  the	  bacterial	  burden	  in	  the	  kidneys,	  heart,	  and	  liver,	  as	  well	  as	  percent	  
weight	  loss	  of	  the	  mice,	  were	  determined.	  For	  the	  sbnG	  single-­‐deletion	  mutant,	  a	  strain	  
with	   the	  potential	   to	  produce	  both	  staphyloferrins,	  we	  observed	  no	  significant	   impact	  
on	   bacterial	   burden	   in	   any	   organ	   versus	   mice	   challenged	   with	   wildtype	   (Fig.	   2.11).	  
Deletion	  of	  citZ	  alone,	  however,	  resulted	  in	  significantly	  decreased	  bacterial	  load	  in	  both	  
the	   liver	  and	  heart,	  albeit	  no	  significant	  differences	   in	  weight	   loss	  (data	  not	  shown)	  or	  
bacterial	  numbers	  in	  the	  kidneys	  (Fig.	  2.11).	  	  Most	  notably,	  the	  combined	  inactivation	  of	  
both	   citZ	   and	   sbnG	   resulted	   in	  marked	   decreases	   in	   staphylococcal	   recovery	   from	   all	  
organs	   (Fig.	   2.11)	   and	   reduced	   overall	   weight	   loss	   relative	   to	   the	   wildtype	   (data	   not	  
shown).	   The	   additive	   effects	   of	   the	   citZ	   and	   sbnG	   mutations	   highlights	   the	   partial	  
functional	  redundancy	  of	  these	  genes	  in	  vivo,	  and	  the	  requirement	  of	  at	  least	  one	  citrate	  
synthase	  for	  maximal	  virulence	  of	  S.	  aureus.	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Figure	  2.11.	  Contribution	  of	  the	  citrate	  synthases,	  citZ	  and	  sbnG,	  to	  the	  survival	  of	  S.	  
aureus	  in	  a	  murine	  bacteraemia	  model.	  	  
BALB/c	  mice	  were	  infected	  with	  wildtype	  S.	  aureus	  Newman,	  citZ,	  sbnG,	  or	  citZ	  sbnG	  (n	  
of	  10	  mice	  per	  strain).	  	  After	  4	  days,	  the	  mice	  were	  sacrificed	  and	  the	  bacterial	  burden	  of	  
the	  kidneys,	  heart,	  and	  liver	  were	  determined	  by	  assessing	  the	  viable	  cell	  count	  on	  TSA.	  
Each	   symbol	   represents	   the	   staphylococcal	   count	   in	   the	   corresponding	   organ	   of	   one	  
animal.	  Data	  are	  representative	  of	  two	  independent	  experiments.	  Statistical	  significance	  
was	  determined	  using	  the	  Student’s	  t-­‐test,	  with	  P-­‐values	  as	  indicated.	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2.3.9. 	  Staphyloferrin	   A,	   and	   thus	   citZ,	   are	   required	   for	   maximal	   formation	   of	  
staphylococcal	  skin	  abscesses	  
Given	   that	   the	   availability	   of	   iron	   and	   various	   carbon	   sources	   (e.g.	   glucose)	   may	  
differ	   substantially	  between	  potential	   sites	  of	   infection	  within	   the	  host,	  we	  sought	  
to	  assess	  the	  contribution	  of	  citZ	  and	  sbnG	  to	  the	  development	  of	  a	  non-­‐invasive	  S.	  
aureus	   skin	   infection,	   a	   common	   clinical	   presentation	   amongst	   the	   staphylococci.	  	  
To	  this	  end,	  we	  employed	  a	  murine	  skin	  abscess	  model,	  where	  groups	  of	  six	  BALB/c	  
mice	  were	   injected	   subcutaneously	  with	  1.5	  –	  2.5	   x	  107	  CFU	  of	  wild-­‐type	  S.	  aureus	  
Newman,	  or	  its	  isogenic	  citZ,	  sbnG,	  or	  citZ	  sbnG	  mutants,	  and	  lesion	  area	  was	  assessed	  
every	   24	   h	   for	   one	   week.	   Disruption	   of	   citZ	   alone	   was	   sufficient	   to	   significantly	  
impair	  subcutaneous	  skin	  abscess	  formation	  relative	  to	  both	  wildtype	  S.	  aureus	  and	  
the	  sbnG	  mutant	   (Figure	  2.12A).	   Interestingly,	  unlike	   in	  the	  bacteremia	  model,	  citZ	  
sbnG	   was	   no	   further	   compromised	   for	   fitness	   relative	   to	   citZ	   in	   this	   mode	   of	  
infection,	   suggesting	   that	   the	   production	   of	   SB	   is	   dispensable	   to	   skin	   abscess	  
formation.	   	   To	   test	   this	   notion,	   we	   similarly	   assessed	   skin	   abscess	   formation	   by	  
siderophore	   biosynthetic	  mutants	   of	   S.	   aureus	   (sfa,	   sbn,	   and	   sfa	   sbn),	   and	   indeed	  
observed	   that	   S.	   aureus	   strains	   unable	   to	   synthesize	   SA	   form	   significantly	   smaller	  
abscesses	  relative	  to	  both	  wildtype	  and	  SB-­‐deficient	  strains	  (Figure	  2.12B).	  Together	  
these	   results	   suggest	   that	   SA	   and	   SB	   may	   play	   distinct	   roles	   in	   staphylococcal	  




Figure	  2.12.	  Staphyloferrin	  A	  is	  required	  for	  maximal	  staphylococcal	  skin	  abscess	  
formation.	  
BALB/c	  mice	  were	  injected	  subcutaneously	  on	  the	  right	  flank	  with	  1.5	  -­‐	  2.5	  x	  107	  CFU	  of	  
wildtype	   S.	   aureus	  Newman	   (WT)	   or	   its	   isogenic	   citrate	   synthase	   (A)	   or	   siderophore	  
biosynthetic	   (B)	  mutants	   (n	  of	   6	  mice	   per	   strain).	   	   Photographs	   of	   each	   abscess	  were	  
taken	   every	   24	   h	   and	   the	   abscess	   area	   was	   quantified	   using	   Image	   J.	   Data	   are	  
representative	  of	  two	  independent	  experiments.	  Statistical	  significance	  was	  determined	  
relative	  to	  the	  WT	  (A)	  or	  sbn	  mutant	  (B)	  using	  a	  two-­‐way	  ANOVA,	  where	  ****P	  <	  0.0001,	  




The	  elaboration	  of	  siderophores	  for	  accessing	  the	  transferrin	  iron	  pool	  is	  one	  of	  the	  key	  
means	   by	   which	   pathogenic	   bacteria	   overcome	   nutritional	   immunity	   within	   the	   host	  
(48–50).	   In	   S.	   aureus,	   the	   production	   of	   two	   chemically	   distinct,	   yet	   seemingly	  
redundant	   siderophores,	   SA	   and	   SB,	   allows	   for	   the	   exploitation	   of	   serum	   transferrin.	  
Indeed,	   the	  expression	  of	  either	  citrate-­‐based	  siderophore	  by	  S.	  aureus	   is	   sufficient	   to	  
promote	  wild-­‐type	  growth	  in	  a	  murine	  model	  of	  systemic	  infection	  (44).	  	  Paradoxically,	  
while	   iron	   limitation	   within	   the	   host	   encourages	   staphyloferrin	   production,	   it	   also	  
promotes	  downregulation	  of	  the	  TCA	  cycle,	  and	  accordingly,	  the	  citrate	  synthase,	  CitZ.	  
In	  this	  study,	  we	  sought	  to	  determine	  the	  enzymatic	  source	  of	  citrate	  as	  a	  precursor	  to	  
SA	  and	  SB	  biosynthesis.	  We	  have	  demonstrated	  that	  SA	  expression	  is	  severely	  hindered	  
in	  glucose-­‐containing,	  iron-­‐restricted	  media,	  owing	  to	  its	  dependence	  on	  the	  TCA	  cycle,	  
and	   specifically	   on	   the	   activity	   of	   CitZ.	   Conversely,	   while	   CitZ	   can	   contribute	   to	   the	  
formation	   of	   SB,	   synthesis	   of	   this	   staphyloferrin	   is	   freed	   from	   its	   reliance	   on	   central	  
metabolism	  through	  provision	  of	  citrate	  by	  the	  iron-­‐regulated	  citrate	  synthase,	  SbnG.	  
A	  central,	  and	  as	  yet	  unanswered	  question	   that	  arises	   from	  this	  work	   is	  why	   is	  
there	  a	  dependency	  on	  CitZ	  activity	  for	  SA	  synthesis,	  whereas	  the	  same	  is	  not	  true	  for	  SB	  
synthesis?	  One	  possibility	  is	  that	  the	  SfaD	  and	  SfaB	  enzymes	  (SA	  synthetases)	  have	  a	  low	  
affinity	   for	   citrate	   and	   require	   high	   concentrations	   of	   intracellular	   citrate	   for	   their	  
activity.	   It	   is	   likely	   that	   high	   intracellular	   concentrations	   of	   citrate	   are	   only	   achieved	  
when	   CitZ,	   a	   catalytically	   efficient	   enzyme,	   is	   expressed	   and	   active.	  We	   suspect	   that	  
under	   iron-­‐restricted	   conditions	   where	   SbnG	   is	   expressed	   (and	   CitZ	   is	   repressed),	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despite	   its	   relatively	   high-­‐level	   expression,	   the	   SbnG	   enzyme	   likely	   does	   not	   generate	  
sufficient	  intracellular	  concentrations	  of	  citrate	  to	  support	  SA	  synthesis.	  	  The	  reasons	  for	  
this	   may	   be	   two-­‐fold.	   	   First,	   as	   we	   have	   previously	   shown,	   purified	   SbnG	   is	  
approximately	  1000-­‐fold	  less	  efficient	  than	  TCA	  cycle	  citrate	  synthases	  (23).	  Second,	  we	  
speculate	   that	   SbnG	   operates	   as	   part	   of	   a	   protein:protein	   complex	   with	   other	   Sbn	  
enzymes,	  which	  is	  consistent	  with	  the	  observation	  that	  while	  exhibiting	  poor	  enzymatic	  
activity	   in	   vitro,	   SbnG	  complements	  SB	  production	   in	  a	  citZ	   sbnG	  mutant.	  As	   such,	  we	  
would	  predict	  that	  the	  system	  works	  efficiently	  to	  generate	  SB,	  and	  free	  citrate	  would	  
not	  be	  released	  into	  the	  cell	  at	  high	  enough	  concentrations	  for	  SA	  synthesis.	  	  This	  may	  
also	  explain	  our	  finding	  that	  sbnG,	  when	  cloned	  in	  multicopy	  into	  a	  citZ	  mutant,	  did	  not	  
complement	   the	   phenotypes	   associated	   with	   a	   citZ	   mutation	   (i.e.	   early	   entry	   into	  
stationary	  phase	  and	  enhanced	  colony	  pigmentation).	  The	  finding	  that	  S.	  aureus	  has	  two	  
citrate	  synthases,	  with	  distinctly	  different	  catalytic	  efficiencies,	  has	  interesting	  parallels	  
to	  the	  findings	  of	  Sonenshein's	  group,	  where	  they	  discovered	  a	  second	  citrate	  synthase	  
in	  B.	  subtilis	  (51).	  Indeed,	  they	  found	  a	  second	  citrate	  synthase	  in	  B.	  subtilis,	  named	  citA,	  
based	  on	  its	  ability	  to	  restore	  glutamate	  prototrophy	  to	  an	  E.	  coli	  gltA	  (encoding	  the	  TCA	  
cycle	   citrate	   synthase)	   mutant,	   but	   showed	   it	   to	   have	   relatively	   poor	   activity	   in	  
comparison	   to	   the	   CitZ	   enzyme.	   Despite	   its	   relatively	   poor	   activity,	   they	   nonetheless	  
demonstrated	  that	  citA	   contributed	  to	  the	   intracellular	  concentration	  of	  citrate,	  based	  
indirectly	  on	  the	  fact	  that	  a	  citA	  mutation	  augmented	  phenotypes	  associated	  with	  a	  citZ	  
mutation,	  specifically	  sporulation	  defects	  and	  glutamate	  auxotrophy.	  	  
Recent	  structural	  elucidation	  of	  SbnG	  has	  revealed	  that	  unlike	  TCA	  cycle	  citrate	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synthases,	   which	   are	   all	   α-­‐helical,	   this	   novel	   citrate	   synthase	   forms	   an	   (α/β)8	   barrel	  
characteristic	  of	  members	  of	  the	  phosphoenolpyruvate/pyruvate	  domain	  superfamily.	  In	  
addition	   to	   conservation	   in	   overall	   architecture,	   SbnG	   possesses	   several	   active	   site	  
residues	  common	  to	  this	  superfamily,	  including	  E46,	  R72,	  E151,	  and	  D177,	  each	  of	  which	  
were	   shown	   to	   be	   required	   for	   maximal	   SB	   production.	   Further,	   several	   catalytic	  
residues	  are	  also	  shared	  between	  SbnG	  and	  type	  I	  and	  II	  citrate	  synthases	  including	  H47	  
and	   H96,	   as	   well	   as	   D177	   (39),	   which	   similarly	   reduce	   citrate	   synthase	   activity	   when	  
mutated	   in	  both	  SbnG	  and	   in	   citrate	   synthase	   type	   I	   from	  porcine	  heart	   (H274,	  H320,	  
and	  D375,	   respectively)	   (52),	   suggesting	  a	  common	  catalytic	  mechanism.	   Interestingly,	  
SbnG	   forms	   a	   separate	   clade	   within	   the	   phosphoenolpyruvate/pyruvate	   superfamily,	  
clustering	   along	  with	   homologs	   found	   in	   siderophore	   biosynthetic	   operons.	   Together,	  
these	   results	   suggest	   that	   SbnG	   represents	   the	   founding	  member	   of	   a	   novel	   class	   of	  
iron-­‐regulated	  citrate	  synthases	  (type	  III	  citrate	  synthases),	  which	  evolved	  convergently	  
to	   provide	   a	   source	   of	   citrate	   for	   siderophore	   production	   when	   TCA	   cycle	   citrate	  
synthases	  are	  not	  expressed	  (39).	  	  	  
Here	  we	  propose	  a	  model	  whereby	  all	  precursors	  of	  SB	  production	  are	  available	  
under	   iron-­‐restricted	   growth	   within	   the	   host,	   and	   without	   requirement	   of	   TCA	   cycle	  
activity.	  As	  illustrated	  in	  Figure	  2.13,	  α-­‐KG,	  L-­‐Dap,	  and	  citrate	  can	  all	  be	  derived	  through	  
the	   metabolism	   of	   glucose	   and/or	   L-­‐glutamine.	   Notably,	   NMR	   metabolomics	   has	  
revealed	  that	  glucose	  is	  the	  second	  most	  abundant	  metabolite	  overall	  in	  human	  serum,	  
whereas	  L-­‐glutamine	  is	  the	  amino	  acid	  of	  highest	  abundance	  (53),	  suggesting	  the	  likely	  
availability	   of	   these	   essential	   biomolecules	   for	   SB	   synthesis	   in	   vivo.	   Additionally,	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induction	  of	  the	  iron-­‐sparing	  response	  upon	  exposure	  to	  low	  levels	  of	  free	  iron	  results	  in	  
an	  upregulation	  of	  glycolytic	  enzymes,	  leading	  to	  a	  commensurate	  increase	  in	  pyruvate	  
for	  use	   in	   fermentative	  metabolism	   (31).	   In	  our	  model,	  pyruvate	  catabolism	   facilitates	  
two	  activities	  necessary	  for	  the	  acquisition	  of	  trace	  amounts	  of	   iron;	  firstly,	   it	  provides	  
substrates	  for	  the	  formation	  of	  SbnG-­‐derived	  citrate,	  as	  discussed	  below,	  and	  secondly,	  
accumulation	   of	   acidic	   metabolic	   end-­‐products	   in	   the	   microenvironment	   surrounding	  
invading	  S.	   aureus	  may	  promote	   iron	   release	   from	  host	   iron-­‐sequestration	  molecules,	  
allowing	  for	  uptake	  by	  the	  staphyloferrins	  (31,	  54).	  
	   As	  has	  been	  recently	  demonstrated,	  and	  is	  highlighted	  in	  Figure	  2.13,	  both	  α-­‐KG	  
and	   L-­‐Dap	   can	   be	   synthesized	   from	   L-­‐glutamate	   and	   O-­‐phospho-­‐L-­‐serine	   through	   the	  
activities	  of	  SbnA	  and	  SbnB	  (22).	  Notably,	  both	  subunits	  of	  glutamate	  synthase	  (GltBD),	  
the	   enzyme	   responsible	   for	   catalyzing	   the	   formation	   of	   L-­‐glutamate	   from	   L-­‐glutamine	  
and	  α-­‐KG,	  are	  expressed	  during	  S.	  aureus	  growth	  in	  human	  serum	  (53,	  55).	  Additionally,	  
the	  pathway	  for	   the	  synthesis	  of	  O-­‐phospho-­‐L-­‐serine	   (serAC)	   from	  L-­‐glutamate	  and	  the	  
glycolytic	   intermediate,	  3-­‐phosphoglycerate,	  was	   similarly	   shown	   to	  be	  upregulated	   in	  
blood	  and	   serum	   (53).	  While	   SbnA	  and	  SbnB	  yield	  equivalent	  amounts	  of	  α-­‐KG	  and	   L-­‐
Dap,	  SB	  synthesis	   requires	   two	  molecules	  of	   the	   latter,	  and	   it	  has	  been	  proposed	  that	  
excess	   α-­‐KG	  may	   be	   diverted	   back	   into	   synthesis	   of	   additional	   L-­‐glutamate	   (22).	   The	  
activities	   of	   SbnA	   and	   SbnB	   under	   iron-­‐restriction,	   coupled	   with	   the	   availability	   of	   L-­‐





Figure	  2.13.	  	  Schematic	  illustrating	  metabolic	  reactions	  in	  S.	  aureus	  that	  lead	  to	  the	  
formation	  of	  precursors	  for	  SA	  and	  SB.	  
	  Reactions	   and	   pathways	   shown	   or	   predicted	   to	   contribute	   to	   the	   formation	   of	   SA	  
(orange)	   or	   SB	   (green)	   are	   illustrated,	   independent	   of	   stoichiometry.	   	   During	   aerobic	  
growth	  on	  glucose,	  carbon	  catabolite	  repression	  in	  S.	  aureus	  represses	  the	  activity	  of	  the	  
TCA	   cycle	   (26),	   and	   glucose	   is	   incompletely	   oxidized	   to	   acetic	   acid	   in	   a	   pta/ackA-­‐
dependent	  manner	   (28);	   the	  acetic	  acid	   is	   secreted	   into	   the	  culture	  media	   (see	  Figure	  
2.2F).	  Once	  the	  preferred	  carbon	  source	  (glucose)	  is	  exhausted,	  S.	  aureus	  will	  transition	  
to	   the	   post-­‐exponential	   phase	   by	   assimilating	   acetic	   acid	   from	   the	   culture	  media	   in	   a	  




which	  both	  α-­‐KG	  and	  L-­‐Dap	  may	  be	  produced	  for	  incorporation	  into	  SB	  (22,	  56).	  	  
	   Similar	   to	   the	   situation	  described	  above	   for	  α-­‐KG	  and	   L-­‐Dap,	   the	  precursors	   to	  
citrate	   synthesis	   by	   SbnG	   are	   also	   likely	   available	   within	   the	   host	   and	   without	  
dependence	  on	  the	  TCA	  cycle.	  OAA	  may	  be	  provided	  through	  anaplerotic	   reactions	  by	  
phosphenolpyruvate	  kinase	  (pckA),	  aspartate	  transaminase	  (NWMN_1871),	  or	  pyruvate	  
carboxylase	   (pycA),	   the	   latter	  of	  which	   is	  upregulated	   in	  S.	  aureus	  grown	   in	  blood	  and	  
serum	   (57).	  Decarboxylation	  of	   pyruvate	   to	   acetyl	   CoA	   is	   predicted	   to	  be	  upregulated	  
during	   the	   iron-­‐sparing	   response	   (31),	   through	   action	   of	   the	   pyruvate	   dehydrogenase	  
complex	  (pdhABC).	  Together,	  all	  the	  substrates	  of	  SbnA,	  SbnB,	  and	  SbnG	  can	  be	  derived	  
under	  iron-­‐restriction,	  and	  independent	  of	  the	  TCA	  cycle	  (Figure	  2.13),	  the	  products	  of	  
which	  can	  be	  condensed	  by	  the	  SbnCEF	  synthetases	  and	  the	  SbnH	  L-­‐Dap	  decarboxylase	  
into	  functional	  SB	  (21).	  	  	  	  
Together	   our	   findings	   and	   proposed	  model	   suggest	   that	   SB	   is	   likely	   the	  more	  
important	   siderophore	   in	   establishing	   systemic	   infections,	   particularly	   where	  
hematogenous	   spread	   is	   involved,	   whereas	   SA	   may	   function	   predominantly	   in	  
promoting	  skin	  colonization	  and/or	  cutaneous	   infections.	   Indeed,	   the	   loci	   for	  both	  the	  
biosynthesis	  (sbn)	  and	  transport	  (sir)	  of	  SB	  are	  amongst	  the	  most	  strongly	  upregulated	  
by	  S.	  aureus	  under	   iron-­‐restriction,	  and	  during	  growth	   in	  human	  blood	  and	  serum	  (31,	  
53).	  Moreover,	  our	  lab	  has	  consistently	  demonstrated	  that	  while	  SA-­‐deficient	  S.	  aureus	  
mutants	  are	  unencumbered	  for	  growth	  in	  media	  containing	  serum,	  SB-­‐deficient	  mutants	  
exhibit	   a	   significant	   growth	   lag	   before	   achieving	   growth	   comparable	   to	   the	  wild-­‐type	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(18,	  44).	  In	  the	  context	  of	  our	  current	  findings,	  the	  production	  of	  SA	  is	  likely	  inhibited	  by	  
glucose	   present	  within	   serum,	   and	   growth	   of	   strains	   capable	   of	   expressing	   only	   SA	   is	  
promoted	  once	  glucose	  is	  consumed,	  the	  TCA	  cycle	  is	  derepressed,	  and	  SA	  is	  synthesized	  
using	  citrate	  derived	  from	  CitZ.	  Similarly,	  we	  predict	  that	  SA	  would	  not	  be	  expressed,	  at	  
least	   maximally,	   during	   staphylococcal	   bacteraemia;	   serum	   glucose	   levels	  
(approximately	   5	   mM,	   up	   to	   11.1	   mM	   in	   diabetics)	   (57,	   58)	   are	   within	   the	   range	   of	  
glucose	  concentrations	  employed	  in	  this	  study	  that	  abolished	  SA	  production	  (RPMI,	  11	  
mM;	  TMG	  and	  CDM-­‐G,	  22	  mM).	  	  
A	   potential	   role	   for	   SB	   in	   virulence	   is	   further	   highlighted	   by	   the	   differential	  
distribution	   of	   SA	   and	   SB	   biosynthetic	   loci	   between	   coagulase-­‐positive	   (CoPS)	   and	  
coagulase-­‐negative	   staphylococci	   (CoNS).	   The	   SA	   biosynthetic	   locus	   (sfa)	   has	   been	  
identified	   in	   the	   vast	  majority	   of	   both	   CoPS	   and	   CoNS	   (18,	   48),	   suggesting	   it	   is	   not	   a	  
determining	   factor	   for	   virulence	   potential.	   CoNS	   are	   commonly	   commensals	   or	  
opportunistic	   pathogens,	   causing	   predominantly	   skin	   and	   soft	   tissue	   infections	   (SSTIs)	  
related	   to	   nosocomial	   acquisition,	   implanted	   medical	   devices	   and/or	   immune-­‐
compromised	   status	   (10,	   59,	   60).	   The	   production	   of	   SA	   in	   CoNS	   suggests	   a	   role	  more	  
akin	   to	   promoting	   colonization	   and/or	   cutaneous	   infections	   than	   deep-­‐seated	   or	  
systemic	   infections.	   Indeed,	   iron	   and	   metabolite	   concentrations	   of	   the	   skin	   and	  
secretions	  differ	   significantly	   from	   that	   of	   serum,	   and	   in	   a	  manner	   that	  may	  promote	  
TCA	   cycle	   activity	   and	   therefore	   SA	   production	   (e.g.	   lower	   glucose,	   higher	   iron	   and	  
oxygen	  concentrations)	  (57,	  61–65).	  In	  contrast,	  while	  early	  reports	  describe	  production	  
of	  SB	  in	  the	  CoNS	  (13,	  16,	  66),	  relatively	  few	  CoNS	  genomes	  (e.g.	  S.	  arlettae,	  S.	  equorum)	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possess	  the	  sbn	  operon	  that	  would	  be	  required	  for	  synthesis	  of	  SB,	  whereas	  all	  S.	  aureus	  
genomes	   contain	   sbn.	   The	   limitation	  of	   SB	  production	   to	  more	   virulent	   staphylococci,	  
coupled	   with	   its	   unfettered	   expression	   in	   the	   face	   of	   iron-­‐restriction	   and	   TCA	   cycle	  
repression	  leads	  us	  to	  assert	  that,	  at	  least	  for	  S.	  aureus,	  SB	  is	  likely	  the	  more	  important	  
of	  the	  two	  staphyloferrins	  during	  invasive	  infections,	  in	  part	  due	  to	  the	  activity	  of	  SbnG.	  	  
In	   an	   effort	   to	   address	   the	   potential	   role	   of	   SA	   in	   colonization	   and	   SSTIs,	   we	  
employed	   a	  murine	   skin	   abscess	  model	   of	   infection.	   	   Consistent	  with	   the	   supposition	  
that	  the	  skin	  environment	  may	  be	  more	  conducive	  to	  SA	  production	  than	  the	  serum	  or	  
blood,	  we	  have	  demonstrated	  that	  strains	  of	  S.	  aureus	  unable	  to	  synthesize	  SA,	  either	  
through	  disruption	  to	  citZ	  or	  the	  sfa	  locus,	  are	  significantly	  and	  comparably	  impaired	  for	  
subcutaneous	   abscess	   formation,	   relative	   to	   both	   wild-­‐type	   and	   SB-­‐deficient	   strains.	  
These	   findings	   represent,	   to	   our	   knowledge,	   the	   first	   investigation	   into	   the	   role	   of	  
staphylococcal	   siderophores	   in	   a	   non-­‐invasive	   infection	   model,	   and	   the	   first	   in	   vivo	  
demonstration	  of	  impaired	  staphylococcal	  fitness	  in	  the	  absence	  of	  SA	  synthesis.	  Further	  
investigation	  is	  required	  to	  elucidate	  the	  relationship	  between	  localized	  host	  metabolite	  
concentrations,	   chiefly	   iron	   and	   glucose,	   and	   the	   respective	   roles	   of	   SA	   and	   SB	   in	  
staphylococcal	  pathogenicity	  within	  these	  microenvironments.	  
Finally,	  despite	  the	  constraint	  of	  CitZ	  activity	  on	  the	  production	  of	  SA,	  the	  role	  of	  
CitZ	  alone	  in	  S.	  aureus	  survival	  and	  pathogenesis	  should	  not	  be	  overlooked.	  Indeed,	  we	  
have	  shown	  that	  SbnG	  is	  not	  capable	  of	  fulfilling	  the	  role	  of	  CitZ	  in	  central	  metabolism,	  
as	  discussed	  above.	   	   Furthermore,	   in	   a	  murine	  bacteraemia	  model	  we	   illustrated	   that	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disruption	   of	   citZ	   alone	   is	   sufficient	   to	   impair	   colonization	   of	   the	   liver	   and	   heart,	  
consistent	   with	   other	   reports	   linking	   alterations	   in	   host-­‐pathogen	   interaction	   to	   TCA	  
cycle	   inactivation	   (47,	   67).	   Combined	   inactivation	   of	   both	   citZ	   and	   sbnG	   abolishes	  
siderophore	   production	   and	   further	   impairs	   the	   survival	   and	   virulence	   of	   S.	   aureus	   in	  
vivo.	   Altogether	   our	   results	   suggest	   that	   while	   citZ	   and	   sbnG	   share	   some	   functional	  
redundancy	   in	   the	   production	   of	   SB,	   both	   fulfill	   unique	   roles	   in	   the	   metabolism	   and	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Chapter	  3	  -­‐ THE	  ROLE	  OF	  ISD	  AND	  PEPTIDE	  PERMEASES	  IN	  HEME-­‐
IRON	  ACQUISITION	  IN	  STAPHYLOCOCCUS	  AUREUS	  
3.1. INTRODUCTION	  
The	   success	   of	   Staphylococcus	   aureus	   as	   a	   pathogen	   is	   partly	   attributable	   to	   its	  
numerous	   and	   often	   redundant	   mechanisms	   for	   iron	   acquisition	   within	   the	   host.	  	  
Although	   siderophores	   are	   critical	   to	   the	   scavenging	   of	   residual	   free	   iron	   from	   the	  
environment	   and	   for	   the	   acquisition	   of	   iron	   from	   serum	   transferrin,	   we	   have	   also	  
demonstrated	   in	   Chapter	   2	   and	   elsewhere,	   that	   siderophore-­‐deficient	   strains	   of	   S.	  
aureus	  (e.g.	  citZ	  sbnG	  and	  sfa	  sbn)	  are	  still	  capable	  of	  causing	  significant	  host	  morbidity	  
(1).	   In	   the	   absence	   of	   siderophore	   production,	   S.	   aureus	   presumably	   relies	   upon	   the	  
acquisition	  of	  iron	  from	  alternate	  host	  reservoirs.	  As	  described	  previously,	  the	  preferred	  
iron	   source	  of	  S.	  aureus	   is	  heme,	  and	  as	  with	   the	  acquisition	  of	   iron	   from	   transferrin,	  
there	  are	  likely	  multiple	  mechanisms	  by	  which	  the	  pathogen	  is	  able	  to	  exploit	  the	  host	  
heme-­‐iron	  pool	  (2,	  3).	  To	  date,	  however,	  the	  sole	  means	  identified	  for	  heme	  uptake	  in	  
the	  staphylococci	  is	  the	  iron-­‐regulated	  surface	  determinant	  (Isd)	  pathway.	  
Isd	   homologues	   or	   functionally	   analogous	   heme-­‐shuttle	   systems	   have	   been	  
identified	   in	  numerous	  Gram-­‐positive	  pathogens	   including	  Staphylococcus	   lugdunensis,	  
Bacillus	  anthracis,	  Listeria	  monocytogenes	  and	  Streptococcus	  pyogenes	  	  (For	  a	  thorough	  
review	   see	   (4)).	   Isd	   has	   been	  most	   extensively	   characterized	   in	   S.	   aureus	   and,	   in	   this	  
species,	   is	  comprised	  of	  nine	  proteins	  directly	   involved	   in	  heme-­‐iron	  acquisition,	  along	  
with	  sortase	  B	  (SrtB)	  (5,	  6).	  In	  brief,	  and	  as	  described	  in	  section	  1.5.2.1	  of	  this	  thesis,	  the	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pathway	   involves	   heme-­‐binding	   proteins	   IsdA,	   IsdB,	   and	   IsdH	   (also	   known	   as	   HarA),	  
which	  are	  C-­‐terminally	  anchored	  to	  peptidoglycan	  by	  sortase	  A	  (SrtA)	  (7).	  IsdC,	  a	  fourth	  
heme-­‐binding	   protein,	   is	   secured	   to	   the	   cell	   wall	   by	   sortase	   B	   (SrtB)	   (5,	   6,	   8,	   9).	   It	   is	  
believed	   that	   the	   spatial	   arrangement	   of	   these	   four	   cell	   envelope-­‐associated	   proteins	  
effectively	  serves	  as	  a	  funnel	  to	  direct	  heme,	  extracted	  from	  hemoglobin	  (Hb)	  at	  the	  cell	  
surface,	  through	  the	  thick	  cell	  wall	  (Figure	  3.1).	  IsdB	  and	  IsdH	  are	  cell	  surface	  receptors,	  
which	  bind	  to	  Hb	  and	  liberate	  heme,	  the	  latter	  of	  which	  is	  subsequently	  transferred	  to	  
IsdA	  or	  IsdC	  (10–13).	   	  Multiple	  IsdC	  molecules,	  functioning	  essentially	  as	  a	  cogwheel	  in	  
the	   system,	   are	   proposed	   to	   facilitate	   unidirectional	   heme	   delivery	   to	   IsdE,	   and	  
subsequently	  IsdF,	  the	  substrate-­‐binding	  lipoprotein	  (SBP)	  and	  permease	  components	  of	  
an	  ABC	   transporter,	   respectively	   (12–15).	  Heme	   transport	   by	   IsdEF	   is	   energized	  by	   an	  
undefined	   ATPase	   and,	   once	   within	   the	   cytosol,	   heme	   is	   degraded	   by	   one	   of	   two	  
paralogous	  heme	  monooxygenases,	  IsdG	  or	  IsdI,	  releasing	  iron	  for	  use	  by	  the	  bacterium	  
(16,	  17).	  
As	  discussed	  in	  Chapter	  1,	  the	  kinetics	  of	  heme-­‐binding	  and	  transfer	  between	  Isd	  
proteins	   of	   S.	   aureus	   has	   been	   extensively	   characterized	   in	   vitro	   using	   mass	  
spectrometry,	   ultraviolet-­‐visible	   (UV-­‐Vis)	   spectroscopy,	   magnetic	   circular	   dichroism,	  
nuclear	   magnetic	   resonance,	   and	   X-­‐ray	   crystallography	   (12,	   18–24).	   In	   vivo,	   single	  
deletion	   mutants	   of	   isdA,	   isdB,	   isdC,	   isdG,	   isdH,	   and	   isdI	   are	   sufficient	   to	   attenuate	  
staphylococcal	  virulence	  and/or	  burden	  in	  murine	  models	  of	  infection,	  and	  are	  required	  
for	   the	   formation	  of	   staphylococcal	  abscesses,	  which	   facilitate	  persistence	  and	   further	  









Figure	  3.1.	  Staphylococcus	  aureus	  iron-­‐regulated	  surface	  determinant	  (Isd)	  pathway.	  
(A)	  Schematic	  of	  the	  S.	  aureus	  Isd	  system.	  Hemoglobin	  tetramers	  (red	  circles)	  are	  bound	  
by	   IsdH	  NEAr	   iron	   Transporter	   (NEAT)	   domains	   1	   and	   2,	   and	   IsdB	  NEAT	   domain	   1,	   as	  
indicated.	   Heme	   (pink	   hexagons)	   is	   extracted	   and	   bound	   by	   the	   heme-­‐binding	   NEAT	  
domains	  IsdH	  NEAT-­‐3	  and	  IsdB	  NEAT-­‐2,	  before	  being	  passaged	  through	  IsdA	  and	  IsdC	  to	  
IsdE	   at	   the	   bacterial	   membrane.	   After	   IsdF-­‐dependent	   translocation	   through	   the	  
membrane,	   cytosolic	   heme	  may	  be	  degraded	  by	  heme	  monooxygenases,	   IsdG	  or	   IsdI.	  
Further	  mechanistic	  details	  on	  the	  Isd	  pathway	  in	  S.	  aureus	  can	  be	  found	  in	  Chapter	  1.	  
(B)	   Organization	   of	   the	   genetic	   loci	   encoding	   the	   Isd	   pathway	   in	   S.	   aureus	  Newman.	  
Genes,	  drawn	  to	  scale,	  are	  coloured	  to	  correspond	  to	  their	  associated	  proteins	  in	  Panel	  
A.	  Small	  arrows	  denote	  promoter	  regions	  and	  the	  direction	  of	   transcription.	  While	  co-­‐





further	  highlighted	  by	  the	  known	  upregulation	  of	   isd	  genes	  in	  human	  blood	  and	  serum	  
(29),	   and	   the	   detection	   of	   anti-­‐IsdA,	   IsdB,	   and	   IsdH	   antibodies	   in	   individuals	   suffering	  
from	  invasive	  staphylococcal	  infections	  (30,	  31).	  In	  spite	  of	  this	  wealth	  of	  knowledge	  on	  
the	  function	  and	  interaction	  of	  individual	  Isd	  proteins,	  and	  the	  known	  expression	  of	  the	  
pathway	  within	  the	  host,	  single	   isd	  deletion	  mutants	  often	  fail	   to	  yield	  robust	  growth-­‐
defective	  phenotypes	  on	  heme	  or	  Hb	  as	  a	  sole	   iron	  source.	   	  Consequently,	  two	  recent	  
papers	   contested	   the	   role	   of	   isd	   in	   heme-­‐iron	   acquisition	   given	   that,	   under	   the	  
experimental	  conditions	  employed,	  S.	  aureus	  strains	  mutated	  for	   isdABH	  or	   isdE	  hemB	  	  
(where	   disruption	   of	   hemB	   results	   in	   heme	   auxotrophic	   small	   colony	   variants	   (SCVs))	  
were	  not	  significantly	  impaired	  for	  growth	  on	  Hb	  or	  heme	  relative	  to	  wildtype	  (32,	  33).	  
Whilst	  no	  isd	  mutation	  appears	  to	  fully	  abrogate	  heme-­‐iron	  acquisition	  in	  S.	  aureus,	  the	  
aforementioned	   studies	   are	   contradictory	   to	   early	   findings	   from	   our	   lab,	   where	  
disruption	  to	  isdE	  or	  isdA	  was	  shown	  to	  result	  in	  a	  growth	  deficiency,	  albeit	  minor,	  when	  
heme	  was	   supplied	   as	   a	   sole	   iron	   source	   (23,	   24),	   and	   those	  of	   Skaar	   and	   colleagues,	  
where	  an	   isdB	  mutant	  was	   similarly	   shown	   to	  be	   impaired	   for	  growth	  on	  Hb	   (11,	  34).	  	  
The	   lack	  of	  a	  cogent	  heme-­‐dependent	  growth	  phenotype	   for	   isd	  mutants	   is,	  however,	  
consistent	  with	  our	  preexisting	  hypothesis	  that	  multiple	  heme-­‐iron	  acquisition	  systems	  
exist	  in	  S.	  aureus	  and	  that	  functional	  redundancy	  of	  these	  systems	  may	  mask	  the	  effects	  
of	  inactivating	  any	  one	  heme	  acquisition	  locus.	  	  
While	  the	  elaboration	  of	  multiple	  mechanisms	  for	  heme-­‐iron	  acquisition	  appears	  
to	  be	  a	  common	  theme	  amongst	  Gram-­‐positive	  pathogens,	   including	  in	  B.	  anthracis,	  L.	  
monocytogenes,	   and	   Corynebacterium	   diphtheriae	   (4),	   no	   alternate	   mechanisms	   for	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heme-­‐iron	   acquisition	   have	   been	   convincingly	   defined	   in	   the	   staphylococci.	   The	   locus	  
known	  to	  be	  responsible	  for	  staphyloferrin	  A	  import,	  htsABC,	  was	  initially	  described	  as	  a	  
heme	  transport	  system	  in	  S.	  aureus	  (3).	  Further	  structural	  characterization	  of	  the	  SBP	  for	  
this	   transporter	   (HtsA)	   suggests	   that	   it	   is	   unlikely	   to	   also	   accommodate	   heme	   as	   a	  
substrate	   (35,	  36,	  37,	   see	   section	  1.5.1.1.2	   for	  details).	   Further,	  while	  FepABC	   (for	  Fe-­‐
dependent	   peroxidase),	   a	   homologue	   of	   the	   enigmatic	   elemental	   ferrous	   iron	   uptake	  
pathway	  of	  Escherichia	  coli	  (EfeUOB),	  has	  been	  implicated	  in	  heme-­‐iron	  acquisition	  in	  S.	  
aureus,	   the	   exact	   role	   of	   this	   locus	   in	   heme-­‐iron	   utilization	   remains	   a	   matter	   of	  
contention	  (38,	  39,	  40	  see	  section	  1.5.3.1	  for	  details).	  	  Additionally,	  clear	  homologues	  to	  
alternate	  heme-­‐acquisition	  systems	   in	  other	  Gram-­‐positive	  pathogens	  (e.g.	  HupDCG	  of	  
L.	  monocytogenes,	  Hal	  and	  BslK	  of	  Bacillus	  spp.)	  are	  notably	  absent	  or	  have	  no	  defined	  
function	  in	  heme	  uptake	  in	  S.	  aureus	  (For	  an	  extensive	  review	  see	  4,	  41–43),	  raising	  the	  
question	   of	   how,	   in	   the	   absence	   of	   a	   functional	   Isd	   heme	   transport	   system,	   does	   S.	  
aureus	  acquire	  heme-­‐iron	  within	  the	  host?	  
The	   transport	   of	   iron	   substrates	   across	   the	   cytoplasmic	   membrane	   of	   both	  
Gram-­‐positive	  and	  Gram-­‐negative	  bacteria	  occurs	   in	  an	  analogous	  fashion,	  and	  usually	  
by	  way	   of	   an	   ABC	   transporter.	   	   In	   E.	   coli,	   the	   uptake	   of	   heme	   from	   the	   periplasm	   is	  
facilitated	   by	   the	   ABC-­‐type	   dipeptide-­‐heme	   permease,	   DppBCDF,	   and	   its	  
interchangeable	   SBPs,	   DppA	   and	   MppA	   (44).	   Both	   DppA	   and	   MppA	   bind	   heme,	   in	  
addition	   to	  binding	  and	   facilitating	   the	   transport	  of	  dipeptides	  and	  L-­‐alanyl-­‐gamma-­‐D-­‐
glutamyl-­‐meso-­‐diaminopimelate,	   respectively	   (44).	   Similarly,	   DppA	   homologues	   in	  
Haemophilus	   influenzae,	   HbpA	   and	   SapA,	   in	   conjunction	   with	   their	   cognate	   ABC	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permeases,	  each	  promote	  heme	  uptake,	  the	  latter	  of	  which	  also	  mediates	  the	  transport	  
of	  antimicrobial	  peptides	  (45,	  46).	  Notably,	  the	  staphylococci	  encode	  a	  putative	  di-­‐/tri-­‐
peptide	   permease,	   DtpT	   (47),	  which	   is	   highly	   conserved	   between	   species,	   and	  whose	  
possible	   function	   in	  heme-­‐iron	  acquisition	  has	  not	  yet	  been	   interrogated.	  Additionally,	  
several	   different	   oligopeptide	   permeases	   (OPPs)	   have	   been	   identified	   in	   S.	   aureus	  
including	   opp1,	   opp2	   and	   its	   SBP	   opp5A,	   opp3	   and	   opp4,	   whose	   functional	  
characterization	  is	  yet	   in	   its	   infancy	  (47,	  48,	  49,	  see	  section	  1.5.3.2	  for	  further	  details).	  
Interestingly	   dtpT,	   opp1,	   opp2	   and	   opp5A	   have	   each	   been	   implicated	   in	   in	   vivo	  
staphylococcal	  survival	  and	  virulence	  (49–52),	  although	  the	  exact	  mechanism	  by	  which	  
these	  permeases	  contribute	  to	  pathogenesis	  is	  unknown.	  	  	  
In	  this	  chapter,	  we	  sought	  to	  reconcile	  the	  conflicting	  reports	  on	  the	  utility	  of	  Isd	  
in	  heme-­‐iron	  acquisition	  by	  addressing	   the	  hypothesis	   that	   Isd	   is	  a	  high-­‐affinity	  heme-­‐
iron	  acquisition	  system,	  whose	  effects	  are	  masked	  by	  an	  alternate	  lower-­‐affinity	  uptake	  
system	   in	   the	   presence	   of	   high	   heme	   concentrations.	   Here	   we	   demonstrate	   that	  
individual	   components	   of	   the	   Isd	   system	   are	   indeed	   required	   for	   growth	   on	   low	  
nanomolar	   concentrations	   of	  Hb,	   a	   finding	   that	   firmly	   establishes	   the	   Isd	   system	  as	   a	  
physiologically	   relevant	   heme-­‐iron	   acquisition	   system	   in	   S.	   aureus.	   Further,	   in	  
elucidating	   the	   function	  of	   isd	  we	  developed	   a	   reliable	  means	  of	   assessing	  heme-­‐iron	  
acquisition	   in	   the	   staphylococci,	   which	  we	   employed	   to	   evaluate	   the	   role	   of	   putative	  
peptide	  permeases	  in	  heme-­‐iron	  acquisition	  in	  S.	  aureus.	  We	  demonstrate	  that	  DtpT	  has	  
a	  minor,	  and	  perhaps	  negligible	  role	  in	  heme-­‐iron	  acquisition,	  and	  that	  none	  of	  the	  OPPs	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in	  S.	   aureus	  appear	   to	   function	   in	   heme	  uptake.	   	   DtpT	  was,	   however,	   confirmed	   as	   a	  
bona	  fide	  transporter	  of	  di-­‐	  and	  tri-­‐peptides.	  	  
3.2. MATERIALS	  AND	  METHODS	  
3.2.1. Bacterial	  strains	  and	  growth	  conditions	  
Bacterial	   strains	   and	   plasmids	   employed	   in	   this	   study	   are	   summarized	   in	   Table	   3.1.	  
Experiments	   were	   performed	   in	   S.	   aureus	   strain	   Newman	   (H627)	   or	   plasmid-­‐cured	  
USA300	  (H2508,	  as	  described	  below),	  or	  their	  respective	  isogenic	  mutants,	  as	  indicated.	  
For	  routine	  manipulations,	  S.	  aureus	  and	  E.	  coli	  were	  routinely	  cultured	  in	  Difco	  tryptic	  
soy	  broth	  (TSB;	  BD	  Canada,	  Mississauga,	  ON,	  Canada)	  or	  Difco	  Luria-­‐Bertani	  Broth	  (LB;	  
BD	  Canada),	  respectively.	  Where	  required,	  agar	  was	  added	  to	  media	  at	  a	  concentration	  
of	  1.5%	  (w/v),	  yielding	  tryptic	  soy	  agar	  (TSA)	  and	  Luria-­‐Bertani	  agar	  (LBA),	  respectively.	  
Antibiotics,	  when	  required	  to	  maintain	  plasmids	  or	  select	  for	  recombinants,	  were	  added	  
to	  media	   at	   the	   following	   concentrations:	   ampicillin,	   100	   μg/mL;	   chloramphenicol,	   10	  
μg/mL;	  kanamycin,	  30	  μg/mL;	  tetracycline,	  4	  μg/mL;	  erythromycin,	  3	  μg/mL;	  neomycin,	  
50	  μg/mL;	  and	  lincomycin,	  20	  μg/mL	  (Sigma	  Aldrich,	  Oakville,	  ON,	  Canada).	  	  
	   Media	   for	   iron-­‐restricted	   bacteria	   growth	   was	   prepared	   in	   sterile	   vessels	  
composed	  of	   polypropylene.	   The	   assessment	  of	   growth	  under	   iron-­‐deplete	   conditions	  
was	   performed	   in	   Roswell	   Park	  Memorial	   Institute	   1640	  medium	   (RPMI),	   prepared	   as	  
directed	  by	  the	  manufacturer	  (Life	  Technologies,	  Burlington,	  ON,	  Canada)	  using	  Milli-­‐Q	  
purified	   water	   (EMB	   Millipore,	   Billerica,	   MA).	   	   Media	   was	   filter	   sterilized	   and	  
supplemented	  with	  the	  non-­‐metabolizable	  iron	  chelator	  ethylenediamine-­‐di(o-­‐	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Table	  3.1.	  Bacterial	  strains	  and	  plasmids	  used	  in	  this	  study.	  	  





Escherichia	  coli	  	  
DH5α	   80dlacZΔM15	   recA1	   endA1	   gyrA96	   thi-­‐1	  




RN4220	   Prophage-­‐cured	   laboratory	   strain;	   rK−	   mK+;	  
accepts	  foreign	  DNA	  
(53)	  
	  
H627	  (Newman)	   Wild-­‐type	  clinical	  osteomyelitis	  isolate	   (54)	  
USA300	  LAC	   Wild-­‐type	   USA300	   Los	   Angeles	   County	   (LAC)	  
clone;	   multilocus	   sequence	   type	   8,	   SCCmec	  
type	  IV;	  KanR,	  NeoR,	  EryR	  	  
(55,	  56)	  
Received	  
from	   B.	  
Kreiswirth	  
H2508	  (USA300)	   USA300	  cured	  of	  plasmid	  conferring	  antibiotic	  
resistance	  (p03)	  
This	  study	  
H734	   Newman	  ΔisdA::tetM;	  TetR	   (23)	  
H2735	   Newman	  ΔisdB::ermC;	  EryR	   (5)	  
H833	   Newman	  ΔisdC::km;	  KmR	   This	  study	  
H852	   (WT	   S.	  
aureus/pALC)	  
H627	  containing	  empty	  pALC2073	  vector;	  CmR	   This	  study	  
H2846	   (WT	  
USA300/pALC)	  





H734/pJS019;	  ΔisdA::tetM	  complemented	  with	  




H735/pJS019;	   ΔisdB::ermC	   complemented	  




H833/pJS019;	   ΔisdC::km	   complemented	   with	  
isdABC;	  	  KmR,	  CmR	  
This	  study	  
H2904	   USA300	  Δopp1	  (markerless	  deletion)	   This	  study	  
H2906	   USA300	  Δopp2	  (markerless	  deletion)	   This	  study	  
H2878	   USA300	  ACME-­‐oppA::ΦNΣ;	  EryR,	  LincR	   This	  study	  
H3265	   USA300	  Δopp3-­‐4	  (markerless	  deletion)	   This	  study	  
H2884	  	   USA300	  Δopp5A	  (markerless	  deletion)	   This	  study	  
H2920	   USA300	  ΔoppU	  (markerless	  deletion)	   This	  study	  
H2883	   USA300	  	  ΔdtpT	  (markerless	  deletion)	   This	  study	  
H2875	  	  	   USA300	  dtpT::ΦNΣ;	  EryR,	  LincR	   This	  study	  
H2979	   USA300	  dtpT::ΦNΣ,	   	   ΔisdA::tetM;	   	   EryR,	   LincR;	  
TetR	  
This	  study	  
H2893	  	   USA300	  Δopp5A,	  ACME-­‐oppA::ΦNΣ;	  EryR,	  LincR	   This	  study	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Table	  3.1.	  Continued.	  	  





H2907	   USA300	   Δopp1,	   opp5A,	   ACME-­‐oppA::ΦNΣ;	  
EryR,	  LincR	  
This	  study	  
H2925	   USA300	   Δopp1,	   opp2,	   opp5A,	   ACME-­‐
oppA::ΦNΣ;	  EryR,	  LincR	  
This	  study	  
H3266	   USA300	   Δopp1,	   opp2,	   opp3-­‐4,	   opp5A,	   ACME-­‐
oppA::ΦNΣ;	  EryR,	  LincR	  
This	  study	  
H3308	   USA300	   Δopp1,	   opp2,	   opp3-­‐4,	   opp5A,	   oppU,	  
ACME-­‐oppA::ΦNΣ;	  EryR,	  LincR	  
This	  study	  
H3310	   USA300	   Δopp1,	   opp2,	   opp3-­‐4,	   opp5A,	   dtpT,	  




H2875/pALC2073;	   dtpT::ΦNΣ/pALC	   containing	  




H2875/pCJ01;	   dtpT::ΦNΣ	   complemented	   with	  





H2979/pALC2073;	   dtpT::ΦNΣ,	   	   ΔisdA::tetM	  





H2979/pJC01;	   dtpT::ΦNΣ,	   	   ΔisdA::tetM	  
complemented	  with	  dtpT;	  EryR,	  LincR,	  CmR	  
This	  study	  
Plasmids	   	   	  
pBC	  SK	  (+)	   pBC	   phagemid	   with	   blue-­‐white	   colour	  




pAUL-­‐A	   Temperature	  sensitive	  E.	  coli/S.	  aureus	  suicide	  
shuttle	   for	   allelic	   replacement	   in	   S.	   aureus;	  
KmR	  
(57)	  
pDG782	   Source	   vector	   for	   kanamycin	   resistance	  
cassette;	  KmR	  	  
(58)	  
pLI50	   E.	   coli/S.	   aureus	   shuttle	   vector	   for	   gene	  
expression	   in	   S.	   aureus;	   AmpR,	   CmR	  
(respectively)	  
(59)	  
pCLV11	   pAUL-­‐A	   derivative	   for	   chromosomal	  
inactivation	   of	   isdC	   through	   insertion	   of	   a	  
kanamycin	  resistance	  cassette;	  KmR	  
This	  study	  
pJS019	   pLI50-­‐isdABC;	   pLI50	   derivative	   for	   expression	  
of	  isdABC	  from	  their	  native	  promoters;	  CmR	  
This	  study	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a. Tc,	   tetracycline	   resistance	   determinant;	   Km,	   kanamycin	   resistance	   determinant;	   TetR,	  
tetracycline-­‐resistant;	   KmR,	   kanamycin-­‐resistant;	   AmpR,	   ampicillin-­‐resistant;	   CmR,	  
chloramphenicol-­‐resistant;	   EryR,	   erythromycin-­‐resistant;	   LincR,	   lincomycin-­‐resistant;	  
NeoR,	  neomycin-­‐resistant.	  
hydroxyphenylacetic	  acid)	  (EDDHA;	  LGC	  Standards	  GmbH,	  Teddington,	  Middlessex,	  UK),	  
as	  indicated,	  to	  remove	  residual	  iron.	  
Assessment	  of	  di-­‐	   and	   tri-­‐peptide	  utilization	  was	  performed	   in	   chemically-­‐defined	  
medium	  with	  glucose	  (complete	  CDM).	  For	  complete	  CDM,	  10X	  stocks	  of	  defined	  amino	  
acids,	   vitamins,	   glucose,	   and	   divalent	   metal	   ions	   were	   prepared	   and	   added	   at	   the	  
following	   concentrations;	   L-­‐alanine	   (60	  μg	  ml-­‐1),	   L-­‐arginine	   (50	  μg	  ml-­‐1),	   L-­‐aspartic	   acid	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  3.1.	  Continued.	  	   	   	  






pALC2073	   E.	   coli/S.	   aureus	   shuttle	   vector	   for	   gene	  
expression	   in	   S.	   aureus;	   AmpR,	   CmR	  
(respectively)	  
(60)	  
pJC01	   pALC2073-­‐dtpT:	   pALC2073	   derivative	   for	  
expression	   of	   dtpT	   from	   its	   native	   promoter	  
AmpR,	  CmR	  
This	  study	  
pKOR1	   E.	   coli/S.	   aureus	   shuttle	   vector	   for	   allelic	  
replacement	   in	   S.	   aureus;	   AmpR,	   CmR	  
(respectively)	  
(61)	  
pKOR1Δopp1	  (pJS003)	  	   pKOR1	   derivative	   for	   in-­‐frame,	   markerless	  
deletion	  of	  opp1	  
This	  study	  	  
pKOR1Δopp2	  (pJS004)	  	   pKOR1	   derivative	   for	   in-­‐frame,	   markerless	  
deletion	  of	  opp2	  
This	  study	  	  
pKOR1Δopp3-­‐4	  
(pJS005)	  
pKOR1	   derivative	   for	   in-­‐frame,	   markerless	  




pKOR1	   derivative	   for	   in-­‐frame,	   markerless	  
deletion	  of	  opp5A	  
This	  study	  
pKOR1ΔoppU	  (pJS007)	   pKOR1	   derivative	   for	   in-­‐frame,	   markerless	  
deletion	  of	  oppU	  
This	  study	  
pKOR1ΔdtpT	  (pJS008)	   pKOR1	   derivative	   for	   in-­‐frame,	   markerless	  




(90	  μg	  ml-­‐1),	  L-­‐cysteine	  (20	  μg	  ml-­‐1),	  L-­‐glutamic	  acid	  (100	  μg	  ml-­‐1),	  glycine	  (50	  μg	  ml-­‐1),	  L-­‐
histidine	  (20	  μg	  ml-­‐1),	  L-­‐isoleucine	  (30	  μg	  ml-­‐1),	  L-­‐leucine	  (90	  μg	  ml-­‐1),	  L-­‐lysine	  (50	  μg	  ml-­‐
1),	  L-­‐methionine	  (3	  μg	  ml-­‐1),	  L-­‐phenylalanine	  (40	  μg	  ml-­‐1),	  L-­‐proline	  (80	  μg	  ml-­‐1),	  L-­‐serine	  
(30	  μg	  ml-­‐1),	  L-­‐threonine	  (30	  μg	  ml-­‐1),	  L-­‐tryptophan	  (10	  μg	  ml-­‐1),	  L-­‐tyrosine	  (50	  μg	  ml-­‐1),	  
and	   L-­‐valine	   (80	   μg	   ml-­‐1),	   L-­‐thiamine	   (169	   μg	   ml-­‐1),	   nicotinic	   acid	   (12.3	   μg	   ml-­‐1),	  
panthotenic	  acid	  (5	  μg	  ml-­‐1),	  biotin	  (1	  μg	  ml-­‐1),	  D-­‐glucose	  (0.5%	  w/v),	  K2HPO4	  (7	  mg	  ml-­‐1),	  
KH2PO4	   (2	  mg	  ml-­‐1),	  MgSO4	  (50	  μg	  ml-­‐1),	   (NH4)2SO4	  (1000	  μg	  ml-­‐1),	  MgCl2	   (95.3	  μg	  ml-­‐1)	  
and	  CaCl2	   (11.1	  μg	  ml-­‐1),	  and	  the	  medium	  was	  sterilized	  via	   filtration.	  Where	  required,	  
proline	  was	   left	   out	   of	   the	  media,	   yielding	   CDM-­‐Pro.	   Di-­‐	   (Phe-­‐Pro	   and	   Tyr-­‐Pro)	   or	   tri-­‐	  
(Ala-­‐Pro-­‐Ala)	  peptides	  (GenScript,	  Piscataway,	  NJ)	  were	  resuspended	  at	  a	  concentration	  
of	  100	  mg/mL	   in	  dimethyl	   sulfoxide	   (DMSO)	  and	  added	   to	  CDM-­‐Pro,	  where	   indicated.	  
Bacteria	  were	  routinely	  cultivated	  at	  37°C,	  unless	  otherwise	   indicated,	  with	  shaking	  at	  
200-­‐220	  rpm.	  
3.2.2. Construction	  and	  complementation	  of	  isd	  mutants	  in	  S.	  aureus	  Newman	  	  
Oligonucleotides	   used	   in	   generating	   or	   complementing	   isd	   mutants	   can	   be	   found	   in	  
Table	  3.2.	  S.	  aureus	  Newman	  ΔisdA::tetM	  (H734)	  and	  Newman	  ΔisdB::ermC	  (H2735)	  
were	   constructed	   as	   previously	   described	   (5,	   23).	   An	   isdC	   mutant	   (Newman	  
ΔisdC:km	   (H833))	  was	  generated	  by	  PCR	  amplifying	  a	  793	  bp	   fragment,	   comprised	  of	  
isdC	  and	   the	   regions	   immediately	   upstream	   and	   downstream	  of	   the	   gene	   using	   KpnI-­‐
isdC-­‐F	  and	  NotI-­‐isdC-­‐R.	  Following	  restriction	  enzyme	  digestion,	  the	  fragment	  was	  cloned	  
into	   the	   plasmid	   pBC	   SK(+)	   (Agilent	   Technologies,	   La	   Jolla,	   CA)	   and	   a	   kanamycin	  
resistance	  determinant,	  derived	  from	  pDG782	  (58)	  was	  subsequently	  inserted,	  in-­‐	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Table	  3.2.	  Oligonucleotides	  used	  in	  this	  study.	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Table	  3.2.	  Continued.	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Table	  3.2.	  Continued.	  	  
Primer	  paira,b	   Sequence	  (5’-­‐3’)	   Application	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Table	  3.2.	  Continued.	  	  
Primer	  paira,b	   Sequence	  (5’-­‐3’)	   Application	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pKOR1.	  
	  
frame,	   into	   isdC	  at	  a	  unique	  ClaI	   restriction	  site.	  The	   isdC::km	   fragment	  was	   then	  Pwo	  
PCR-­‐amplified	  using	  the	  aforementioned	  primer	  pair	  and	  inserted	  into	  pAUL-­‐A	  through	  
blunt	   end	   ligation,	   yielding	   pCLV11	   (57).	   The	   vector	  was	   passaged	   through	  RN4220,	   a	  
restriction-­‐negative,	  modification-­‐positive	  strain	  of	  S.	  aureus,	  prior	  to	  introduction	  into	  
S.	  aureus	  Newman.	  Recombination	  with	   the	  S.	  aureus	  chromosome	  was	  performed	  as	  
described	  elsewhere	  (37).	  Strains	  mutated	  for	  isdA,	   isdB,	  or	   isdC	  were	  complemented	  
in	  trans	  using	  a	  plasmid	  expressing	  isdAB	  and	  isdC	  from	  their	  native	  promoters	  (Figure	  
3.1).	   In	  brief,	   the	   isdABC	   locus	  was	  PCR	  amplified	  using	  KpnI-­‐isdABC-­‐comp-­‐F	  and	  SacI-­‐
isdABC-­‐comp-­‐R	  and	  cloned	  into	  pLI50	  at	  the	  corresponding	  restriction	  sites	  (59),	  yielding	  
pJS019.	  The	  plasmid	  was	  passaged	  through	  RN4220,	  and	  introduced	  into	  the	  S.	  aureus	  




3.2.3. Generation	  of	  a	  plasmid	  cured	  strain	  of	  USA300	  	  
To	   avoid	   plasmid	   incompatibility	   and	   to	   enhance	   the	   number	   of	   selective	   markers	  
available	   for	   use	   in	   generating	   marked	   mutations,	   S.	   aureus	   strain	   USA300	   LAC	   was	  
cured	  of	  a	  27-­‐kb	  plasmid	  (p03),	  which	  confers	  resistance	  to	  kanamycin,	  neomycin,	  and	  
erythromycin	  (62).	  	  In	  brief,	  USA300	  LAC	  was	  cultured	  in	  ½	  strength	  TSB	  (½	  TSB)	  at	  42°C	  
overnight,	  and	  dilutions	  of	  this	  culture	  were	  spread	  on	  agar	  plates	  containing	  ½	  TSB	  (½	  
TSA)	  without	  antibiotics.	  Following	  incubation	  overnight	  at	  42°C,	  isolated	  colonies	  were	  
patched	   onto	   both	   ½	   TSA	   without	   antibiotics	   and	   TSA	   containing	   kanamycin	   and	  
neomycin,	   or	   erythromycin,	   and	   incubated	   overnight	   at	   37°C.	   Isolates	   exhibiting	  
sensitivity	  to	  the	  aforementioned	  antibiotics	  were	  streaked	  for	  isolated	  colonies	  on	  TSA	  
without	   antibiotics	   and	   incubated	   again	   overnight	   at	   42°C.	   The	   selection	   process	  was	  
repeated	  until	   isolates	   fully	   sensitive	   to	  kanamycin,	  neomycin,	  and	  erythromycin	  were	  
obtained.	  Plasmid	  extractions	  were	  performed	  to	  confirm	  the	  absence	  of	  p03,	  and	  the	  
plasmid	  cured	  strain	  was	  designated	  H2508	  (herein	  referred	  to	  as	  USA300).	  
3.2.4. Generation	   and	   complementation	   of	   dtpT	   and	   dtpT	   isdA	   mutants	   in	   S.	  
aureus	  USA300	  
A	   transposon	   mutant	   of	   dtpT	   (SAUSA300_0712)	   was	   identified	   in	   the	   Nebraska	  
Transposon	   Mutant	   Library,	   with	   a	   strain	   ID	   of	   NE971	   and	   was	   mobilized	   into	   our	  
plasmid-­‐cured	   strain	   of	   USA300	   (H2508)	   using	   transduction	   with	   phage	   80α	   (63).	  
Successful	   mutation	   of	   dtpT	   was	   confirmed	   through	   PCR	   using	   primer	   pair	  
USA300_0712-­‐F	  and	  USA300_0712-­‐R	  (Table	  3.2),	  which	  span	  the	  region	  of	  insertion,	  and	  
the	  strain	  was	  designated	  USA300	  dtpT::ΦNΣ	  (H2875).	  Phage	  transduction	  was	  similarly	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used	  mobilize	  the	   isdA	  mutation	  from	  S.	  aureus	  Newman	  (H734)	  to	  H2875,	  generating	  
USA300	  dtpT::ΦNΣ,	   ΔisdA::tetM	   (H2979).	   Complementation	   of	   the	  dtpT	  mutation	  was	  
performed	   by	   amplifying	   the	   gene	   and	   its	   native	   promoter	   using	   primers	  dtpT-­‐F-­‐KpnI	  
and	  dtpT-­‐R-­‐SacI.	  The	  amplicon	  was	  cloned	  into	  pALC2073,	  generating	  pJC01,	  where	  dtpT	  
was	   constitutively	   expressed	   without	   induction	   by	   the	   leaky	   Pxyl/tetO	   promoter	   of	  
pALC2073	  (60).	  
3.2.5. Identification	  of	  loci	  encoding	  for	  putative	  OPPs	  in	  S.	  aureus	  USA300	  
In	   addition	   to	  dtpT,	   five	   loci	   were	   previously	   identified	   as	   putative	   OPPs	   in	   S.	   aureus	  
NCTC8325;	  opp1,	  opp2	  (renamed	  nikBCDE),	  opp3,	  opp4	  and	  opp5A	  (renamed	  nikA)	  and	  
dtpT	  (47,	  49).	  Comparative	  analyses	  using	  the	  nucleotide	  Basic	  Local	  Alignment	  Search	  
Tool	   (BLASTn)	  were	  used	   to	   identify	   similar	   loci	   in	   the	   genome	   sequence	  of	  S.	   aureus	  
USA300	  FPR3757	  (GenBank	   ID	  CP000255.1).	  A	  search	  for	  outstanding	  putative	  peptide	  
permeases	   was	   similarly	   performed	   using	   both	   the	   nucleotide	   and	   amino	   acid	  
sequences	  of	  each	  individual	  gene	  identified	  within	  the	  aforementioned	  loci,	  in	  an	  effort	  
to	   identify	   alternate	   peptide	   permease-­‐encoding	   loci	   that	   may	   deviate	   from	   the	  
prescribed	   structure	   for	   opp	   operons.	   Multiple	   amino	   acid	   sequence	   alignments	   and	  
corresponding	   percent	   identities	   between	   each	  putative	   SBP,	   integral	   transmembrane	  
protein,	  and	  ATPase,	  respectively,	  were	  determined	  using	  Clustal	  Omega	  (64).	  
3.2.6. Construction	  of	  S.	  aureus	  OPP	  mutants	  	  
Oligonuclotides	   used	   in	   generating	   peptide	   permease	  mutants	   can	   be	   found	   in	   Table	  
3.2.	  Markerless	  deletion	  mutants	  were	  generated	  in	  S.	  aureus	  USA300	  (H2508)	  for	  each	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opp1,	  opp2,	  opp5A,	  oppU,	  as	  well	  as	  dtpT.	  Due	  to	  the	  close	  proximity	  of	  opp3	  and	  opp4	  
within	  the	  genome	  (212	  bp	  separating	  the	  two	  operons),	  a	  single	  deletion	  mutant	  was	  
generated	   for	   opp3	   and	   opp4	   together	   (opp3-­‐4).	   Mutants	   were	   generated	   using	   the	  
plasmid	  pKOR1	  and	  methods	  modified	  from	  those	  of	  Bae	  and	  Schneewind	  (61).	  In	  brief,	  
~1000	  bp	  regions	  flanking	  each	   locus	  of	   interest	  were	  amplified	  using	  the	  primer	  pairs	  
indicated	  in	  Table	  3.2,	  where	  “UP”	  denotes	  an	  upstream	  flanking	  sequence	  bearing	  a	  5’	  
attB1	  site	  and	  3’	  SacII	  cut	  site,	  and	  “DOWN”	  denotes	  a	  downstream	  flanking	  sequence	  
bearing	  a	  5’	  SacII	  cut	   site	  and	  3’	  attB2	   site.	   Each	  pair	  of	   fragments	  was	  digested	  with	  
SacII	  and	  ligated	  together,	  and	  the	  linear	  construct	  was	  introduced	  into	  pKOR1	  through	  
site-­‐specific	   recombination	   yielding	   the	   pKOR1	   entry	   vectors	   pJS003,	   pJS004,	   pJS005,	  
pJS006,	  pJS007,	  and	  pJS008,	  for	  deletion	  of	  opp1,	  opp2,	  opp3-­‐4,	  opp5A,	  oppU,	  and	  dtpT,	  
respectively	   (Table	   3.1).	   Insertion	   of	   the	   appropriate	   linear	   fragment	   in	   pKOR1	   was	  
confirmed	   by	   PCR	   using	   primers	   specific	   to	   each	   locus	   (Table	   3.2;	   primers	   designated	  
“short”),	   and	   sequenced	   using	   pKOR1-­‐F	   and	   pKOR1-­‐R.	   The	   entry	   vectors	   were	  
constructed	   in	   E.	   coli	  DH5α	   and	   passaged	   through	   S.	   aureus	   RN4220	   at	   30°C	   before	  
introduction	   into	   S.	   aureus	   USA300	   (H2508)	   by	   electroporation.	   Recombination	   and	  
selection	   were	   performed	   as	   previously	   described	   (61).	   Mutants	   were	   confirmed	  
through	   PCR	   and	   DNA	   sequencing	   using	   primers	   spanning	   the	   entire	   deleted	   region,	  
designated	   “full”	   in	   Table	   3.2.	   The	   resulting	   USA300	   strains	   were	   designated	   H2094	  
(Δopp1),	  H2906	  (Δopp2),	  H3265	  (Δopp3-­‐4),	  H2884	  (Δopp5A),	  H2920	  (ΔoppU),	  and	  H2883	  
(ΔdtpT)	   (see	   Table	   3.1).	   Transposon	   mutagenesis	   was	   used	   to	   generate	   an	   insertion	  
mutation	  in	  the	  gene	  encoding	  the	  SBP	  for	  ACME-­‐opp	  (SAUSA300_0073;	  herein,	  ACME-­‐
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oppA).	   As	   with	   dtpT,	   a	   transposon	   insertion	   was	   identified	   in	   ACME-­‐oppA	   in	   the	  
Nebraska	  Transposon	  Mutant	  Library,	  with	  a	  strain	  IDs	  NE227,	  and	  was	  transduced	  into	  
H2508	   as	   above.	   Confirmation	   of	   USA300	   ACME-­‐oppA::ΦNΣ	   (H2878)	   was	   performed	  
through	   PCR	   and	   sequencing	   using	   the	   primer	   pair	   and	   USA300_0073-­‐F	   and	  
USA300_0073-­‐R.	  	  
	   In	  order	  to	  lessen	  the	  risk	  of	  possible	  of	  functional	  redundancy,	  a	  USA300	  strain	  
deficient	  for	  all	  of	  the	  aforementioned	  peptide	  permeases	  was	  generated.	  In	  brief,	  using	  
the	  pKOR1	  entry	   clones	   previously	   described,	  markerless	  mutations	  were	   successively	  
introduced	   into	   USA300	   ACME	   oppA::ΦNΣ	   (H2878),	   starting	   with	   pJS006,	   yielding	  
USA300	   Δopp5A,	   ACME-­‐oppA::ΦNΣ	   (H2893);	   followed	   by	   pJS003,	   yielding	   USA300	  
Δopp1,	   opp5A,	   ACME-­‐	   oppA::ΦNΣ	   	   (H2907);	   pJS004,	   yielding	   USA300	   Δopp1,	   opp2,	  
opp5A,	   ACME-­‐oppA::ΦNΣ	   (H2925);	   pJS005,	   yielding	   USA300	   Δopp1,	   opp2,	   opp3-­‐4,	  
opp5A,	   ACME-­‐oppA::ΦNΣ	   (H3266),	   pJS007,	   yielding	   USA300	   Δopp1,	   opp2,	   opp3-­‐4,	  
opp5A,	   oppU,	   ACME-­‐oppA::ΦNΣ;	   (H3308),	   and	   finally	   pJS008	   yielding	   USA300	   Δopp1,	  
opp2,	  opp3-­‐4,	  opp5A,	  dtpT,	  oppU,	  ACME-­‐oppA::ΦNΣ	  (H3310).	  Mutants	  were	  confirmed	  
through	  PCR	  using	  the	  primers	  previously	  described	  (Table	  3.2).	  The	  complete	  peptide	  
permease-­‐deficient	  mutant	  (H3310)	  was	  confirmed	  by	  PCR	  and	  sequencing	  of	  the	  region	  
spanning	  each	  of	  the	  deleted	  loci.	  
3.2.7. Preparation	  of	  lyophilized	  heme	  and	  hemoglobin	  
A	  stock	  solution	  of	  bovine	  hemin	  (Sigma	  Aldrich)	  was	  first	  prepared	  at	  an	  approximate	  
concentration	   of	   5	   mM	   in	   0.1	   N	   NaOH,	   where	   the	   heme	   solution	   was	   vortexed	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vigorously	  until	   fully	  solubilized.	  Following	  sterilization	  through	  a	  0.2	  μm	  syringe	   filter,	  
the	   final	   concentration	   of	   heme	   was	   determined	   spectrophotometrically.	   In	   brief,	  
dilutions	  (1:500	  to	  1:2000)	  of	  the	  stock	  solution	  were	  prepared	  in	  0.1	  N	  NaOH,	  and	  UV-­‐
Visible	  (UV-­‐Vis)	  scans	  of	  the	  samples	  were	  run	  between	  200	  nm	  and	  800	  nm.	  The	  molar	  
extinction	  coefficient	  for	  heme	  in	  0.1	  N	  NaOH	  of	  58,400	  cm-­‐1	  M-­‐1	  at	  385	  nm	  was	  used	  to	  
determine	   the	   exact	   concentration	   of	   the	   solution	   (65).	   Similarly,	   bovine	   hemoglobin	  
(Sigma	  Aldrich)	  was	  reconstituted	  from	  lyophilized	  powder	   in	  50	  mM	  Tris	  pH	  8.0	  at	  an	  
approximate	   concentration	   of	   2	   mM	   and	   sterilized	   by	   syringe	   filtration.	   The	   final	  
concentration	  of	  reconstituted	  bovine	  hemoglobin	  was	  determined	  using	  the	  published	  
extinction	  coefficients	  for	  hemoglobin	  at	  560	  nm	  (36,500	  cm-­‐1	  M-­‐1)	  and	  577	  nm	  (66,000	  
cm-­‐1	  M-­‐1)	   (66).	   Single-­‐use	  aliquots	  of	  both	   reconstituted	  heme	  and	  hemoglobin	   (10-­‐50	  
μL)	   were	   stored	   at	   -­‐20°C	   and	   -­‐80°C,	   respectively,	   and	   were	   diluted	   in	   growth	   media	  
immediately	  prior	  to	  use.	  	  	  	  
3.2.8. Extraction	  of	  fresh	  human	  hemoglobin	  from	  whole	  blood	  
For	   hemoglobin	   purification,	   25	   mL	   of	   fresh	   human	   blood	   heparinized	   with	   ~0.01	  M	  
sodium	  citrate	  was	  centrifuged	  at	  1,500	  g	  at	  4°C	   for	  10	  minutes	  to	  pellet	  erythrocytes	  
(see	  Figure	  3.2	  for	  a	  schematic	  of	  the	  procedure).	  Erythrocytes	  were	  washed	  three	  times	  
in	  three	  pellet	  volumes	  of	  ice-­‐cold	  sterile	  saline,	  and	  subsequently	  lysed	  in	  50	  mM	  Tris	  
pH	  8.6,	  2	  mM	  ethylenediaminetetraacetic	  acid	  (EDTA)	  at	  room	  temperature	  for	  30	  min,	  
mixing	   periodically	   by	   gentle	   inversion.	   Cell	   debris	   was	   removed	   by	   centrifugation	   at	  
11,000	  g	  for	  30	  min	  at	  4°C.	  The	  supernatant	  from	  the	  lysate	  was	  transferred	  to	  a	  fresh	  








	  removed	   by	   centrifugation	   at	   11,000	   g	   for	   30	  min	   at	   4°C.	   The	   resulting	   hemoglobin-­‐
containing	  supernatant	  was	  removed	  and	  dialyzed	  overnight	  against	  50	  mM	  Tris	  pH	  8.6,	  
1	   mM	   EDTA	   (Buffer	   A)	   using	   Spectra/Por	   12,000-­‐14,000	   Da	   molecular	   weight	   cut-­‐off	  
(MWCO)	   dialysis	   tubing	   (25	   mm	   flat	   width,	   16	   mm	   diameter;	   Spectra/Por,	   Rancho	  
Dominguez,	  CA).	  Following	  dialysis,	  the	  hemoglobin	  solution	  was	  passed	  once	  through	  a	  
0.4	   μm	   syringe	   filter	   prior	   to	   purification	   via	   anion	   exchange	   on	   a	  Mono	  Q	  HR	   16/10	  
column	   (GE	   Healthcare,	   Mississauga,	   ON,	   Canada).	   Briefly,	   dialyzed	   hemoglobin	   was	  
loaded	  in	  4-­‐6	  mL	  batches	  on	  the	  column	  and	  a	  gradient	  run	  using	  50	  mM	  Tris	  pH	  8.6,	  1	  
mM	  EDTA,	  and	  0.5	  M	  NaCl	  as	  Buffer	  B,	  where	  hemoglobin	  eluted	  in	  fractions	  between	  
50	  and	  100	  mM	  NaCl.	  The	  resulting	  purified	  fractions	  were	  dialyzed	  twice	   into	  50	  mM	  
Tris	   pH	   8.0	   and	   sterilized	   by	   syringe	   filtration.	   As	   detailed	   above,	   hemoglobin	  
concentration	   was	   determined	   using	   the	   published	   extinction	   coefficients	   for	   the	  
protein	  at	  560	  nm	  and	  577	  nm	  (66).	  The	  dialyzed	  hemoglobin	  was	  concentrated	  to	  ~2	  
mM	  using	  Amicon	  Ultra-­‐15	  centrifugation	  units	  (30	  kDa	  nominal	  molecular	  weight	  limit;	  
Millipore)	  and	  the	  final	  concentration	  was	  determined.	  Small	  single-­‐use	  aliquots	  (10-­‐20	  
μL)	  were	   flash	   frozen	   in	   a	  dry	   ice-­‐ethanol	   bath	  prior	   to	   storage	  at	   -­‐80°C.	   Immediately	  
prior	  to	  use,	  hemoglobin	  was	  thawed	  on	  ice	  and	  diluted	  in	  growth	  media.	  
3.2.9. Assessment	  of	  hemoglobin	  integrity	  
To	  assess	   for	   the	  presence	  of	   intact	  hemoglobin	   tetramers,	  both	   reconstituted	  bovine	  
hemoglobin	  and	   fresh	  human	  hemoglobin	  were	  visualized	  using	  native	  polyacrylamide	  
gel	  electrophoresis	  (PAGE).	  	  In	  brief,	  10,	  20,	  and	  50	  μg	  quantities	  of	  hemoglobin,	  diluted	  
where	   required	   in	   50	  mM	   Tris	   pH	   8.0,	   were	  mixed	   1:1	   with	   non-­‐reducing	   2X	   sample	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buffer	  (62.5	  mM	  Tris-­‐HCl	  pH	  6.8;	  25%	  glycerol;	  and	  1%	  Bromophenol	  Blue).	  To	  maintain	  
protein	   integrity,	   samples	   were	   loaded,	   without	   heating,	   on	   a	   10%	   native	   bis-­‐Tris	  
acrylamide	  gel	  and	  run	   for	  70	  min	  at	  100V	   in	  buffer	  consisting	  of	  25	  mM	  Tris-­‐HCl	  and	  
192	  mM	  glycine.	  Gels	  were	  stained	  upon	  completion	  with	  Coomassie	  Brilliant	  Blue	  R-­‐250	  
dye.	  	  
	   In	   addition	   to	   assessing	   concentration,	   UV-­‐Vis	   spectroscopy	   was	   employed	   to	  
assess	   the	   structural	   integrity	   and	   state	   of	   the	   reconstituted	   and	   freshly	   extracted	  
hemoglobin.	  As	  described	  above,	  a	  spectral	  scan	  was	  run	  between	  200	  nm	  and	  800	  nm	  
(medium	  speed)	  on	  dilutions	  of	  hemoglobin	  in	  50	  mM	  Tris;	  a	  characteristic	  Soret	  peak	  at	  
415	  nm,	  distinct	  α576	  nm	  and	  β541	  nm	  bands,	  and	  a	  peak	  at	  345	  nm	  are	  indicative	  of	  intact	  
ferrous	  oxyhemoglobin.	  	  
3.2.10. Assessing	  heme	  and	  hemoglobin-­‐dependent	  growth	  by	  S.	  aureus	  	  
Single,	   isolated	  colonies	  of	  S.	  aureus	  Newman	  or	  USA300,	  and	   their	   isogenic	  mutants,	  
grown	   from	   -­‐80°C	   freezer	   stocks	   for	   24	  h	  on	  TSA	  plates,	  were	   resuspended	   in	   120	  µL	  
RPMI	   supplemented	   with	   the	   indicated	   concentrations	   of	   EDDHA.	   One	   hundred	  
microliters	  of	  the	  colony	  resuspension	  were	  used	  to	  inoculate	  2	  mL	  of	  the	  same	  media,	  
and	   cultures	   were	   grown	   for	   8-­‐10	   hours,	   until	   the	   OD600	   was	   approximately	   1.	  	  
Preculture	   cells	  were	   collected	   by	   centrifugation,	  washed	   twice	   in	   1	  mL	  of	   RPMI,	   and	  
normalized	   to	  an	  OD600	  of	  1,	  prior	   to	   subculture	   (1:400)	   into	  2	  mL	  of	   the	   same	  media	  
with	  fresh	  human	  hemoglobin,	  or	  reconstituted	  heme	  or	  bovine	  hemoglobin	  supplied	  as	  
a	   sole	   iron	   source.	   Cultures	   were	   incubated	   at	   37°C	   in	   14-­‐mL	   round-­‐bottom	  
polypropylene	   tubes,	   shaken	   at	   200–220	   rpm.	   Culture	   densities	   were	   assessed	   by	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determining	   the	  OD600	   every	   4	   h	   for	   high	   heme/hemoglobin	   concentrations	   (500	   nM)	  
and	  every	  12	  h	  for	  low	  heme/hemoglobin	  concentrations	  (5-­‐200	  nM).	  Where	  OD600	  was	  
determined	   using	   microtiter	   plates,	   a	   pathlength	   correction	   included	   in	   the	   Gen5	  
microtiter	  plate	  software	  (Bio-­‐Tek,	  Winooski,	  VT)	  was	  applied	  such	  that	  the	  absorbance	  
values	   are	   comparable	   to	   the	   1-­‐cm	   horizontal	   path	   length	   of	   standard	  
spectrophotometers.	  	  
3.2.11. Bacterial	  growth	  curves	  in	  CDM	  with	  and	  without	  peptides	  
Growth	  assessment	  of	  wildtype	  USA300	  relative	  to	  its	  isogenic	  mutants	  was	  performed	  
in	   CDM	   or	   CDM-­‐Pro	   supplemented	   with	   peptides	   or	   proline.	   In	   brief,	   single	   isolated	  
colonies	  grown	  for	  24	  h	  on	  TSA	  plates	  were	  resuspended	  in	  120	  µL	  complete	  CDM.	  One	  
hundred	  microliters	  of	  the	  colony	  resuspension	  were	  used	  to	  inoculate	  2	  mL	  of	  the	  same	  
media,	   and	   cultures	   were	   grown	   for	   4-­‐5	   h	   until	   the	   OD600	   was	   approximately	   1.	  
Preculture	  cells	  were	  collected	  by	  centrifugation,	  washed	  twice	  in	  1	  mL	  of	  CDM-­‐Pro,	  and	  
normalized	   to	   an	   OD600	   of	   0.01.	   A	   two-­‐fold	   dilution	   series	   ranging	   from	   4	   mM	   to	  
0.015625	  mM	  for	  each	  Phe-­‐Pro,	  Tyr-­‐Pro,	  Ala-­‐Pro-­‐Ala,	  or	   free	  proline	   in	  CDM-­‐Pro	  were	  
prepared	   in	  100-­‐well	  Bioscreen	  C	  growth	  plates	   (Growth	  Curves	  USA,	  Piscataway,	  NJ),	  
with	  a	  volume	  of	  100	  μL	  per	  well.	  To	  each	  well,	  100	  μL	  of	  colony	  resuspension	  in	  CDM-­‐
Pro	  was	  added,	  such	  that	  the	  starting	  OD600	  was	  approximately	  0.005,	  and	  the	  starting	  
peptide/proline	  concentrations	  ranged	  from	  2	  mM	  to	  0.0078	  mM.	  Cultures	  were	  grown	  
in	   a	   Bioscreen	   C	   machine	   (Growth	   Curves	   USA)	   at	   37°C	   with	   continuous	   medium	  
amplitude	  shaking,	  and	  OD600	  was	  assessed	  every	  15	  min.	  For	  graphical	  clarity,	  growth	  at	  




3.3.1. S.	   aureus	   isd	   genes	   are	   not	   required	   for	   growth	   on	   supraphysiological	  
concentrations	  of	  heme	  or	  hemoglobin	  
As	  described	  above,	  despite	  being	  the	  sole	  mechanism	  characterized	  for	  the	  acquisition	  
of	  heme-­‐iron	  in	  the	  staphylococci,	  mutation	  of	  genes	  within	  the	  isd	  pathway	  often	  fails	  
to	   yield	   mutants	   with	   compelling	   and	   reproducible	   growth-­‐defective	   phenotypes	   on	  
heme	  or	  hemoglobin	  as	  a	  sole	   iron	  source	  (32,	  33).	   Indeed,	  as	  demonstrated	   in	  Figure	  
3.3,	   wildtype	   S.	   aureus	   Newman	   and	   its	   isogenic	   isdA,	   isdB,	   and	   isdC	   mutants	   grow	  
comparably	  when	   supplied	  with	   high	   concentrations	   (500	   nM)	   of	   reconstituted	   heme	  
and	  bovine	  hemoglobin	  in	   iron-­‐restricted	  RPMI,	  using	  a	  methodology	  similar	  to	  that	  of	  
previous	  studies	  that	  failed	  to	  demonstrate	  an	  appreciable	  effect	  for	   isd	  on	  heme-­‐iron	  
utilization	   (32,	   33).	   	   Given	   the	   apparent	   discrepancy	   between	   the	   aforementioned	  
findings	   and	   the	   extensive	   in	   vitro	   demonstration	   of	   the	   role	   of	   Isd	   proteins	   in	   heme	  
capture	   and	   protein-­‐to-­‐protein	   heme	   transfer	   (12,	   18–24),	   we	   reasoned	   that	   the	  
necessity	  of	   isd	  genes	  for	  growth	  might	  be	  masked	  under	  the	  experimental	  conditions	  
employed,	  namely	  the	  provision	  of	  high	  concentrations	  of	  reconstituted	  hemoglobin	  as	  
an	   iron	   source.	   Specifically,	   at	   supraphysiological	   concentrations	   of	   reconstituted	  
hemoglobin	  (>	  100	  nM)	  (10),	  we	  hypothesize	  that	  the	  function	  of	  Isd	  in	  the	  acquisition	  
of	  heme	  from	  hemoglobin	  may	  be	  eclipsed	  by	  the	  uptake	  of	  free	  heme	  through	  an	  as-­‐




Figure	  3.3.	  S.	  aureus	  isd	  mutants	  are	  not	  debilitated	  for	  growth	  on	  high	  concentrations	  
of	  reconstituted	  heme	  (A)	  or	  bovine	  hemoglobin	  (B).	  
S.	   aureus	  Newman	   and	   its	   isogenic	   isdA,	   isdB,	   and	   isdC	  mutants,	   as	   indicated,	   were	  
cultured	  	  in	  RPMI	  supplemented	  with	  50	  μM	  EDDHA	  and	  500	  nM	  of	  reconstituted	  heme	  
or	  bovine	  hemoglobin	  as	  a	  sole	  iron	  source.	  Culture	  densities	  were	  assessed	  every	  4	  h	  by	  
determining	  the	  OD600.	  Data	  shown	  are	  representative	  of	  at	  least	  3	  experiments,	  where	  




3.3.2. Lyophilized	  hemoglobin	  lacks	  structural	  integrity	  
To	  address	  the	  possibility	  that	  the	  presence	  of	  free	  heme	  in	  reconstituted	  hemoglobin	  
may	  inhibit	  a	  hypothesized	  observation	  of	  a	  hemoglobin-­‐specific	  phenotype	  for	  isd,	  we	  
developed	   a	   protocol	   for	   the	   acquisition	   of	   fresh	   human	   hemoglobin,	   designed	   to	  
maintain	  the	  integrity	  of	  the	  protein	  throughout	  the	  process	  of	  extraction,	  purification,	  
and	  storage.	  Commercially	  prepared	  lyophilized	  hemoglobin	  has	  previously	  been	  shown	  
to	   contain	   a	   heterogeneous	   mixture	   of	   tetramers,	   heme-­‐replete	   and	   heme-­‐deplete	  
dimers	   and	   monomers,	   and	   free	   dissociated	   heme	   (67).	   Erythrocyte	   lysis	   and	   the	  
removal	   of	   stromata	   in	   these	   preparations	   are	   achieved	   through	   the	   use	   of	   organic	  
solvents,	  such	  as	  toluene,	  diethyl	  ether,	  or	  dichloromethane,	  often	  with	  heat	  treatment	  
to	   inactivate	   water-­‐soluble	   proteins,	   prior	   to	   lyophilization.	   As	   all	   of	   these	   processes	  
may	   adversely	   impact	   hemoglobin	   stability,	   we	   thus	   employed	   hypotonic	   shock	   to	  
liberate	   hemoglobin	   from	   erythrocytes,	   and	   the	   stromata	   were	   precipitated	   with	  
sodium	   chloride,	   prior	   to	   further	   purification	   via	   anion	   exchange	   chromatography	  
(Figure	  3.2).	  Using	  the	  latter	  method,	  we	  reliably	  were	  able	  to	  obtain	  approximately	  70	  
milligrams	  of	  hemoglobin	  per	  milliliter	  of	  whole	  blood	  (data	  not	  shown).	  	  
	   To	  assess	   the	   structural	   integrity	  of	   reconstituted	  versus	   fresh	  hemoglobin,	  we	  
first	   resolved	   the	   proteins	   using	   non-­‐denaturing,	   non-­‐reducing	   PAGE.	   	   As	   shown	   in	  
Figure	  3.4A,	  hemoglobin	  extracted	  from	  fresh	  human	  blood	  appears	  as	  a	  single	  distinct	  
protein	   band	   with	   an	   apparent	   molecular	   mass	   of	   64	   kDa,	   consistent	   with	   the	  






Figure	  3.4.	  Lyophilized	  hemoglobin	  lacks	  structural	  integrity.	  	  
(A)	  Coomassie	  blue-­‐stained	  native	  PAGE	  visualization	  of	  hemoglobin	  purified	  from	  fresh	  
blood	   (fHb)	   or	   reconstituted	   from	   a	   lyophilized	   state	   (lHb).	   Hemoglobin	   was	   dialyzed	  
into	  or	  reconstituted	  in	  50	  mM	  Tris	  pH	  8.0	  (for	  fHb	  and	  lHb,	  respectively),	  mixed	  with	  1:1	  
with	  2X	  sample	  buffer	  without	  SDS	  or	  β-­‐mercaptoethanol,	  and	   loaded	  at	   the	  amounts	  
indicated.	   Gels	   and	   buffers	   were	   also	   prepared	   without	   SDS	   to	  maintain	   the	   existing	  
protein	   structure.	   (B)	   Hemoglobin	   structural	   integrity	   as	   assessed	   by	   UV-­‐Vis	  
spectroscopy.	   Lyophilized	  hemoglobin	   (red)	  and	   freshly	  extracted	  hemoglobin	   (purple)	  
were	   diluted	   1:1000	   from	   3	   mM	   stock	   solutions	   in	   50	   mM	   Tris	   pH	   8.0	   and	   UV-­‐Vis	  
spectral	   scans	   were	   run	   between	   200-­‐800	   nm.	   For	   graphical	   clarity,	   only	   the	   range	  
between	   300-­‐700	   nm	   is	   shown.	   Relative	   to	   fresh	   hemoglobin,	   lyophilized	   hemoglobin	  
exhibits	   numerous	   spectral	   features	   indicative	   of	   hemoglobin	   degradation,	   including;	  
abatement	  or	  abolition	  of	  the	  peaks	  at	  345	  nm,	  541	  nm	  (β	  band),	  and	  575	  nm	  (α	  band)	  
(small	  solid	  arrows	  with	  wavelength,	   in	  nanometers,	  as	   indicated),	  a	  blue	  spectral	  shift	  
in	   the	   Soret	   peak	   from	   the	   expected	   415	   nm	   for	   fresh	   hemoglobin	   to	   408	   nm	   in	  
lyophilized	  hemoglobin,	  and	  the	  presence	  of	  a	  broad,	  blue-­‐shifted	  shoulder	  on	  the	  Soret	  






reconstituted	   hemoglobin	   also	   demonstrates	   a	   discernable	   protein	   band	   at	  
approximately	  64	  kDa,	  it	   is	  accompanied	  by	  diffuse	  smearing	  running	  the	  length	  of	  the	  
gel,	  suggesting	  that	  the	  protein	  may	  be	  at	  least	  partially	  dissociated	  and/or	  degraded.	  	  
	   The	   quality	   (and	   quantity)	   of	   freshly	   extracted	   hemoglobin	   relative	   to	  
reconstituted	   lyophilized	   hemoglobin	   was	   assessed	   through	   UV-­‐Vis	   spectroscopy.	   As	  
demonstrated	   in	   Figure	   3.4B,	   subtle	   yet	   discernable	   differences	   exist	   between	   the	  
spectral	  profiles	  of	  these	  two	  hemoglobin	  preparations.	  Most	  notably,	  the	  Soret	  peak	  in	  
reconstituted	   hemoglobin	   is	   blue-­‐shifted	   (i.e.	   shifted	   towards	   shorter	   wavelengths)	  
relative	  to	  fresh	  hemoglobin,	  where	  the	  λmaxSoret	  is	  407	  nm	  and	  415	  nm,	  respectively.	  	  A	  
blue	  spectral	  shift	  in	  the	  Soret	  peak	  for	  hemoglobin,	  coupled	  with	  the	  disappearance	  of	  
bands	  at	  345	  nm,	  541	  nm	  (β	  band),	  and	  577	  nm	  (α	  band),	  as	  observed	  for	  reconstituted	  
hemoglobin	  (Figure	  3.4B),	  is	  indicative	  of	  degradation	  of	  the	  protein	  (67,	  68).	  Further,	  a	  
blue-­‐shifted	   shoulder	   is	   evident	   on	   the	   Soret	   peak	   of	   reconstituted	   hemoglobin,	  
corresponding	   to	   the	   Soret	   band	   for	   free	   heme,	   but	   is	   absent	   from	   that	   of	   fresh	  
hemoglobin.	   Together	   these	   results	   suggest	   that	   the	   structural	   integrity	   of	   lyophilized	  
hemoglobin	   is	   compromised,	   and	   likely	   contains	   notable	   amounts	   of	   free	   heme.	   	   In	  
contrast,	   the	   spectra	   for	   freshly	   extracted	   human	   hemoglobin	   is	   consistent	   with	   the	  
published	   spectra	   for	   intact	   ferrous	   oxyhemoglobin	   (67).	   All	   subsequent	   experiments	  
employing	   hemoglobin	   as	   a	   sole	   iron	   source	  were	   thus	   performed	  using	   fresh	  human	  




3.3.3. Components	   of	   the	   isd	   system	   are	   required	   for	   growth	   on	   low	   nanomolar	  
concentrations	  of	  human	  hemoglobin	  
With	   intact	   fresh	   human	   hemoglobin	   in	   hand,	   we	   sought	   to	   determine	   whether	  
physiological	   concentrations	   of	   this	   heme-­‐iron	   source	   would	   support	   growth	   of	   S.	  
aureus	  in	  the	  absence	  of	  specific	  cell	  wall-­‐associated	  Isd	  proteins.	  To	  this	  end,	  wildtype	  
S.	   aureus	   Newman	   and	   its	   isogenic	   isd	   knockout	   mutants	   were	   grown	   under	   iron-­‐
restriction	  and	  subcultured	  into	  media	  containing	  human	  hemoglobin	  at	  concentrations	  
ranging	   from	   5	   to	   100	   nM.	   Under	   our	   growth	   conditions,	   5	   nM	   hemoglobin	   was	  
insufficient	   to	   support	   growth	   of	   any	   strain,	   with	   the	   exception	   of	   ΔisdA	   (H734)	  
complemented	  with	  pJS019,	  which	  exhibited	  minimal	  growth	  by	  36	  hours	   (Figure	  3.5)	  
The	   addition	   of	   10	   nM	   hemoglobin	   promoted	   growth	   of	   the	   wildtype	   and	  
complemented	   mutant	   strains	   but	   did	   not	   promote	   growth	   of	   ΔisdA	   (H734),	   ΔisdB	  
(H2735),	  or	  ΔisdC	  (H833).	  Increasing	  the	  hemoglobin	  concentration	  to	  20	  nM	  facilitated	  
more	   rapid	   and	   robust	   growth,	  where	   the	   isd	  mutants	  were	   still	   strongly	   deficient	   in	  
hemoglobin-­‐dependent	   growth	   relative	   to	   the	   wildtype.	   Consistent	   with	   previous	  
findings,	   and	   our	   hypothesis	   that	   Isd	   has	   utility	   at	   low	   heme-­‐iron	   concentrations,	  
hemoglobin	  at	  concentrations	  at	  or	  above	  100	  nM	  promoted	   the	  growth	  of	  all	   strains	  
and	   reduced	   discernible	   differences	   between	   the	   wildtype	   and	   isd	   knockout	   strains	  
(Figure	  3.5).	  The	  preceding	  observations	  suggest	  that	  an	  alternate	  lower	  affinity	  heme-­‐
iron	  acquisition	  system	  likely	  exists	   in	  S.	  aureus,	  which	  masks	  the	  function	  of	  Isd	  when	  




Figure	  3.5.	  Isd	  exhibits	  utility	  at	  low	  nanomolar	  concentrations	  of	  fresh	  hemoglobin.	  	  
Hemoglobin-­‐dependent	  growth	  of	  S.	  aureus	  Newman	  WT,	  its	  isogenic	  isd	  mutants,	  and	  
corresponding	  complemented	  strains.	  Strains	  were	  cultured	  in	  RPMI	  chelated	  with	  1	  μM	  
EDDHA	  and	  5,	  10,	  20,	  or	  100	  nM	  of	  human	  hemoglobin	  was	  supplied	  as	  the	  sole	  source	  
of	  iron.	  Culture	  densities	  were	  assessed	  at	  12,	  24,	  and	  36	  h	  by	  determining	  OD600.	  Data	  
shown	  are	  representative	  of	  at	  least	  3	  experiments,	  where	  samples	  were	  performed	  in	  
quintuplicate	  and	  error	  bars	   represent	   standard	  error	  of	   the	  mean.	   Statistical	   analysis	  
was	   performed	   using	   a	   2-­‐way	   analysis	   of	   variance	   coupled	   with	   Bonferroni	   post	   hoc	  




3.3.4. Mutation	  of	  dtpT	  results	  in	  a	  minor	  growth	  defect	  on	  heme	  	  
With	  a	  newly	  established	  protocol	   for	  more	  thoroughly	  assessing	  heme-­‐iron	  utilization	  
in	  the	  staphylococci,	  we	  next	  turned	  our	  attention	  to	  addressing	  the	  hypothesis	  that	  the	  
low	   affinity	   acquisition	   of	   heme	   in	   S.	   aureus	   occurs	   by	   way	   of	   the	   di-­‐/tri-­‐peptide	  
permease,	   DtpT	   (47).	   As	   discussed	   in	   the	   Introduction	   of	   this	   chapter,	   peptide	  
permeases	  facilitate	  heme	  acquisition	  in	  E.	  coli	  and	  H.	  influenzae	  (44,	  45),	  a	  function	  not	  
yet	  investigated	  for	  dtpT	  in	  the	  staphylococci.	  To	  investigate	  the	  potential	  role	  of	  dtpT	  in	  
S.	   aureus,	   USA300	   and	   its	   isogenic	   dtpT::ΦNΣ	   (H2875)	   and	   dtpT::ΦNΣ	   ΔisdA	   (H2979)	  
mutants	   were	   assessed	   for	   growth	   in	   RPMI	   chelated	   with	   1	   μM	   EDDHA	   and	  
supplemented	   with	   heme	   at	   concentrations	   of	   20,	   50,	   100,	   200	   and	   500	   nM.	   As	  
illustrated	  in	  Figure	  3.6,	  while	  20	  nM	  heme	  did	  not	  support	  appreciable	  growth	  of	  any	  
strain,	  both	  the	  wildtype	  and	  mutant	  strains	  grew	  robustly	  at	  concentrations	  of	  heme	  at	  
and	  above	  50	  nM.	  While	  the	  dtpT::ΦNΣ	  exhibited	  significantly	  reduced	  growth	  relative	  
the	  wildtype	  at	  50	  nM	  heme,	  and	  an	  overall	  trend	  towards	  slightly	  reduced	  growth	  at	  all	  
heme	   concentrations,	   this	   defect	   was	   only	   apparent	   at	   12	   h.	   The	   dtpT::ΦNΣ	   ΔisdA	  
double	  mutant	  was	  further	  impaired	  for	  growth	  on	  50	  and	  100	  nM	  heme	  relative	  to	  the	  
wildtype,	   however,	   this	   minor	   reduction	   in	   growth	   was	   not	   significant	   relative	   to	  
dtpT::ΦNΣ	  alone,	  suggesting	  that	  the	  growth	  deficiency	  was	  largely	  due	  to	  dtpT.	  Indeed,	  
complementation	   of	   both	   dtpT::ΦNΣ	   and	   dtpT::ΦNΣ	   ΔisdA	   with	   dtpT	   constitutively	  
expressed	  in	  trans	  from	  the	  plasmid	  pJC01	  restored	  growth	  relative	  to	  wildtype,	  and	  this	  
overexpression	  of	  dtpT	  appeared	  to	  slightly	  enhance	  growth	  on	  100	  and	  200	  nM	  heme	  




Figure	  3.6.	  Inactivation	  of	  dtpT	  reduces	  but	  does	  not	  abolish	  growth	  on	  heme.	  	  
Heme-­‐dependent	  growth	  of	  S.	  aureus	  USA300	  wildtype	  (WT),	  its	  isogenic	  dtpT	  and	  dtpT	  
isdA	  mutants,	  and	  corresponding	  complemented	  strains.	  Strains	  were	  cultured	  in	  RPMI	  
chelated	  with	  1	  μM	  EDDHA	  and	  20,	  50,	  100,	  200,	  or	  500	  nM	  heme	  was	  supplied	  as	  the	  
sole	   source	   of	   iron.	   Culture	   densities	  were	   assessed	   at	   12	   and	   24	   h	   (top	   and	   bottom	  
panels,	  respectively)	  by	  determining	  OD600.	  Data	  shown	  are	  representative	  of	  at	  least	  3	  
experiments,	   where	   samples	   were	   performed	   in	   triplicate	   and	   error	   bars	   represent	  
standard	  error	  of	  the	  mean.	  Statistical	  analysis	  was	  performed	  using	  a	  2-­‐way	  analysis	  of	  
variance	   coupled	   with	   Bonferroni	   post	   hoc	   tests	   where	   the	   wildtype	   was	   set	   as	   the	  
comparator;	  a,	  P	  <	  .0001;	  b,	  P	  <	  .001,	  c,	  P	  <	  .01,	  and	  d,	  P	  <	  0.05.	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heme	  utilization	  in	  S.	  aureus,	  the	  failure	  of	  the	  combinatorial	  deletion	  of	  dtpT	  and	  isdA	  
to	  abolish	  growth	  on	  heme	  as	  a	  sole	  iron	  source	  suggests	  that	  dtpT	  is	  not	  a	  low-­‐affinity	  
heme	  permease.	  
3.3.5. Identification	   of	   oligopeptide	   permease	   loci	   in	   USA300	   and	   generation	   of	  
isogenic	  mutants	  
In	  addition	  to	  dtpT,	  five	  other	  loci	  have	  previously	  been	  identified	  as	  putative	  OPPs	  in	  S.	  
aureus	   (47).	   As	   disruption	   of	   dtpT	   and	   isdA	   together	   failed	   to	   eliminate	   growth	   of	   S.	  
aureus	  on	  heme	  as	  a	   sole	   iron	   source,	  we	   reasoned	   that	  one	  of	   these	  other	  potential	  
permeases	  might	   also	   function	   in	   heme	   acquisition.	   To	   investigate	   this	   possibility,	  we	  
identified	   these	   five	   loci	   in	   S.	   aureus	   USA300	   FPR3757	   based	   on	   DNA	   sequence	  
homology	   to	   those	   found	   in	  NCTC8325	   (each	  with	  ≥	  99%	  similarity),	   comprised	  of	   the	  
following:	  opp1ABCDF	  (SAUSA300_2711	  to	  2707,	  and	  the	  co-­‐transcribed	  putative	  major	  
facilitator	  superfamily	  efflux	  protein,	  NorD)	  (52);	  opp2BCDF	  (SAUSA300_1276	  to	  1273),	  
and	   its	   independently	   encoded	   SBP	   opp5A	   (SAUSA300_0231);	   opp3BCDFA	  
(SAUSA300_0887	   to	   0891)	   and	   opp4AFDBC	   (SAUSA300_0892	   to	   0896),	   which	   are	  
encoded	  within	  212	  bp	  of	  each	  other.	  Bioinformatic	  analyses	  also	  revealed	  a	  previously	  
unrecognized	  putative	  OPP	   in	  both	  NCTC8325	  and	  USA300	   (SAUSA300_0200	  to	  0203),	  
designated	   oppU	   (for	   unknown,	   Figure	   3.7).	   Unlike	   other	   OPPs,	   a	   single	   ATPase	   is	  
encoded	  in	  proximity	  to	  but	  divergently	  transcribed	  from	  the	  purported	  SBP	  and	  integral	  
transmembrane	  proteins	  of	  opp;	   interestingly,	   this	   gene	   (SAUSA300_0200)	   appears	   to	  





Figure	  3.7.	  Genomic	  context	  and	  organization	  of	  the	  peptide	  permease	  operons	  in	  S.	  
aureus	  USA300.	  	  
The	  ID	  for	  the	  first	  applicable	  gene	  of	  each	  peptide	  permease	  locus	  in	  USA300	  FPR3757	  
is	  indicated.	  Grey	  stripes,	  substrate-­‐binding	  protein	  (A);	  white,	  permease	  component	  (B	  
and	   C);	   grey,	   ATPase	   (D	   and	   F);	   black,	   unrelated	   and/or	   uncharacterized	   gene;	   HP,	  
hypothetical	   protein;	   norD,	   putative	   major	   facilitator	   superfamily	   efflux	   pump;	   ggt,	  
putative	  gamma-­‐glutamyl	  transpeptidase.	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  amino	   acid	   identity;	   58.5%	   similarity).	   As	   with	   S.	   aureus	   NCTC8325,	   and	   as	  
demonstrated	  in	  Figure	  3.7,	  poor	  conservation	  exists	  both	  in	  the	  organization	  of	  the	  opp	  
operons,	  as	  well	   as	   in	   their	  amino	  acid	   sequences,	  particularly	   in	   the	  case	  of	   the	  SBP,	  
which	  bear	  an	  overall	  identity	  of	  19%	  (transmembrane	  proteins,	  24%;	  ATPases,	  32%;	  see	  
Tables	  S1	  to	  S3	  in	  Appendix	  1	  for	  details).	  Whilst	  no	  conclusions	  can	  be	  drawn	  based	  on	  
amino	   acid	   sequence	   similarity	   alone,	   it	   is	   reasonable	   to	   speculate	   that	   this	   lack	   of	  
conservation	   reflects	  differences	   in	   substrate	   recognition,	   although	   this	  has	  been	  only	  
preliminarily	  investigated	  in	  S.	  aureus	  (47,	  49,	  69).	  
	   	  In	  our	  effort	  to	  characterize	  the	  role	  of	  the	  above	  OPPs	  in	  heme	  acquisition,	  we	  
opted	   to	   pursue	   this	   endeavor	   in	   S.	   aureus	   USA300,	   instead	   of	  Newman	   (as	  with	   the	  
characterization	  of	  isd),	  the	  reasons	  of	  which	  were	  threefold.	  Firstly,	  S.	  aureus	  Newman	  
possesses	   a	   revertible	   point	   mutation	   in	   the	   sensor	   histidine	   kinase	   of	   the	   S.	   aureus	  
exoprotein	   expression	   two-­‐component	   regulatory	   system,	   sae,	   which	   results	   in	  
constitutive	   expression	   of	   the	   operon	   and	   associated	   virulence	   factors	   (70).	   The	  
aforementioned	   mutation	   may	   revert	   upon	   serial	   culturing	   during	   mutagenesis	  
procedures,	   confounding	   the	   interpretation	   of	   results,	   particularly	   with	   respect	   to	   in	  
vivo	  survival	  and	  virulence.	  Secondly,	  USA300	  is	  now	  endemic	   in	  most	  populous	  areas,	  
and	   a	   serious	   burden	   on	   healthcare	   communities	   worldwide	   (71,	   72),	   and	   thus	  
represents	   a	   topical	   and	   clinically	   relevant	  model	   organism,	   and	   thirdly	   (and	   possibly	  
relatedly),	   USA300	   is	   known	   to	   possess	   an	   additional	   operon	   annotated	   as	   an	   OPP,	  
encoded	   from	   within	   the	   ACME	   cassette	   	   (ACME-­‐oppABCDF;	   USA300_0073	   to	   0077,	  
Figure	  3.7),	  whose	  function	  is	  currently	  unknown.	  	  	  
	  	  
216	  
	   To	   investigate	   the	   role	   of	   the	   supposed	   peptide	   permeases,	   including	   ACME-­‐
oppABCDF	   (ACME-­‐opp),	   in	   heme	   acquisition	   necessitated	   the	   inactivation	   of	   each	   of	  
their	  seven	  encoding	  loci.	  Single,	  markerless	  deletion	  mutants	  were	  generated	  for	  each	  
opp1,	  opp2,	  opp5A	  and	  oppU	   (as	  well	  as	  dtpT)	   in	  S.	  aureus	  USA300.	   	  Due	  to	   the	  close	  
proximity	  of	  opp3	  and	  opp4	  in	  the	  genome,	  these	  loci	  were	  knocked	  out	  simultaneously	  
in	  a	  single	  deletion	  mutant,	  whereas	  the	  gene	  encoding	  the	  SBP	  for	  ACME-­‐opp	  (ACME-­‐
oppA)	   was	   disrupted	   through	   transposon	  mutagenesis.	   In	   the	   case	   of	   each	   opp1	   and	  
oppU,	  the	  mutations	  generated	  left	  the	  promoter,	  frame,	  and	  downstream	  gene	  (norD	  
and	  ggt,	  respectively)	  intact.	  Successful	  disruption	  of	  each	  locus	  was	  confirmed	  through	  
PCR	   and	   DNA	   sequencing	   (data	   not	   shown).	   	   To	   avoid	   confounding	   effects	   due	   to	  
possible	   functional	   redundancy	  between	  these	  transporters,	  we	  generated	  a	  complete	  
peptide	   permease-­‐deficient	   strain	   of	   S.	   aureus,	   by	   sequentially	   introducing	   each	  
individual	   mutation	   to	   USA300,	   as	   described	   in	   detail	   in	   the	  Materials	   and	  Methods,	  
generating	   the	   septuple	   mutant	   USA300	   Δopp1,	   opp2,	   opp3-­‐4,	   opp5A,	   dtpT,	   oppU,	  
ACME-­‐oppA::ΦNΣ	   (H3310).	  To	  account	   for	   the	  minor	   role	  of	  dtpT	   in	  heme	  acquisition,	  
we	   opted	   to	   introduce	   dtpT	   to	   the	   complete	   deletion	   mutant	   last,	   such	   that	   the	  
preceding	   strain	   has	  dtpT	   intact	   (H3308;	   USA300	  Δopp1,	   opp2,	   opp3-­‐4,	   opp5A,	   oppU,	  
ACME-­‐oppA::ΦNΣ)	  and	  can	  serve	  as	  a	  comparator	  to	  H3310.	  
3.3.6. Peptide	   permease-­‐deficient	   S.	   aureus	   mutants	   have	   no	   appreciable	   deficit	  
for	  heme-­‐iron	  acquisition	  
With	   individual	   and	   combined	   peptide	   permease	   mutants,	   along	   with	   the	   complete	  
peptide	  permease-­‐deficient	  USA300	  strain	  at	  our	  disposal,	  we	  were	  poised	  to	  assess	  the	  
	  	  
217	  
potential	   role	   of	   these	   transporters	   in	   heme-­‐iron	   acquisition	   in	   S.	   aureus.	   Using	   the	  
methodology	  derived	  above,	  we	  assessed	  the	  growth	  of	  H3310	  (complete	  OPP	  mutant	  
along	  with	  ΔdtpT)	  relative	  to	  both	  H3308	  (complete	  OPP	  mutant	  with	  dtpT	   intact)	  and	  
wildtype	  USA300	   in	  RPMI	  chelated	  with	  1	  μM	  EDDHA	  and	  supplemented	  with	  various	  
concentrations	  of	  heme	  or	  human	  hemoglobin	   supplied	  as	  a	   sole	   iron	   source.	  Though	  
devoid	   of	   all	   identified	   peptide	   permeases,	   we	   found	   that	   H3310	   was	   no	   further	  
debilitated	  for	  the	  acquisition	  of	  heme	  than	  H3308,	  nor	  was	  any	  defect	  in	  hemoglobin-­‐
dependent	   growth	   observed	   (data	   not	   shown).	   In	   spite	   of	   our	   hypothesis	   to	   the	  
contrary,	  the	  preceding	  results	  suggest	  that	  none	  of	  the	  aforementioned	  permeases	  are	  
involved	  in	  the	  acquisition	  of	  heme-­‐iron	  in	  S.	  aureus	  USA300.	  
3.3.7. DtpT	  is	  a	  bona	  fide	  di-­‐/tri-­‐peptide	  permease	  
As	  the	  role	  of	  dtpT,	  insofar	  as	  heme-­‐iron	  acquisition	  is	  concerned,	  appears	  to	  be	  minor	  
and	  perhaps	   inconsequential,	  we	  next	   sought	   to	  verify	   its	   function	  as	  a	   transporter	  of	  
peptides.	   DtpT	   in	   S.	   aureus	   RN6390	   (a	   derivative	   of	   NCTC8325)	   was	   previously	  
implicated	  in	  the	  uptake	  of	  both	  di-­‐	  and	  tri-­‐peptides,	  and	  indeed	  was	  shown	  to	  be	  the	  
dedicated	   permease	   of	   the	   former	   in	   this	   strain	   (47).	   Peptide	   acquisition	   in	   USA300,	  
however,	  has	  not	  yet	  been	  interrogated,	  and	  in	  particular,	  it	  is	  not	  known	  if	  ACME-­‐OPP	  
exhibits	  functional	  redundancy	  with	  any	  of	  the	  previously	  described	  peptide	  permeases,	  
including	   dtpT.	   To	   address	   some	   of	   these	   outstanding	   questions,	   we	   utilized	   our	  
previously	   constructed	   H3310	   strain	   to	   elucidate	   the	   function	   of	   dtpT	   in	   di-­‐	   and	   tri-­‐
peptide	   acquisition	   relative	   to	   wildtype	   and	   H3308	   (complete	   OPP	  mutant	   with	   dtpT	  
intact).	  In	  order	  to	  evaluate	  the	  ability	  of	  these	  strains	  to	  utilize	  peptides	  as	  a	  source	  of	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essential	  amino	  acids,	  we	   first	  determined	   the	  amino	  acid	  auxotrophies	  of	  USA300	  by	  
assessing	  the	  24	  h	  endpoint	  growth	  of	  the	  wildtype	  in	  20	  variants	  of	  CDM,	  each	  lacking	  
an	  individual	  amino	  acid.	  We	  confirmed	  that	  USA300	  is	  auxotrophic	  for	  proline,	  arginine,	  
and	   cysteine	   (See	   Figure	   S1,	   Appendix	   2).	   With	   this	   information	   in	   hand,	   we	   then	  
assessed	  growth	  of	  the	  aforementioned	  strains	  over	  a	  24	  h	  period	  in	  CDM	  lacking	  free	  
proline	  (CDM-­‐Pro)	  or	  CDM-­‐Pro	  supplemented	  with	  di-­‐	  or	  tri-­‐	  peptides	  (Phe-­‐Pro	  and	  Tyr-­‐
Pro,	  and	  Ala-­‐Pro-­‐Ala,	  respectively)	  at	  various	  concentrations	  (2	  mM	  in	  2-­‐fold	  dilutions	  to	  
0.0078	  mM)	  as	  a	  sole	  source	  of	  proline.	  As	  shown	  in	  Figure	  3.8,	  while	  strains	  with	  dtpT	  
intact	  (wildtype	  and	  H3308)	  were	  capable	  of	  robust	  growth	  on	  Phe-­‐Pro	  concentrations	  
at	   or	   above	   0.015625	   mM,	   the	   strain	   bearing	   inactivated	   dtpT	   (H3310)	   was	   severely	  
impaired	   for	   growth	   on	   the	   highest	   concentration	   of	   dipeptide	   tested	   (2	   mM)	   and	  
incapable	   of	   growth	   on	   concentrations	   at	   or	   below	   0.5	   mM.	   Similar	   results	   were	  
obtained	  using	  the	  peptide	  Tyr-­‐Pro	  (data	  not	  shown).	  Although	  only	  two	  dipeptides	  have	  
been	  tested	  thus	  far,	  these	  results	  strongly	  suggest	  that	  dtpT	  is	  the	  primary	  transporter	  
of	  this	  substrate	  in	  USA300.	  In	  contrast,	  the	  absence	  of	  dtpT	  did	  not	  abolish	  growth	  on	  
any	   concentration	  of	   tripeptide,	   and	  a	   significant	   growth	  defect	  was	  only	   apparent	   at	  
concentrations	   at	   or	   below	  0.0625	  mM	  Ala-­‐Pro-­‐Ala	   relative	   to	   strains	   expressing	  dtpT	  
(wildtype	   and	   H3308,	   see	   Figure	   3.9).	   	   Interestingly,	   while	   opp3	   has	   previously	   been	  
implicated	  in	  tripeptide	  acquisition	  in	  S.	  aureus	  RN6390,	  at	  least	  with	  regards	  to	  Ala-­‐Pro-­‐
Ala	  it	  appears	  that	  this	  transporter	  is	  not	  essential	  to	  tripeptide	  uptake	  in	  the	  absence	  of	  









Figure	  3.8.	  A	  dtpT	  mutant	  is	  severely	  impaired	  for	  growth	  on	  dipeptides	  as	  a	  sole	  
source	  of	  essential	  amino	  acids.	  	  
Growth	   curves	   (in	   a	   Bioscreen	   C	  machine)	   of	   S.	   aureus	  USA300	  wildtype	   (WT;	   closed	  
circles),	   USA300	   Δopp1,	   opp2,	   opp3-­‐4,	   opp5A,	   oppU,	   ACME-­‐oppA::ΦNΣ	   (H3308,	   dtpT	  
intact;	   open	   triangles)	   and	   USA300	   Δopp1,	   opp2,	   opp3-­‐4,	   opp5A,	   dtpT,	   oppU,	   ACME-­‐
oppA::ΦNΣ	   (H3310,	   Δdtp;	   open	   squares)	   in	   CDM-­‐Pro	   supplemented	   with	   various	  
concentrations	  of	  the	  dipeptide	  Phe-­‐Pro,	  as	  indicated.	  Data	  shown	  are	  representative	  of	  
at	   least	   3	   experiments,	   where	   samples	   were	   performed	   in	   triplicate	   and	   error	   bars	  














Figure	  3.9.	  A	  dtpT	  mutant	  is	  impaired	  for	  growth	  on	  low	  concentrations	  of	  tripeptides	  
as	  a	  sole	  source	  of	  essential	  amino	  acids.	  	  
Growth	   curves	   (in	   a	   Bioscreen	   C	  machine)	   of	   S.	   aureus	  USA300	  wildtype	   (WT;	   closed	  
circles),	   USA300	   Δopp1,	   opp2,	   opp3-­‐4,	   opp5A,	   oppU,	   ACME-­‐oppA::ΦNΣ	   (H3308,	   dtpT	  
intact;	   open	   triangles)	   and	   USA300	   Δopp1,	   opp2,	   opp3-­‐4,	   opp5A,	   dtpT,	   oppU,	   ACME-­‐
oppA::ΦNΣ	   (H3310,	   Δdtp;	   open	   squares)	   in	   CDM-­‐Pro	   supplemented	   with	   various	  
concentrations	   of	   the	   tripeptide	   Ala-­‐Pro-­‐Ala,	   as	   indicated.	   Data	   shown	   are	  
representative	   of	   at	   least	   3	   experiments,	  where	   samples	  were	  performed	   in	   triplicate	  






this	  tripeptide	  as	  a	  sole	  source	  of	  proline.	  	  Further,	  it	  similarly	  appears	  that	  ACME-­‐opp	  is	  
not	  essential	   to	   tripeptide	  uptake.	   	  The	  aforementioned	  growth	  defects	   for	  dtpT	  were	  
shown	   to	   be	   proline-­‐dependent,	   as	   replacing	   peptides	   in	   the	   media	   with	   equivalent	  
concentrations	  of	  free	  proline	  supported	  growth	  of	  all	  strains	   in	  a	  manner	  comparable	  
to	  wildtype	   (data	   not	   shown).	   Together	   these	   preliminary	   results	   suggest	   that	  dtpT	   is	  
likely	  the	  dedicated	  transporter	  of	  dipeptides	   in	  USA300,	  and	  contributes	  to	  tripeptide	  
utilization,	   however	   it	   appears	   that,	   as	  with	   heme,	   an	   as	   yet	   unidentified	   transporter	  
exists	  for	  uptake	  of	  the	  latter.	  
3.4. DISCUSSION	  
Numerous	  studies	  published	  over	  the	  past	  decade	  have	  assigned	  functions	  to	  individual	  
Isd	  components	  relating	  to	  the	  extraction,	  binding,	  import,	  and	  cytosolic	  degradation	  of	  
heme	   (5,	   11,	   12,	   16–19,	   21–24,	   73–79).	   However,	   this	   wealth	   of	   knowledge	   on	   the	  
contribution	   of	   Isd	   to	   heme-­‐iron	   acquisition	   was	   recently	   contested	   by	   two	   reports,	  
based	  on	  the	  failure	  of	  isd	  mutants	  to	  demonstrate	  growth-­‐defective	  phenotypes	  when	  
grown	  on	  heme	  or	  hemoglobin	   as	   a	   sole	   iron	   source	   (32,	   33).	   Specifically,	  Hurd	  et	   al.	  
(2012)	   reported	   that	   IsdA,	   IsdB,	   and	   IsdH	   are	   not	   required	   for	   the	   acquisition	   of	   iron	  
from	   heme	   or	   hemoglobin,	   whereas	   Wright	   and	   Nair	   (2012)	   argued	   that	   IsdE	   is	  
dispensable	   for	   the	   acquisition	   of	   iron	   from	   heme.	   We	   suggest	   that	   the	   incongruity	  
between	   these	   reports,	   and	   the	   abundant	   data	   implicating	   the	   Isd	   in	   heme-­‐iron	  
acquisition,	  stems	  from	  the	  utility	  of	  the	  Isd	  system	  at	  low	  extracellular	  concentrations	  
of	  heme/hemoglobin	  that	  were	  not	  used	  in	  these	  two	  studies.	  Indeed	  we	  demonstrate	  




high	  concentrations	  of	  heme	  (500	  nM)	  as	  a	  sole	  iron	  source	  (Figure	  3.3).	  Further,	  both	  of	  
the	  aforementioned	  studies	  utilized	  hemoglobin	  reconstituted	   from	  a	   lyophilized	  state	  
which,	  relative	  to	  hemoglobin	  purified	  from	  fresh	  blood,	  appears	  as	  a	  diffuse	  smear	  on	  
native	   gels	   (Figure	   3.4A)	   and	   exhibits	   hallmarks	   of	   degradation	   in	   its	   UV-­‐Vis	   spectral	  
profile	  (Figure	  3.4B);	  thus,	   it	   is	   likely	  that	  these	  reconstituted	  hemoglobin	  preparations	  
also	   contain	   a	   substantial	   amount	   of	   free	   dissociated	   heme,	   a	   contention	   that	   is	  
supported	   by	   the	   appearance	   of	   a	   blue-­‐shifted	   shoulder	   on	   the	   Soret	   peak	   of	  
reconstituted	  hemoglobin	  observed	  using	  UV-­‐Vis	  spectroscopy	  (Figure	  3.4B)	  (67,	  68,	  80).	  
Our	   data	   suggest	   that	   Isd	   is	   a	   high	   affinity	   heme-­‐iron	   acquisition	   system	   that	   has	  
maximal	   utility	   at	   low	   nanomolar	   concentrations	   of	   heme/hemoglobin	   (Figure	   3.5),	  
consistent	  with	   the	   predicted	   physiological	   concentrations	   of	   free	   heme	   and	   cell-­‐free	  
plasma	  hemoglobin	  of	  30	  nM	  and	  150	  nM,	  respectively	  (10,	  81).	  The	  role	  of	  isd	  in	  heme-­‐
iron	  acquisition	  may	  therefore	  be	  masked	  by	  a	  hypothesized	  lower	  affinity	  system	  when	  
heme-­‐iron	  sources	  are	  applied	  in	  excess.	  	  
	   In	   this	   Chapter,	   we	   also	   investigated	   the	   possibility	   that	   a	   putative	   peptide	  
permease	  may	  function	  as	  the	  purported	  alternate	  heme	  uptake	  pathway	  in	  S.	  aureus,	  
as	  even	  isd	  mutants	  grow	  on	  heme	  as	  a	  sole	  iron	  source	  at	  and	  above	  concentrations	  of	  
approximately	   50	   nM	   (Figure	   3.5).	   As	   discussed	   previously,	   this	   notion	   is	   not	  without	  
precedence,	   as	   heme	   has	   been	   reported,	   or	   proposed,	   as	   the	   substrate	   of	  
multifunctional	  peptide	  permeases	   in	  other	  bacteria	  (44,	  46,	  82–84).	  Unlike	  E.	  coli	  and	  
H.	  influenzae,	  however,	  it	  appears	  that	  peptide	  permeases	  do	  not	  play	  a	  significant	  role	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in	  heme-­‐iron	  acquisition	  in	  S.	  aureus.	  While	  a	  minor	  growth	  defect	  was	  observed	  for	  S.	  
aureus	  inactivated	  for	  dtpT	  when	  heme	  was	  supplied	  as	  a	  sole	  iron	  source	  (Figure	  3.6),	  
the	   restricted	   nature	   of	   this	   phenotype	   (only	   apparent	   at	   12	   h	   on	   50-­‐100	   nM	   heme)	  
raises	   questions	   of	   its	   biological	   relevance.	   However,	   it	   is	   possible	   that	   under	   the	  
conditions	  tested,	  dtpT	  was	  not	  maximally	  expressed	  and	  that	   the	  difference	  between	  
the	   wildtype	   and	   dtpT	  mutant	  may	   be	   exacerbated	   in	   other	   circumstances,	   including	  
infectious	  niches	  within	  the	  host,	   the	   latter	  of	  which	  has	  not	  yet	  been	   investigated.	   In	  
terms	   of	   the	   regulation	   of	   peptide	   permeases,	   the	   availability	   of	   specific	   nitrogenous	  
sources	   such	   as	   peptides,	   aromatic	   amino	   acids,	   and	   branched-­‐chain	   amino	   acids	  
(BCAAs)	   is	  known	  to	  alter	   their	  expression	  (47,	  85–87).	   In	  S.	  aureus,	  BCAAs	  are	  known	  
effectors	   of	   the	   global	   transcriptional	   regulator,	   CodY	   which,	   under	   nutrient	   replete	  
conditions,	  together	  function	  to	  inhibit	  transcription	  of	  over	  100	  genes,	  many	  of	  which	  
are	  thought	  to	  function	  in	  amino	  acid	  transport	  and	  metabolism	  (86,	  88–93).	  Although	  
CodY	  was	   initially	   identified	  as	  a	  regulator	  of	  a	  dipeptide	  permease	   in	  Bacillus	  subtilus	  
(hence	   the	   name	   control	   of	   dciA,	   a	   dipeptide	   transport	   complex)	   (94–96),	   CodY	  
regulation	  of	  dtpT	   in	  S.	  aureus	  has	  not	  been	  specifically	   interrogated.	   If	  dtpT	   is	   indeed	  
regulated	  by	  CodY,	  it	  is	  possible	  that	  limiting	  the	  concentration	  of	  BCAAs	  in	  the	  culture	  
medium,	   or	  mutation	   of	   codY,	  may	   enhance	  dtpT	   transcription,	   and	   hence	   heme-­‐iron	  
acquisition,	   in	  S.	  aureus.	   If	   the	  aforementioned	   is	   true,	   the	   in	  vivo	   importance	  of	  dtpT	  
will	   likely	   be	   proven	   during	   colonization	   of	   the	   nose.	   Indeed,	   Peschel	   and	   colleagues	  
recently	  showed	  that	  nasal	  secretions	  are	  limited	  in	  their	  concentrations	  of	  BCAAs	  (97).	  
Using	   a	   nasal	   colonization	   mouse	   model,	   we	   will	   be	   investigating	   the	   colonization	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potential	  of	   the	  dtpT	  mutant.	   Further,	   it	   is	  possible	   that	   the	  expression	  of	  dtpT	   is	  not	  
iron-­‐dependent,	  and	  that	  it	  functions	  in	  the	  acquisition	  of	  heme	  not	  as	  an	  iron	  source,	  
but	  rather	  for	  utilization,	  intact,	  as	  a	  cofactor;	  thus,	  DtpT	  may	  have	  utility	  in	  iron-­‐replete	  
conditions	  not	  assessed	  in	  this	  study.	  Indeed,	  as	  highlighted	  by	  the	  contention	  over	  the	  
function	   of	   Isd	   in	   heme-­‐iron	   acquisition,	   more	   rigorous	   testing	   is	   required	   before	  
decisively	  discounting	  dtpT	  as	  a	  legitimate	  heme	  permease.	  
	   While	  DtpT	  may	  yet	  have	  a	  role	  identified	  in	  heme-­‐iron	  acquisition,	  it	  is	  evident	  
from	  the	  ability	  of	  the	  dtpT	  isdA	  double	  mutant	  to	  thrive	  on	  heme	  as	  a	  sole	  iron	  source	  
(minor	   growth	   defect	   aside),	   that	   dtpT	   is	   not	   essential	   to	   heme-­‐iron	   acquisition	   in	   S.	  
aureus.	  Further,	  none	  of	  the	  staphylococcal	  OPPs	  assessed	  in	  this	  study	  including	  opp1,	  
opp5A/opp2,	   opp3,	   opp4,	  ACME-­‐opp,	   or	   the	   newly	   identified	   oppU,	   was	   found	   to	   be	  
deficient	   for	   the	   utilization	   of	   heme-­‐iron	   (data	   not	   shown).	   As	   previously	   detailed,	   S.	  
aureus	   lacks	  homologues	  to	  other	  known	  heme	  uptake	  pathways	  and,	   interestingly,	  to	  
date,	   no	   combination	   of	   mutations	   to	   heme	   acquisition	   loci	   in	   any	   Gram-­‐positive	  
pathogen	   has	   rendered	   a	   bacterium	   completely	   incapable	   of	   growth	   on	   high	  
concentrations	   of	   heme	   (4,	   98).	   These	   observations	   raise	   the	   possibility	   that	   no	  
alternate	  (i.e.	  non-­‐Isd)	  heme	  acquisition	  mechanism	  exists	   in	  S.	  aureus	  and	  that,	  when	  
present	   in	  excess,	  heme	   is	   internalized	   through	   receptor	   independent	   insertion	  of	   the	  
planar	  molecule	  into	  the	  cell	  membrane.	  Diffusion	  of	  heme	  across	  bacterial	  membranes,	  
however,	   has	   not	   been	   experimentally	   demonstrated	   and	   remains	   a	   matter	   of	  
considerable	  debate	  (99).	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   Although	   a	   role	   for	   DtpT	   in	   heme-­‐iron	   acquisition	   appears	   tenuous,	   the	  
preliminary	   characterization	  of	  DtpT	  performed	   in	   this	   Chapter	   reveals	   that	   it	   is	   likely	  
the	  predominant,	  if	  not	  sole,	  transporter	  of	  dipeptides,	  as	  well	  a	  verified	  transporter	  of	  
tripeptides,	  in	  S.	  aureus.	  In	  the	  absence	  of	  dtpT,	  S.	  aureus	  was	  incapable	  of	  growth	  on	  all	  
but	  the	  highest	  concentrations	  of	  dipeptides	  tested	  (Figure	  3.8).	  We	  speculate	  that	  the	  
limited	   growth	   of	   the	  dtpT	  mutant	   on	  millimolar	   concentrations	   of	   dipeptide	  may	   be	  
attributable	   to	   the	   presence	   of	   free	   amino	   acids	   in	   the	  media,	   as	   a	   result	   of	   peptide	  
degradation,	  that	  are	  taken	  up	  by	  the	  high-­‐affinity	  proline	  transporter,	  PutP	  (100–102).	  
Efforts	  are	  currently	  underway	  to	  investigate	  this	  possibility.	  In	  contrast,	  it	  appears	  that	  
an	   alternate	  unknown	   transporter	   exists	   for	   the	  uptake	  of	   tripeptides,	   as	  mutation	  of	  
dtpT,	   as	   well	   as	   all	   other	   OPPs,	   failed	   to	   abolish	   growth	   on	   any	   concentration	   of	  
tripeptide	   as	   a	   sole	   source	   of	   essential	   amino	   acids	   (Figure	   3.9).	   These	   findings	   are	  
contradictory	   to	   an	   earlier	   report,	   which	   suggested	   that	   dtpT	   and	   opp3	   alone	   are	  
responsible	  for	  the	  transport	  of	  tripeptides	   in	  S.	  aureus	  (47).	  No	  alternate	  transporter,	  
to	  date,	   has	  been	   identified,	   although	  one	  possibility	   is	   that	  disruption	  of	   the	   SBP	   for	  
ACME-­‐Opp	   through	   transposon	  mutagenesis	   failed	   to	   inactivate	   uptake	   of	   tripeptides	  
through	  the	  associated	  permease,	  which	  may	  function	  with	  an	  alternate	  unknown	  SBP.	  
To	   date,	   this	   is	   the	   first	   report	   investigating	   the	   function	   of	   ACME-­‐Opp,	   and	   further	  
investigation	   is	   required	   to	   address	   the	   aforementioned	   possibility.	   As	   S.	   aureus	   is	  
reportedly	  able	  to	  utilize	  DtpT	  and	  OPPs	  to	  acquire	  peptides	  of	  two	  to	  eight	  amino	  acids	  
in	  length	  (47),	  future	  efforts	  will	  focus	  on	  identifying	  the	  function	  and	  specificity	  of	  these	  
permeases	  with	   respect	   to	   oligopeptide	   acquisition.	   Indeed,	   as	  opp1,	   opp2,	   and	  dtpT	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have	   all	   been	   implicated	   in	   virulence,	   this	   study	   lays	   important	   groundwork	   towards	  
fully	  elucidating	  the	  role	  of	  peptide	  permeases	  in	  the	  acquisition	  of	  essential	  nutrients,	  
other	   than	   heme,	   that	  may	   contribute	   to	   the	   survival	   and	   pathogenicity	   of	   S.	   aureus	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Chapter	  4	  -­‐ CONCLUDING	  REMARKS	  AND	  FUTURE	  DIRECTIONS	  
4.1. OVERALL	  SUMMARY	  AND	  SIGNIFICANCE	  
A	  common	  theme	  arising	  from	  the	  past	  decade	  of	  research	  into	  the	  iron	  mechanisms	  of	  
bacterial	  pathogens	  is	  that	  these	  organisms	  are	  highly	  adept	  at	  acquiring	  this	  essential	  
nutrient	   from	   within	   the	   iron-­‐restricted	   host	   due	   not	   only	   to	   their	   ability	   to	   exploit	  
multiple	   host	   iron	   sources,	   but	   also	   by	   virtue	   of	   high	   levels	   of	   functional	   redundancy	  
between	   the	   systems	  employed	   (1–4).	   Indeed,	  as	  detailed	  extensively	   in	  Chapter	  1,	  S.	  
aureus	   employs	   a	   multitude	   of	   siderophore-­‐dependent	   uptake	   mechanisms,	   which	  
ultimately	   function	   in	   the	   acquisition	  of	   iron	   from	   serum	   transferrin.	   Two	   functionally	  
similar	   yet	   chemically-­‐distinct	   siderophores,	   staphyloferrins	   A	   and	   B	   (SA	   and	   SB),	   are	  
synthesized	  endogenously	  for	  the	  acquisition	  of	  iron	  directly	  from	  host	  glycoproteins	  (5–
8).	   The	   ferric	   hydroxamate	   uptake	   system,	   FhuCBG,	   employs	   two	   paralogous	   and	  
partially	   redundant	   substrate-­‐binding	   proteins	   (SBPs),	   FhuD1	   and	   FhuD2,	   in	   the	  
acquisition	   of	   iron	   from	   a	   diverse	   array	   of	   hydroxamate	   xenosiderophores	   (9–12).	  
SstABCD,	   a	   staphylococcal	   siderophore	   transporter,	   has	   specificity	   not	   only	   for	  
catecholate	   siderophores,	  but	  also	   for	   catecholamine	   stress	  hormones	   (13).	  While	   the	  
iron-­‐regulated	   surface	  determinant	  pathway	   (Isd)	   is	   the	   sole	   transporter	   identified,	   to	  
date,	  for	  the	  siderophore-­‐independent	  acquisition	  of	  heme-­‐iron	  (14,	  15),	  the	  ability	  of	  S.	  
aureus	  strains	  inactivated	  for	  Isd	  to	  utilize	  high	  concentrations	  of	  this	  source	  of	  iron	  to	  
support	   growth	   suggests	   that	   alternate	   means	   of	   uptake	   for	   this	   substrate	   (16–19).	  	  
Further,	  while	   it	   is	   not	   yet	   known	   how	   S.	   aureus	  acquires	   free	   ferrous	   iron,	   both	   the	  
highly	   conserved	   ferrous	   iron	   importer,	   FeoAB(C)	   and	   FepABC	   (Fe-­‐dependent	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peroxidase),	  have	  been	  implicated	  in	  this	  function	  (20–29).	  	  Thus,	  as	  summarized	  above,	  
for	  every	   iron	  source	  that	   is	  known	  to	  be	  or	   is	  ostensibly	  exploited	  by	  S.	  aureus,	  more	  
than	   one	   potential	   means	   of	   acquisition	   exists.	   Functional	   redundancy	   in	   systems	  
employed	   in	   the	   acquisition	   of	   essential	   nutrients	   is	   not,	   however,	   limited	   to	   iron.	  
Indeed,	  although	  characterization	  of	  these	  systems	  is	  yet	  in	  its	  infancy,	  and	  as	  described	  
in	  Chapter	  3,	  S.	  aureus	  also	  appears	  to	  elaborate	  multiple	  potential	  permeases	  for	  the	  
acquisition	  of	  peptides	  as	  a	  source	  of	  essential	  amino	  acids	  (30,	  31).	  
	   In	   this	   thesis,	   we	   began	   to	   dissect	   the	   functional	   overlap	   within	   both	  
siderophore-­‐dependent	  and	   siderophore-­‐independent	   iron	  acquisition	  mechanisms,	   as	  
well	   as	   peptide	  uptake	   systems	   in	  S.	   aureus.	  Whilst	   both	   the	  biosynthetic	   and	   import	  
pathways	  for	  SA	  and	  SB	  have	  been	  well-­‐characterized	  (13,	  32–38),	  and	  much	  is	  known	  
about	   the	   means	   by	   which	   Isd	   proteins	   extract,	   bind,	   and	   facilitate	   heme	   transfer	  
through	   direct	   protein-­‐protein	   interactions	   (18,	   19,	   39–44),	   relatively	   little	   is	   known	  
about	   the	   factors	   influencing	   the	   expression	   of	   these	   systems	   in	   vivo	   and	   how	   they	  
specifically	  relate	  to	  the	  pathophysiology	  of	  the	  bacterium.	  	  Similarly,	  while	  early	  studies	  
have	  identified	  multiple	  peptide	  permeases	  as	  being	  involved	  in	  nitrogen	  metabolism	  in	  
S.	  aureus	  (30,	  45),	  it	  is	  not	  yet	  known	  how	  the	  availability	  of	  specific	  nitrogenous	  sources	  
may	   alter	   the	   expression	   of	   these	   peptide	   permeases	   within	   the	   host.	   The	   research	  
performed	   in	  the	  preceding	  Chapters,	  and	  summarized	  briefly	  below,	  has	  substantially	  
enhanced	   our	   understanding	   of	   how	   the	   availability	   of	   key	   precursor	   molecules	   or	  
substrates	  may	  govern	  the	  expression	  and/or	  utility	  of	  specific	  acquisition	  pathways	  for	  
essential	  nutrients	  within	  the	  host.	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   As	  previously	  discussed,	  both	  SA	  and	  SB	  are	  α-­‐hydroxycarboxylate	  siderophores	  
that	   coordinate	   iron	   through	   citrate-­‐derived	  moieties.	   In	   Chapter	   2,	  we	   identified	   the	  
enzymatic	   sources	   of	   precursor	   citrate	   for	   the	   synthesis	   of	   both	   SA	   and	   SB.	   We	  
demonstrated	   that	   activity	   of	   the	   TCA	   cycle	   citrate	   synthase,	   CitZ,	   is	   essential	   to	   the	  
production	   of	   SA.	   In	   contrast,	   while	   CitZ	   may	   contribute	   to	   the	   production	   of	   SB,	  
synthesis	  of	  this	  siderophore	  is	  freed	  from	  reliance	  on	  central	  metabolism	  through	  the	  
activity	   of	   the	   novel	   iron-­‐regulated	   citrate	   synthase,	   SbnG	   (46,	   47).	  We	   thus	   identify	  
intracellular	  citrate	  availability	  as	  a	  fulcrum	  governing	  the	  elaboration	  of	  SA,	  but	  not	  SB.	  
	   Given	   that	   TCA	   cycle	   activity	   is	   inhibited	   under	   iron-­‐restriction	   and	   in	   the	  
presence	   of	   glucose,	   the	   dependence	   of	   SA	   biosynthesis	   on	   CitZ-­‐derived	   citrate	   has	  
significant	  implications	  for	  the	  expression	  of	  this	  siderophore	  in	  vivo.	  The	  concentration	  
of	  glucose	   in	  human	  blood	  is	  within	  the	  range	  found	  to	  be	   inhibitory	  to	  SA	  production	  
(48,	  49),	  suggesting	  that	  this	  siderophore	  is	  unlikely	  to	  be	  highly	  expressed	  in	  blood	  and	  
serum,	   and	   thus	   is	   not	   a	   likely	   contributor	   to	   iron	   acquisition	   during	   invasive	  
staphylococcal	  infections,	  such	  as	  bacteremia.	  Concentrations	  of	  iron	  and	  glucose	  on	  the	  
skin	  and	   in	  secretions,	  however,	  are	  more	   likely	  to	  be	  conducive	  to	  SA	  expression	  (48,	  
50–54),	   Indeed	  we	   demonstrate	   that	   expression	   of	   both	   SA	   and	   citZ	   are	   required	   for	  
maximal	   staphylococcal	   abscess	   formation	   in	   a	  murine	   skin	   infection	  model.	   Findings	  
from	   this	   thesis	   support	   the	   notion	   that	   SA	   may	   play	   an	   important	   role	   in	   iron	  
acquisition	  during	  skin	  colonization	  (and	  infection)	  in	  both	  the	  coagulase-­‐positive	  (CoPS)	  
and	  coagulase-­‐negative	  staphylococci	  (CoNS)	  in	  which	  it	  is	  expressed.	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   Unlike	  with	  SA,	  all	  of	  the	  precursors	  to	  SB	  synthesis	  appear	  to	  be	  readily	  available	  
within	   the	   iron-­‐restricted	  host,	   in	   the	  absence	  of	  TCA	  cycle	  activity,	   as	  detailed	   in	   the	  
model	   developed	   in	  Chapter	   2.	  As	   such,	  we	  would	   expect	   that	   SB	  plays	   a	   role	   in	   iron	  
acquisition	   during	   infections	   involving	   hematogenous	   spread,	   supported	   by	   the	  
observation	  that	  SB	  biosynthetic	  (sbn)	  and	  transport	  (sir)	  genes	  are	  upregulated	  in	  blood	  
and	   serum	   (55,	   56).	   A	   role	   for	   SB	   in	   severe	   and	   invasive	   staphylococcal	   infections	   is	  
further	   supported	   its	   narrow	   distribution	  within	   the	   often	   pathogenic	   CoPS.	   Together	  
these	  findings	  indicate	  that	  while	  seemingly	  functionally	  redundant,	  SA	  and	  SB	  likely	  are	  
expressed	   within	   specific	   host	   niches,	   and	   thus	   uniquely	   impact	   the	   survival	   and	  
pathogenicity	  of	  S.	  aureus	  within	  the	  host.	  
	   Despite	   the	   extensive	   in	   vitro	   characterization	   of	   the	   Isd	   pathway,	   two	   recent	  
studies	   contesting	   the	   role	   of	   Isd	   in	   heme-­‐iron	   acquisition	   prompted	   us	   to	   further	  
investigate	   the	   role	   of	   this	   pathway	   on	   the	   utilization	   of	   varying	   concentrations	   and	  
sources	  of	  heme-­‐iron	   (16,	  17).	   	   In	  Chapter	  3,	  we	  demonstrate	   that	   Isd	   is	   a	  biologically	  
relevant,	  high-­‐affinity	  heme-­‐iron	  acquisition	   system	   through	   its	  utility	  on	  physiological	  
concentrations	  of	  human	  hemoglobin.	  	  When	  heme	  is	  present	  in	  excess,	  the	  function	  of	  
Isd	   in	   heme-­‐iron	   acquisition	   is	   masked,	   suggesting	   that	   an	   alternate	   means	   of	   heme	  
uptake	  exists	  in	  S.	  aureus.	  The	  aforementioned	  findings	  help	  to	  reconcile	  differences	  in	  
the	   literature,	  where	   evaluation	  of	   Isd	   as	   a	   heme	  acquisition	   system	  has	   largely	   been	  
performed	   using	   supraphysiological	   concentrations	   of	   heme/hemoglobin	   (16,	   17).	  
Indeed,	  by	  utilizing	  the	  methodology	  developed	  in	  Chapter	  3,	  we	  were	  able	  not	  only	  to	  
demonstrate	   that	   Isd	   is	   required	   for	   the	   acquisition	   of	   nanomolar	   concentrations	   of	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heme-­‐iron	   in	   S.	   aureus,	   but	   also	   in	   the	   opportunistic	   pathogen	   Staphylococcus	  
lugdunensis	  (57).	  	  
	   In	   an	   effort	   to	   elucidate	   the	   alternate	   heme-­‐iron	   acquisition	   pathway	   in	   S.	  
aureus,	   we	   investigated	   the	   role	   of	   putative	   peptide	   permeases	   as	   low-­‐affinity	   heme	  
uptake	   systems.	   	  None	  of	   the	   putative	   oligopeptide	   permeases	   (OPPs)	   identified	   in	  S.	  
aureus	   appear	   function	   in	   heme-­‐iron	   acquisition,	   while	   the	   di-­‐/tri-­‐peptide	   permease	  
DtpT	  was	   found	   to	   exhibit	   a	  minor,	   yet	   reproducible,	   growth	   defect	  when	   heme	  was	  
supplied	  as	   a	   sole	   iron	   source,	   the	   significance	  of	  which	   is	  not	   yet	   known.	   	  DtpT	  was,	  
however,	  confirmed	  as	  the	  predominant,	  and	  likely	  sole,	  transporter	  of	  dipeptides,	  and	  
a	   genuine	   tripeptide	   permease,	   in	   S.	   aureus.	   	   The	   groundwork	   laid	   in	   Chapter	   3	   in	  
investigating	   the	   function	   of	   DtpT	   and	   the	   OPPs	   in	   heme-­‐iron	   acquisition	   will	   be	  
invaluable	  to	  identifying	  the	  substrates	  of	  these	  currently	  ill-­‐characterized	  permeases.	  	  
4.2. FUTURE	  DIRECTIONS	  
4.2.1. Investigating	   the	   function	   of	   redundancy	   in	   iron	   acquisition	   systems	  
throughout	  infection	  within	  the	  host	  
Future	  studies	  stemming	  from	  the	  research	  presented	  in	  this	  thesis	  will	  largely	  focus	  on	  
further	  elucidating	  factors	   influencing	  the	  expression	  of	  staphylococcal	   iron	  acquisition	  
systems	   in	   vivo	   and	   assessing	   how	   expression	   of	   these	   systems	   influences	   the	  
pathophysiology	  and/or	  pathogenic	  potential	  of	  the	  staphylococci.	   	  Our	   lab	   is	  uniquely	  
poised	   within	   Canada	   to	   assess	   factors	   contributing	   to	   staphylococcal	   pathogenicity,	  
with	   well-­‐developed	   methods	   for	   generating	   deletion	   mutants	   in	   the	   staphylococci,	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used	  extensively	   throughout	   this	   thesis,	   and	   six	  approved	  murine	  models	  of	   infection,	  
including	  systemic,	   intraperitoneal	  infection,	  skin	  colonization	  and	  cutaneous	  infection,	  
nasal	  colonization,	  and	  pneumonia.	  Further,	  with	  the	  forthcoming	  acquisition	  of	  an	  IVIS	  
in	  vivo	  imaging	  system,	  staphylococcal	  infections	  can	  be	  assessed	  non-­‐invasively	  in	  real-­‐
time	  using	  strains	  labeled	  with	  either	  bioluminescence	  (e.g.	  lux)	  or	  fluorescence	  (e.g.	  red	  
fluorescent	  protein)	  (58–60).	  Combining	  these	  resources	  with	  our	  unique	  and	  extensive	  
collection	  of	  S.	  aureus	  mutants,	  we	  hope	  to	  address	  the	  respective	  roles	  SA	  and	  SB	  play	  
in	  iron	  acquisition	  in	  specific	  host	  reservoirs,	  niches,	  and	  stages	  of	  infection.	  	  
	   Although	   in	   Chapter	   2	   we	   identify	   SA	   as	   contributing	   to	   the	   formation	   of	  
staphylococcal	  skin	  abscesses,	  it	  is	  not	  yet	  known	  if	  iron	  acquisition	  by	  this	  siderophore	  
facilitates	   colonization	   of	   the	   host.	   Elucidating	   this	   potential	   role	   of	   SA	   may	   be	  
particularly	   relevant	   in	   the	   CoNS,	   the	   vast	   majority	   of	   which	   express	   only	   SA	   as	   a	  
siderophore	   (37,	  61),	  and	  while	   found	  as	  common	  constituents	  of	   the	  skin	  microflora,	  
may	  act	  as	  opportunistic	  pathogens	   (62).	   	  Using	  SA-­‐deficient	   strains	  of	  both	  CoPS	  and	  
CoNS,	  and	  the	  skin	  and	  nasal	  colonization	  models	  described	  above,	  we	  may	  definitively	  
ascertain	   if	   SA	   contributes	   to	   staphylococcal	   survival	   on	   the	   skin	   and	   in	   the	   nares.	   As	  
described	   previously,	   colonization	   is	   major	   risk	   factor	   for	   subsequent	   staphylococcal	  
infection,	  yet	  relatively	  little	  is	  known	  about	  this	  pre-­‐infectious	  state.	  More	  broadly,	  by	  
using	   IVIS	   technology	   and	   strains	   deleted	   for	   either	   staphyloferrin,	   it	   may	   also	   be	  
possible	  to	   identify	  the	  specific	  host	  niches	   in	  which	  these	  siderophores	  are	  employed	  
by	  comparing	   localization	  of	   these	  mutants,	   relative	  to	  wildtype,	  during	  various	  stages	  
of	   infection.	   A	   detailed	   understanding	   of	   how	   redundancy	   in	   iron	   acquisition	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mechanisms	   serves	   the	   pathogen	   during	   the	   infectious	   process,	   as	   well	   in	   different	  
organs	   and	   tissues,	   will	   impact	   on	   the	   success	   of	   any	   future	   therapeutics	   targeting	  
aspects	  of	  iron	  acquisition.	  
4.2.2. Elucidating	  the	  function	  of	  the	  peptide	  permeases	  in	  S.	  aureus	  	  
Although	   the	   characterization	   of	   DtpT	   and	   the	   OPPs	   of	   S.	   aureus	   is	   in	   its	   preliminary	  
stages,	   the	   dtpT	   and	   opp	   mutants	   generated	   in	   Chapter	   3	   will	   be	   indispensible	   to	  
identifying	   the	   substrates	   of	   these	   transporters,	   and	   in	   assessing	   their	   role	   in	  
staphylococcal	  pathogenicity,	   as	  described	  above.	   Immediate	   future	  directions	   include	  
more	   rigorous	   assessment	  of	  DtpT	  on	  di-­‐	   and	   tri-­‐	   peptide	   acquisition,	   by	   employing	   a	  
broader	   array	   of	   proline,	   arginine,	   and/or	   cysteine-­‐containing	   peptides.	   	   Further,	   we	  
intend	  on	  generating	  a	  putP	  mutation	   in	  our	  dtpT	  mutant	  background	   to	  determine	   if	  
residual	  growth	  on	  proline-­‐containing	  peptides	  can	  be	  attributed	  to	  the	  presence	  of	  free	  
amino	  acids	  in	  the	  media.	  In	  this	  manner,	  we	  should	  be	  able	  to	  determine	  if	  DtpT	  is	  the	  
sole	  dipeptide	  permease	  in	  S.	  aureus	  USA300.	  	  
	   In	  characterizing	   the	   function	  of	   the	  OPPs	  of	  S.	  aureus,	  we	   intend	  on	  assessing	  
the	   complete	   OPP	   deletion	   mutant	   for	   utilization	   of	   peptides	   of	   varying	   lengths	   and	  
compositions.	  While	  S.	  aureus	  RN6390	  reportedly	  utilizes	  opp3	  in	  the	  import	  of	  peptides	  
of	  3-­‐8	  amino	  acids	  (30,	  45),	  it	  is	  not	  yet	  known	  if	  the	  same	  holds	  true	  for	  the	  epidemic,	  
highly	   successful,	   skin-­‐colonizing	  MRSA	   variant	   USA300	   and,	  more	   importantly,	   if	   the	  
ACME-­‐cassette	  encoded	  Opp	   (ACME-­‐Opp)	   functions	   in	  nitrogen	  metabolism.	  Although	  
the	  presence	  of	  the	  ACME	  cassette	  has	  been	  implicated	  in	  virulence	  (63),	  no	  substrate	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has	  yet	  been	   identified	  for	  ACME-­‐Opp;	   it	  would	  be	   interesting,	  even	   in	  the	  absence	  of	  
functional	   characterization	   of	   this	   permease,	   to	   assess	   for	   its	   role	   in	   staphylococcal	  
survival	  and	  virulence	  using	  the	  methodologies	  and	  models	  described	  above.	  	  
	   To	  date,	  regulation	  of	  the	  peptide	  permeases	  in	  S.	  aureus	  has	  not	  been	  directly	  
interrogated,	  although	  CodY	  has	  been	   implicated	   in	  regulating	  the	  expression	  of	  opp1,	  
opp3,	  opp3,	  and	  oppU	   through	  genome-­‐wide	  approaches	   identifying	  the	  CodY	  regulon	  
(64,	  65).	  As	  detailed	  in	  Chapter	  3,	  we	  speculate	  that	  CodY-­‐regulated	  peptide	  permeases	  
will	   play	   an	   important	   role	   in	   nasal	   colonization,	   where	   the	   availability	   of	   branched-­‐
chain	   amino	   acids	   is	   limited;	   following	   confirmation	   through	   RT-­‐PCR,	   we	   intend	   on	  
assessing	   the	   survival	   of	   CodY-­‐regulated	   peptide	   permease	   mutants	   in	   this	   model.	  
Indeed,	   given	   the	   multitude	   of	   mutants	   at	   our	   disposal,	   along	   with	   their	  
complementation	  vectors,	  and	  our	  potential	  to	  assess	  their	  role	  in	  S.	  aureus	  survival	  and	  
virulence	   in	   numerous	   in	   vivo	  models,	   there	   are	  many	   exciting	   possibilities	   for	   future	  
projects	  in	  the	  laboratory	  that	  will	  further	  define	  the	  inter-­‐relationship	  of	  staphylococcal	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APPENDIX	  1-­‐	  PERCENT	  IDENTITIES	  BETWEEN	  OLIGOPEPTIDE	  
PERMEASE	  PROTEINS	  IN	  S.	  AUREUS	  
Table	  S1.	  Percent	  amino	  acid	  identity	  between	  SBPs	  of	  the	  oligopeptide	  permeases	  of	  
S.	  aureus	  USA300	  FPR3757	  and	  DppA	  of	  E.	  coli	  K-­‐12	  MG1655.	  
Protein	   Opp1A	   Opp5A	   Opp3A	   Opp4A	   ACME-­‐	  
OppA	  
OppU-­‐A	   E.	  coli	  DppA	  
Opp1A	   100	   21	   20	   21	   27	   17	   28	  
Opp5A	   	   100	   20	   24	   20	   15	   18	  
Opp3A	   	   	   100	   21	   21	   13	   19	  
Opp4A	   	   	   	   100	   19	   16	   24	  
ACME-­‐OppA	   	   	   	   	   100	   16	   20	  
OppU-­‐A	   	   	   	   	   	   100	   16	  
E.	  coli	  DppA	   	   	   	   	   	   	   100	  
	  
Table	  S2.	  Percent	  amino	  acid	  identity	  between	  integral	  transmembrane	  proteins	  of	  
the	  oligopeptide	  permeases	  of	  S.	  aureus	  USA300	  FPR3757.	  	  
Protein	   Opp1	   Opp2	   Opp3	   Opp4	   ACME-­‐
Opp	  
OppU	  
B	   C	   B	   C	   B	   C	   B	   C	   B	   C	   B	   C	  
Opp1	   B	   100	   20	   31	   19	   31	   16	   29	   20	   27	   22	   29	   21	  
C	   	   100	   18	   29	   20	   31	   22	   33	   19	   28	   21	   32	  
Opp2	   B	   	   	   100	   20	   28	   21	   31	   18	   26	   20	   28	   18	  
C	   	   	   	   100	   17	   26	   20	   29	   17	   28	   23	   33	  
Opp3	   B	   	   	   	   	   100	   17	   36	   17	   20	   17	   29	   21	  
C	   	   	   	   	   	   100	   20	   33	   16	   23	   20	   25	  
Opp4	   B	   	   	   	   	   	   	   100	   19	   27	   20	   31	   21	  
C	   	   	   	   	   	   	   	   100	   17	   25	   20	   29	  
ACME-­‐
Opp	  
B	   	   	   	   	   	   	   	   	   100	   16	   20	   16	  
C	   	   	   	   	   	   	   	   	   	   100	   20	   31	  
OppU	   B	   	   	   	   	   	   	   	   	   	   	   100	   20	  




Table	  S3.	  Percent	  amino	  acid	  identity	  between	  the	  ATPases	  of	  the	  oligopeptide	  
permeases	  of	  S.	  aureus	  USA300	  FPR3757.	  	  
Protein	   Opp1	   Opp2	   Opp3	   Opp4	   ACME-­‐Opp	   OppU	  
D	   F	   D	   F	   D	   F	   D	   F	   D	   F	   D	  
Opp1	   D	   100	   30	   30	   28	   39	   32	   32	   43	   30	   31	   42	  
F	   	   100	   26	   27	   30	   32	   35	   33	   30	   29	   34	  
Opp2	   D	   	   	   100	   24	   30	   30	   29	   32	   26	   28	   31	  
F	   	   	   	   100	   28	   31	   31	   29	   25	   33	   28	  
Opp3	   D	   	   	   	   	   100	   41	   39	   46	   28	   30	   42	  
F	   	   	   	   	   	   100	   49	   41	   27	   30	   36	  
Opp4	   D	   	   	   	   	   	   	   100	   40	   29	   30	   35	  
F	   	   	   	   	   	   	   	   100	   27	   31	   41	  
ACME-­‐Opp	   D	   	   	   	   	   	   	   	   	   100	   24	   30	  
F	   	   	   	   	   	   	   	   	   	   100	   35	  








Figure	  S1.	  S.	  aureus	  USA300	  is	  auxotrophic	  for	  proline,	  arginine,	  and	  cysteine.	  	  
The	   amino	   acid	   auxotrophies	   for	   S.	   aureus	   USA300	   were	   determined	   by	   assessing	  
growth	   of	   the	   wild-­‐type	   in	   chemically-­‐defined	   media	   lacking	   a	   single	   amino	   acid,	   as	  
indicated	  on	  the	  x-­‐axis,	  at	  24	  and	  48	  h.	  The	  strain	  was	  determined	  to	  be	  auxotrophic	  for	  
proline,	   arginine,	   and	   cysteine,	   as	   indicated	   by	   its	   inability	   to	   grow	   in	   the	   absence	   of	  
these	  amino	  acids.	  S.	  aureus	  USA300	  was	  determined	  not	  to	  be	  auxotrophic	  for	  valine	  as	  
growth	  results	  after	  extended	  incubation	  or	  in	  media	  containing	  iron	  (data	  not	  shown).	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